#BEGIN_DRUGCARD DB00142

# AHFS_Codes:
40:04.00

# ATC_Codes:
A09AB01

# Absorption:
Absorbed from the lumen of the small intestine into the enterocytes.Absorption is efficient and occurs by an active transport mechanism.

# Biotransformation:
Hepatic

# Brand_Mixtures:
Not Available

# Brand_Names:
Aciglut
Glusate
Glutacid
Glutamicol
Glutamidex
Glutaminol
Glutaton

# CAS_Registry_Number:
56-86-0

# ChEBI_ID:
16015

# Chemical_Formula:
C5H9NO4

# Chemical_IUPAC_Name:
(2S)-2-aminopentanedioic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A peptide that is a homopolymer of glutamic acid. [PubChem]

# Dosage_Forms:
Capsule	Oral

# Drug_Category:
Dietary supplement
Micronutrient
Non-Essential Amino Acids

# Drug_Interactions:
Not Available

# Drug_Reference:
10736365	Reeds PJ, Burrin DG, Stoll B, Jahoor F: Intestinal glutamate metabolism. J Nutr. 2000 Apr;130(4S Suppl):978S-82S.
10736373	Smith QR: Transport of glutamate and other amino acids at the blood-brain barrier. J Nutr. 2000 Apr;130(4S Suppl):1016S-22S.
15939876	Okumoto S, Looger LL, Micheva KD, Reimer RJ, Smith SJ, Frommer WB: Detection of glutamate release from neurons by genetically encoded surface-displayed FRET nanosensors. Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8740-5. Epub 2005 Jun 6.
17202478	Augustin H, Grosjean Y, Chen K, Sheng Q, Featherstone DE: Nonvesicular release of glutamate by glial xCT transporters suppresses glutamate receptor clustering in vivo. J Neurosci. 2007 Jan 3;27(1):111-23.
7901400	Corrie JE, DeSantis A, Katayama Y, Khodakhah K, Messenger JB, Ogden DC, Trentham DR: Postsynaptic activation at the squid giant synapse by photolytic release of L-glutamate from a 'caged' L-glutamate. J Physiol. 1993 Jun;465:1-8.

# Drug_Type:
Approved
Nutraceutical
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-3.69

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
8570 mg/L (at 25 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
L-Glutamic Acid

# HET_ID:
GLU

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C5H9NO4/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m0/s1

# InChI_Key:
InChIKey=WHUUTDBJXJRKMK-VKHMYHEASA-N

# Indication:
Considered to be nature's "Brain food" by improving mental capacities; helps speed the healing of ulcers; gives a "lift" from fatigue; helps control alcoholism, schizophrenia and the craving for sugar.

# KEGG_Compound_ID:
C00025

# KEGG_Drug_ID:
D00007

# LIMS_Drug_ID:
142

# Mechanism_Of_Action:
Glutamate activates both ionotropic and metabotropic glutamate receptors. The ionotropic ones being non-NMDA (AMPA and kainate) and NMDA receptors. Free glutamic acid cannot cross the blood-brain barrier in appreciable quantities; instead it is converted into L-glutamine, which the brain uses for fuel and protein synthesis. It is conjectured that glutamate is involved in cognitive functions like learning and memory in the brain, though excessive amounts may cause neuronal damage associated in diseases like amyotrophic lateral sclerosis, lathyrism, and Alzheimer's disease. Also, the drug phencyclidine (more commonly known as PCP) antagonizes glutamate at the NMDA receptor, causing behavior reminiscent of schizophrenia. Glutamate in action is extremely difficult to study due to its transient nature.

# Melting_Point:
224 dec °C

# Molecular_Weight_Avg:
147.1293

# Molecular_Weight_Mono:
147.053157781

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
1BGV

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA449776

# Pharmacology:
In addition to being one of the building blocks in protein synthesis, it is the most widespread neurotransmitter in brain function, as an excitatory neurotransmitter and as a precursor for the synthesis of GABA in GABAergic neurons.

# Predicted_LogP_Hydrophobicity:
-3.5

# Predicted_LogS:
-0.26

# Predicted_Water_Solubility:
8.06e+01 g/l

# Primary_Accession_No:
DB00142

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
33032

# PubChem_Substance_ID:
46505816

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
NUTR00027

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
N[C@@H](CCC(O)=O)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
(2S)-2-Aminopentanedioic acid
(S)-(+)-Glutamic acid
(S)-2-Aminopentanedioic acid
(S)-Glutamic acid
1-Aminopropane-1,3-dicarboxylic acid
2-Aminoglutaric acid
2-Aminopentanedioic acid
Glutamic acid
Glutaminic acid
L-(+)-Glutamic acid
L-Glutamate
L-Glutaminic acid
L-a-Aminoglutaric acid
a-Aminoglutaric acid
a-Glutamic acid

# Synthesis_Reference:
Not Available

# Toxicity:
Glutamate causes neuronal damage and eventual cell death, particularly when NMDA receptors are activated, High dosages of glutamic acid may include symptoms such as headaches and neurological problems.

# Update_Date:
2013-02-08 16:19:08 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/L-Glutamic_Acid

# pKa_Isoelectric_Point:
2.23 (at 0 °C)

# Drug_Target_10_Cellular_Location:
Isoform A:Mitochondrion. Isoform B:Cytoplasm

# Drug_Target_10_Chromosome_Location:
Not Available

# Drug_Target_10_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_10_Essentiality:
Non-Essential

# Drug_Target_10_GenAtlas_ID:
BCAT2

# Drug_Target_10_GenBank_ID_Gene:
U68418

# Drug_Target_10_GenBank_ID_Protein:
2342862

# Drug_Target_10_GeneCard_ID:
BCAT2

# Drug_Target_10_Gene_Name:
BCAT2

# Drug_Target_10_Gene_Sequence:
>1179 bp
ATGGCCGCAGCCGCTCTGGGGCAGATCTGGGCACGAAAGCTTCTCTCTGTCCCTTGGCTT
CTGTGTGGTCCCAGAAGATATGCCTCCTCCAGTTTCAAGGCTGCAGACCTGCAGCTGGAA
ATGACACAGAAGCCTCATAAGAAGCCTGGCCCCGGCGAGCCCCTGGTGTTTGGGAAGACA
TTTACCGACCACATGCTGATGGTGGAATGGAATGACAAGGGCTGGGGCCAGCCCCGAATC
CAGCCCTTCCAGAACCTCACGCTGCACCCAGCCTCCTCCAGCCTCCACTACTCCCTGCAG
CTGTTTGAGGGCATGAAGGCGTTCAAAGGCAAAGACCAGCAGGTGCGCCTCTTCCGCCCC
TGGCTCAACATGGACCGGATGCTGCGCTCAGCCATGCGCCTGTGCCTGCCGAGTTTCGAC
AAGCTGGAGTTGCTGGAGTGCATCCGCCGGCTCATCGAAGTGGACAAGGACTGGGTCCCC
GATGCCGCCGGCACCAGCCTCTATGTGCGGCCTGTGCTCATTGGGAACGAGCCCTCGCTG
GGTGTCAGCCAGCCCAGGCGCGCGCTCCTGTTCGTCATTCTCTGCCCAGTGGGTGCCTAC
TTCCCTGGAGGCTCCGTGACCCCGGTCTCCCTCCTGGCCGACCCAGCCTTCATCCGGGCC
TGGGTGGGCGGGGTCGGCAACTACAAGTTAGGTGGGAATTATGGGCCCACCGTGTTAGTG
CAACAGGAGGCACTCAAGCGGGGCTGTGAACAGGTCCTCTGGCTGTATGGGCCCGACCAC
CAGCTCACCGAGGTGGGAACCATGAACATCTTTGTCTACTGGACCCACGAAGATGGGGTG
CTGGAGCTGGTGACGCCCCCGCTGAATGGTGTTATCCTGCCTGGAGTGGTCAGACAGAGT
CTACTGGACATGGCTCAGACCTGGGGTGAGTTCCGGGTGGTGGAGCGCACGATCACCATG
AAGCAGTTGCTGCGGGCCTTGGAGGAGGGCCGCGTGCGGGAAGTCTTTGGCTCGGGCACC
GCTTGCCAGGTCTGCCCAGTGCACCGAATCCTGTACAAAGACAGGAACCTCCATATTCCC
ACCATGGAAAATGGGCCTGAGCTGATCCTCCGCTTCCAGAAGGAGCTGAAGGAGATCCAG
TACGGAATCAGAGCCCACGAGTGGATGTTCCCGGTGTGA

# Drug_Target_10_General_Function:
Amino acid transport and metabolism

# Drug_Target_10_General_References:
11170829	Than NG, Sumegi B, Than GN, Bellyei S, Bohn H: Molecular cloning and characterization of placental tissue protein 18 (PP18a)/human mitochondrial branched-chain aminotransferase (BCATm) and its novel alternatively spliced PP18b variant. Placenta. 2001 Feb-Mar;22(2-3):235-43.
11264579	Yennawar N, Dunbar J, Conway M, Hutson S, Farber G: The structure of human mitochondrial branched-chain aminotransferase. Acta Crystallogr D Biol Crystallogr. 2001 Apr;57(Pt 4):506-15.
12269802	Yennawar NH, Conway ME, Yennawar HP, Farber GK, Hutson SM: Crystal structures of human mitochondrial branched chain aminotransferase reaction intermediates: ketimine and pyridoxamine phosphate forms. Biochemistry. 2002 Oct 1;41(39):11592-601.
8702755	Eden A, Simchen G, Benvenisty N: Two yeast homologs of ECA39, a target for c-Myc regulation, code for cytosolic and mitochondrial branched-chain amino acid aminotransferases. J Biol Chem. 1996 Aug 23;271(34):20242-5.
9165094	Bledsoe RK, Dawson PA, Hutson SM: Cloning of the rat and human mitochondrial branched chain aminotransferases (BCATm). Biochim Biophys Acta. 1997 Apr 25;1339(1):9-13.

# Drug_Target_10_HGNC_ID:
HGNC:977

# Drug_Target_10_HPRD_ID:
00217

# Drug_Target_10_ID:
795

# Drug_Target_10_Locus:
19q13

# Drug_Target_10_Molecular_Weight:
44288

# Drug_Target_10_Name:
Branched-chain-amino-acid aminotransferase, mitochondrial

# Drug_Target_10_Number_of_Residues:
392

# Drug_Target_10_PDB_ID:
1KTA

# Drug_Target_10_Pathway:
Not Available

# Drug_Target_10_Pfam_Domain_Function:
PF01063	Aminotran_4

# Drug_Target_10_Protein_Sequence:
>Branched-chain-amino-acid aminotransferase, mitochondrial precursor
MAAAALGQIWARKLLSVPWLLCGPRRYASSSFKAADLQLEMTQKPHKKPGPGEPLVFGKT
FTDHMLMVEWNDKGWGQPRIQPFQNLTLHPASSSLHYSLQLFEGMKAFKGKDQQVRLFRP
WLNMDRMLRSAMRLCLPSFDKLELLECIRRLIEVDKDWVPDAAGTSLYVRPVLIGNEPSL
GVSQPTRALLFVILCPVGAYFPGGSVTPVSLLADPAFIRAWVGGVGNYKLGGNYGPTVLV
QQEALKRGCEQVLWLYGPDHQLTEVGTMNIFVYWTHEDGVLELVTPPLNGVILPGVVRQS
LLDMAQTWGEFRVVERTITMKQLLRALEEGRVREVFGSGTACQVCPVHRILYKDRNLHIP
TMENGPELILRFQKELKEIQYGIRAHEWMFPV

# Drug_Target_10_Reaction:
L-leucine + 2-oxoglutarate = 4-methyl-2-oxopentanoate + L-glutamate

# Drug_Target_10_Signals:
None

# Drug_Target_10_Specific_Function:
Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine. May also function as a transporter of branched chain alpha-keto acids

# Drug_Target_10_SwissProt_ID:
O15382

# Drug_Target_10_SwissProt_Name:
BCAT2_HUMAN

# Drug_Target_10_Synonyms:
BCAT(m)
Branched-chain-amino-acid aminotransferase, mitochondrial precursor
EC 2.6.1.42
PP18
Placental protein 18

# Drug_Target_10_Theoretical_pI:
8.82

# Drug_Target_10_Transmembrane_Regions:
None

# Drug_Target_11_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_11_Chromosome_Location:
Not Available

# Drug_Target_11_Drug_References:
11755246	Pliss L, Jezova D, Mares V, Balcar VJ, St'astny F: N-Acetyl-L-aspartyl-L-glutamate changes functional and structural properties of rat blood-brain barrier. Neurosci Lett. 2002 Jan 11;317(2):85-8.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
8886398	Bresink I, Benke TA, Collett VJ, Seal AJ, Parsons CG, Henley JM, Collingridge GL: Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells. Br J Pharmacol. 1996 Sep;119(2):195-204.
9417820	Sundstrom E, Whittemore S, Mo LL, Seiger A: Analysis of NMDA receptors in the human spinal cord. Exp Neurol. 1997 Dec;148(2):407-13.

# Drug_Target_11_Essentiality:
Non-Essential

# Drug_Target_11_GenAtlas_ID:
GRIN2D

# Drug_Target_11_GenBank_ID_Gene:
U77783

# Drug_Target_11_GenBank_ID_Protein:
2444026

# Drug_Target_11_GeneCard_ID:
GRIN2D

# Drug_Target_11_Gene_Name:
GRIN2D

# Drug_Target_11_Gene_Sequence:
>4011 bp
ATGCGCGGCGCCGGTGGCCCCCGCGGCCCTCGGGGCCCCGCTAAGATGCTGCTGCTGCTG
GCGCTGGCCTGCGCCAGCCCGTTCCCGGAGGAGGCGCCGGGGCCGGGCGGGGCCGGTGGG
CCCGGCGGCGGCCTCGGCGGGGCGCGGCCGCTCAACGTGGCGCTCGTGTTCTCGGGGCCC
GCGTACGCGGCCGAGGCGGCACGCCTGGGCCCGGCCGTGGCGGCGGCGGTGCGCAGCCCG
GGCCTAGACGTGCGGCCCGTGGCGCTGGTGCTCAACGGCTCGGACCCGCGCAGCCTCGTG
CTGCAGCTCTGCGACCTGCTGTCGGGGTTGCGCGTGCACGGCGTGGTCTTCGAAGACGAC
TCGCGCGCGCCCGCCGTCGCGCCCATCCTCGACTTCCTGTCGGCGCAGACCTCGCTGCCC
ATCGTGGCCGTGCACGGCGGCGCCGCGCTCGTGCTCACGCCCAAGGAGAAGGGCTCCACC
TTCCTGCAGCTGGGCTCTTCCACCGAGCAACAGCTTCAGGTCATCTTTGAGGTGCTGGAG
GAGTATGACTGGACGTCCTTTGTAGCCGTGACCACTCGTGCCCCTGGCCACCGGGCCTTC
CTGTCCTACATTGAGGTGCTGACTGACGGTAGTCTGGTGGGCTGGGAGCACCGCGGAGCG
CTGACGCTGGACCCTGGGGCGGGCGAGGCCGTGCTCAGTGCCCAGCTCCGCAGTGTCAGC
GCGCAGATCCGCCTGCTCTTCTGCGCCCGAGAGGAGGCCGAGCCCGTGTTCCGCGCAGCT
GAGGAGGCTGGCCTCACTGGATCTGGCTACGTCTGGTTCATGGTGGGGCCCCAGCTGGCT
GGAGGCGGGGGCTCTGGGGCCCCTGGTGAGCCCCCTCTTCTGCCAGGAGGCGCCCCCCTG
CCTGCCGGGCTGTTTGCAGTGCGCTCGGCTGGCTGGCGGGATGACCTGGCTCGGCGAGTG
GCAGCTGGCGTGGCCGTAGTGGCCAGAGGTGCCCAGGCCCTGCTGCGTGATTATGGTTTC
CTTCCTGAGCTCGGCCACGACTGTCGCGCCCAGAACCGCACCCACCGCGGCGAGAGTCTG
CATAGGTACTTCATGAACATCACGTGGGATAACCGGGATTACTCCTTCAATGAGGACGGC
TTCCTAGTGAACCCCTCCCTGGTGGTCATCTCCCTCACCAGAGACAGGACGTGGGAGGTG
GTGGGCAGCTGGGAGCAGCAGACGCTCCGCCTCAAGTACCCGCTGTGGTCCCGCTATGGT
CGCTTCCTGCAGCCAGTGGACGACACGCAGCACCTCACGGTGGCCACGCTGGAGGAAAGG
CCGTTTGTCATCGTGGAGCCTGCAGACCCTATCAGCGGCACCTGCATCCGAGACTCCGTC
CCCTGCCGGAGCCAGCTCAACCGAACCCACAGCCCTCCACCGGATGCCCCCCGCCCGGAA
AAGCGCTGCTGCAAGGGTTTCTGCATCGACATTCTGAAGCGGCTGGCGCATACCATCGGC
TTCAGCTACGACCTCTACCTGGTCACCAATGGCAAGCACGGAAAGAAGATCGATGGCGTC
TGGAACGGCATGATCGGGGAGGTGTTCTACCAGCGCGCAGACATGGCCATCGGCTCCCTC
ACCATCAACGAGGAGCGCTCCGAGATCGTGGACTTCTCCGTCCCCTTCGTGGAGACCGGC
ATCAGCGTCATGGTGGCGCGCAGCAATGGCACGGTGTCCCCCTCGGCCTTCCTCGAGCCC
TACAGCCCCGCCGTGTGGGTGATGATGTTCGTCATGTGCCTCACTGTGGTCGCCGTCACT
GTTTTCATCTTCGAGTACCTCAGTCCTGTTGGTTACAACCGCAGCCTGGCCACGGGCAAG
CGCCCTGGCGGTTCAACCTTCACCATTGGGAAATCCATCTGGCTGCTCTGGGCCCTGGTG
TTCAATAATTCGGTGCCCGTGGAGAACCCCCGGGGAACCACCAGCAAAATCATGGTGCTG
GTGTGGGCCTTCTTCGCCGTCATCTTCCTCGCCAGCTACACAGCCAACCTGGCCGCCTTC
ATGATCCAGGAGGAGTACGTGGATACTGTGTCTGGGCTCAGTGACCGCAAGTTCCAGAGG
CCCCAGGAGCAGTACCCGCCCCTGAAGTTTGGGACCGTGCCCAACGGCTCCACGGAGAAG
AACATCCGCAGCAACTATCCCGACATGCACAGCTACATGGTGCGCTACAACCAGCCCCGC
GTAGAGGAAGCGCTCACTCAGCTCAAGGCAGGGAAGCTGGACGCCTTCATCTACGATGCT
GCAGTGCTCAATTACATGGCCCGCAAGGACGAGGGCTGCAAGCTTGTCACCATCGGCTCC
GGCAAGGTCTTCGCCACGACAGGCTATGGCATCGCCCTGCACAAGGGCTCCCGCTGGAAG
CGGCCCATCGACCTGGCGTTGCTGCAGTTCCTGGGGGATGATGAGATCGAGATGCTGGAG
CGGCTGTGGCTCTCTGGGATCTGCCACAATGACAAAATCGAGGTGATGAGCAGCAAGCTG
GACATCGACAACATGGCGGGCGTCTTCTACATGCTCCTGGTGGCCATGGGCCTGTCCCTG
CTGGTCTTCGCCTGGGAGCACCTGGTGTACTGGCGCCTGCGGCACTGCCTGGGGCCCACC
CACCGCATGGACTTCCTGCTGGCCTTCTCCAGGGGCATGTACAGCTGCTGCAGCGCTGAG
GCCGCCCCACCGCCCGCCAAGCCCCCGCCGCCGCCACAGCCCCTGCCCAGCCCCGCGTAC
CCCGCGCCGGGGCCGGCTCCCGGGCCCGCACCTTTCGTGCCCCGCGAGCGCGCCTCAGTG
GACCGCTGGCGCCGGACCAAGGGCGCGGGGCCGCCGGGGGGCGCGGGCCTGGCCGACGGC
TTCCACCGCTACTACGGCCCCATCGAGCCGCAGGGCCTAGGCCTCGGCCTGGGCGAAGCG
CGCGCGGCACCGCGGGGCGCAGCCGGGCGCCCGCTGTCCCCGCCGGCCGCTCAGCCCCCG
CAGAAGCCGCCGGCCTCCTATTTCGCCATCGTACGCGACAAGGAGCCAGCCGAGCCCCCC
GCCGGCGCCTTCCCCGGCTTCCCGTCGCCGCCCGCGCCCCCCGCCGCCGCGGCCACCGCC
GTCGGGCCGCCACTCTGCCGCTTGGCCTTCGAGGACGAGAGCCCGCCGGCGCCCGCGCGG
TGGCCGCGCTCGGACCCCGAGAGCCAACCCCTGCTGGGGCCAGGCGCGGGCGGCGCGGGG
GGCACGGGGGGCGCAGGCGGAGGAGCCCCGGCCGCTCCGCCCCCGTGCTGCGCCGCGCCG
CCCCCGTGCCCTTACCTCGATCTCGAGCCGTCGCCGTCGGACTCGGAGGACTCGGAGAGC
CTGGGCGGCGCGTCGCTGGGCGGCCTGGATCCCTGGTGGTTCGCCGACTTCCCTTACCCG
TATGCCGAGCGCCTCGGGCCGCCGCCCGGCCGCTACTGGTCGGTCGACAAGCTCGGGGGC
TGGCGCGCCGGGAGCTGGGACTACCTGCCCCCGCGCAGCGGTCCGGCCGCCTGGCACTGT
CGGCACTGCGCCAGCCTGGAGCTGCTGCCGCCGCCGCGCCATCTCAGCTGCTCGCACGAT
GGCCTGGACGGCGGCTGGTGGGCGCCACCGCCTCCACCCTGGGCCGCCGGGCCCCTGCCC
CGACGCCGGGCCCGCTGCGGGTGCCCGCGGTCGCACCCGCACCGCCCGCGGGCCTCGCAC
CGCACGCCCGCCGCTGCCGCGCCCCACCACCACAGGCACCGGCGCGCCGCTGGGGGCTGG
GACCTCCCGCCGCCCGCGCCCACCTCGCGCTCGCTCGAGGACCTCAGCTCGTGCCCTCGC
GCCGCCCCTGCGCGCAGGCTTACCGGGCCCTCCCGCCACGCTCGCAGGTGTCCGCACGCC
GCGCACTGGGGGCCGCCGCTGCCCACAGCTTCCCACCGGAGACACCGGGGCGGGGACCTG
GGCACCCGCAGGGGCTCGGCGCACTTCTCTAGCCTCGAGTCCGAGGTATGA

# Drug_Target_11_General_Function:
Secondary metabolites biosynthesis, transport and catabolism

# Drug_Target_11_General_References:
9489750	Hess SD, Daggett LP, Deal C, Lu CC, Johnson EC, Velicelebi G: Functional characterization of human N-methyl-D-aspartate subtype 1A/2D receptors. J Neurochem. 1998 Mar;70(3):1269-79.

# Drug_Target_11_HGNC_ID:
HGNC:4588

# Drug_Target_11_HPRD_ID:
04095

# Drug_Target_11_ID:
439

# Drug_Target_11_Locus:
19q13.1-qter

# Drug_Target_11_Molecular_Weight:
143561

# Drug_Target_11_Name:
Glutamate [NMDA] receptor subunit epsilon-4

# Drug_Target_11_Number_of_Residues:
1336

# Drug_Target_11_PDB_ID:
Not Available

# Drug_Target_11_Pathway:
Not Available

# Drug_Target_11_Pfam_Domain_Function:
PF00060	Lig_chan
PF01094	ANF_receptor

# Drug_Target_11_Protein_Sequence:
>Glutamate [NMDA] receptor subunit epsilon 4 precursor
MRGAGGPRGPRGPAKMLLLLALACASPFPEEAPGPGGAGGPGGGLGGARPLNVALVFSGP
AYAAEAARLGPAVAAAVRSPGLDVRPVALVLNGSDPRSLVLQLCDLLSGLRVHGVVFEDD
SRAPAVAPILDFLSAQTSLPIVAVHGGAALVLTPKEKGSTFLQLGSSTEQQLQVIFEVLE
EYDWTSFVAVTTRAPGHRAFLSYIEVLTDGSLVGWEHRGALTLDPGAGEAVLSAQLRSVS
AQIRLLFCAREEAEPVFRAAEEAGLTGSGYVWFMVGPQLAGGGGSGAPGEPPLLPGGAPL
PAGLFAVRSAGWRDDLARRVAAGVAVVARGAQALLRDYGFLPELGHDCRAQNRTHRGESL
HRYFMNITWDNRDYSFNEDGFLVNPSLVVISLTRDRTWEVVGSWEQQTLRLKYPLWSRYG
RFLQPVDDTQHLTVATLEERPFVIVEPADPISGTCIRDSVPCRSQLNRTHSPPPDAPRPE
KRCCKGFCIDILKRLAHTIGFSYDLYLVTNGKHGKKIDGVWNGMIGEVFYQRADMAIGSL
TINEERSEIVDFSVPFVETGISVMVARSNGTVSPSAFLEPYSPAVWVMMFVMCLTVVAVT
VFIFEYLSPVGYNRSLATGKRPGGSTFTIGKSIWLLWALVFNNSVPVENPRGTTSKIMVL
VWAFFAVIFLASYTANLAAFMIQEEYVDTVSGLSDRKFQRPQEQYPPLKFGTVPNGSTEK
NIRSNYPDMHSYMVRYNQPRVEEALTQLKAGKLDAFIYDAAVLNYMARKDEGCKLVTIGS
GKVFATTGYGIALHKGSRWKRPIDLALLQFLGDDEIEMLERLWLSGICHNDKIEVMSSKL
DIDNMAGVFYMLLVAMGLSLLVFAWEHLVYWRLRHCLGPTHRMDFLLAFSRGMYSCCSAE
AAPPPAKPPPPPQPLPSPAYPAPGPAPGPAPFVPRERASVDRWRRTKGAGPPGGAGLADG
FHRYYGPIEPQGLGLGLGEARAAPRGAAGRPLSPPAAQPPQKPPASYFAIVRDKEPAEPP
AGAFPGFPSPPAPPAAAATAVGPPLCRLAFEDESPPAPARWPRSDPESQPLLGPGAGGAG
GTGGAGGGAPAAPPPCCAAPPPCPYLDLEPSPSDSEDSESLGGASLGGLDPWWFADFPYP
YAERLGPPPGRYWSVDKLGGWRAGSWDYLPPRSGPAAWHCRHCASLELLPPPRHLSCSHD
GLDGGWWAPPPPPWAAGPLPRRRARCGCPRSHPHRPRASHRTPAAAAPHHHRHRRAAGGW
DLPPPAPTSRSLEDLSSCPRAAPARRLTGPSRHARRCPHAAHWGPPLPTASHRRHRGGDL
GTRRGSAHFSSLESEV

# Drug_Target_11_Reaction:
Not Available

# Drug_Target_11_Signals:
1-27

# Drug_Target_11_Specific_Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine

# Drug_Target_11_SwissProt_ID:
O15399

# Drug_Target_11_SwissProt_Name:
NMDE4_HUMAN

# Drug_Target_11_Synonyms:
EB11
Glutamate receptor subunit epsilon-4 precursor
N-methyl D- aspartate receptor subtype 2D
NMDAR2D
NR2D

# Drug_Target_11_Theoretical_pI:
8.27

# Drug_Target_11_Transmembrane_Regions:
584-604
627-647
657-677
845-865

# Drug_Target_12_Cellular_Location:
Membrane

# Drug_Target_12_Chromosome_Location:
Not Available

# Drug_Target_12_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_12_Essentiality:
Non-Essential

# Drug_Target_12_GenAtlas_ID:
GRID2

# Drug_Target_12_GenBank_ID_Gene:
AF009014

# Drug_Target_12_GenBank_ID_Protein:
2853315

# Drug_Target_12_GeneCard_ID:
GRID2

# Drug_Target_12_Gene_Name:
GRID2

# Drug_Target_12_Gene_Sequence:
>3024 bp
ATGGAAGTTTTCCCCTTGCTCTTGGTTTTGTCCGTCTGGTGGTCTCGAACCTGGGACTCG
GCGAATGCGGATTCGATCATTCACATCGGAGCAATTTTTGATGAATCTGCCAAAAAGGAT
GATGAGGTATTTCGCACTGCGGTTGGTGACCTTAACCAGAATGAAGAGATCTTACAGACT
GAGAAAATCACATTTTCAGTGACGTTTGTTGATGGCAACAACCCTTTCCAAGCAGTTCAA
GAAGCCTGTGAACTTATGAATCAAGGCATCTTGGCCCTGGTCAGCTCCATTGGCTGCACG
TCAGCAGGATCCCTCCAGTCTTTGGCAGACGCCATGCATATCCCCCACCTCTTCATTCAG
CGCTCAACAGCTGGGACCCCAAGGAGTGGCTGTGGACTCACCCGGAGCAACAGGAATGAT
GACTACACTCTCTCAGTTCGCCCACCTGTCTACTTGCATGATGTTATCCTAAGAGTGGTC
ACAGAGTATGCCTGGCAGAAATTCATTATATTCTATGATAGTGAATACGATATCCGTGGA
ATACAGGAGTTCTTGGACAAAGTCTCTCAGCAGGGAATGGATGTTGCACTTCAGAAGGTA
GAAAACAACATCAATAAAATGATTACCACTCTCTTTGACACCATGAGAATAGAAGAACTG
AATCGCTATCGAGACACTCTTAGGCGAGCGATCCTTGTTATGAATCCTGCTACAGCCAAA
TCCTTCATTACTGAGGTTGTGGAGACTAATTTGGTTGCTTTTGACTGTCACTGGATCATT
ATAAATGAGGAAATAAACGATGTGGACGTACAGGAACTTGTAAGAAGGTCAATTGGAAGG
TTAACGATTATTCGGCAGACATTTCCAATTCCCCAGAACATAAGTCAGCGGTGTTTCCGT
GGCAACCATCGAATATCTTCAACATTGTGTGATCCAAAGGATCCATTTGCTCAGAATATG
GAGATTTCCAACCTTTACATATATGACACGGTGCTTCTGCTTGCTAATGCTTTTCATAAG
AAGCTGGAGGACCGAAAGTGGCACAGCATGGCAAGTCTGTCATGTATCAGAAAGAACTCA
AAGCCCTGGCAGGGTGGGCGCTCCATGTTGGAGACCATCAAGAAGGGTGGAGTTAGTGGG
TTGACTGGAGAGCTAGAATTTGGAGAAAATGGAGGCAATCCCAATGTCCACTTTGAAATC
CTTGGAACCAACTATGGAGAAGAGCTTGGCAGAGGTGTTCGAAAACTTGGGTGCTGGAAT
CCTGTCACAGGTCTGAATGGGTCACTGACTGACAAGAAATTGGAGAATAACATGCGTGGA
GTGGTTCTACGTGTAGTAACTGTTCTGGAAGAACCTTTTGTGATGGTCTCTGAAAATGTC
TTGTGTAAGCCGAAGAAATACCAGGGCTTCTCCATTGATGTTTTGGATGCCTTATCTAAC
TACCTGGGTTTTAACTACGAAATTTACGTAGCACCGGATCACAAATACGGAAGCCCACAA
GAAGATGGGACATGGAATGGCTTGGTAGGAGAACTTGTCTTTAAGAGAGCCGACATAGGG
ATTTCTGCTTTAACCATCACTCCAGATCGTGAAAATGTGGTGGACTTTACGACACGTTAC
ATGGACTACTCAGTGGGGGTACTACTTCGAAGGGCTGAAAAGACAGTGGATATGTTTGCC
TGTCTTGCACCATTTGATCTCTCTCTATGGGCTTGCATTGCTGGCACAGTCCTTCTGGTG
GGTCTACTGGTCTACCTCTTGAACTGGCTTAATCCCCCACGATTACAAATGGGATCAATG
ACGTCTACTACTCTCTACAACTCCATGTGGTTTGTGTATGGATCTTTTGTACAACAAGGC
GGGGAAGTCCCGTACACGACTCTGGCTACCCGAATGATGATGGGGGCTTGGTGGCTATTT
GCTTTGATTGTTATCTCATCTTACACGGCAAACCTCGCTGCTTTCCTCACTATTACACGC
ATTGAAAGTTCCATCCAGTCTCTCCAGGACCTTTCCAAGCAAACAGAAATCCCTTATGGC
ACAGTCCTAGACTCTGCGGTATATGAGCATGTCCGCATGAAAGGACTGAATCCTTTTGAG
AGGGACAGCATGTATTCCCAAATGTGGCGGATGATCAACCGAAGCAATGGATCGGAGAAC
AATGTTCTGGAGTCCCAGGCAGGCATTCAAAAGGTAAAATATGGAAATTATGCTTTCGTA
TGGGATGCAGCTGTATTGGAATATGTGGCTATCTATGACCCAGATTGTTCCTTTTACACC
ATTGGAAATACTGTTGCTGATCGGGGATATGGAATTGCATTACAACATGGCAGTCCTTAC
CGAGATGTTTTTTCACAAAGGATCCTGGAGCTTCAGCAGAATGGTGACATGGACATCCTG
AAGCACAAATGGTGGCCTAAGAATGGCCAGTGTGACCTGTACTCGTCAGTGGACACAAAG
CAGAAAGGAGGCGCCCTGGACATAAAGAGCTTTGCAGGGGTCTTTTGTATCCTGGCTGCT
GGAATTGTCCTCTCCTGCTTCATAGCCATGCTGGAGACGTGGTGGAACAAGAGGAAAGGC
TCCCGGGTTCCATCAAAAGAGGATGACAAGGAAATTGACCTGGAGCACCTCCATAGACGT
GTAAATAGCTTGTGCACAGATGACGACAGCCCCCATAAACAGTTTTCCACCTCGTCAATT
GATTTGACCCCTCTGGACATTGACACTTTGCCAACACGACAAGCACTGGAGCAAATCAGT
GATTTCAGGAACACTCATATTACCACAACAACCTTTATCCCAGAGCAGATCCAGACTCTT
AGCCGCACACTGTCAGCTAAAGCTGCTTCTGGTTTCACTTTTGGCAACGTGCCTGAGCAC
CGAACTGGCCCTTTTAGGCACAGGGCACCTAATGGGGGCTTTTTCAGGAGTCCTATAAAA
ACAATGTCATCTATTCCTTATCAACCAACTCCTACCCTGGGGCTCAATCTGGGTAATGAT
CCAGACCGAGGCACCTCCATATGA

# Drug_Target_12_General_Function:
Not Available

# Drug_Target_12_General_References:
9465309	Hu W, Zuo J, De Jager PL, Heintz N: The human glutamate receptor delta 2 gene (GRID2) maps to chromosome 4q22. Genomics. 1998 Jan 1;47(1):143-5.

# Drug_Target_12_HGNC_ID:
HGNC:4576

# Drug_Target_12_HPRD_ID:
Not Available

# Drug_Target_12_ID:
4018

# Drug_Target_12_Locus:
4q22

# Drug_Target_12_Molecular_Weight:
113433

# Drug_Target_12_Name:
Glutamate receptor delta-2 subunit

# Drug_Target_12_Number_of_Residues:
1007

# Drug_Target_12_PDB_ID:
Not Available

# Drug_Target_12_Pathway:
Not Available

# Drug_Target_12_Pfam_Domain_Function:
PF00060	Lig_chan
PF01094	ANF_receptor

# Drug_Target_12_Protein_Sequence:
>Glutamate receptor delta-2 subunit
MEVFPLLLVLSVWWSRTWDSANADSIIHIGAIFDESAKKDDEVFRTAVGDLNQNEEILQT
EKITFSVTFVDGNNPFQAVQEACELMNQGILALVSSIGCTSAGSLQSLADAMHIPHLFIQ
RSTAGTPRSGCGLTRSNRNDDYTLSVRPPVYLHDVILRVVTEYAWQKFIIFYDSEYDIRG
IQEFLDKVSQQGMDVALQKVENNINKMITTLFDTMRIEELNRYRDTLRRAILVMNPATAK
SFITEVVETNLVAFDCHWIIINEEINDVDVQELVRRSIGRLTIIRQTFPIPQNISQRCFR
GNHRISSTLCDPKDPFAQNMEISNLYIYDTVLLLANAFHKKLEDRKWHSMASLSCIRKNS
KPWQGGRSMLETIKKGGVSGLTGELEFGENGGNPNVHFEILGTNYGEELGRGVRKLGCWN
PVTGLNGSLTDKKLENNMRGVVLRVVTVLEEPFVMVSENVLCKPKKYQGFSIDVLDALSN
YLGFNYEIYVAPDHKYGSPQEDGTWNGLVGELVFKRADIGISALTITPDRENVVDFTTRY
MDYSVGVLLRRAEKTVDMFACLAPFDLSLWACIAGTVLLVGLLVYLLNWLNPPRLQMGSM
TSTTLYNSMWFVYGSFVQQGGEVPYTTLATRMMMGAWWLFALIVISSYTANLAAFLTITR
IESSIQSLQDLSKQTEIPYGTVLDSAVYEHVRMKGLNPFERDSMYSQMWRMINRSNGSEN
NVLESQAGIQKVKYGNYAFVWDAAVLEYVAIYDPDCSFYTIGNTVADRGYGIALQHGSPY
RDVFSQRILELQQNGDMDILKHKWWPKNGQCDLYSSVDTKQKGGALDIKSFAGVFCILAA
GIVLSCFIAMLETWWNKRKGSRVPSKEDDKEIDLEHLHRRVNSLCTDDDSPHKQFSTSSI
DLTPLDIDTLPTRQALEQISDFRNTHITTTTFIPEQIQTLSRTLSAKAASGFTFGNVPEH
RTGPFRHRAPNGGFFRSPIKTMSSIPYQPTPTLGLNLGNDPDRGTSI

# Drug_Target_12_Reaction:
Not Available

# Drug_Target_12_Signals:
1-23

# Drug_Target_12_Specific_Function:
Receptor for glutamate. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists

# Drug_Target_12_SwissProt_ID:
O43424

# Drug_Target_12_SwissProt_Name:
GRID2_HUMAN

# Drug_Target_12_Synonyms:
GluR delta-2
Glutamate receptor delta-2 subunit precursor

# Drug_Target_12_Theoretical_pI:
5.95

# Drug_Target_12_Transmembrane_Regions:
567-587
636-656
831-851

# Drug_Target_13_Cellular_Location:
Cell membrane
multi-pass membrane protein. Requires the presence of GRIN1 to be targeted at the pla

# Drug_Target_13_Chromosome_Location:
Not Available

# Drug_Target_13_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_13_Essentiality:
Non-Essential

# Drug_Target_13_GenAtlas_ID:
GRIN3B

# Drug_Target_13_GenBank_ID_Gene:
AC004528

# Drug_Target_13_GenBank_ID_Protein:
3025446

# Drug_Target_13_GeneCard_ID:
GRIN3B

# Drug_Target_13_Gene_Name:
GRIN3B

# Drug_Target_13_Gene_Sequence:
>3132 bp
ATGGAGTTTGTGCGGGCGCTGTGGCTGGGCCTGGCGCTGGCGCTGGGGCCGGGGTCCGCG
GGGGGCCACCCTCAGCCGTGCGGCGTCCTGGCGCGCCTCGGGGGCTCCGTGCGCCTGGGC
GCCCTCCTGCCCCGCGCGCCTCTCGCCCGCGCCCGCGCCCGCGCCGCCCTGGCCCGGGCC
GCCCTGGCGCCGCGGCTGCCGCACAACCTGAGCTTGGAGCTGGTGGTCGCCGCGCCCCCC
GCCCGCGACCCCGCCTCGCTGACCCGCGGCCTGTGCCAGGCGCTGGTGCCTCCGGGCGTG
GCGGCCCTGCTCGCCTTTCCCGAGGCTCGGCCCGAGCTGCTGCAGCTGCACTTCCTGGCG
GCGGCCACCGAGACCCCCGTGCTCAGCCTGCTGCGGCGGGAGGCGCGCGCGCCCCTCGGA
GCCCCGAACCCATTCCACCTGCAGCTGCACTGGGCCAGCCCCCTGGAGACGCTGCTGGAT
GTGCTGGTGGCGGTGCTGCAGGCGCACGCCTGGGAAGACGTCGGCCTGGCCCTGTGCCGC
ACTCAGGACCCCGGCGGCCTGGTGGCCCTCTGGACAAGCCGGGCTGGCCGGCCCCCACAG
CTGGTCCTGGACCTAAGCCGGCGGGACACGGGAGATGCAGGACTGCGGGCACGCCTGGCC
CCGATGGCGGCGCCAGTGGGGGGTGAAGCACCGGTACCCGCGGCGGTCCTCCTCGGCTGT
GACATCGCCCGTGCCCGTCGGGTGCTGGAGGCCGTACCTCCCGGCCCCCACTGGCTGTTG
GGGACACCACTGCCGCCCAAGGCCCTGCCCACCGCGGGGCTGCCACCAGGGCTGCTGGCG
CTGGGCGAGGTGGCACGACCCCCGCTGGAGGCCGCCATCCATGACATTGTGCAACTGGTG
GCCCGGGCGCTGGGCAGTGCGGCCCAGGTGCAGCCGAAGCGAGCCCTCCTCCCCGCCCCG
GTCAACTGCGGGGACCTGCAGCCGGCCGGGCCCGAGTCCCCGGGGCGCTTCTTGGCACGG
TTCCTGGCCAACACGTCCTTCCAGGGCCGCACGGGCCCCGTGTGGGTGACAGGCAGCTCC
CAGGTACACATGTCTCGGCACTTTAAGGTGTGGAGCCTTCGCCGGGACCCACGGGGCGCC
CCGGCCTGGGCCACGGTGGGCAGCTGGCGGGACGGCCAGCTGGACTTGGAACCGGGAGGT
GCCTCTGCACGGCCCCCGCCCCCACAGGGTGCCCAGGTCTGGCCCAAGCTGCGTGTGGTA
ACGCTGTTGGAACACCCATTTGTGTTTGCCCGTGATCCAGACGAAGACGGGCAGTGCCCA
GCGGGGCAGCTGTGCCTGGACCCTGGCACCAACGACTCGGCCACCCTGGACGCACTGTTC
GCCGCGCTGGCCAACGGCTCAGCGCCCCGTGCCCTGCGCAAGTGCTGCTACGGCTACTGC
ATTGACCTGCTGGAGCGGCTGGCGGAGGACACGCCCTTCGACTTCGAGCTGTACCTCGTG
GGTGACGGCAAGTACGGCGCCCTGCGGGACGGCCGCTGGACCGGCCTGGTCGGGGACCTG
CTGGCCGGCCGGGCCCACATGGCGGTCACCAGCTTCAGTATCAACTCCGCCCGCTCACAG
GTGGTGGACTTCACCAGCCCCTTCTTCTCCACCAGCCTGGGCATCATGGTGCGGGCACGG
GACACGGCCTCACCCATCGGTGCCTTTATGTGGCCCCTGCACTGGTCCACGTGGCTGGGC
GTCTTTGCGGCCCTGCACCTCACCGCGCTCTTCCTCACCGTGTACGAGTGGCGTAGCCCC
TACGGCCTCACGCCACGTGGCCGCAACCGCAGCACCGTCTTCTCCTACTCCTCAGCCCTC
AACCTGTGCTACGCCATCCTCTTCAGACGCACCGTGTCCAGCAAGACGCCCAAGTGCCCC
ACGGGCCGCCTGCTCATGAACCTCTGGGCCATCTTCTGCCTGCTGGTGCTGTCCAGCTAC
ACGGCCAACCTGGCTGCCGTCATGGTCGGGGACAAGACCTTCGAGGAGCTGTCGGGGATC
CACGACCCCAAGCTGCACCACCCGGCGCAGGGCTTCCGCTTCGGCACCGTGTGGGAGAGC
AGCGCCGAGGCGTACATCAAGAAGAGCTTCCCCGACATGCACGCACACATGCGGCGCCAC
AGCGCGCCCACCACGCCCCGCGGCGTCGCCATGCTCACGAGCGACCCCCCCAAGCTCAAC
GCCTTCATCATGGACAAGTCGCTCCTGGACTACGAGGTCTCCATCGACGCCGACTGCAAA
CTGCTGACCGTGGGAAAGCCCTTCGCCATTGAGGGCTATGGGATCGGACTGCCCCAGAAC
TCGCCGCTCACCTCCAACCTGTCCGAGTTCATCAGCCGCTACAAGTCCTCCGGCTTCATC
GACCTGCTCCACGACAAGTGGTACAAGATGGTGCCTTGCGGCAAGCGGGTCTTTGCGGTT
ACAGAGACCCTGCAGATGAGCATCTACCACTTCGCGGGCCTCTTCGTGTTGCTGTGCCTG
GGCCTGGGCAGCGCTCTGCTCAGCTCGCTGGGCGAGCACGCCTTCTTCCGCCTGGCGCTG
CCGCGCATCCGCAAGGGGAGCAGGCTGCAGTACTGGCTGCACACCAGCCAGAAAATCCAC
CGCGCCCTCAACACGGAGCCACCAGAGGGGTCGAAGGAGGAGACGGCAGAGGCGGAGCCC
AGCGGCCCCGAGGTGGAGCAGCAGCAGCAGCAGCAGGACCAGCCAACGGCTCCGGAGGGC
TGGAAACGGGCGCGCCGGGCCGTGGACAAGGAGCGCCGCGTGCGCTTCCTGCTGGAGCCC
GCCGTGGTTGTGGCACCCGAAGCGGACGCGGAGGCGGAGGCTGCGCCGCGAGAGGGCCCC
GTCTGGCTGTGCTCCTACGGCCGCCCGCCCGCCGCAAGGCCCACGGGGGCCCCCCAGCCC
GGGGAGCTGCAGGAGCTGGAGCGCCGCATCGAAGTCGCGCGTGAGCGGCTCCGCCAGGCC
CTGGTGCGGCGCGGCCAGCTCCTGGCACAGCTCGGGGACAGCGCACGTCACCGGCCTCGG
CGCTTGCTTCAGGCCAGAGCGGCCCCCGCGGAGGCCCCACCACACTCTGGCCGACCGGGG
AGCCAGGAATGA

# Drug_Target_13_General_Function:
Involved in ionotropic glutamate receptor activity

# Drug_Target_13_General_References:
11717388	Nishi M, Hinds H, Lu HP, Kawata M, Hayashi Y: Motoneuron-specific expression of NR3B, a novel NMDA-type glutamate receptor subunit that works in a dominant-negative manner. J Neurosci. 2001 Dec 1;21(23):RC185.
11735224	Andersson O, Stenqvist A, Attersand A, von Euler G: Nucleotide sequence, genomic organization, and chromosomal localization of genes encoding the human NMDA receptor subunits NR3A and NR3B. Genomics. 2001 Dec;78(3):178-84.

# Drug_Target_13_HGNC_ID:
HGNC:16768

# Drug_Target_13_HPRD_ID:
09444

# Drug_Target_13_ID:
591

# Drug_Target_13_Locus:
19p13.3

# Drug_Target_13_Molecular_Weight:
112993

# Drug_Target_13_Name:
Glutamate [NMDA] receptor subunit 3B

# Drug_Target_13_Number_of_Residues:
1043

# Drug_Target_13_PDB_ID:
Not Available

# Drug_Target_13_Pathway:
Not Available

# Drug_Target_13_Pfam_Domain_Function:
PF00060	Lig_chan

# Drug_Target_13_Protein_Sequence:
>Glutamate [NMDA] receptor subunit 3B precursor
MEFVRALWLGLALALGPGSAGGHPQPCGVLARLGGSVRLGALLPRAPLARARARAALARA
ALAPRLPHNLSLELVVAAPPARDPASLTRGLCQALVPPGVAALLAFPEARPELLQLHFLA
AATETPVLSLLRREARAPLGAPNPFHLQLHWASPLETLLDVLVAVLQAHAWEDVGLALCR
TQDPGGLVALWTSRAGRPPQLVLDLSRRDTGDAGLRARLAPMAAPVGGEAPVPAAVLLGC
DIARARRVLEAVPPGPHWLLGTPLPPKALPTAGLPPGLLALGEVARPPLEAAIHDIVQLV
ARALGSAAQVQPKRALLPAPVNCGDLQPAGPESPGRFLARFLANTSFQGRTGPVWVTGSS
QVHMSRHFKVWSLRRDPRGAPAWATVGSWRDGQLDLEPGGASARPPPPQGAQVWPKLRVV
TLLEHPFVFARDPDEDGQCPAGQLCLDPGTNDSATLDALFAALANGSAPRALRKCCYGYC
IDLLERLAEDTPFDFELYLVGDGKYGALRDGRWTGLVGDLLAGRAHMAVTSFSINSARSQ
VVDFTSPFFSTSLGIMVRARDTASPIGAFMWPLHWSTWLGVFAALHLTALFLTVYEWRSP
YGLTPRGRNRSTVFSYSSALNLCYAILFRRTVSSKTPKCPTGRLLMNLWAIFCLLVLSSY
TANLAAVMVGDKTFEELSGIHDPKLHHPAQGFRFGTVWESSAEAYIKKSFPDMHAHMRRH
SAPTTPRGVAMLTSDPPKLNAFIMDKSLLDYEVSIDADCKLLTVGKPFAIEGYGIGLPQN
SPLTSNLSEFISRYKSSGFIDLLHDKWYKMVPCGKRVFAVTETLQMSIYHFAGLFVLLCL
GLGSALLSSLGEHAFFRLALPRIRKGSRLQYWLHTSQKIHRALNTEPPEGSKEETAEAEP
SGPEVEQQQQQQDQPTAPEGWKRARRAVDKERRVRFLLEPAVVVAPEADAEAEAAPREGP
VWLCSYGRPPAARPTGAPQPGELQELERRIEVARERLRQALVRRGQLLAQLGDSARHRPR
RLLQARAAPAEAPPHSGRPGSQE

# Drug_Target_13_Reaction:
Not Available

# Drug_Target_13_Signals:
1-22

# Drug_Target_13_Specific_Function:
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine

# Drug_Target_13_SwissProt_ID:
O60391

# Drug_Target_13_SwissProt_Name:
NMD3B_HUMAN

# Drug_Target_13_Synonyms:
Glutamate receptor subunit 3B precursor
N-methyl-D-aspartate receptor subtype NR3B
NMDAR3B
NR3B

# Drug_Target_13_Theoretical_pI:
9.50

# Drug_Target_13_Transmembrane_Regions:
565-585
649-669
831-851

# Drug_Target_14_Cellular_Location:
Mitochondrion

# Drug_Target_14_Chromosome_Location:
Not Available

# Drug_Target_14_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_14_Essentiality:
Non-Essential

# Drug_Target_14_GenAtlas_ID:
PET112L

# Drug_Target_14_GenBank_ID_Gene:
AF026851

# Drug_Target_14_GenBank_ID_Protein:
3599964

# Drug_Target_14_GeneCard_ID:
PET112L

# Drug_Target_14_Gene_Name:
PET112L

# Drug_Target_14_Gene_Sequence:
>1674 bp
ATGGCGGCGCCCATGCTGCGCTGGGGCTGCCGTGGAAGACGTTGGGCTTTCGCCCGGGTT
GACGGTGGTTCTTGCCACCGAAGAGGGGCTCCGACTGGGTCCACATCCAACCAGATTAGG
GGAGAGAGCTCAGTGGCTCAGCAGCCCCTCCACACGGCCCAGAAGACGAGGAAAGGTGAA
CACAAATGGGCTGCTGTGGTAGGTTTGGAAATTCATGCCCAGATTTCCTCCAACTCTAAA
CTCTTCTCTGGATCTCAAGTTCGCTTTTCAGCACCTCCAAATTCTTTGGTTTCTTTTTTT
GATGCATCTCTACCTGGAACTTTGCCGGTTCTCAACAGGAGGTGTGTAGAAGCGGCGGTG
ATGACAGGCCTGGCTCTGAACTGCCACATAAACAAGAAGTCCTTGTTTGACAGGAAGCAC
TACTTCTATGCAGACCTCCCTGCAGGCTACCAAATTACCCAGCAGAGGCTCCCAATTGCT
GTGAATGGGAGCTTGATATATGGCGTCTGTGCAGGGAAGAAGCAGAGTCAGGTGATCCCC
AAGACGGTGAGGATCAAGCAGATCCAGTTGGAGCAAGACAGTGGCAAAAGCCTCCACGAC
AACCTGAGGTCTCAGACGCTCATTGATTTGAACAGGGCAGGAGTGGGCCTTCTGGAGGTG
GTCCTGGAGCCCGACATGTCCTGTGGAGAAGAGGCGGCAACAGCTGTCAGGGAGCTGCAG
CTGATCCTTCAAGCCCTGGGGACCAGCCAGGCGAACATGGCAGAGGGCCAGTTGAGAGTG
GATGCCAATATATCCGTGCATCACCCTGGGGAGCCTTTGGGCGTTCGAACGGAAGTGAAG
AATCTCAACAGCATCAGGTTCCTGGCCAAAGCCATAGACTATGAAATTCAGAGGCAAATC
AATGAACTTGAGAATGGAGGTGAAATTCTGAACGAAACACGCTCATTTCATCACAAGCTG
GGGTGCACCATGTCAATGAGAGACAAAGAAGGAAAACAGGACTACAGGTTCATGCCAGAA
CCCAACCTGCCTCCCCTGGTGCTCTACGACGCCACATCTCTGCCCGCAGGTGCAGACCCA
CAGCAAGTGATCAATATTGACCAGATTCGGGAGACACTCCCGGAGCTCCCCAGTGTGACC
CGAGAGAAGCTTGTCCAACAGTATGGGATGCTGCTGGAACACAGCTTCACTTTGCTGAAC
GAAGTCGGCCTACTGGAGTTCTTCCAAAATGTGATAAAAGAAACTAGGGCAGAGCCAAAA
AAGGTGACTAGTTGGGTCCTCAACACTTTTCTGGGCTATTTAAAGCAACAGAACCTCGCT
GTCAGTGAGAGTCCTGTCACACCCTCTGCACTCGCTGAGCTTCTTGACCTGCTGGACAGC
AGAACAATTTCTTCATCAGCAGCTAAACAGGTGTTTGAGGAACTGTGGAAGAGGGAAGGC
AAGACTCCAGGGCAGATTGTTTCAGAAAAGCAGCTTGAACTGATGCAGGACCAGGGGGCA
CTGGAGCAGCTCTGCCACTCTGTGATGGAGGCCCATCCTCAAGTGGTAATGGATGTGAAG
AACAGAAACCCCAGAGCTATAAATAAACTGATTGGGTTGGTCCGGAAAGCGACTCAAAGC
CGAGCAGATCCAGTCATGATAAAGGAGATCCTGGAGAAGAAGCTGTCATTGTGA

# Drug_Target_14_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_14_General_References:
11042152	Zhang QH, Ye M, Wu XY, Ren SX, Zhao M, Zhao CJ, Fu G, Shen Y, Fan HY, Lu G, Zhong M, Xu XR, Han ZG, Zhang JW, Tao J, Huang QH, Zhou J, Hu GX, Gu J, Chen SJ, Chen Z: Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells. Genome Res. 2000 Oct;10(10):1546-60.
12665801	Gevaert K, Goethals M, Martens L, Van Damme J, Staes A, Thomas GR, Vandekerckhove J: Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003 May;21(5):566-9. Epub 2003 Mar 31.
9878253	Petruzzella V, Tiranti V, Fernandez P, Ianna P, Carrozzo R, Zeviani M: Identification and characterization of human cDNAs specific to BCS1, PET112, SCO1, COX15, and COX11, five genes involved in the formation and function of the mitochondrial respiratory chain. Genomics. 1998 Dec 15;54(3):494-504.

# Drug_Target_14_HGNC_ID:
HGNC:8849

# Drug_Target_14_HPRD_ID:
Not Available

# Drug_Target_14_ID:
3984

# Drug_Target_14_Locus:
4q27-q28

# Drug_Target_14_Molecular_Weight:
61865

# Drug_Target_14_Name:
Probable glutamyl-tRNA(Gln) amidotransferase subunit B, mitochondrial

# Drug_Target_14_Number_of_Residues:
557

# Drug_Target_14_PDB_ID:
Not Available

# Drug_Target_14_Pathway:
Not Available

# Drug_Target_14_Pfam_Domain_Function:
PF01162	GatB
PF02637	GatB_Yqey
PF02934	GatB_N

# Drug_Target_14_Protein_Sequence:
>Probable glutamyl-tRNA(Gln) amidotransferase subunit B, mitochondrial
MAAPMLRWGCRGRRWAFARVDGGSCHRRGAPTGSTSNQIRGESSVAQQPLHTAQKTRKGE
HKWAAVVGLEIHAQISSNSKLFSGSQVRFSAPPNSLVSFFDASLPGTLPVLNRRCVEAAV
MTGLALNCHINKKSLFDRKHYFYADLPAGYQITQQRLPIAVNGSLIYGVCAGKKQSQVIP
KTVRIKQIQLEQDSGKSLHDNLRSQTLIDLNRAGVGLLEVVLEPDMSCGEEAATAVRELQ
LILQALGTSQANMAEGQLRVDANISVHHPGEPLGVRTEVKNLNSIRFLAKAIDYEIQRQI
NELENGGEILNETRSFHHKLGCTMSMRDKEGKQDYRFMPEPNLPPLVLYDATSLPAGADP
QQVINIDQIRETLPELPSVTREKLVQQYGMLLEHSFTLLNEVGLLEFFQNVIKETRAEPK
KVTSWVLNTFLGYLKQQNLAVSESPVTPSALAELLDLLDSRTISSSAAKQVFEELWKREG
KTPGQIVSEKQLELMQDQGALEQLCHSVMEAHPQVVMDVKNRNPRAINKLIGLVRKATQS
RADPVMIKEILEKKLSL

# Drug_Target_14_Reaction:
Not Available

# Drug_Target_14_Signals:
None

# Drug_Target_14_Specific_Function:
Furnishes a means for formation of correctly charged Gln-tRNA(Gln) through the transamidation of misacylated Glu- tRNA(Gln) in the mitochondria. The reaction takes place in the presence of glutamine and ATP through an activated gamma-phospho- Glu-tRNA(Gln) (Potential)

# Drug_Target_14_SwissProt_ID:
O75879

# Drug_Target_14_SwissProt_Name:
GATB_HUMAN

# Drug_Target_14_Synonyms:
Cytochrome oxidase assembly factor PET112 homolog
EC 6.3.5.-
Gln
Glu-ADT subunit B
Probable glutamyl-tRNA(Gln) amidotransferase subunit B, mitochondrial precursor

# Drug_Target_14_Theoretical_pI:
8.86

# Drug_Target_14_Transmembrane_Regions:
None

# Drug_Target_15_Cellular_Location:
Cytoplasmic

# Drug_Target_15_Chromosome_Location:
Not Available

# Drug_Target_15_Drug_References:
16720907	Shi F, Xu Z, Cen P: Efficient production of poly-gamma-glutamic acid by Bacillus subtilis ZJU-7. Appl Biochem Biotechnol. 2006 Jun;133(3):271-82.
16815871	Yang XX, Hu ZP, Xu AL, Duan W, Zhu YZ, Huang M, Sheu FS, Zhang Q, Bian JS, Chan E, Li X, Wang JC, Zhou SF: A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor. J Pharmacol Exp Ther. 2006 Oct;319(1):82-104. Epub 2006 Jun 30.
16824605	Karmaker S, Saha TK, Yoshikawa Y, Yasui H, Sakurai H: A novel drug delivery system for type 1 diabetes: insulin-mimetic vanadyl-poly(gamma-glutamic acid) complex. J Inorg Biochem. 2006 Sep;100(9):1535-46. Epub 2006 May 24.
16861819	Ashiuchi M, Shimanouchi K, Horiuchi T, Kamei T, Misono H: Genetically engineered poly-gamma-glutamate producer from Bacillus subtilis ISW1214. Biosci Biotechnol Biochem. 2006 Jul;70(7):1794-7.
16952838	Ashiuchi M, Nakamura H, Yamamoto M, Misono H: Novel poly-gamma-glutamate-processing enzyme catalyzing gamma-glutamyl DD-amidohydrolysis. J Biosci Bioeng. 2006 Jul;102(1):60-5.

# Drug_Target_15_Essentiality:
Non-Essential

# Drug_Target_15_GenAtlas_ID:
GLS

# Drug_Target_15_GenBank_ID_Gene:
AF158555

# Drug_Target_15_GenBank_ID_Protein:
5690372

# Drug_Target_15_GeneCard_ID:
GLS

# Drug_Target_15_Gene_Name:
GLS

# Drug_Target_15_Gene_Sequence:
>2010 bp
ATGATGCGGCTGCGAGGCTCGGGGATGCTGCGGGACCTGCTCCTGCGGTCGCCCGCCGGC
GTGAGCGCGACTCTGCGGCGGGCACAGCCCTTGGTCACCCTGTGCCGGCGTCCCCGAGGC
GGGGGACGGCCGGCCGCGGGCCCGGCTGCCGCCGCGCGACTCCACCCGTGGTGGGGCGGG
GGCGGCTGGCCGGCGGAGCCCCTCGCGCGGGGCCTGTCCAGCTCTCCTTCGGAGATCTTG
CAGGAGCTGGGCAAGGGGAGCACGCATCCGCAGCCCGGGGTGTCGCCACCCGCTGCCCCG
GCGGCGCCCGGCCCCAAGGACGGCCCCGGGGAGACGGACGCGTTTGGCAACAGCGAGGGC
AAAGAGCTGGTGGCCTCAGGTGAAAATAAAATAAAACAGGGTCTGTTACCTAGCTTGGAA
GATTTGCTGTTCTATACAATTGCTGAAGGACAAGAGAAAATACCTGTTCATAAATTTATT
ACAGCACTCAAATCTACAGGATTGCGAACGTCTGATCCCAGGTTGAAAGAGTGTATGGAT
ATGTTAAGATTAACTCTTCAAACAACATCAGATGGTGTCATGCTAGACAAAGATCTTTTT
AAAAAATGTGTTCAGAGCAACATTGTTTTGTTGACACAAGCATTTAGAAGAAAGTTTGTG
ATTCCTGACTTTATGTCTTTTACCTCACACATTGATGAGTTATATGAAAGTGCTAAAAAG
CAGTCTGGAGGAAAGGTTGCAGATTATATTCCTCAACTGGCCAAATTCAGTCCCGATTTG
TGGGGTGTGTCTGTTTGTACAGTAGATGGACAGAGGCATTCTACTGGAGATACCAAAGTT
CCCTTCTGTCTTCAGTCCTGTGTAAAACCTTTGAAATATGCCATTGCTGTTAATGATCTT
GGAACTGAATATGTGCATCGATATGTTGGAAAAGAGCCGAGTGGACTAAGATTCAACAAA
CTATTTTTGAATGAAGATGATAAACCACATAATCCTATGGTAAATGCTGGAGCAATTGTT
GTGACTTCACTAATAAAGCAAGGAGTAAATAATGCTGAAAAATTTGACTATGTCATGCAG
TTTTTGAATAAGATGGCTGGTAATGAATATGTTGGATTCAGTAATGCAACGTTTCAGTCT
GAAAGAGAAAGTGGAGATCGAAATTTTGCAATAGGATATTACTTAAAAGAAAAGAAGTGT
TTTCCAGAAGGCACAGACATGGTTGGTATATTAGACTTCTACTTCCAGCTGTGCTCCATT
GAAGTGACTTGTGAATCAGCCAGTGTGATGGCTGCGACACTGGCTAATGGTGGTTTCTGC
CCAATTACTGGTGAAAGAGTACTGAGCCCTGAAGCAGTTCGAAATACATTGAGTTTGATG
CATTCCTGTGGCATGTATGACTTCTCAGGGCAGTTTGCTTTCCATGTTGGTCTTCCTGCA
AAATCTGGAGTTGCTGGGGGCATTCTTTTAGTTGTCCCCAATGTTATGGGTATGATGTGC
TGGTCTCCTCCTCTGGATAAGATGGGCAACAGTGTTAAGGGAATTCACTTTTGTCACGAT
CTTGTTTCTCTGTGTAATTTCCATAACTATGATAATTTGAGACACTTTGCAAAAAAACTT
GATCCTCGAAGAGAAGGTGGTGATCAAAGGGTAAAGTCAGTGATAAATCTTTTGTTTGCT
GCATATACTGGAGATGTGTCTGCACTTCGAAGATTTGCTTTGTCAGCTATGGACATGGAA
CAGCGGGACTATGATTCTAGAACAGCACTCCATGTAGCTGCTGCAGAGGGTCATGTTGAA
GTTGTTAAATTTTTGCTGGAAGCCTGCAAAGTAAACCCTTTCCCCAAGGACAGGTGGAAT
AACACTCCCATGGATGAAGCACTGCACTTTGGACACCATGATGTATTTAAAATTCTCCAA
GAATACCAAGTCCAGTACACACCTCAAGGAGATTCTGACAACGGGAAGGAAAATCAAACC
GTCCATAAGAATCTTGATGGATTGTTGTAA

# Drug_Target_15_General_Function:
Amino acid transport and metabolism

# Drug_Target_15_General_References:
10048485	Nagase T, Ishikawa K, Suyama M, Kikuno R, Hirosawa M, Miyajima N, Tanaka A, Kotani H, Nomura N, Ohara O: Prediction of the coding sequences of unidentified human genes. XII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. DNA Res. 1998 Dec 31;5(6):355-64.
10719215	Holcomb T, Taylor L, Trohkimoinen J, Curthoys NP: Isolation, characterization and expression of a human brain mitochondrial glutaminase cDNA. Brain Res Mol Brain Res. 2000 Mar 10;76(1):56-63.
11015561	Elgadi KM, Meguid RA, Qian M, Souba WW, Abcouwer SF: Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing. Physiol Genomics. 1999 Aug 31;1(2):51-62.

# Drug_Target_15_HGNC_ID:
HGNC:4331

# Drug_Target_15_HPRD_ID:
00700

# Drug_Target_15_ID:
917

# Drug_Target_15_Locus:
2q32-q34

# Drug_Target_15_Molecular_Weight:
73462

# Drug_Target_15_Name:
Glutaminase kidney isoform, mitochondrial

# Drug_Target_15_Number_of_Residues:
669

# Drug_Target_15_PDB_ID:
Not Available

# Drug_Target_15_Pathway:
Not Available

# Drug_Target_15_Pfam_Domain_Function:
PF00023	Ank
PF04960	Glutaminase

# Drug_Target_15_Protein_Sequence:
>Glutaminase kidney isoform, mitochondrial precursor
MMRLRGSGMLRDLLLRSPAGVSATLRRAQPLVTLCRRPRGGGRPAAGPAAAARLHPWWGG
GGWPAEPLARGLSSSPSEILQELGKGSTHPQPGVSPPAAPAAPGPKDGPGETDAFGNSEG
KELVASGENKIKQGLLPSLEDLLFYTIAEGQEKIPVHKFITALKSTGLRTSDPRLKECMD
MLRLTLQTTSDGVMLDKDLFKKCVQSNIVLLTQAFRRKFVIPDFMSFTSHIDELYESAKK
QSGGKVADYIPQLAKFSPDLWGVSVCTVDGQRHSTGDTKVPFCLQSCVKPLKYAIAVNDL
GTEYVHRYVGKEPSGLRFNKLFLNEDDKPHNPMVNAGAIVVTSLIKQGVNNAEKFDYVMQ
FLNKMAGNEYVGFSNATFQSERESGDRNFAIGYYLKEKKCFPEGTDMVGILDFYFQLCSI
EVTCESASVMAATLANGGFCPITGERVLSPEAVRNTLSLMHSCGMYDFSGQFAFHVGLPA
KSGVAGGILLVVPNVMGMMCWSPPLDKMGNSVKGIHFCHDLVSLCNFHNYDNLRHFAKKL
DPRREGGDQRVKSVINLLFAAYTGDVSALRRFALSAMDMEQRDYDSRTALHVAAAEGHVE
VVKFLLEACKVNPFPKDRWNNTPMDEALHFGHHDVFKILQEYQVQYTPQGDSDNGKENQT
VHKNLDGLL

# Drug_Target_15_Reaction:
L-glutamine + H2O = L-glutamate + NH3

# Drug_Target_15_Signals:
None

# Drug_Target_15_Specific_Function:
Catalyzes the first reaction in the primary pathway for the renal catabolism of glutamine

# Drug_Target_15_SwissProt_ID:
O94925

# Drug_Target_15_SwissProt_Name:
GLSK_HUMAN

# Drug_Target_15_Synonyms:
EC 3.5.1.2
GLS
Glutaminase kidney isoform, mitochondrial precursor
K-glutaminase
L-glutamine amidohydrolase

# Drug_Target_15_Theoretical_pI:
7.82

# Drug_Target_15_Transmembrane_Regions:
None

# Drug_Target_16_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_16_Chromosome_Location:
Not Available

# Drug_Target_16_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
261660	Recasens M, Mandel P: Similarities between cysteinesulphinate transaminase and aspartate aminotransferase. Ciba Found Symp. 1979;(72):259-70.

# Drug_Target_16_Essentiality:
Non-Essential

# Drug_Target_16_GenAtlas_ID:
GOT2

# Drug_Target_16_GenBank_ID_Gene:
M22632

# Drug_Target_16_GenBank_ID_Protein:
179104

# Drug_Target_16_GeneCard_ID:
GOT2

# Drug_Target_16_Gene_Name:
GOT2

# Drug_Target_16_Gene_Sequence:
>1293 bp
ATGGCCCTGCTGCACTCCGGCCGCGTCCTCCCCGGGATCGCCGCCGCCTTCCACCCGGGC
CTCGCCGCCGCGGCCTCTGCCAGAGCCAGCTCCTGGTGGACCCATGTGGAAATGGGACCT
CCAGATCCCATTCTGGGAGTCACTGAAGCCTTTAAGAGGGACACCAATAGCAAAAAGATG
AATCTGGGAGTTGGTGCCTACCGGGATGATAATGGAAAGCCTTACGTTCTGCCTAGCGTC
CGCAAGGCAGAGGCCCAGATTGCCGCAAAAAATTTGGACAAGGAATACCTGCCCATTGGG
GGACTGGCTGAATTTTGCAAGGCATCTGCAGAACTAGCCCTGGGTGAGAACAGCGAAGTC
TTGAAGAGTGGCCGGTTTGTCACTGTGCAGACCATTTCTGGAACTGGAGCCTTAAGGATC
GGAGCCAGTTTTCTGCAAAGATTTTTTAAGTTCAGCCGAGATGTCTTTCTGCCCAAACCA
ACCTGGGGAAACCACACACCCATCTTCAGGGATGCTGGCATGCAGCTACAAGGTTATCGG
TATTATGACCCCAAGACTTGCGGTTTTGACTTCACAGGCGCTGTGGAGGATATTTCAAAA
ATACCAGAGCAGAGTGTTCTTCTTCTGCATGCCTGCGCCCACAATCCCACGGGAGTGGAC
CCGCGTCCGGAACAGTGGAAGGAAATAGCAACAGTGGTGAAGAAAAGGAATCTCTTTGCG
TTCTTTGACATGGCCTACCAAGGCTTTGCCAGTGGTGATGGTGATAAGGATGCCTGGGCT
GTGCGCCACTTCATCGAACAGGGCATTAATGTTTGCCTCTGCCAATCATATGCCAAGAAC
ATGGGCTTATATGGTGAGCGTGTAGGAGCCTTCACTATGGTCTGCAAAGATGCGGATGAA
GCCAAAAGGGTAGAGTCACAGTTGAAGATCTTGATCCGTCCCATGTATTCCAACCCTCCC
CTCAATGGGGCCCGGATTGCTGCTGCCATTCTGAACACCCCAGATTTGCGAAAACAATGG
CTGCAAGAAGTGAAAGGCATGGCTGACCGCATCATTGGCATGCGGACTCAACTGGTCTCC
AACCTCAAGAAGGAGGGTTCCACCCACAATTGGCAACACATCACCGACCAAATTGGCATG
TTCTGTTTCACAGGGCTAAAGCCTGAACAGGTGGAGCGGCTGATCAAGGAGTTCTCCATC
TACATGACAAAAGATGGCCGCATCTCTGTGGCAGGGGTCACCTCCAGCAACGTGGGCTAC
CTTGCCCATGCCATTCACCAGGTCACCAAGTAA

# Drug_Target_16_General_Function:
Amino acid transport and metabolism

# Drug_Target_16_General_References:
3207426	Pol S, Bousquet-Lemercier B, Pave-Preux M, Pawlak A, Nalpas B, Berthelot P, Hanoune J, Barouki R: Nucleotide sequence and tissue distribution of the human mitochondrial aspartate aminotransferase mRNA. Biochem Biophys Res Commun. 1988 Dec 30;157(3):1309-15.
4052435	Martini F, Angelaccio S, Barra D, Pascarella S, Maras B, Doonan S, Bossa F: The primary structure of mitochondrial aspartate aminotransferase from human heart. Biochim Biophys Acta. 1985 Nov 8;832(1):46-51.

# Drug_Target_16_HGNC_ID:
HGNC:4433

# Drug_Target_16_HPRD_ID:
00684

# Drug_Target_16_ID:
426

# Drug_Target_16_Locus:
16q21

# Drug_Target_16_Molecular_Weight:
47476

# Drug_Target_16_Name:
Aspartate aminotransferase, mitochondrial

# Drug_Target_16_Number_of_Residues:
430

# Drug_Target_16_PDB_ID:
Not Available

# Drug_Target_16_Pathway:
Not Available

# Drug_Target_16_Pfam_Domain_Function:
PF00155	Aminotran_1_2

# Drug_Target_16_Protein_Sequence:
>Aspartate aminotransferase, mitochondrial precursor
MALLHSGRVLPGIAAAFHPGLAAAASARASSWWTHVEMGPPDPILGVTEAFKRDTNSKKM
NLGVGAYRDDNGKPYVLPSVRKAEAQIAAKNLDKEYLPIGGLAEFCKASAELALGENSEV
LKSGRFVTVQTISGTGALRIGASFLQRFFKFSRDVFLPKPTWGNHTPIFRDAGMQLQGYR
YYDPKTCGFDFTGAVEDISKIPEQSVLLLHACAHNPTGVDPRPEQWKEIATVVKKRNLFA
FFDMAYQGFASGDGDKDAWAVRHFIEQGINVCLCQSYAKNMGLYGERVGAFTMVCKDADE
AKRVESQLKILIRPMYSNPPLNGARIAAAILNTPDLRKQWLQEVKGMADRIIGMRTQLVS
NLKKEGSTHNWQHITDQIGMFCFTGLKPEQVERLIKEFSIYMTKDGRISVAGVTSSNVGY
LAHAIHQVTK

# Drug_Target_16_Reaction:
L-aspartate + 2-oxoglutarate = oxaloacetate + L-glutamate

# Drug_Target_16_Signals:
None

# Drug_Target_16_Specific_Function:
Not Available

# Drug_Target_16_SwissProt_ID:
P00505

# Drug_Target_16_SwissProt_Name:
AATM_HUMAN

# Drug_Target_16_Synonyms:
Aspartate aminotransferase, mitochondrial precursor
EC 2.6.1.1
Glutamate oxaloacetate transaminase 2
Transaminase A

# Drug_Target_16_Theoretical_pI:
9.38

# Drug_Target_16_Transmembrane_Regions:
None

# Drug_Target_17_Cellular_Location:
Not Available

# Drug_Target_17_Chromosome_Location:
Not Available

# Drug_Target_17_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
8132637	Ting SM, Dignam JD: Post-transcriptional regulation of glutamyl-prolyl-tRNA synthetase in rat salivary gland. J Biol Chem. 1994 Mar 25;269(12):8993-8.
9063462	Cerini C, Semeriva M, Gratecos D: Evolution of the aminoacyl-tRNA synthetase family and the organization of the Drosophila glutamyl-prolyl-tRNA synthetase gene. Intron/exon structure of the gene, control of expression of the two mRNAs, selective advantage of the multienzyme complex. Eur J Biochem. 1997 Feb 15;244(1):176-85.

# Drug_Target_17_Essentiality:
Non-Essential

# Drug_Target_17_GenAtlas_ID:
EPRS

# Drug_Target_17_GenBank_ID_Gene:
X54326

# Drug_Target_17_GenBank_ID_Protein:
31958

# Drug_Target_17_GeneCard_ID:
EPRS

# Drug_Target_17_Gene_Name:
EPRS

# Drug_Target_17_Gene_Sequence:
>4323 bp
ATGGAACATACTGAGATTGATCACTGGTTGGAGTTCAGTGCTACAAAATTATCTTCATGT
GATTCCTTTACTTCTACAATTAATGAACTCAATCATTGCCTGTCTCTGAGAACATACTTA
GTTGGAAACTCCTTGAGTTTAGCAGATTTATGTGTTTGGGCCACCCTAAAAGGAAATGCT
GCCTGGCAAGAACAGTTGAAACAGAAGAAAGCTCCAGTTCATGTAAAACGTTGGTTTGGC
TTTCTTGAAGCCCAGCAGGCCTTCCAGTCAGTAGGTACCAAGTGGGATGTTTCAACAACC
AAAGCTCGAGTGGCACCTGAGAAAAAGCAAGATGTTGGGAAATTTGTTGAGCTTCCAGGT
GCGGAGATGGGAAAGGTTACCGTCAGATTTCCTCCAGAGGCCAGTGGTTACTTACACATT
GGGCATGCAAAAGCTGCTCTTCTGAACCAGCACTACCAGGTTAACTTTAAAGGGAAACTG
ATCATGAGATTTGATGACACAAATCCTGAAAAAGAAAAGGAAGATTTTGAGAAGGTTATC
TTGGAAGATGTTGCAATGTTGCATATCAAACCAGATCAATTTACTTATACTTCGGATCAT
TTTGAAACTATAATGAAGTATGCAGAGAAGCTAATTCAAGAAGGGAAGGCTTATGTGGAT
GATACTCCTGCTGAACAGATGAAAGCAGAACGTGAGCAGAGGATAGAATCTAAACATAGA
AAAAACCCTATTGAGAAGAATCTACAAATGTGGGAAGAAATGAAAAAAGGGAGCCAGTTT
GGTCACTCCTGTTGTTTGCGAGCAAAAATTGACATGAGTAGTAACAATGGATGCATGAGA
GATCCAACCCTTTATCGCTGCAAAATTCAACCACATCCAAGAACTGGAAATAAATACAAT
GTTTATCCAACATATGATTTTGCCTGCCCCATAGTTGACAGCATCGAAGGTGTTACACAT
GCCCTGAGAACAACAGAATACCATGACAGAGATGAGCAGTTTTACTGGATTATTGAAGCT
TTAGGCATAAGAAAACCATATATTTGGGAATATAGTCGGCTAAATCTCAACAACACAGTG
CTATCCAAAAGAAAACTCACATGGTTTGTCAATGAAGGACTAGTAGATGGATGGGATGAC
CCAAGATTTCCTACGGTTCGTGGTGTACTGAGAAGAGGGATGACAGTTGAAGGACTGAAA
CAGTTTATTGCTGCTCAGGGCTCCTCACGTTCAGTCGTGAACATGGAGTGGGACAAAATC
TGGGCGTTTAACAAAAAGGTTATTGACCCAGTGGCTCCACGATATGTTGCATTACTGAAG
AAAGAAGTGATCCCAGTGAATGTACCTGAAGCTCAGGAGGAGATGAAAGAAGTAGCCAAA
CACCCAAAGAATCCTGAGGTTGGCTTGAAGCCTGTGTGGTATAGTCCCAAAGTTTTCATT
GAAGGTGCTGATGCAGAGACTTTTTCGGAGGGTGAGATGGTTACATTTATAAATTGGGGC
AACCTCAACATTACAAAAATACACAAAAATGCAGATGGAAAAATCATATCTCTTGATGCA
AAGTTTAATTTGGAAAACAAAGACTACAAGAAAACCACTAAGGTCACTTGGCTTGCAGAG
ACTACACATGCTCTTCCTATTCCAGTAATCTGTGTCACTTATGAGCACTTGATCACAAAG
CCAGTGCTAGGAAAAGACGAGGACTTTAAGCAGTATGTCAACAAGAACAGTAAGCATGAA
GAGCTAATGCTAGGGGATCCCTGCCTTAAGGATTTGAAAAAAGGAGATATTATACAACTC
CAGAGAAGAGGATTCTTCATATGTGATCAACCTTATGAACCTGTTAGCCCATATAGTTGC
AAGGAAGCCCCGTGTGTTTTGATATACATTCCTGATGGGCACACAAAGGAAATGCCAACA
TCAGGGTCAAAGGAAAAGACCAAAGTAGAAGCCACAAAAAATGAGACCTCTGCTCCTTTT
AAGGAAAGACCAACACCTTCTCTGAATAATAATTGTACTACATCTGAGGATTCCTTGGTC
CTTTACAATAGAGTGGCTGTTCAAGGAGATGTGGTTCGTGAATTAAAAGCCAAGAAAGCA
CCAAAGGAAGATGTAGATGCAGCTGTAAAACAGCTTTTGTCTTTGAAAGCTGAATATAAG
GAGAAAACTGGCCAGGAATATAAACCTGGAAACCCTCCTGCTGAAATAGGACAGAATATT
TCTTCTAATTCCTCAGCAAGTATTCTGGAAAGTAAATCTCTGTATGATGAAGTTGCTGCA
CAAGGGGAGGTGGTTCGTAAGCTAAAAGCTGAAAAATCCCCTAAGGCTAAAATAAATGAA
GCTGTAGAATGCTTACTGTCCCTGAAGGCTCAGTATAAAGAAAAAACTGGGAAGGAGTAC
ATACCTGGTCAGCCCCCATTATCTCAAAGTTCGGATTCAAGCCCAACCAGAAATTCTGAA
CCTGCTGGTTTAGAAACACCAGAAGCGAAAGTACTTTTTGACAAAGTAGCTTCTCAAGGG
GAAGTAGTTCGGAAACTTAAAACTGAAAAAGCCCCTAAGGATCAAGTAGATATAGCTGTT
CAAGAACTCCTTCAGCTAAAGGCACAGTACAAGTCTTTGATAGGAGTAGAGTATAAGCCT
GTGTCGGCCACTGGAGCTGAGGACAAAGATAAGAAGAAGAAAGAAAAAGAAAATAAATCT
GAAAAGCAGAATAAGCCTCAGAAACAAAATGATGGCCAAAGGAAAGACCCTTCTAAAAAC
CAAGGAGGTGGGCTCTCATCAAGTGGAGCAGGAGAAGGGCAGGGGCCTAAGAAACAGACC
AGGTTGGGTCTTGAGGCAAAAAAAGAAGAAAATCTTGCTGATTGGTATTCTCAGGTCATC
ACAAAGTCAGAAATGATTGAATACCATGACATAAGTGGCTGTTATATTCTTCGTCCCTGG
GCCTATGCCATTTGGGAAGCCATCAAGGACTTTTTTGATGCTGAGATCAAGAAACTTGGT
GTTGAAAACTGCTACTTCCCCATGTTTGTGTCTCAAAGTGCATTAGAGAAAGAGAAGACT
CATGTTGCTGACTTTGCCCCAGAGGTTGCTTGGGTTACAAGATCTGGCAAAACCGAGCTG
GCAGAACCAATTGCCATTCGTCCTACTAGTGAAACAGTAATGTATCCTGCATATGCAAAA
TGGGTACAATCACACAGAGACCTGCCCATCAAGCTCAATCAGTGGTGCAATGTGGTGCGT
TGGGAATTCAAGCATCCTCAGCCTTTCCTACGTACTCGTGAATTTCTTTGGCAGGAAGGG
CACAGTGCTTTTGCTACCATGGAAGAGGCAGCGGAAGAGGTCTTGCAGATACTTGACTTA
TATGCTCAGGTATATGAAGAACTCCTGGCAATTCCTGTTGTTAAAGGAAGAAAGACGGAA
AAGGAAAAATTTGCAGGAGGAGACTATACAACTACAATAGAAGCATTTATATCTGCTAGT
GGAAGAGCTATCCAGGGAGGAACATCACATCATTTAGGGCAGAATTTTTCCAAAATGTTT
GAAATCGTTTTTGAAGATCCAAAGATACCAGGAGAGAAGCAATTTGCCTATCAAAACTCC
TGGGGCCTGACAACTCGAACTATTGGTGTTATGACCATGGTTCATGGGGACAACATGGGT
TTAGTATTACCACCCCGTGTAGCATGTGTTCAGGTGGTGATTATTCCTTGTGGCATTACC
AATGCACTTTCTGAAGAAGACAAAGAAGCGCTGATTGCAAAATGCAATGATTATCGAAGG
CGATTACTCAGTGTTAACATCCGCGTTAGAGCTGATTTACGAGATAATTATTCTCCAGGT
TGGAAATTCAATCACTGGGAGCTCAAGGGAGTTCCCATTAGACTTGAAGTTGGGCCACGT
GATATGAAGAGCTGTCAGTTTGTAGCCGTCAGACGAGATACTGGAGAAAAGCTGACAGTT
GCTGAAAATGAGGCAGAGACTAAACTTCAAGCTATTTTGGAAGACATCCAGGTCACCCTT
TTCACAAGGGCTTCTGAAGACCTTAAGACTCATATGGTTGTGGCTAATACAATGGAAGAC
TTTCAGAAGATACTAGATTCTGGAAAGATTGTTCAGATTCCATTCTGTGGGGAAATTGAC
TGTGAGGACTGGATCAAAAAGACCACTGCCAGGGATCAAGATCTTGAACCTGGTGCTCCA
TCCATGGGAGCTAAAAGCCTTTGCATCCCCTTCAAACCACTCTGTGAACTGCAGCCTGGA
GCCAAATGTGTCTGTGGCAAGAACCCTGCCAAGTACTACACCTTATTTGGTCGCAGCTAC
TGA

# Drug_Target_17_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_17_General_References:
11123902	Jeong EJ, Hwang GS, Kim KH, Kim MJ, Kim S, Kim KS: Structural analysis of multifunctional peptide motifs in human bifunctional tRNA synthetase: identification of RNA-binding residues and functional implications for tandem repeats. Biochemistry. 2000 Dec 26;39(51):15775-82.
1556743	Kaiser E, Eberhard D, Knippers R: Exons encoding the highly conserved part of human glutaminyl-tRNA synthetase. J Mol Evol. 1992 Jan;34(1):45-53.
1756734	Cerini C, Kerjan P, Astier M, Gratecos D, Mirande M, Semeriva M: A component of the multisynthetase complex is a multifunctional aminoacyl-tRNA synthetase. EMBO J. 1991 Dec;10(13):4267-77.
1988429	Fett R, Knippers R: The primary structure of human glutaminyl-tRNA synthetase. A highly conserved core, amino acid repeat regions, and homologies with translation elongation factors. J Biol Chem. 1991 Jan 25;266(3):1448-55.
3290852	Thommes P, Fett R, Schray B, Kunze N, Knippers R: The core region of human glutaminyl-tRNA synthetase homologies with the Escherichia coli and yeast enzymes. Nucleic Acids Res. 1988 Jun 24;16(12):5391-406.

# Drug_Target_17_HGNC_ID:
HGNC:3418

# Drug_Target_17_HPRD_ID:
00703

# Drug_Target_17_ID:
210

# Drug_Target_17_Locus:
1q41-q42

# Drug_Target_17_Molecular_Weight:
163028

# Drug_Target_17_Name:
Bifunctional aminoacyl-tRNA synthetase [Includes: Glutamyl-tRNA synthetase

# Drug_Target_17_Number_of_Residues:
1440

# Drug_Target_17_PDB_ID:
Not Available

# Drug_Target_17_Pathway:
Not Available

# Drug_Target_17_Pfam_Domain_Function:
PF00458	WHEP-TRS
PF00587	tRNA-synt_2b
PF00749	tRNA-synt_1c
PF03129	HGTP_anticodon
PF03950	tRNA-synt_1c_C

# Drug_Target_17_Protein_Sequence:
>Bifunctional aminoacyl-tRNA synthetase [Includes: Glutamyl-tRNA synthetase
MEHTEIDHWLEFSATKLSSCDSFTSTINELNHCLSLRTYLVGNSLSLADLCVWATLKGNA
AWQEQLKQKKAPVHVKRWFGFLEAQQAFQSVGTKWDVSTTKARVAPEKKQDVGKFVELPG
AEMGKVTVRFPPEASGYLHIGHAKAALLNQHYQVNFKGKLIMRFDDTNPEKEKEDFEKVI
LEDVAMLHIKPDQFTYTSDHFETIMKYAEKLIQEGKAYVDDTPAEQMKAEREQRIESKHR
KNPIEKNLQMWEEMKKGSQFGHSCCLRAKIDMSSNNGCMRDPTLYRCKIQPHPRTGNKYN
VYPTYDFACPIVDSIEGVTHALRTTEYHDRDEQFYWIIEALGIRKPYIWEYSRLNLNNTV
LSKRKLTWFVNEGLVDGWDDPRFPTVRGVLRRGMTVEGLKQFIAAQGSSRSVVNMEWDKI
WAFNKKVIDPVAPRYVALLKKEVIPVNVPEAQEEMKEVAKHPKNPEVGLKPVWYSPKVFI
EGADAETFSEGEMVTFINWGNLNITKIHKNADGKIISLDAKFNLENKDYKKTTKVTWLAE
TTHALPIPVICVTYEHLITKPVLGKDEDFKQYVNKNSKHEELMLGDPCLKDLKKGDIIQL
QRRGFFICDQPYEPVSPYSCKEAPCVLIYIPDGHTKEMPTSGSKEKTKVEATKNETSAPF
KERPTPSLNNNCTTSEDSLVLYNRVAVQGDVVRELKAKKAPKEDVDAAVKQLLSLKAEYK
EKTGQEYKPGNPPAEIGQNISSNSSASILESKSLYDEVAAQGEVVRKLKAEKSPKAKINE
AVECLLSLKAQYKEKTGKEYIPGQPPLSQSSDSSPTRNSEPAGLETPEAKVLFDKVASQG
EVVRKLKTEKAPKDQVDIAVQELLQLKAQYKSLIGVEYKPVSATGAEDKDKKKKEKENKS
EKQNKPQKQNDGQRKDPSKNQGGGLSSSGAGEGQGPKKQTRLGLEAKKEENLADWYSQVI
TKSEMIEYHDISGCYILRPWAYAIWEAIKDFFDAEIKKLGVENCYFPMFVSQSALEKEKT
HVADFAPEVAWVTRSGKTELAEPIAIRPTSETVMYPAYAKWVQSHRDLPIKLNQWCNVVR
WEFKHPQPFLRTREFLWQEGHSAFATMEEAAEEVLQILDLYAQVYEELLAIPVVKGRKTE
KEKFAGGDYTTTIEAFISASGRAIQGGTSHHLGQNFSKMFEIVFEDPKIPGEKQFAYQNS
WGLTTRTIGVMTMVHGDNMGLVLPPRVACVQVVIIPCGITNALSEEDKEALIAKCNDYRR
RLLSVNIRVRADLRDNYSPGWKFNHWELKGVPIRLEVGPRDMKSCQFVAVRRDTGEKLTV
AENEAETKLQAILEDIQVTLFTRASEDLKTHMVVANTMEDFQKILDSGKIVQIPFCGEID
CEDWIKKTTARDQDLEPGAPSMGAKSLCIPFKPLCELQPGAKCVCGKNPAKYYTLFGRSY

# Drug_Target_17_Reaction:
ATP + L-proline + tRNAPro = AMP + diphosphate + L-prolyl-tRNAPro

# Drug_Target_17_Signals:
None

# Drug_Target_17_Specific_Function:
Not Available

# Drug_Target_17_SwissProt_ID:
P07814

# Drug_Target_17_SwissProt_Name:
SYEP_HUMAN

# Drug_Target_17_Synonyms:
EC 6.1.1.15
EC 6.1.1.17
Glutamate--tRNA ligase
Prolyl-tRNA synthetase

# Drug_Target_17_Theoretical_pI:
7.75

# Drug_Target_17_Transmembrane_Regions:
None

# Drug_Target_18_Cellular_Location:
Not Available

# Drug_Target_18_Chromosome_Location:
Not Available

# Drug_Target_18_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_18_Essentiality:
Non-Essential

# Drug_Target_18_GenAtlas_ID:
ASNS

# Drug_Target_18_GenBank_ID_Gene:
M27396

# Drug_Target_18_GenBank_ID_Protein:
179100

# Drug_Target_18_GeneCard_ID:
ASNS

# Drug_Target_18_Gene_Name:
ASNS

# Drug_Target_18_Gene_Sequence:
>1686 bp
ATGTGTGGCATTTGGGCGCTGTTTGGCAGTGATGATTGCCTTTCTGTTCAGTGTCTGAGT
GCTATGAAGATTGCACACAGAGGTCCAGATGCATTCCGTTTTGAGAATGTCAATGGATAC
ACCAACTGCTGCTTTGGATTTCACCGGTTGGCGGTAGTTGACCCGCTGTTTGGAATGCAG
CCAATTCGAGTGAAGAAATATCCGTATTTGTGGCTCTGTTACAATGGTGAAATCTACAAC
CATAAGAAGATGCAACAGCATTTTGAATTTGAATACCAGACCAAAGTGGATGGTGAGATA
ATCCTTCATCTTTATGACAAAGGAGGAATTGAGCAAACAATTTGTATGTTGGATGGTGTG
TTTGCATTTGTTTTACTGGATACTGCCAATAAGAAAGTGTTCCTGGGTAGAGATACATAT
GGAGTCAGACCTTTGTTTAAAGCAATGACAGAAGATGGATTTTTGGCTGTATGTTCAGAA
GCTAAAGGTCTTGTTACATTGAAGCACTCCGCGACTCCCTTTTTAAAAGTGGAGCCTTTT
CTTCCTGGACACTATGAAGTTTTGGATTTAAAGCCAAATGGCAAAGTTGCATCCGTGGAA
ATGGTTAAATATCATCACTGTCGGGATGTACCCCTGCACGCCCTCTATGACAATGTGGAG
AAACTCTTTCCAGGTTTTGAGATAGAAACTGTGAAGAACAACCTCAGGATCCTTTTTAAT
AATGCTGTAAAGAAACGTTTGATGACAGACAGAAGGATTGGCTGCCTTTTATCAGGGGGC
TTGGACTCCAGCTTGGTTGCTGCCACTCTGTTGAAGCAGCTGAAAGAAGCCCAAGTACAG
TATCCTCTCCAGACATTTGCAATTGGCATGGAAGACAGCCCCGATTTACTGGCTGCTAGA
AAGGTGGCAGATCATATTGGAAGTGAACATTATGAAGTCCTTTTTAACTCTGAGGAAGGC
ATTCAGGCTCTGGATGAAGTCATATTTTCCTTGGAAACTTATGACATTACAACAGTTCGT
GCTTCAGTAGGTATGTATTTAATTTCCAAGTATATTCGGAAGAACACAGATAGCGTGGTG
ATCTTCTCTGGAGAAGGATCAGATGAACTTACGCAGGGTTACATATATTTTCACAAGGCT
CCTTCTCCTGAAAAAGCCGAGGAGGAGAGTGAGAGGCTTCTGAGGGAACTCTATTTGTTT
GATGTTCTCCGCGCAGATCGAACTACTGCTGCCCATGGTCTTGAACTGAGAGTCCCATTT
CTAGATCATCGATTTTTTTCCTATTACTTGTCTCTGCCACCAGAAATGAGAATTCCAAAG
AATGGGATAGAAAAACATCTCCTGAGAGAGACGTTTGAGGATTCCAATCTGATACCCAAA
GAGATTCTCTGGCGACCAAAAGAAGCCTTCAGTGATGGAATAACTTCAGTTAAGAATTCC
TGGTTTAAGATTTTACAGGAATACGTTGAACATCAGGTTGATGATGCAATGATGGCAAAT
GCAGCCCAGAAATTTCCCTTCAATACTCCTAAAACCAAAGAAGGATATTACTACCGTCAA
GTCTTTGAACGCCATTACCCAGGCCGGGCTGACTGGCTGAGCCATTACTGGATGCCCAAG
TGGATCAATGCCACTGACCCTTCTGCCCGCACGCTGACCCACTACAAGTCAGCTGTCAAA
GCTTAG

# Drug_Target_18_General_Function:
Amino acid transport and metabolism

# Drug_Target_18_General_References:
12853948	Hillier LW, Fulton RS, Fulton LA, Graves TA, Pepin KH, Wagner-McPherson C, Layman D, Maas J, Jaeger S, Walker R, Wylie K, Sekhon M, Becker MC, O'Laughlin MD, Schaller ME, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Cordes M, Du H, Sun H, Edwards J, Bradshaw-Cordum H, Ali J, Andrews S, Isak A, Vanbrunt A, Nguyen C, Du F, Lamar B, Courtney L, Kalicki J, Ozersky P, Bielicki L, Scott K, Holmes A, Harkins R, Harris A, Strong CM, Hou S, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Leonard S, Rohlfing T, Rock SM, Tin-Wollam AM, Abbott A, Minx P, Maupin R, Strowmatt C, Latreille P, Miller N, Johnson D, Murray J, Woessner JP, Wendl MC, Yang SP, Schultz BR, Wallis JW, Spieth J, Bieri TA, Nelson JO, Berkowicz N, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Bedell JA, Mardis ER, Clifton SW, Chissoe SL, Marra MA, Raymond C, Haugen E, Gillett W, Zhou Y, James R, Phelps K, Iadanoto S, Bubb K, Simms E, Levy R, Clendenning J, Kaul R, Kent WJ, Furey TS, Baertsch RA, Brent MR, Keibler E, Flicek P, Bork P, Suyama M, Bailey JA, Portnoy ME, Torrents D, Chinwalla AT, Gish WR, Eddy SR, McPherson JD, Olson MV, Eichler EE, Green ED, Waterston RH, Wilson RK: The DNA sequence of human chromosome 7. Nature. 2003 Jul 10;424(6945):157-64.
2564390	Van Heeke G, Schuster SM: Expression of human asparagine synthetase in Escherichia coli. J Biol Chem. 1989 Apr 5;264(10):5503-9.
2565875	Zhang YP, Lambert MA, Cairney AE, Wills D, Ray PN, Andrulis IL: Molecular structure of the human asparagine synthetase gene. Genomics. 1989 Apr;4(3):259-65.
2569668	Greco A, Gong SS, Ittmann M, Basilico C: Organization and expression of the cell cycle gene, ts11, that encodes asparagine synthetase. Mol Cell Biol. 1989 Jun;9(6):2350-9.
2573597	Van Heeke G, Schuster SM: The N-terminal cysteine of human asparagine synthetase is essential for glutamine-dependent activity. J Biol Chem. 1989 Nov 25;264(33):19475-7.
2886907	Andrulis IL, Chen J, Ray PN: Isolation of human cDNAs for asparagine synthetase and expression in Jensen rat sarcoma cells. Mol Cell Biol. 1987 Jul;7(7):2435-43.
3470743	Greco A, Ittmann M, Basilico C: Molecular cloning of a gene that is necessary for G1 progression in mammalian cells. Proc Natl Acad Sci U S A. 1987 Mar;84(6):1565-9.

# Drug_Target_18_HGNC_ID:
HGNC:753

# Drug_Target_18_HPRD_ID:
00153

# Drug_Target_18_ID:
242

# Drug_Target_18_Locus:
7q21.3

# Drug_Target_18_Molecular_Weight:
64239

# Drug_Target_18_Name:
Asparagine synthetase [glutamine-hydrolyzing]

# Drug_Target_18_Number_of_Residues:
560

# Drug_Target_18_PDB_ID:
Not Available

# Drug_Target_18_Pathway:
Not Available

# Drug_Target_18_Pfam_Domain_Function:
PF00310	GATase_2
PF00733	Asn_synthase

# Drug_Target_18_Protein_Sequence:
>Asparagine synthetase [glutamine-hydrolyzing]
CGIWALFGSDDCLSVQCLSAMKIAHRGPDAFRFENVNGYTNCCFGFHRLAVVDPLFGMQP
IRVKKYPYLWLCYNGEIYNHKKMQQHFEFEYQTKVDGEIILHLYDKGGIEQTICMLDGVF
AFVLLDTANKKVFLGRDTYGVRPLFKAMTEDGFLAVCSEAKGLVTLKHSATPFLKVEPFL
PGHYEVLDLKPNGKVASVEMVKYHHCRDVPLHALYDNVEKLFPGFEIETVKNNLRILFNN
AVKKRLMTDRRIGCLLSGGLDSSLVAATLLKQLKEAQVQYPLQTFAIGMEDSPDLLAARK
VADHIGSEHYEVLFNSEEGIQALDEVIFSLETYDITTVRASVGMYLISKYIRKNTDSVVI
FSGEGSDELTQGYIYFHKAPSPEKAEEESERLLRELYLFDVLRADRTTAAHGLELRVPFL
DHRFSSYYLSLPPEMRIPKNGIEKHLLRETFEDSNLIPKEILWRPKEAFSDGITSVKNSW
FKILQEYVEHQVDDAMMANAAQKFPFNTPKTKEGYYYRQVFERHYPGRADWLSHYWMPKW
INATDPSARTLTHYKSAVKA

# Drug_Target_18_Reaction:
(1) ATP + L-aspartate + L-glutamine + H2O = AMP + diphosphate + L-asparagine + L-glutamate

# Drug_Target_18_Signals:
None

# Drug_Target_18_Specific_Function:
Not Available

# Drug_Target_18_SwissProt_ID:
P08243

# Drug_Target_18_SwissProt_Name:
ASNS_HUMAN

# Drug_Target_18_Synonyms:
Cell cycle control protein TS11
EC 6.3.5.4
Glutamine- dependent asparagine synthetase

# Drug_Target_18_Theoretical_pI:
6.85

# Drug_Target_18_Transmembrane_Regions:
None

# Drug_Target_19_Cellular_Location:
Cytoplasm

# Drug_Target_19_Chromosome_Location:
Not Available

# Drug_Target_19_Drug_References:
16673373	Re DB, Nafia I, Melon C, Shimamoto K, Kerkerian-Le Goff L, Had-Aissouni L: Glutamate leakage from a compartmentalized intracellular metabolic pool and activation of the lipoxygenase pathway mediate oxidative astrocyte death by reversed glutamate transport. Glia. 2006 Jul;54(1):47-57.
16876704	Scaraffia PY, Zhang Q, Wysocki VH, Isoe J, Wells MA: Analysis of whole body ammonia metabolism in Aedes aegypti using [15N]-labeled compounds and mass spectrometry. Insect Biochem Mol Biol. 2006 Aug;36(8):614-22. Epub 2006 May 19.
16973920	Singh U, Sarkar D: Development of a simple high-throughput screening protocol based on biosynthetic activity of Mycobacterium tuberculosis glutamine synthetase for the identification of novel Inhibitors. J Biomol Screen. 2006 Dec;11(8):1035-42. Epub 2006 Sep 14.
17284842	Yamamoto S, Wakayama M, Tachiki T: Characterization of theanine-forming enzyme from Methylovorus mays no. 9 in respect to utilization of theanine production. Biosci Biotechnol Biochem. 2007 Feb;71(2):545-52. Epub 2007 Feb 7.

# Drug_Target_19_Essentiality:
Non-Essential

# Drug_Target_19_GenAtlas_ID:
GLUL

# Drug_Target_19_GenBank_ID_Gene:
Y00387

# Drug_Target_19_GenBank_ID_Protein:
31833

# Drug_Target_19_GeneCard_ID:
GLUL

# Drug_Target_19_Gene_Name:
GLUL

# Drug_Target_19_Gene_Sequence:
>1122 bp
ATGACCACCTCAGCAAGTTCCCACTTAAATAAAGGCATCAAGCAGGTGTACATGTCCCTG
CCTCAGGGTGAGAAAGTCCAGGCCATGTATATCTGGATCGATGGTACTGGAGAAGGACTG
CGCTGCAAGACCCGGACCCTGGACAGTGAGCCCAAGTGTGTGGAAGAGTTGCCTGAGTGG
AATTTCGATGGCTCCAGTACTTTACAGTCTGAGGGTTCCAACAGTGACATGTATCTCGTG
CCTGCTGCCATGTTTCGGGACCCCTTCCGTAAGGACCCTAACAAGCTGGTGTTATGTGAA
GTTTTCAAGTACAATCGAAGGCCTGCAGAGACCAATTTGAGGCACACCTGTAAACGGATA
ATGGACATGGTGAGCAACCAGCACCCCTGGTTTGGCATGGAGCAGGAGTATACCCTCATG
GGGACAGATGGGCACCCCTTTGGTTGGCCTTCCAACGGCTTCCCAGGGCCCCAGGGTCCA
TATTACTGTGGTGTGGGAGCAGACAGAGCCTATGGCAGGGACATCGTGGAGGCCCATTAC
CGGGCCTGCTTGTATGCTGGAGTCAAGATTGCGGGGACTAATGCCGAGGTCATGCCTGCC
CAGTGGGAATTTCAGATTGGACCTTGTGAAGGAATCAGCATGGGAGATCATCTCTGGGTG
GCCCGTTTCATCTTGCATCGTGTGTGTGAAGACTTTGGAGTGATAGCAACCTTTGATCCT
AAGCCCATTCCTGGGAACTGGAATGGTGCAGGCTGCCATACCAACTTCAGCACCAAGGCC
ATGCGGGAGGAGAATGGTCTGAAGTACATCGAGGAGGCCATTGAGAAACTAAGCAAGCGG
CACCAGTACCACATCCGTGCCTATGATCCCAAGGGAGGCCTGGACAATGCCCGACGTCTA
ACTGGATTCCATGAAACCTCCAACATCAACGACTTTTCTGGTGGTGTAGCCAATCGTAGC
GCCAGCATACGCATTCCCCGGACTGTTGGCCAGGAGAAGAAGGGTTACTTTGAAGATCGT
CGCCCCTCTGCCAACTGCGACCCCTTTTCGGTGACAGAAGCCCTCATCCGCACGTGTCTT
CTCAATGAAACCGGCGATGAGCCCTTCCAGTACAAAAATTAA

# Drug_Target_19_General_Function:
Amino acid transport and metabolism

# Drug_Target_19_General_References:
12387715	Boksha IS, Schonfeld HJ, Langen H, Muller F, Tereshkina EB, Burbaeva GSh: Glutamine synthetase isolated from human brain: octameric structure and homology of partial primary structure with human liver glutamine synthetase. Biochemistry (Mosc). 2002 Sep;67(9):1012-20.
1681907	Van den Hoff MJ, Geerts WJ, Das AT, Moorman AF, Lamers WH: cDNA sequence of the long mRNA for human glutamine synthase. Biochim Biophys Acta. 1991 Oct 8;1090(2):249-51.
2888076	Gibbs CS, Campbell KE, Wilson RH: Sequence of a human glutamine synthetase cDNA. Nucleic Acids Res. 1987 Aug 11;15(15):6293.
7909780	Christa L, Simon MT, Flinois JP, Gebhardt R, Brechot C, Lasserre C: Overexpression of glutamine synthetase in human primary liver cancer. Gastroenterology. 1994 May;106(5):1312-20.

# Drug_Target_19_HGNC_ID:
HGNC:4341

# Drug_Target_19_HPRD_ID:
00701

# Drug_Target_19_ID:
3987

# Drug_Target_19_Locus:
1q31

# Drug_Target_19_Molecular_Weight:
42065

# Drug_Target_19_Name:
Glutamine synthetase

# Drug_Target_19_Number_of_Residues:
373

# Drug_Target_19_PDB_ID:
Not Available

# Drug_Target_19_Pathway:
Not Available

# Drug_Target_19_Pfam_Domain_Function:
PF00120	Gln-synt_C
PF03951	Gln-synt_N

# Drug_Target_19_Protein_Sequence:
>Glutamine synthetase
MTTSASSHLNKGIKQVYMSLPQGEKVQAMYIWIDGTGEGLRCKTRTLDSEPKCVEELPEW
NFDGSSTLQSEGSNSDMYLVPAAMFRDPFRKDPNKLVLCEVFKYNRRPAETNLRHTCKRI
MDMVSNQHPWFGMEQEYTLMGTDGHPFGWPSNGFPGPQGPYYCGVGADRAYGRDIVEAHY
RACLYAGVKIAGTNAEVMPAQWEFQIGPCEGISMGDHLWVARFILHRVCEDFGVIATFDP
KPIPGNWNGAGCHTNFSTKAMREENGLKYIEEAIEKLSKRHQYHIRAYDPKGGLDNARRL
TGFHETSNINDFSAGVANRSASIRIPRTVGQEKKGYFEDRRPSANCDPFSVTEALIRTCL
LNETGDEPFQYKN

# Drug_Target_19_Reaction:
ATP + L-glutamate + NH3 = ADP + phosphate + L-glutamine

# Drug_Target_19_Signals:
None

# Drug_Target_19_Specific_Function:
ATP + L-glutamate + NH(3) = ADP + phosphate + L-glutamine

# Drug_Target_19_SwissProt_ID:
P15104

# Drug_Target_19_SwissProt_Name:
GLNA_HUMAN

# Drug_Target_19_Synonyms:
EC 6.3.1.2
GS
Glutamate--ammonia ligase

# Drug_Target_19_Theoretical_pI:
6.88

# Drug_Target_19_Transmembrane_Regions:
None

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
16751798	Chiocchetti A, Miglio G, Mesturini R, Varsaldi F, Mocellin M, Orilieri E, Dianzani C, Fantozzi R, Dianzani U, Lombardi G: Group I mGlu receptor stimulation inhibits activation-induced cell death of human T lymphocytes. Br J Pharmacol. 2006 Jul;148(6):760-8. Epub 2006 Jun 5.
17331504	San Gabriel AM, Maekawa T, Uneyama H, Yoshie S, Torii K: mGluR1 in the fundic glands of rat stomach. FEBS Lett. 2007 Mar 20;581(6):1119-23. Epub 2007 Feb 22.
17360958	Suzuki G, Kimura T, Satow A, Kaneko N, Fukuda J, Hikichi H, Sakai N, Maehara S, Kawagoe-Takaki H, Hata M, Azuma T, Ito S, Kawamoto H, Ohta H: Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N- methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC). J Pharmacol Exp Ther. 2007 Jun;321(3):1144-53. Epub 2007 Mar 14.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
GRM1

# Drug_Target_1_GenBank_ID_Gene:
U31215

# Drug_Target_1_GenBank_ID_Protein:
945097

# Drug_Target_1_GeneCard_ID:
GRM1

# Drug_Target_1_Gene_Name:
GRM1

# Drug_Target_1_Gene_Sequence:
>3585 bp
ATGGTCGGGCTCCTTTTGTTTTTTTTCCCAGCGATCTTTTTGGAGGTGTCCCTTCTCCCC
AGAAGCCCCGGCAGGAAAGTGTTGCTGGCAGGAGCGTCGTCTCAGCGCTCGGTGGCCAGA
ATGGACGGAGATGTCATCATTGGAGCCCTCTTCTCAGTCCATCACCAGCCTCCGGCCGAG
AAAGTGCCCGAGAGGAAGTGTGGGGAGATCAGGGAGCAGTATGGCATCCAGAGGGTGGAG
GCCATGTTCCACACGTTGGATAAGATCAACGCGGACCCGGTCCTCCTGCCCAACATCACC
CTGGGCAGTGAGATCCGGGACTCCTGCTGGCACTCTTCCGTGGCTCTGGAACAGAGCATT
GAGTTCATTAGGGACTCTCTGATTTCCATTCGAGATGAGAAGGATGGGATCAACCGGTGT
CTGCCTGACGGCCAGTCCCTCCCCCCAGGCAGGACTAAGAAGCCCATTGCGGGAGTGATC
GGTCCCGGCTCCAGCTCTGTAGCCATTCAAGTGCAGAACCTGCTCCAGCTCTTCGACATC
CCCCAGATCGCTTATTCAGCCACAAGCATCGACCTGAGTGACAAAACTTTGTACAAATAC
TTCCTGAGGGTTGTCCCTTCTGACACTTTGCAGGCAAGGGCCATGCTTGACATAGTCAAA
CGTTACAATTGGACCTATGTCTCTGCAGTCCACACGGAAGGGAATTATGGGGAGAGCGGA
ATGGACGCTTTCAAAGAGCTGGCTGCCCAGGAAGGCCTCTGTATCGCCCATTCTGACAAA
ATCTACAGCAACGCTGGGGAGAAGAGCTTTGACCGACTCTTGCGCAAACTCCGAGAGAGG
CTTCCCAAGGCTAGAGTGGTGGTCTGCTTCTGTGAAGGCATGACAGTGCGAGGACTCCTG
AGCGCCATGCGGCGCCTTGGCGTCGTGGGCGAGTTCTCACTCATTGGAAGTGATGGATGG
GCAGACAGAGATGAAGTCATTGAAGGTTATGAGGTGGAAGCCAACGGGGGAATCACGATA
AAGCTGCAGTCTCCAGAGGTCAGGTCATTTGATGATTATTTCCTGAAACTGAGGCTGGAC
ACTAACACGAGGAATCCCTGGTTCCCTGAGTTCTGGCAACATCGGTTCCAGTGCCGCCTT
CCAGGACACCTTCTGGAAAATCCCAACTTTAAACGAATCTGCACAGGCAATGAAAGCTTA
GAAGAAAACTATGTCCAGGACAGTAAGATGGGGTTTGTCATCAATGCCATCTATGCCATG
GCACATGGGCTGCAGAACATGCACCATGCCCTCTGCCCTGGCCACGTGGGCCTCTGCGAT
GCCATGAAGCCCATCGACGGCAGCAAGCTGCTGGACTTCCTCATCAAGTCCTCATTCATT
GGAGTATCTGGAGAGGAGGTGTGGTTTGATGAGAAAGGAGACGCTCCTGGAAGGTATGAT
ATCATGAATCTGCAGTACACTGAAGCTAATCGCTATGACTATGTGCACGTTGGAACCTGG
CATGAAGGAGTGCTGAACATTGATGATTACAAAATCCAGATGAACAAGAGTGGAGTGGTG
CGGTCTGTGTGCAGTGAGCCTTGCTTAAAGGGCCAGATTAAGGTTATACGGAAAGGAGAA
GTGAGCTGCTGCTGGATTTGCACGGCCTGCAAAGAGAATGAATATGTGCAAGATGAGTTC
ACCTGCAAAGCTTGTGACTTGGGATGGTGGCCCAATGCAGATCTAACAGGCTGTGAGCCC
ATTCCTGTGCGCTATCTTGAGTGGAGCAACATCGAACCCATTATAGCCATCGCCTTTTCA
TGCCTGGGAATCCTTGTTACCTTGTTTGTCACCCTAATCTTTGTACTGTACCGGGACACA
CCAGTGGTCAAATCCTCCAGTCGGGAGCTCTGCTACATCATCCTAGCTGGCATCTTCCTT
GGTTATGTGTGCCCATTCACTCTCATTGCCAAACCTACTACCACCTCCTGCTACCTCCAG
CGCCTCTTGGTTGGCCTCTCCTCTGCGATGTGCTACTCTGCTTTAGTGACTAAAACCAAT
CGTATTGCACGCATCCTGGCTGGCAGCAAGAAGAAGATCTGCACCCGGAAGCCCAGGTTC
ATGAGTGCCTGGGCTCAGGTGATCATTGCCTCAATTCTGATTAGTGTGCAACTAACCCTG
GTGGTAACCCTGATCATCATGGAACCCCCTATGCCCATTCTGTCCTACCCAAGTATCAAG
GAAGTCTACCTTATCTGCAATACCAGCAACCTGGGTGTGGTGGCCCCTTTGGGCTACAAT
GGACTCCTCATCATGAGCTGTACCTACTATGCCTTCAAGACCCGCAACGTGCCCGCCAAC
TTCAACGAGGCCAAATATATCGCGTTCACCATGTACACCACCTGTATCATCTGGCTAGCT
TTTGTGCCCATTTACTTTGGGAGCAACTACAAGATCATCACAACTTGCTTTGCAGTGAGT
CTCAGTGTAACAGTGGCTCTGGGGTGCATGTTCACTCCCAAGATGTACATCATTATTGCC
AAGCCTGAGAGGAATGTCCGCAGTGCCTTCACCACCTCTGATGTTGTCCGCATGCATGTT
GGCGATGGCAAGCTGCCCTGCCGCTCCAACACTTTCCTCAACATCTTCCGAAGAAAGAAG
GCAGGGGCAGGGAATGCCAATTCTAATGGCAAGTCTGTGTCATGGTCTGAACCAGGTGGA
GGACAGGTGCCCAAGGGACAGCATATGTGGCACCGCCTCTCTGTGCACGTGAAGACCAAT
GAGACGGCCTGCAACCAAACAGCCGTCATCAAACCCCTCACTAAAAGTTACCAAGGCTCT
GGCAAGAGCCTGACCTTTTCAGATACCAGCACCAAGACCCTTTACAACGTAGAGGAGGAG
GAGGATGCCCAGCCGATTCGCTTTAGCCCGCCTGGTAGCCCTTCCATGGTGGTGCACAGG
CGCGTGCCAAGCGCGGCGACCACTCCGCCTCTGCCGCCCCACCTGACCGCAGAGGAGACC
CCCCTCTTCCTGGCCGAACCAGCCCTCCCCAAGGGCTTGCCCCCTCCTCTCCAGCAGCAG
CAGCAACCCCCTCCACAGCAGAAATCGCTGATGGACCAGCTCCAGGGAGTGGTCAGCAAC
TTCAGTACCGCGATCCCGGATTTTCACGCGGTGCTGGCAGGCCCCGGGGGTCCCGGGAAC
GGGCTGCGGTCCCTGTACCCGCCCCCGCCACCTCCGCAGCACCTGCAGATGCTGCCGCTG
CAGCTGAGCACCTTTGGGGAGGAGCTGGTCTCCCCGCCCGCGGACGACGACGACGACAGC
GAGAGGTTTAAGCTCCTCCAGGAGTACGTGTATGAGCACGAGCGGGAAGGGAACACCGAA
GAAGACGAACTGGAAGAGGAGGAGGAGGACCTGCAGGCGGCCAGCAAACTGACCCCGGAT
GATTCGCCTGCGCTGACGCCTCCGTCGCCTTTCCGCGACTCGGTGGCCTCGGGCAGCTCG
GTGCCCAGCTCCCCAGTGTCCGAGTCGGTGCTCTGCACCCCTCCCAACGTATCCTACGCC
TCTGTCATTCTGCGGGACTACAAGCAAAGCTCTTCCACCCTGTAA

# Drug_Target_1_General_Function:
Involved in metabotropic glutamate, GABA-B-like receptor activity

# Drug_Target_1_General_References:
10945991	Ray K, Hauschild BC: Cys-140 is critical for metabotropic glutamate receptor-1 dimerization. J Biol Chem. 2000 Nov 3;275(44):34245-51.
14574404	Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE, Gilbert JG, Clamp ME, Bethel G, Milne S, Ainscough R, Almeida JP, Ambrose KD, Andrews TD, Ashwell RI, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beare DM, Beasley H, Beasley O, Bird CP, Blakey S, Bray-Allen S, Brook J, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Clark SY, Clark G, Clee CM, Clegg S, Cobley V, Collier RE, Collins JE, Colman LK, Corby NR, Coville GJ, Culley KM, Dhami P, Davies J, Dunn M, Earthrowl ME, Ellington AE, Evans KA, Faulkner L, Francis MD, Frankish A, Frankland J, French L, Garner P, Garnett J, Ghori MJ, Gilby LM, Gillson CJ, Glithero RJ, Grafham DV, Grant M, Gribble S, Griffiths C, Griffiths M, Hall R, Halls KS, Hammond S, Harley JL, Hart EA, Heath PD, Heathcott R, Holmes SJ, Howden PJ, Howe KL, Howell GR, Huckle E, Humphray SJ, Humphries MD, Hunt AR, Johnson CM, Joy AA, Kay M, Keenan SJ, Kimberley AM, King A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd CR, Lloyd DM, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, Maslen GL, Matthews L, McCann OT, McLaren SJ, McLay K, McMurray A, Moore MJ, Mullikin JC, Niblett D, Nickerson T, Novik KL, Oliver K, Overton-Larty EK, Parker A, Patel R, Pearce AV, Peck AI, Phillimore B, Phillips S, Plumb RW, Porter KM, Ramsey Y, Ranby SA, Rice CM, Ross MT, Searle SM, Sehra HK, Sheridan E, Skuce CD, Smith S, Smith M, Spraggon L, Squares SL, Steward CA, Sycamore N, Tamlyn-Hall G, Tester J, Theaker AJ, Thomas DW, Thorpe A, Tracey A, Tromans A, Tubby B, Wall M, Wallis JM, West AP, White SS, Whitehead SL, Whittaker H, Wild A, Willey DJ, Wilmer TE, Wood JM, Wray PW, Wyatt JC, Young L, Younger RM, Bentley DR, Coulson A, Durbin R, Hubbard T, Sulston JE, Dunham I, Rogers J, Beck S: The DNA sequence and analysis of human chromosome 6. Nature. 2003 Oct 23;425(6960):805-11.
7476890	Desai MA, Burnett JP, Mayne NG, Schoepp DD: Cloning and expression of a human metabotropic glutamate receptor 1 alpha: enhanced coupling on co-transfection with a glutamate transporter. Mol Pharmacol. 1995 Oct;48(4):648-57.
9076744	Stephan D, Bon C, Holzwarth JA, Galvan M, Pruss RM: Human metabotropic glutamate receptor 1: mRNA distribution, chromosome localization and functional expression of two splice variants. Neuropharmacology. 1996;35(12):1649-60.

# Drug_Target_1_HGNC_ID:
HGNC:4593

# Drug_Target_1_HPRD_ID:
05129

# Drug_Target_1_ID:
916

# Drug_Target_1_Locus:
6q24

# Drug_Target_1_Molecular_Weight:
132368

# Drug_Target_1_Name:
Metabotropic glutamate receptor 1

# Drug_Target_1_Number_of_Residues:
1194

# Drug_Target_1_PDB_ID:
1ISS

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00003	7tm_3
PF01094	ANF_receptor
PF07562	NCD3G

# Drug_Target_1_Protein_Sequence:
>Metabotropic glutamate receptor 1 precursor
MVGLLLFFFPAIFLEVSLLPRSPGRKVLLAGASSQRSVARMDGDVIIGALFSVHHQPPAE
KVPERKCGEIREQYGIQRVEAMFHTLDKINADPVLLPNITLGSEIRDSCWHSSVALEQSI
EFIRDSLISIRDEKDGINRCLPDGQSLPPGRTKKPIAGVIGPGSSSVAIQVQNLLQLFDI
PQIAYSATSIDLSDKTLYKYFLRVVPSDTLQARAMLDIVKRYNWTYVSAVHTEGNYGESG
MDAFKELAAQEGLCIAHSDKIYSNAGEKSFDRLLRKLRERLPKARVVVCFCEGMTVRGLL
SAMRRLGVVGEFSLIGSDGWADRDEVIEGYEVEANGGITIKLQSPEVRSFDDYFLKLRLD
TNTRNPWFPEFWQHRFQCRLPGHLLENPNFKRICTGNESLEENYVQDSKMGFVINAIYAM
AHGLQNMHHALCPGHVGLCDAMKPIDGSKLLDFLIKSSFIGVSGEEVWFDEKGDAPGRYD
IMNLQYTEANRYDYVHVGTWHEGVLNIDDYKIQMNKSGVVRSVCSEPCLKGQIKVIRKGE
VSCCWICTACKENEYVQDEFTCKACDLGWWPNADLTGCEPIPVRYLEWSNIESIIAIAFS
CLGILVTLFVTLIFVLYRDTPVVKSSSRELCYIILAGIFLGYVCPFTLIAKPTTTSCYLQ
RLLVGLSSAMCYSALVTKTNRIARILAGSKKKICTRKPRFMSAWAQVIIASILISVQLTL
VVTLIIMEPPMPILSYPSIKEVYLICNTSNLGVVAPLGYNGLLIMSCTYYAFKTRNVPAN
FNEAKYIAFTMYTTCIIWLAFVPIYFGSNYKIITTCFAVSLSVTVALGCMFTPKMYIIIA
KPERNVRSAFTTSDVVRMHVGDGKLPCRSNTFLNIFRRKKAGAGNANSNGKSVSWSEPGG
GQVPKGQHMWHRLSVHVKTNETACNQTAVIKPLTKSYQGSGKSLTFSDTSTKTLYNVEEE
EDAQPIRFSPPGSPSMVVHRRVPSAATTPPLPPHLTAEETPLFLAEPALPKGLPPPLQQQ
QQPPPQQKSLMDQLQGVVSNFSTAIPDFHAVLAGPGGPGNGLRSLYPPPPPPQHLQMLPL
QLSTFGEELVSPPADDDDDSERFKLLQEYVYEHEREGNTEEDELEEEEEDLQAASKLTPD
DSPALTPPSPFRDSVASGSSVPSSPVSESVLCTPPNVSYASVILRDYKQSSSTL

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-18

# Drug_Target_1_Specific_Function:
Receptor for glutamate. The activity of this receptor is mediated by a G-protein that activates a phosphatidylinositol- calcium second messenger system. May participate in the central action of glutamate in the CNS, such as long-term potentiation in the hippocampus and long-term depression in the cerebellum

# Drug_Target_1_SwissProt_ID:
Q13255

# Drug_Target_1_SwissProt_Name:
GRM1_HUMAN

# Drug_Target_1_Synonyms:
Metabotropic glutamate receptor 1 precursor
mGluR1

# Drug_Target_1_Theoretical_pI:
6.67

# Drug_Target_1_Transmembrane_Regions:
593-615
630-650
662-680
707-727
751-772
786-808
815-840

# Drug_Target_20_Cellular_Location:
Cytoplasm

# Drug_Target_20_Chromosome_Location:
Not Available

# Drug_Target_20_Drug_References:
17444813	Yudkoff M, Daikhin Y, Melo TM, Nissim I, Sonnewald U, Nissim I: The Ketogenic Diet and Brain Metabolism of Amino Acids: Relationship to the Anticonvulsant Effect. Annu Rev Nutr. 2007 Aug 21;27:415-430.

# Drug_Target_20_Essentiality:
Non-Essential

# Drug_Target_20_GenAtlas_ID:
GOT1

# Drug_Target_20_GenBank_ID_Gene:
M37400

# Drug_Target_20_GenBank_ID_Protein:
179067

# Drug_Target_20_GeneCard_ID:
GOT1

# Drug_Target_20_Gene_Name:
GOT1

# Drug_Target_20_Gene_Sequence:
>1242 bp
ATGGCACCTCCGTCAGTCTTTGCCGAGGTTCCGCAGGCCCAGCCTGTCCTGGTCTTCAAG
CTCACTGCCGACTTCAGGGAGGATCCGGACCCCCGCAAGGTCAACCTGGGAGTGGGAGCA
TATCGCACGGATGACTGCCATCCCTGGGTTTTGCCAGTAGTGAAGAAAGTGGAGCAGAAG
ATTGCTAATGACAATAGCCTAAATCACGAGTATCTGCCAATCCTGGGCCTGGCTGAGTTC
CGGAGCTGTGCTTCTCGTCTTGCCCTTGGGGATGACAGCCCAGCACTCAAGGAGAAGCGG
GTAGGAGGTGTGCAATCTTTGGGGGGAACAGGTGCACTTCGAATTGGAGCTGATTTCTTA
GCGCGTTGGTACAATGGAACAAACAACAAGAACACACCTGTCTATGTGTCCTCACCAACC
TGGGAGAATCACAATGCTGTGTTTTCCGCTGCTGGTTTTAAAGACATTCGGTCCTATCGC
TACTGGGATGCAGAGAAGAGAGGATTGGACCTCCAGGGCTTCCTGAATGATCTGGAGAAT
GCTCCTGAGTTCTCCATTGTTGTCCTCCACGCCTGTGCACACAACCCAACTGGGATTGAC
CCAACTCCGGAGCAGTGGAAGCAGATTGCTTCTGTCATGAAGCACCGGTTTCTGTTCCCC
TTCTTTGACTCAGCCTATCAGGGCTTCGCATCTGGAAACCTGGAGAGAGATGCCTGGGCC
ATTCGCTATTTTGTGTCTGAAGGCTTCGAGTTCTTCTGTGCCCAGTCCTTCTCCAAGAAC
TTCGGGCTCTACAATGAGAGAGTCGGGAATCTGACTGTGGTTGGAAAAGAACCTGAGAGC
ATCCTGCAAGTCCTTTCCCAGATGGAGAAGATCGTGCGGATTACTTGGTCCAATCCCCCC
GCCCAGGGAGCACGAATTGTGGCCAGCACCCTCTCTAACCCTGAGCTCTTTGAGGAATGG
ACAGGTAATGTGAAGACAATGGCTGACCGGATTCTGACCATGAGATCTGAACTCAGGGCA
CGACTAGAAGCCCTCAAAACCCCTGGGACCTGGAACCACATCACTGATCAAATTGGCATG
TTCAGCTTCACTGGGTTGAACCCCAAGCAGGTTGAGTATCTGGTCAATGAAAAGCACATC
TACCTGCTGCCAAGTGGTCGAATCAACGTGAGTGGCTTAACCACCAAAAATCTAGATTAC
GTGGCCACCTCCATCCATGAAGCAGTCACCAAAATCCAGTGA

# Drug_Target_20_General_Function:
Amino acid transport and metabolism

# Drug_Target_20_General_References:
1974457	Bousquet-Lemercier B, Pol S, Pave-Preux M, Hanoune J, Barouki R: Properties of human liver cytosolic aspartate aminotransferase mRNAs generated by alternative polyadenylation site selection. Biochemistry. 1990 Jun 5;29(22):5293-9.
2241899	Doyle JM, Schinina ME, Bossa F, Doonan S: The amino acid sequence of cytosolic aspartate aminotransferase from human liver. Biochem J. 1990 Sep 15;270(3):651-7.

# Drug_Target_20_HGNC_ID:
HGNC:4432

# Drug_Target_20_HPRD_ID:
00687

# Drug_Target_20_ID:
586

# Drug_Target_20_Locus:
10q24.1-q25.1

# Drug_Target_20_Molecular_Weight:
46117

# Drug_Target_20_Name:
Aspartate aminotransferase, cytoplasmic

# Drug_Target_20_Number_of_Residues:
412

# Drug_Target_20_PDB_ID:
1AJS

# Drug_Target_20_Pathway:
Not Available

# Drug_Target_20_Pfam_Domain_Function:
PF00155	Aminotran_1_2

# Drug_Target_20_Protein_Sequence:
>Aspartate aminotransferase, cytoplasmic
APPSVFAEVPQAQPVLVFKLTADFREDPDPRKVNLGVGAYRTDDCHPWVLPVVKKVEQKI
ANDNSLNHEYLPILGLAEFRSCASRLALGDDSPALKEKRVGGVQSLGGTGALRIGADFLA
RWYNGTNNKNTPVYVSSPTWENHNAVFSAAGFKDIRSYRYWDAEKRGLDLQGFLNDLENA
PEFSIVVLHACAHNPTGIDPTPEQWKQIASVMKHRFLFPFFDSAYQGFASGNLERDAWAI
RYFVSEGFEFFCAQSFSKNFGLYNERVGNLTVVGKEPESILQVLSQMEKIVRITWSNPPA
QGARIVASTLSNPELFEEWTGNVKTMADRILTMRSELRARLEALKTPGTWNHITDQIGMF
SFTGLNPKQVEYLVNEKHIYLLPSGRINVSGLTTKNLDYVATSIHEAVTKIQ

# Drug_Target_20_Reaction:
L-aspartate + 2-oxoglutarate = oxaloacetate + L-glutamate

# Drug_Target_20_Signals:
None

# Drug_Target_20_Specific_Function:
Not Available

# Drug_Target_20_SwissProt_ID:
P17174

# Drug_Target_20_SwissProt_Name:
AATC_HUMAN

# Drug_Target_20_Synonyms:
EC 2.6.1.1
Glutamate oxaloacetate transaminase 1
Transaminase A

# Drug_Target_20_Theoretical_pI:
7.01

# Drug_Target_20_Transmembrane_Regions:
None

# Drug_Target_21_Cellular_Location:
Not Available

# Drug_Target_21_Chromosome_Location:
Not Available

# Drug_Target_21_Drug_References:
16840830	Ozturk M, Chiu CY, Akdeniz N, Jenq SF, Chang SC, Hsa CY, Jap TS: Two novel mutations in the MEN1 gene in subjects with multiple endocrine neoplasia-1. J Endocrinol Invest. 2006 Jun;29(6):523-7.

# Drug_Target_21_Essentiality:
Non-Essential

# Drug_Target_21_GenAtlas_ID:
TAT

# Drug_Target_21_GenBank_ID_Gene:
X52520

# Drug_Target_21_GenBank_ID_Protein:
36713

# Drug_Target_21_GeneCard_ID:
TAT

# Drug_Target_21_Gene_Name:
TAT

# Drug_Target_21_Gene_Sequence:
>1365 bp
ATGGACCCATACATGATTCAGATGAGCAGCAAAGGCAACCTCCCCTCAATTCTGGACGTG
CATGTCAACGTTGGTGGGAGAAGCTCTGTGCCGGGAAAAATGAAAGGCAGAAAGGCCAGG
TGGTCTGTGAGGCCCTCAGACATGGCCAAGAAAACTTTCAACCCCATCCGAGCCATTGTG
GACAACATGAAGGTGAAACCAAATCCAAACAAAACCATGATTTCCCTGTCCATTGGGGAC
CCTACTGTGTTTGGAAACCTGCCTACAGACCCTGAAGTTACCCAGGCAATGAAAGATGCC
CTGGACTCGGGCAAATATAATGGCTATGCCCCATCCATCGGCTTCCTATCCAGTCGGGAG
GAGATTGCTTCTTATTACCACTGTCCTGAGGCACCCCTAGAAGCTAAGGACGTCATTCTG
ACAAGTGGCTGCAGCCAAGCTATTGACCTTTGTTTAGCTGTGTTGGCCAACCCAGGGCAG
AACATCCTGGTTCCAAGACCTGGTTTCTCTCTCTACAAGACTCTGGCTGAGTCTATGGGA
ATTGAGGTCAAACTCTACAATTTGTTGCCAGAGAAATCTTGGGAAATTGACCTGAAACAA
CTGGAATATCTAATTGATGAAAAGACAGCTTGTCTCATTGTCAATAATCCATCAAACCCC
TGTGGGTCAGTGTTCAGCAAACGTCATCTTCAGAAGATTCTGGCAGTGGCTGCACGGCAG
TGTGTCCCCATCTTAGCTGATGAGATCTATGGAGACATGGTGTTTTCGGATTGCAAATAT
GAACCACTGGCCACCCTCAGCACCGATGTCCCCATCCTGTCCTGTGGAGGGCTGGCCAAG
CGCTGGCTGGTTCCTGGCTGGAGGTTGGGCTGGATCCTCATTCATGACCGAAGAGACATT
TTTGGCAATGAGATCCGAGATGGGCTGGTGAAGCTGAGTCAGCGCATTTTGGGACCCTGT
ACCATTGTCCAGGGAGCTCTGAAAAGCATCCTATGTCGCACCCCGGGAGAGTTTTACCAC
AACACTCTGAGCTTCCTCAAGTCCAATGCTGATCTCTGTTATGGGGCGTTGGCTGCCATC
CCTGGACTCCGGCCAGTCCGCCCTTCTGGGGCTATGTACCTCATGGTTGGAATTGAGATG
GAACATTTCCCAGAATTTGAGAACGATGTGGAGTTCACGGAGCGGTTAGTTGCTGAGCAG
TCTGTCCACTGCCTCCCAGCAACGTGCTTTGAGTACCCGAATTTCATCCGAGTGGTCATC
ACAGTCCCCGAGGTGATGATGCTGGAGGCGTGCAGCCGGATCCAGGAGTTCTGTGAGCAG
CACTACCATTGTGCTGAAGGCAGCCAGGAGGAGTGTGATAAATAG

# Drug_Target_21_General_Function:
Amino acid transport and metabolism

# Drug_Target_21_General_References:
1357662	Natt E, Kida K, Odievre M, Di Rocco M, Scherer G: Point mutations in the tyrosine aminotransferase gene in tyrosinemia type II. Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9297-301.
1973834	Rettenmeier R, Natt E, Zentgraf H, Scherer G: Isolation and characterization of the human tyrosine aminotransferase gene. Nucleic Acids Res. 1990 Jul 11;18(13):3853-61.
7908801	Zelenin SM, Mertvetsov NP: [Nucleotide sequence of the human tyrosine aminotransferase gene] Bioorg Khim. 1994 Feb;20(2):196-204.
7999802	Seralini GE, Luu-The V, Labrie F: Cloning and expression of human tyrosine aminotransferase cDNA. Biochim Biophys Acta. 1995 Jan 2;1260(1):97-101.

# Drug_Target_21_HGNC_ID:
HGNC:11573

# Drug_Target_21_HPRD_ID:
11776

# Drug_Target_21_ID:
763

# Drug_Target_21_Locus:
16q22.1

# Drug_Target_21_Molecular_Weight:
50400

# Drug_Target_21_Name:
Tyrosine aminotransferase

# Drug_Target_21_Number_of_Residues:
454

# Drug_Target_21_PDB_ID:
Not Available

# Drug_Target_21_Pathway:
Not Available

# Drug_Target_21_Pfam_Domain_Function:
PF00155	Aminotran_1_2
PF07706	TAT_ubiq

# Drug_Target_21_Protein_Sequence:
>Tyrosine aminotransferase
MDPYMIQMSSKGNLPSILDVHVNVGGRSSVPGKMKGRKARWSVRPSDMAKKTFNPIRAIV
DNMKVKPNPNKTMISLSIGDPTVFGNLPTDPEVTQAMKDALDSGKYNGYAPSIGFLSSRE
EIASYYHCPEAPLEAKDVILTSGCSQAIDLCLAVLANPGQNILVPRPGFSLYKTLAESMG
IEVKLYNLLPEKSWEIDLKQLEYLIDEKTACLIVNNPSNPCGSVFSKRHLQKILAVAARQ
CVPILADEIYGDMVFSDCKYEPLATLSTDVPILSCGGLAKRWLVPGWRLGWILIHDRRDI
FGNEIRDGLVKLSQRILGPCTIVQGALKSILCRTPGEFYHNTLSFLKSNADLCYGALAAI
PGLRPVRPSGAMYLMVGIEMEHFPEFENDVEFTERLVAEQSVHCLPATCFEYPNFIRVVI
TVPEVMMLEACSRIQEFCEQHYHCAEGSQEECDK

# Drug_Target_21_Reaction:
L-tyrosine + 2-oxoglutarate = 4-hydroxyphenylpyruvate + L-glutamate

# Drug_Target_21_Signals:
None

# Drug_Target_21_Specific_Function:
Not Available

# Drug_Target_21_SwissProt_ID:
P17735

# Drug_Target_21_SwissProt_Name:
ATTY_HUMAN

# Drug_Target_21_Synonyms:
EC 2.6.1.5
L-tyrosine:2-oxoglutarate aminotransferase
TAT

# Drug_Target_21_Theoretical_pI:
6.24

# Drug_Target_21_Transmembrane_Regions:
None

# Drug_Target_22_Cellular_Location:
Cytoplasm

# Drug_Target_22_Chromosome_Location:
Not Available

# Drug_Target_22_Drug_References:
16854580	Ohgami N, Upadhyay S, Kabata A, Morimoto K, Kusakabe H, Suzuki H: Determination of the activities of glutamic oxaloacetic transaminase and glutamic pyruvic transaminase in a microfluidic system. Biosens Bioelectron. 2007 Feb 15;22(7):1330-6. Epub 2006 Jul 18.

# Drug_Target_22_Essentiality:
Non-Essential

# Drug_Target_22_GenAtlas_ID:
GPT

# Drug_Target_22_GenBank_ID_Gene:
U70732

# Drug_Target_22_GenBank_ID_Protein:
1763096

# Drug_Target_22_GeneCard_ID:
GPT

# Drug_Target_22_Gene_Name:
GPT

# Drug_Target_22_Gene_Sequence:
>1491 bp
ATGGCCTCGAGCACAGGTGACCGGAGCCAGGCGGTGAGGCATGGACTGAGGGCGAAGGTG
CTGACGCTGGACGGCATGAACCCGCGTGTGCGGAGAGTGGAGTACGCAGTGCGTGGCCCC
ATAGTGCAGCGAGCCTTGGAGCTGGAGCAGGAGCTGCGCCAGGGTGTGAAGAAGCCTTTC
ACCGAGGTCATCCGTGCCAACATCGGGGACGCACAGGCTATGGGGCAGAGGCCCATCACC
TTCCTGCGCCAGGTCTTGGCCCTCTGTGTTAACCCTGATCTTCTGAGCAGCCCCAACTTC
CCTGACGATGCCAAGAAAAGGGCGGAGCGCATCTTGCAGGCGTGTGGGGGCCACAGTCTG
GGGGCCTACAGCGTCAGCTCCGGCATCCAGCTGATCCGGGAGGACGTGGCGCGGTACATT
GAGAGGCGTGACGGAGGCATCCCTGCGGACCCCAACAACGTCTTCCTGTCCACAGGGGCC
AGCGATGCCATCGTGACGGTGCTGAAGCTGCTGGTGGCCGGCGAGGGCCACACACGCACG
GGTGTGCTCATCCCCATCCCCCAGTACCCACTCTACTCGGCCACGCTGGCAGAGCTGGGC
GCAGTGCAGGTGGATTACTACCTGGACGAGGAGCGTGCCTGGGCGCTGGACGTGGCCGAG
CTTCACCGTGCACTGGGCCAGGCGCGTGACCACTGCCGCCCTCGTGCGCTCTGTGTCATC
AACCCTGGCAACCCCACCGGGCAGGTGCAGACCCGCGAGTGCATCGAGGCCGTGATCCGC
TTCGCCTTCGAAGAGCGGCTCTTTCTGCTGGCGGACGAGGTGTACCAGGACAACGTGTAC
GCCGCGGGTTCGCAGTTCCACTCATTCAAGAAGGTGCTCATGGAGATGGGGCCGCCCTAC
GCCGGGCAGCAGGAGCTTGCCTCCTTCCACTCCACCTCCAAGGGCTACATGGGCGAGTGC
GGGTTCCGCGGCGGCTATGTGGAGGTGGTGAACATGGACGCTGCAGTGCAGCAGCAGATG
CTGAAGCTGATGAGTGTGCGGCTGTGCCCGCCGGTGCCAGGACAGGCCCTGCTGGACCTG
GTGGTCAGCCCGCCCGCGCCCACCGACCCCTCCTTTGCGCAGTTCCAGGCTGAGAAGCAG
GCAGTGCTGGCAGAGCTGGCGGCCAAGGCCAAGCTCACCGAGCAGGTCTTCAATGAGGCT
CCTGGCATCAGCTGCAACCCAGTGCAGGGCGCCATGTACTCCTTCCCGCGCGTGCAGCTG
CCCCCGCGGGCGGTGGAGCGCGCTCAGGAGCTGGGCCTGGCCCCCGATATGTTCTTCTGC
CTGCGCCTCCTGGAGGAGACCGGCATCTGCGTGGTGCCAGGGAGCGGCTTTGGGCAGCGG
GAAGGCACCTACCACTTCCGGATGACCATTCTGCCCCCCTTGGAGAAACTGCGGCTGCTG
CTGGAGAAGCTGAGCAGGTTCCATGCCAAGTTCACCCTCGAGTACTCCTGA

# Drug_Target_22_General_Function:
Amino acid transport and metabolism

# Drug_Target_22_General_References:
11863375	Yang RZ, Blaileanu G, Hansen BC, Shuldiner AR, Gong DW: cDNA cloning, genomic structure, chromosomal mapping, and functional expression of a novel human alanine aminotransferase. Genomics. 2002 Mar;79(3):445-50.
1931970	Ishiguro M, Takio K, Suzuki M, Oyama R, Matsuzawa T, Titani K: Complete amino acid sequence of human liver cytosolic alanine aminotransferase (GPT) determined by a combination of conventional and mass spectral methods. Biochemistry. 1991 Oct 29;30(43):10451-7.
9119391	Sohocki MM, Sullivan LS, Harrison WR, Sodergren EJ, Elder FF, Weinstock G, Tanase S, Daiger SP: Human glutamate pyruvate transaminase (GPT): localization to 8q24.3, cDNA and genomic sequences, and polymorphic sites. Genomics. 1997 Mar 1;40(2):247-52.

# Drug_Target_22_HGNC_ID:
HGNC:4552

# Drug_Target_22_HPRD_ID:
00689

# Drug_Target_22_ID:
735

# Drug_Target_22_Locus:
8q24.3

# Drug_Target_22_Molecular_Weight:
54506

# Drug_Target_22_Name:
Alanine aminotransferase 1

# Drug_Target_22_Number_of_Residues:
495

# Drug_Target_22_PDB_ID:
Not Available

# Drug_Target_22_Pathway:
Not Available

# Drug_Target_22_Pfam_Domain_Function:
PF00155	Aminotran_1_2

# Drug_Target_22_Protein_Sequence:
>Alanine aminotransferase 1
ASSTGDRSQAVRHGLRAKVLTLDGMNPRVRRVEYAVRGPIVQRALELEQELRQGVKKPFT
EVIRANIGDAQAMGQRPITFLRQVLALCVNPDLLSSPNFPDDAKKRAERILQACGGHSLG
AYSVSSGIQLIREDVARYIERRDGGIPADPNNVFLSTGASDAIVTVLKLLVAGEGHTRTG
VLIPIPQYPLYSATLAELGAVQVDYYLDEERAWALDVAELHRALGQARDHCRPRALCVIN
PGNPTGQVQTRECIEAVIRFAFEERLFLLADEVYQDNVYAAGSQFHSFKKVLMEMGPPYA
GQQELASFHSTSKGYMGECGFRGGYVEVVNMDAAVQQQMLKLMSVRLCPPVPGQALLDLV
VSPPAPTDPSFAQFQAEKQAVLAELAAKAKLTEQVFNEAPGISCNPVQGAMYSFPRVQLP
PRAVERAQELGLAPDMFFCLRLLEETGICVVPGSGFGQREGTYHFRMTILPPLEKLRLLL
EKLSRFHAKFTLEYS

# Drug_Target_22_Reaction:
L-alanine + 2-oxoglutarate = pyruvate + L-glutamate

# Drug_Target_22_Signals:
None

# Drug_Target_22_Specific_Function:
Participates in cellular nitrogen metabolism and also in liver gluconeogenesis starting with precursors transported from skeletal muscles

# Drug_Target_22_SwissProt_ID:
P24298

# Drug_Target_22_SwissProt_Name:
ALAT1_HUMAN

# Drug_Target_22_Synonyms:
ALT1
EC 2.6.1.2
GPT 1
Glutamic--alanine transaminase 1
Glutamic--pyruvic transaminase 1

# Drug_Target_22_Theoretical_pI:
7.20

# Drug_Target_22_Transmembrane_Regions:
None

# Drug_Target_23_Cellular_Location:
Endoplasmic reticulum
endoplasmic reticulum membrane
multi-pass membrane protein

# Drug_Target_23_Chromosome_Location:
Not Available

# Drug_Target_23_Drug_References:
17112295	Lal S, Jada SR, Xiang X, Lim WT, Lee EJ, Chowbay B: Pharmacogenetics of target genes across the warfarin pharmacological pathway. Clin Pharmacokinet. 2006;45(12):1189-200.
17327402	Zhu A, Sun H, Raymond RM Jr, Furie BC, Furie B, Bronstein M, Kaufman RJ, Westrick R, Ginsburg D: Fatal hemorrhage in mice lacking gamma-glutamyl carboxylase. Blood. 2007 Jun 15;109(12):5270-5. Epub 2007 Feb 27.

# Drug_Target_23_Essentiality:
Non-Essential

# Drug_Target_23_GenAtlas_ID:
GGCX

# Drug_Target_23_GenBank_ID_Gene:
M81592

# Drug_Target_23_GenBank_ID_Protein:
184028

# Drug_Target_23_GeneCard_ID:
GGCX

# Drug_Target_23_Gene_Name:
GGCX

# Drug_Target_23_Gene_Sequence:
>2277 bp
ATGGCGGTGTCTGCCGGGTCCGCGCGGACCTCGCCCAGCTCAGATAAAGTACAGAAAGAC
AAGGCTGAACTGATCTCAGGGCCCAGGCAGGACAGCCGAATAGGGAAACTCTTGGGTTTT
GAGTGGACAGATTTGTCCAGTTGGCGGAGGCTGGTGACCCTGCTGAATCGACCAACGGAC
CCTGCAAGCTTAGCTGTCTTTCGTTTTCTTTTTGGGTTCTTGATGGTGCTAGACATTCCC
CAGGAGCGGGGGCTCAGCTCTCTGGACCGGAAATACCTTGATGGGCTGGATGTGTGCCGC
TTCCCCTTGCTGGATGCCCTACGCCCACTGCCACTTGACTGGATGTATCTTGTCTACACC
ATCATGTTTCTGGGGGCACTGGGCATGATGCTGGGCCTGTGCTACCGGATAAGCTGTGTG
TTATTCCTGCTGCCATACTGGTATGTGTTTCTCCTGGACAAGACATCATGGAACAACCAC
TCCTATCTGTATGGGTTGTTGGCCTTTCAGCTAACATTCATGGATGCAAACCACTACTGG
TCTGTGGACGGTCTGCTGAATGCCCATAGGAGGAATGCCCACGTGCCCCTTTGGAACTAT
GCAGTGCTCCGTGGCCAGATCTTCATTGTGTACTTCATTGCGGGTGTGAAAAAGCTGGAT
GCAGACTGGGTTGAAGGCTATTCCATGGAATATTTGTCCCGGCACTGGCTCTTCAGTCCC
TTCAAACTGCTGTTGTCTGAGGAGCTGACTAGCCTGCTGGTCGTGCACTGGGGTGGGCTG
CTGCTTGACCTCTCAGCTGGTTTCCTGCTCTTTTTTGATGTCTCAAGATCCATTGGCCTG
TTCTTTGTGTCCTACTTCCACTGCATGAATTCCCAGCTTTTCAGCATTGGTATGTTCTCC
TACGTCATGCTGGCCAGCAGCCCTCTCTTCTGCTCCCCTGAGTGGCCTCGGAAGCTGGTG
TCCTACTGCCCCCAAAGGTTGCAACAACTGTTGCCCCTCAAGGCAGCCCCTCAGCCCAGT
GTTTCCTGTGTGTATAAGAGGAGCCGGGGCAAAAGTGGCCAGAAGCCAGGGCTGCGCCAT
CAGCTGGGAGCTGCCTTCACCCTGCTCTACCTCCTGGAGCAGCTATTCCTGCCCTATTCT
CATTTTCTCACCCAGGGCTATAACAACTGGACAAATGGGCTGTATGGCTATTCCTGGGAC
ATGATGGTGCACTCCCGTTCCCACCAGCACGTGAAGATCACCTACCGTGATGGCCGCACT
GGCGAACTGGGCTACCTTAACCCTGGGGTATTTACACAGAGTCGGCGATGGAAGGATCAT
GCAGACATGCTGAAGCAATATGCCACTTGCCTGAGCCGCCTGCTTCCCAAGTATAATGTC
ACTGAGCCCCAGATCTACTTTGATATTTGGGTCTCCATCAATGACCGCTTCCAGCAGAGG
ATTTTTGACCCTCGTGTGGACATCGTGCAGGCCGCTTGGTCACCCTTTCAGCGCACATCC
TGGGTGCAACCACTCTTGATGGACCTGTCTCCCTGGAGGGCCAAGTTACAGGAAATCAAG
AGCAGCCTAGACAACCACACTGAGGTGGTCTTCATTGCAGATTTCCCTGGACTGCACTTG
GAGAATTTTGTGAGTGAAGACCTGGGCAACACTAGCATCCAGCTGCTGCAGGGGGAAGTG
ACTGTGGAGCTTGTGGCAGAACAGAAGAACCAGACTCTTCGAGAGGGAGAAAAAATGCAG
TTGCCTGCTGGTGAGTACCATAAGGTGTATACGACATCACCTAGCCCTTCTTGCTACATG
TACGTCTATGTCAACACTACAGAGCTTGCACTGGAGCAAGACCTGGCATATCTGCAAGAA
TTAAAGGAAAAGGTGGAGAATGGAAGTGAAACAGGGCCTCTACCCCCAGAGCTGCAGCCT
CTGTTGGAAGGGGAAGTAAAAGGGGGCCCTGAGCCAACACCTCTGGTTCAGACCTTTCTT
AGACGCCAACAAAGGCTCCAGGAGATTGAACGCCGGCGAAATACTCCTTTCCATGAGCGA
TTCTTCCGCTTCTTGTTGCGAAAGCTCTATGTCTTTCGCCGCAGCTTCCTGATGACTTGT
ATCTCACTTCGAAATCTGATATTAGGCCGTCCTTCCCTGGAGCAGCTGGCCCAGGAGGTG
ACTTATGCAAACTTGAGACCCTTTGAGGCAGTTGGAGAACTGAATCCCTCAAACACGGAT
TCTTCACATTCTAATCCTCCTGAGTCAAATCCTGATCCTGTCCACTCAGAGTTCTGA

# Drug_Target_23_General_Function:
Involved in gamma-glutamyl carboxylase activity

# Drug_Target_23_General_References:
11071668	Spronk HM, Farah RA, Buchanan GR, Vermeer C, Soute BA: Novel mutation in the gamma-glutamyl carboxylase gene resulting in congenital combined deficiency of all vitamin K-dependent blood coagulation factors. Blood. 2000 Nov 15;96(10):3650-2.
1749935	Wu SM, Cheung WF, Frazier D, Stafford DW: Cloning and expression of the cDNA for human gamma-glutamyl carboxylase. Science. 1991 Dec 13;254(5038):1634-6.
9166845	Wu SM, Stafford DW, Frazier LD, Fu YY, High KA, Chu K, Sanchez-Vega B, Solera J: Genomic sequence and transcription start site for the human gamma-glutamyl carboxylase. Blood. 1997 Jun 1;89(11):4058-62.
9845520	Brenner B, Sanchez-Vega B, Wu SM, Lanir N, Stafford DW, Solera J: A missense mutation in gamma-glutamyl carboxylase gene causes combined deficiency of all vitamin K-dependent blood coagulation factors. Blood. 1998 Dec 15;92(12):4554-9.

# Drug_Target_23_HGNC_ID:
HGNC:4247

# Drug_Target_23_HPRD_ID:
00665

# Drug_Target_23_ID:
448

# Drug_Target_23_Locus:
2p12

# Drug_Target_23_Molecular_Weight:
87562

# Drug_Target_23_Name:
Vitamin K-dependent gamma-carboxylase

# Drug_Target_23_Number_of_Residues:
758

# Drug_Target_23_PDB_ID:
Not Available

# Drug_Target_23_Pathway:
Acenocoumarol Pathway	SMP00269
Dicumarol Pathway	SMP00270
Phenprocoumon Pathway	SMP00271
Warfarin Pathway	SMP00268

# Drug_Target_23_Pfam_Domain_Function:
PF05090	VKG_Carbox

# Drug_Target_23_Protein_Sequence:
>Vitamin K-dependent gamma-carboxylase
MAVSAGSARTSPSSDKVQKDKAELISGPRQDSRIGKLLGFEWTDLSSWRRLVTLLNRPTD
PASLAVFRFLFGFLMVLDIPQERGLSSLDRKYLDGLDVCRFPLLDALRPLPLDWMYLVYT
IMFLGALGMMLGLCYRISCVLFLLPYWYVFLLDKTSWNNHSYLYGLLAFQLTFMDANHYW
SVDGLLNAHRRNAHVPLWNYAVLRGQIFIVYFIAGVKKLDADWVEGYSMEYLSRHWLFSP
FKLLLSEELTSLLVVHWGGLLLDLSAGFLLFFDVSRSIGLFFVSYFHCMNSQLFSIGMFS
YVMLASSPLFCSPEWPRKLVSYCPRRLQQLLPLKAAPQPSVSCVYKRSRGKSGQKPGLRH
QLGAAFTLLYLLEQLFLPYSHFLTQGYNNWTNGLYGYSWDMMVHSRSHQHVKITYRDGRT
GELGYLNPGVFTQSRRWKDHADMLKQYATCLSRLLPKYNVTEPQIYFDIWVSINDRFQQR
IFDPRVDIVQAAWSPFQRTSWVQPLLMDLSPWRAKLQEIKSSLDNHTEVVFIADFPGLHL
ENFVSEDLGNTSIQLLQGEVTVELVAEQKNQTLREGEKMQLPAGEYHKVYTTSPSPSCYM
YVYVNTTELALEQDLAYLQELKEKVENGSETGPLPPELQPLLEGEVKGGPEPTPLVQTFL
RRQQRLQEIERRRNTPFHERFFRFLLRKLYVFRRSFLMTCISLRNLILGRPSLEQLAQEV
TYANLRPFEAVGELNPSNTDSSHSNPPESNPDPVHSEF

# Drug_Target_23_Reaction:
Not Available

# Drug_Target_23_Signals:
None

# Drug_Target_23_Specific_Function:
Mediates the vitamin K-dependent carboxylation of glutamate residues to calcium binding gamma-carboxyglutamate (Gla) residues with the concomitant convertion of the reduced hydroquinone form of vitamin K to vitamin K epoxide

# Drug_Target_23_SwissProt_ID:
P38435

# Drug_Target_23_SwissProt_Name:
VKGC_HUMAN

# Drug_Target_23_Synonyms:
EC 6.4.-.-
Gamma-glutamyl carboxylase
Vitamin K gamma glutamyl carboxylase

# Drug_Target_23_Theoretical_pI:
8.10

# Drug_Target_23_Transmembrane_Regions:
61-81
114-134
137-157
293-313
362-382

# Drug_Target_24_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_24_Chromosome_Location:
Not Available

# Drug_Target_24_Drug_References:
16855093	Glowatzki E, Cheng N, Hiel H, Yi E, Tanaka K, Ellis-Davies GC, Rothstein JD, Bergles DE: The glutamate-aspartate transporter GLAST mediates glutamate uptake at inner hair cell afferent synapses in the mammalian cochlea. J Neurosci. 2006 Jul 19;26(29):7659-64.
16959378	Nickell J, Salvatore MF, Pomerleau F, Apparsundaram S, Gerhardt GA: Reduced plasma membrane surface expression of GLAST mediates decreased glutamate regulation in the aged striatum. Neurobiol Aging. 2007 Nov;28(11):1737-48. Epub 2006 Sep 7.
17088867	Beart PM, O'Shea RD: Transporters for L-glutamate: an update on their molecular pharmacology and pathological involvement. Br J Pharmacol. 2007 Jan;150(1):5-17. Epub 2006 Nov 6.

# Drug_Target_24_Essentiality:
Non-Essential

# Drug_Target_24_GenAtlas_ID:
SLC1A3

# Drug_Target_24_GenBank_ID_Gene:
L19158

# Drug_Target_24_GenBank_ID_Protein:
Not Available

# Drug_Target_24_GeneCard_ID:
SLC1A3

# Drug_Target_24_Gene_Name:
SLC1A3

# Drug_Target_24_Gene_Sequence:
Not Available

# Drug_Target_24_General_Function:
Energy production and conversion

# Drug_Target_24_General_References:
7521911	Arriza JL, Fairman WA, Wadiche JI, Murdoch GH, Kavanaugh MP, Amara SG: Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex. J Neurosci. 1994 Sep;14(9):5559-69.
8123008	Kawakami H, Tanaka K, Nakayama T, Inoue K, Nakamura S: Cloning and expression of a human glutamate transporter. Biochem Biophys Res Commun. 1994 Feb 28;199(1):171-6.
8647279	Stoffel W, Sasse J, Duker M, Muller R, Hofmann K, Fink T, Lichter P: Human high affinity, Na(+)-dependent L-glutamate/L-aspartate transporter GLAST-1 (EAAT-1): gene structure and localization to chromosome 5p11-p12. FEBS Lett. 1996 May 20;386(2-3):189-93.

# Drug_Target_24_HGNC_ID:
HGNC:10941

# Drug_Target_24_HPRD_ID:
02523

# Drug_Target_24_ID:
1912

# Drug_Target_24_Locus:
5p13

# Drug_Target_24_Molecular_Weight:
59573

# Drug_Target_24_Name:
Excitatory amino acid transporter 1

# Drug_Target_24_Number_of_Residues:
542

# Drug_Target_24_PDB_ID:
Not Available

# Drug_Target_24_Pathway:
Not Available

# Drug_Target_24_Pfam_Domain_Function:
PF00375	SDF

# Drug_Target_24_Protein_Sequence:
>Excitatory amino acid transporter 1
MTKSNGEEPKMGGRMERFQQGVRKRTLLAKKKVQNITKEDVKSYLFRNAFVLLTVTAVIV
GTILGFTLRPYRMSYREVKYFSFPGELLMRMLQMLVLPLIISSLVTGMAALDSKASGKMG
MRAVVYYMTTTIIAVVIGIIIVIIIHPGKGTKENMHREGKIVRVTAADAFLDLIRNMFPP
NLVEACFKQFKTNYEKRSFKVPIQANETLVGAVINNVSEAMETLTRITEELVPVPGSVNG
VNALGLVVFSMCFGFVIGNMKEQGQALREFFDSLNEAIMRLVAVIMWYAPVGILFLIAGK
IVEMEDMGVIGGQLAMYTVTVIVGLLIHAVIVLPLLYFLVTRKNPWVFIGGLLQALITAL
GTSSSSATLPITFKCLEENNGVDKRVTRFVLPVGATINMDGTALYEALAAIFIAQVNNFE
LNFGQIITISITATAASIGAAGIPQAGLVTMVIVLTSVGLPTDDITLIIAVDWFLDRLRT
TTNVLGDSLGAGIVEHLSRHELKNRDVEMGNSVIEENEMKKPYQLIAQDNETEKPIDSET
KM

# Drug_Target_24_Reaction:
Not Available

# Drug_Target_24_Signals:
None

# Drug_Target_24_Specific_Function:
Transports L-glutamate and also L- and D-aspartate. Essential for terminating the postsynaptic action of glutamate by rapidly removing released glutamate from the synaptic cleft. Acts as a symport by cotransporting sodium

# Drug_Target_24_SwissProt_ID:
P43003

# Drug_Target_24_SwissProt_Name:
EAA1_HUMAN

# Drug_Target_24_Synonyms:
GLAST-1
Sodium-dependent glutamate/aspartate transporter 1
Solute carrier family 1 member 3

# Drug_Target_24_Theoretical_pI:
8.69

# Drug_Target_24_Transmembrane_Regions:
48-68
91-111
123-145
238-260
281-302
319-340

# Drug_Target_25_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_25_Chromosome_Location:
Not Available

# Drug_Target_25_Drug_References:
16718509	King N, Lin H, McGivan JD, Suleiman MS: Expression and activity of the glutamate transporter EAAT2 in cardiac hypertrophy: implications for ischaemia reperfusion injury. Pflugers Arch. 2006 Sep;452(6):674-82. Epub 2006 May 23.
16855093	Glowatzki E, Cheng N, Hiel H, Yi E, Tanaka K, Ellis-Davies GC, Rothstein JD, Bergles DE: The glutamate-aspartate transporter GLAST mediates glutamate uptake at inner hair cell afferent synapses in the mammalian cochlea. J Neurosci. 2006 Jul 19;26(29):7659-64.
16959378	Nickell J, Salvatore MF, Pomerleau F, Apparsundaram S, Gerhardt GA: Reduced plasma membrane surface expression of GLAST mediates decreased glutamate regulation in the aged striatum. Neurobiol Aging. 2007 Nov;28(11):1737-48. Epub 2006 Sep 7.
17088867	Beart PM, O'Shea RD: Transporters for L-glutamate: an update on their molecular pharmacology and pathological involvement. Br J Pharmacol. 2007 Jan;150(1):5-17. Epub 2006 Nov 6.

# Drug_Target_25_Essentiality:
Non-Essential

# Drug_Target_25_GenAtlas_ID:
SLC1A2

# Drug_Target_25_GenBank_ID_Gene:
U03505

# Drug_Target_25_GenBank_ID_Protein:
487341

# Drug_Target_25_GeneCard_ID:
SLC1A2

# Drug_Target_25_Gene_Name:
SLC1A2

# Drug_Target_25_Gene_Sequence:
>1725 bp
ATGGCATCTACGGAAGGTGCCAACAATATGCCCAAGCAGGTGGAAGTGCGAATGCCAGAC
AGTCATCTTGGCTCAGAGGAACCCAAGCACCGGCACCTGGGCCTGCGCCTGTGTGACAAG
CTGGGGAAGAATCTGCTGCTCACCCTGACGGTGTTTGGTGTCATCCTGGGAGCAGTGTGT
GGAGGGCTTCTTCGCTTGGCATCTCCCATCCACCCTGATGTGGTTATGTTAATAGCCTTC
CCAGGGGATATACTCATGAGGATGCTAAAAATGCTCATTCTCCCTCTAATCATCTCCAGC
TTAATCACAGGGTTGTCAGGCCTGGATGCTAAGGCTAGTGGCCGCTTGGGCACGAGAGCC
ATGGTGTATTACATGTCCACGACCATCATTGCTGCAGTACTGGGGGTCATTCTGGTCTTG
GCTATCCATCCAGGCAATCCCAAGCTCAAGAAGCAGCTGGGGCCTGGGAAGAAGAATGAT
GAAGTGTCCAGCCTGGATGCCTTCCTGGACCTTATTCGAAATCTCTTCCCTGAAAACCTT
GTCCAAGCCTGCTTTCAACAGATTCAAACAGTGACGAAGAAAGTCCTGGTTGCACCACCG
CCAGACGAGGAGGCCAACGCAACCAGCGCTGAAGTCTCTCTGTTGAACGAGACTGTGACT
GAGGTGCCGGAGGAGACTAAGATGGTTATCAAGAAGGGCCTGGAGTTCAAGGATGGGATG
AACGTCTTAGGTCTGATAGGGTTTTTCATTGCTTTTGGCATCGCTATGGGGAAGATGGGA
GATCAGGCCAAGCTGATGGTGGATTTCTTCAACATTTTGAATGAGATTGTAATGAAGTTA
GTGATCATGATCATGTGGTACTCTCCCCTGGGTATCGCCTGCCTGATCTGTGGAAAGATC
ATTGCAATCAAGGACTTAGAAGTGGTTGCTAGGCAACTGGGGATGTACATGGTAACAGTG
ATCATAGGCCTCATCATCCACGGGGGCATCTTTCTCCCCTTGATTTACTTTGTAGTGACC
AGGAAAAACCCCTTCTCCCTTTTTGCTGGCATTTTCCAAGCTTGGATCACTGCCCTGGGC
ACCGCTTCCAGTGCTGGAACTTTGCCTGTCACCTTTCGTTGCCTGGAAGAAAATCTGGGG
ATTGATAAGCGTGTGACTAGATTCGTCCTTCCTGTTGGAGCAACCATTAACATGGATGGT
ACAGCCCTTTATGAAGCGGTGGCCGCCATCTTTATAGCCCAAATGAATGGTGTTGTCCTG
GATGGAGGACAGATTGTGACTGTAAGCCTCACAGCCACCCTGGCAAGCGTCGGCGCGGCC
AGTATCCCCAGTGCCGGGCTGGTCACCATGCTCCTCATTCTGACAGCCGTGGGCCTGCCA
ACAGAGGACATCAGCTTGCTGGTGGCTGTGGACTGGCTGCTGGACAGGATGAGAACTTCA
GTCAATGTTGTGGGTGACTCTTTTGGGGCTGGGATAGTCTATCACCTCTCCAAGTCTGAG
CTGGATACCATTGACTCCCAGCATCGAGTGCATGAAGATATTGAAATGACCAAGACTCAA
TCCATTTATGATGACATGAAGAACCACAGGGAAAGCAACTCTAATCAATGTGTCTATGCT
GCACACAACTCTGTCATAGTAGATGAATGCAAGGTAACTCTGGCAGCCAATGGAAAGTCA
GCCGACTGCAGTGTTGAGGAAGAACCTTGGAAACGTGAGAAATAA

# Drug_Target_25_General_Function:
Energy production and conversion

# Drug_Target_25_General_References:
7521911	Arriza JL, Fairman WA, Wadiche JI, Murdoch GH, Kavanaugh MP, Amara SG: Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex. J Neurosci. 1994 Sep;14(9):5559-69.
7522567	Manfras BJ, Rudert WA, Trucco M, Boehm BO: Cloning and characterization of a glutamate transporter cDNA from human brain and pancreas. Biochim Biophys Acta. 1994 Oct 12;1195(1):185-8.
8172925	Shashidharan P, Wittenberg I, Plaitakis A: Molecular cloning of human brain glutamate/aspartate transporter II. Biochim Biophys Acta. 1994 May 11;1191(2):393-6.
9463476	Shimamoto K, Lebrun B, Yasuda-Kamatani Y, Sakaitani M, Shigeri Y, Yumoto N, Nakajima T: DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters. Mol Pharmacol. 1998 Feb;53(2):195-201.

# Drug_Target_25_HGNC_ID:
HGNC:10940

# Drug_Target_25_HPRD_ID:
02625

# Drug_Target_25_ID:
1047

# Drug_Target_25_Locus:
11p13-p12

# Drug_Target_25_Molecular_Weight:
62105

# Drug_Target_25_Name:
Excitatory amino acid transporter 2

# Drug_Target_25_Number_of_Residues:
574

# Drug_Target_25_PDB_ID:
Not Available

# Drug_Target_25_Pathway:
Not Available

# Drug_Target_25_Pfam_Domain_Function:
PF00375	SDF

# Drug_Target_25_Protein_Sequence:
>Excitatory amino acid transporter 2
MASTEGANNMPKQVEVRMHDSHLGSEEPKHRHLGLRLCDKLGKNLLLTLTVFGVILGAVC
GGLLRLASPIHPDVVMLIAFPGDILMRMLKMLILPLIISSLITGLSGLDAKASGRLGTRA
MVYYMSTTIIAAVLGVILVLAIHPGNPKLKKQLGPGKKNDEVSSLDAFLDLIRNLFPENL
VQACFQQIQTVTKKVLVAPPPDEEANATSAVVSLLNETVTEVPEETKMVIKKGLEFKDGM
NVLGLIGFFIAFGIAMGKMGDQAKLMVDFFNILNEIVMKLVIMIMWYSPLGIACLICGKI
IAIKDLEVVARQLGMYMVTVIIGLIIHGGIFLPLIYFVVTRKNPFSFFAGIFQAWITALG
TASSAGTLPVTFRCLEENLGIDKRVTRFVLPVGATINMDGTALYEAVAAIFIAQMNGVVL
DGGQIVTVSLTATLASVGAASIPSAGLVTMLLILTAVGLPTEDISLLVAVDWLLDRMRTS
VNVVGDSFGAGIVYHLSKSELDTIDSQHRVHEDIEMTKTQSIYDDMKNHRESNSNQCVYA
AHNSVIVDECKVTLAANGKSADCSVEEEPWKREK

# Drug_Target_25_Reaction:
Not Available

# Drug_Target_25_Signals:
None

# Drug_Target_25_Specific_Function:
Transports L-glutamate and also L- and D-aspartate. Essential for terminating the postsynaptic action of glutamate by rapidly removing released glutamate from the synaptic cleft. Acts as a symport by cotransporting sodium

# Drug_Target_25_SwissProt_ID:
P43004

# Drug_Target_25_SwissProt_Name:
EAA2_HUMAN

# Drug_Target_25_Synonyms:
Glutamate/aspartate transporter II
Sodium-dependent glutamate/aspartate transporter 2
Solute carrier family 1 member 2

# Drug_Target_25_Theoretical_pI:
6.51

# Drug_Target_25_Transmembrane_Regions:
45-64
88-108
121-142
240-259
280-301
317-339
406-430
437-459

# Drug_Target_26_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_26_Chromosome_Location:
Not Available

# Drug_Target_26_Drug_References:
16831195	Menaker D, Bendahan A, Kanner BI: The substrate specificity of a neuronal glutamate transporter is determined by the nature of the coupling ion. J Neurochem. 2006 Oct;99(1):20-8. Epub 2006 Jul 11.
16959378	Nickell J, Salvatore MF, Pomerleau F, Apparsundaram S, Gerhardt GA: Reduced plasma membrane surface expression of GLAST mediates decreased glutamate regulation in the aged striatum. Neurobiol Aging. 2007 Nov;28(11):1737-48. Epub 2006 Sep 7.
17382927	Yun JY, Park KS, Kim JH, Do SH, Zuo Z: Propofol reverses oxidative stress-attenuated glutamate transporter EAAT3 activity: evidence of protein kinase C involvement. Eur J Pharmacol. 2007 Jun 22;565(1-3):83-8. Epub 2007 Mar 3.
17389249	Tao Z, Grewer C: Cooperation of the conserved aspartate 439 and bound amino acid substrate is important for high-affinity Na+ binding to the glutamate transporter EAAC1. J Gen Physiol. 2007 Apr;129(4):331-44.

# Drug_Target_26_Essentiality:
Non-Essential

# Drug_Target_26_GenAtlas_ID:
SLC1A1

# Drug_Target_26_GenBank_ID_Gene:
U08989

# Drug_Target_26_GenBank_ID_Protein:
507898

# Drug_Target_26_GeneCard_ID:
SLC1A1

# Drug_Target_26_Gene_Name:
SLC1A1

# Drug_Target_26_Gene_Sequence:
>1575 bp
ATGGGGAAACCGGCGAGGAAAGGATGCGAGTGGAAGCGCTTCCTGAAGAATAACTGGGTG
TTGCTGTCCACCGTGGCCGCGGTGGTGCTAGGCATTACCACAGGAGTCTTGGTTCGAGAA
CACAGCAACCTCTCAACTCTAGAGAAATTCTACTTTGCTTTTCCTGGAGAAATTCTAATG
CGGATGCTGAAACTCATCATTTTGCCATTAATTATATCCAGCATGATTACAGGTGTTGCT
GCACTGGATTCCAACGTATCCGGAAAAATTGGTCTGCGCGTCGTCGTGTATTATTTCTGT
ACCACTCTCATTGCTGTTATTCTAGGTATTGTGCTGGTGGTGAGCATCAAGCCTGGTGTC
ACCCAGAAAGTGGGTGAAATTGCGAGGACAGGCAGCACCCCTGAAGTCAGTACGGTGGAT
GCCATGTTAGATCTCATCAGGAATATGTTCCCTGAGAATCTTGTCCAGGCCTGTTTTCAG
CAGTACAAAACTAAGCGTGAAGAAGTGAAGCCTCCCAGCGATCCAGAGATGAACATGACA
GAAGAGTCCTTCACAGCTGTCATGACAACTGCAATTTCCAAGAACAAAACAAAGGAATAC
AAAATTGTTGGCATGTATTCAGATGGCATAAACGTCCTGGGCTTGATTGTCTTTTGCCTT
GTCTTTGGACTTGTCATTGGAAAAATGGGAGAAAAGGGACAAATTCTGGTGGATTTCTTC
AATGCTTTGAGTGATGCAACCATGAAAATCGTTCAGATCATCATGTGTTATATGCCACTA
GGTATTTTGTTCCTGATTGCTGGGAAGATCATAGAAGTTGAAGACTGGGAAATATTCGCA
AAGCTGGGCCTTTACATGGCCACAGTCCTGACTGGGCTTGCAATCCACTCCATTGTAATT
CTCCCGCTGATATATTTCATAGTCGTACGAAAGAACCCTTTCCGATTTGCCATGGGAATG
GCCCAGGCTCTCCTGACAGCTCTCATGATCTCTTCCAGTTCAGCAACACTGCCTGTCACC
TTCCGCTGTGCTGAAGAAAATAACCAGGTGGACAAGAGGATCACTCGATTCGTGTTACCC
GTTGGTGCAACAATCAACATGGATGGGACTGCGCTCTATGAAGCAGTGGCAGCGGTGTTT
ATTGCACAGTTGAATGACCTGGACTTGGGCATTGGGCAGATCATCACCATCAGTATCACG
GCCACATCTGCCAGCATCGGAGCTGCTGGCGTGCCCCAGGCTGGCCTGGTGACCATGGTG
ATTGTGCTGAGTGCCGTGGGCCTGCCCGCCGAGGATGTCACCCTGATCATTGCTGTCGAC
TGGCTCCTGGACCGGTTCAGGACCATGGTCAACGTCCTTGGTGATGCTTTTGGGACGGGC
ATTGTGGAAAAGCTCTCCAAGAAGGAGCTGGAGCAGATGGATGTTTCATCTGAAGTCAAC
ATTGTGAATCCTTTTGCCTTGGAATCCACAATCCTTGACAACGAAGACTCAGACACCAAG
AAGTCTTATGTCAATGGAGGCTTTGCAGTAGACAAGTCTGACACCATCTCATTCACCCAG
ACCTCACAGTTCTAG

# Drug_Target_26_General_Function:
Energy production and conversion

# Drug_Target_26_General_References:
7521911	Arriza JL, Fairman WA, Wadiche JI, Murdoch GH, Kavanaugh MP, Amara SG: Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex. J Neurosci. 1994 Sep;14(9):5559-69.
7859077	Shashidharan P, Huntley GW, Meyer T, Morrison JH, Plaitakis A: Neuron-specific human glutamate transporter: molecular cloning, characterization and expression in human brain. Brain Res. 1994 Oct 31;662(1-2):245-50.
7914198	Kanai Y, Stelzner M, Nussberger S, Khawaja S, Hebert SC, Smith CP, Hediger MA: The neuronal and epithelial human high affinity glutamate transporter. Insights into structure and mechanism of transport. J Biol Chem. 1994 Aug 12;269(32):20599-606.

# Drug_Target_26_HGNC_ID:
HGNC:10939

# Drug_Target_26_HPRD_ID:
00597

# Drug_Target_26_ID:
1671

# Drug_Target_26_Locus:
9p24

# Drug_Target_26_Molecular_Weight:
57101

# Drug_Target_26_Name:
Excitatory amino acid transporter 3

# Drug_Target_26_Number_of_Residues:
524

# Drug_Target_26_PDB_ID:
Not Available

# Drug_Target_26_Pathway:
Not Available

# Drug_Target_26_Pfam_Domain_Function:
PF00375	SDF

# Drug_Target_26_Protein_Sequence:
>Excitatory amino acid transporter 3
MGKPARKGCEWKRFLKNNWVLLSTVAAVVLGITTGVLVREHSNLSTLEKFYFAFPGEILM
RMLKLIILPLIISSMITGVAALDSNVSGKIGLRAVVYYFCTTLIAVILGIVLVVSIKPGV
TQKVGEIARTGSTPEVSTVDAMLDLIRNMFPENLVQACFQQYKTKREEVKPPSDPEMNMT
EESFTAVMTTAISKNKTKEYKIVGMYSDGINVLGLIVFCLVFGLVIGKMGEKGQILVDFF
NALSDATMKIVQIIMCYMPLGILFLIAGKIIEVEDWEIFRKLGLYMATVLTGLAIHSIVI
LPLIYFIVVRKNPFRFAMGMAQALLTALMISSSSATLPVTFRCAEENNQVDKRITRFVLP
VGATINMDGTALYEAVAAVFIAQLNDLDLGIGQIITISITATSASIGAAGVPQAGLVTMV
IVLSAVGLPAEDVTLIIAVDWLLDRFRTMVNVLGDAFGTGIVEKLSKKELEQMDVSSEVN
IVNPFALESTILDNEDSDTKKSYVNGGFAVDKSDTISFTQTSQF

# Drug_Target_26_Reaction:
Not Available

# Drug_Target_26_Signals:
None

# Drug_Target_26_Specific_Function:
Transports L-glutamate and also L- and D-aspartate. Essential for terminating the postsynaptic action of glutamate by rapidly removing released glutamate from the synaptic cleft. Acts as a symport by cotransporting sodium. Negatively regulated by ARL6IP5

# Drug_Target_26_SwissProt_ID:
P43005

# Drug_Target_26_SwissProt_Name:
EAA3_HUMAN

# Drug_Target_26_Synonyms:
Excitatory amino-acid carrier 1
Neuronal and epithelial glutamate transporter
Sodium-dependent glutamate/aspartate transporter 3
Solute carrier family 1 member 1

# Drug_Target_26_Theoretical_pI:
5.36

# Drug_Target_26_Transmembrane_Regions:
19-38
62-82
94-114
210-229
254-273
290-309
316-335
362-381
392-411
420-439

# Drug_Target_27_Cellular_Location:
Cytoplasmic

# Drug_Target_27_Chromosome_Location:
Not Available

# Drug_Target_27_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_27_Essentiality:
Non-Essential

# Drug_Target_27_GenAtlas_ID:
GCLC

# Drug_Target_27_GenBank_ID_Gene:
M90656

# Drug_Target_27_GenBank_ID_Protein:
183039

# Drug_Target_27_GeneCard_ID:
GCLC

# Drug_Target_27_Gene_Name:
GCLC

# Drug_Target_27_Gene_Sequence:
>1914 bp
ATGGGGCTGCTGTCCCAGGGCTCGCCGCTGAGCTGGGAGGAAACCAAGCGCCATGCCGAC
CACGTGCGGCGGCACGGGATCCTCCAGTTCCTGCACATCTACCACGCCGTCAAGGACCGG
CACAAGGACGTTCTCAAGTGGGGCGATGAGGTGGAATACATGTTGGTATCTTTTGATCAT
GAAAATAAAAAAGTCCGGTTGGTCCTGTCTGGGGAGAAAGTTCTTGAAACTCTGCAAGAG
AAGGGGGAAAGGACAAACCCAAACCATCCTACCCTTTGGAGACCAGAGTATGGGAGTTAC
ATGATTGAAGGGACACCAGGACAGCCCTACGGAGGAACAATGTCCGAGTTCAATACAGTT
GAGGCCAACATGCGAAAACGCCGGAAGGAGGCTACTTCTATATTAGAAGAAAATCAGGCT
CTTTGCACAATAACTTCATTTCCCAGATTAGGCTGTCCTGGGTTCACACTGCCCGAGGTC
AAACCCAACCCAGTGGAAGGAGGAGCTTCCAAGTCCCTCTTCTTTCCAGATGAAGCAATA
AACAAGCACCCTCGCTTCAGTACCTTAACAAGAAATATCCGACATAGGAGAGGAGAAAAG
GTTGTCATCAATGTACCAATATTTAAGGACAAGAATACACCATCTCCATTTATAGAAACA
TTTACTGAGGATGATGAAGCTTCAAGGGCTTCTAAGCCGGATCATATTTACATGGATGCC
ATGGGATTTGGAATGGGCAATTGCTGTCTCCAGGTGACATTCCAAGCCTGCAGTATATCT
GAGGCCAGATACCTTTATGATCAGTTGGCTACTATCTGTCCAATTGTTATGGCTTTGAGT
GCTGCATCTCCCTTTTACCGAGGCTATGTGTCAGACATTGATTGTCGCTGGGGAGTGATT
TCTGCATCTGTAGATGATAGAACTCGGGAGGAGCGAGGACTGGAGCCATTGAAGAACAAT
AACTATAGGATCAGTAAATCCCGATATGACTCAATAGACAGCTATTTATCTAAGTGTGGT
GAGAAATATAATGACATCGACTTGACGATAGATAAAGAGATCTACGAACAGCTGTTGCAG
GAAGGCATTGATCATCTCCTGGCCCAGCATGTTGCTCATCTCTTTATTAGAGACCCACTG
ACACTGTTTGAAGAGAAAATACACCTGGATGATGCTAATGAGTCTGACCATTTTGAGAAT
ATTCAGTCCACAAATTGGCAGACAATGAGATTTAAGCCCCCTCCTCCAAACTCAGACATT
GGATGGAGAGTAGAATTTCGACCCATGGAGGTGCAATTAACAGACTTTGAGAACTCTGCC
TATGTGGTGTTTGTGGTACTGCTCACCAGAGTGATCCTTTCCTACAAATTGGATTTTCTC
ATTCCACTGTCAAAGGTTGATGAGAACATGAAGGTAGCACAGAAAAGAGATGCTGTCTTG
CAGGGAATGTTTTATTTCAGGAAAGATATTTGCAAAGGTGGCAATGCAGTGGTGGATGGT
TGTGGCAAGGCCCAGAACAGCACGGAGCTCGCTGCAGAGGAGTACACCCTCATGAGCATA
GACACCATCATCAATGGGAAGGAAGGTGTGTTTCCTGGACTGATCCCAATTCTGAACTCT
TACCTTGAAAACATGGAAGTGGATGTGGACACCAGATGTAGTATTCTGAACTACCTAAAG
CTAATTAAGAAGAGAGCATCTGGAGAACTAATGACAGTTGCCAGATGGATGAGGGAGTTT
ATCGCAAACCATCCTGACTACAAGCAAGACAGTGTCATAACTGATGAAATGAATTATAGC
CTTATTTTGAAGTGTAACCAAATTGCAAATGAATTATGTGAATGCCCAGAGTTACTTGGA
TCAGCATTTAGGAAAGTAAAATATAGTGGAAGTAAAACTGACTCATCCAACTAG

# Drug_Target_27_General_Function:
Involved in glutamate-cysteine ligase activity

# Drug_Target_27_General_References:
10515893	Beutler E, Gelbart T, Kondo T, Matsunaga AT: The molecular basis of a case of gamma-glutamylcysteine synthetase deficiency. Blood. 1999 Oct 15;94(8):2890-4.
10733484	Ristoff E, Augustson C, Geissler J, de Rijk T, Carlsson K, Luo JL, Andersson K, Weening RS, van Zwieten R, Larsson A, Roos D: A missense mutation in the heavy subunit of gamma-glutamylcysteine synthetase gene causes hemolytic anemia. Blood. 2000 Apr 1;95(7):2193-6.
1350904	Gipp JJ, Chang C, Mulcahy RT: Cloning and nucleotide sequence of a full-length cDNA for human liver gamma-glutamylcysteine synthetase. Biochem Biophys Res Commun. 1992 May 29;185(1):29-35.
14574404	Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE, Gilbert JG, Clamp ME, Bethel G, Milne S, Ainscough R, Almeida JP, Ambrose KD, Andrews TD, Ashwell RI, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beare DM, Beasley H, Beasley O, Bird CP, Blakey S, Bray-Allen S, Brook J, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Clark SY, Clark G, Clee CM, Clegg S, Cobley V, Collier RE, Collins JE, Colman LK, Corby NR, Coville GJ, Culley KM, Dhami P, Davies J, Dunn M, Earthrowl ME, Ellington AE, Evans KA, Faulkner L, Francis MD, Frankish A, Frankland J, French L, Garner P, Garnett J, Ghori MJ, Gilby LM, Gillson CJ, Glithero RJ, Grafham DV, Grant M, Gribble S, Griffiths C, Griffiths M, Hall R, Halls KS, Hammond S, Harley JL, Hart EA, Heath PD, Heathcott R, Holmes SJ, Howden PJ, Howe KL, Howell GR, Huckle E, Humphray SJ, Humphries MD, Hunt AR, Johnson CM, Joy AA, Kay M, Keenan SJ, Kimberley AM, King A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd CR, Lloyd DM, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, Maslen GL, Matthews L, McCann OT, McLaren SJ, McLay K, McMurray A, Moore MJ, Mullikin JC, Niblett D, Nickerson T, Novik KL, Oliver K, Overton-Larty EK, Parker A, Patel R, Pearce AV, Peck AI, Phillimore B, Phillips S, Plumb RW, Porter KM, Ramsey Y, Ranby SA, Rice CM, Ross MT, Searle SM, Sehra HK, Sheridan E, Skuce CD, Smith S, Smith M, Spraggon L, Squares SL, Steward CA, Sycamore N, Tamlyn-Hall G, Tester J, Theaker AJ, Thomas DW, Thorpe A, Tracey A, Tromans A, Tubby B, Wall M, Wallis JM, West AP, White SS, Whitehead SL, Whittaker H, Wild A, Willey DJ, Wilmer TE, Wood JM, Wray PW, Wyatt JC, Young L, Younger RM, Bentley DR, Coulson A, Durbin R, Hubbard T, Sulston JE, Dunham I, Rogers J, Beck S: The DNA sequence and analysis of human chromosome 6. Nature. 2003 Oct 23;425(6960):805-11.
7726839	Mulcahy RT, Gipp JJ: Identification of a putative antioxidant response element in the 5'-flanking region of the human gamma-glutamylcysteine synthetase heavy subunit gene. Biochem Biophys Res Commun. 1995 Apr 6;209(1):227-33.

# Drug_Target_27_HGNC_ID:
HGNC:4311

# Drug_Target_27_HPRD_ID:
06032

# Drug_Target_27_ID:
186

# Drug_Target_27_Locus:
6p12

# Drug_Target_27_Molecular_Weight:
72635

# Drug_Target_27_Name:
Glutamate--cysteine ligase catalytic subunit

# Drug_Target_27_Number_of_Residues:
636

# Drug_Target_27_PDB_ID:
Not Available

# Drug_Target_27_Pathway:
Not Available

# Drug_Target_27_Pfam_Domain_Function:
PF03074	GCS

# Drug_Target_27_Protein_Sequence:
>Glutamate--cysteine ligase catalytic subunit
GLLSQGSPLSWEETKRHADHVRRHGILQFLHIYHAVKDRHKDVLKWGDEVEYMLVSFDHE
NKKVRLVLSGEKVLETLQEKGERTNPNHPTLWRPEYGSYMIEGTPGQPYGGTMSEFNTVE
ANMRKRRKEATSILEENQALCTITSFPRLGCPGFTLPEVKPNPVEGGASKSLFFPDEAIN
KHPRFSTLTRNIRHRRGEKVVINVPIFKDKNTPSPFIETFTEDDEASRASKPDHIYMDAM
GFGMGNCCLQVTFQACSISEARYLYDQLATICPIVMALSAASPFYRGYVSDIDCRWGVIS
ASVDDRTREERGLEPLKNNNYRISKSRYDSIDSYLSKCGEKYNDIDLTIDKEIYEQLLQE
GIDHLLAQHVAHLFIRDPLTLFEEKIHLDDANESDHFENIQSTNWQTMRFKPPPPNSDIG
WRVEFRPMEVQLTDFENSAYVVFVVLLTRVILSYKLDFLIPLSKVDENMKVAQKRDAVLQ
GMFYFRKDICKGGNAVVDGCGKAQNSTELAAEEYTLMSIDTIINGKEGVFPGLIPILNSY
LENMEVDVDTRCSILNYLKLIKKRASGELMTVARWMREFIANHPDYKQDSVITDEMNYSL
ILKCNQIANELCECPELLGSAFRKVKYSGSKTDSSN

# Drug_Target_27_Reaction:
ATP + L-glutamate + L-cysteine = ADP + phosphate + gamma-L-glutamyl-L-cysteine

# Drug_Target_27_Signals:
None

# Drug_Target_27_Specific_Function:
Not Available

# Drug_Target_27_SwissProt_ID:
P48506

# Drug_Target_27_SwissProt_Name:
GSH1_HUMAN

# Drug_Target_27_Synonyms:
EC 6.3.2.2
GCS heavy chain
Gamma- glutamylcysteine synthetase
Gamma-ECS

# Drug_Target_27_Theoretical_pI:
5.98

# Drug_Target_27_Transmembrane_Regions:
None

# Drug_Target_28_Cellular_Location:
Membrane

# Drug_Target_28_Chromosome_Location:
Not Available

# Drug_Target_28_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9224806	Gegelashvili G, Schousboe A: High affinity glutamate transporters: regulation of expression and activity. Mol Pharmacol. 1997 Jul;52(1):6-15.
9838098	Lin CL, Tzingounis AV, Jin L, Furuta A, Kavanaugh MP, Rothstein JD: Molecular cloning and expression of the rat EAAT4 glutamate transporter subtype. Brain Res Mol Brain Res. 1998 Dec 10;63(1):174-9.

# Drug_Target_28_Essentiality:
Non-Essential

# Drug_Target_28_GenAtlas_ID:
SLC1A6

# Drug_Target_28_GenBank_ID_Gene:
U18244

# Drug_Target_28_GenBank_ID_Protein:
930337

# Drug_Target_28_GeneCard_ID:
SLC1A6

# Drug_Target_28_Gene_Name:
SLC1A6

# Drug_Target_28_Gene_Sequence:
>1695 bp
ATGAGCAGCCATGGCAACAGCCTGTTCCTTCGGGAGAGCGGCCAGCGGCTGGGCCGGGTG
GGCTGGCTGCAGCGGCTGCAGGAAAGCCTGCAGCAGAGAGCACTGCGCACGCGCCTGCGC
CTGCAGACCATGACCCTCGAGCACGTGCTGCGCTTCCTGCGCCGAAACGCCTTCATTCTG
CTGACGGTCAGCGCCGTGGTCATTGGGGTCAGCCTGGCCTTTGCCCTGCGCCCATATCAG
CTCACCTACCGCCAGATCAAGTACTTCTCTTTTCCTGGAGAGCTTCTGATGAGGATGCTG
CAGATGCTGGTGTTACCTCTCATTGTCTCCAGCCTGGTCACAGGTATGGCATCCCTGGAC
AACAAGGCCACGGGGCGGATGGGGATGCGGGCAGCTGTGTACTACATGGTGACCACCATC
ATCGCGGTCTTCATCGGCATCCTCATGGTCACCATCATCCATCCCGGGAAGGGCTCCAAG
GAGGGGCTGCACCGGGAGGGCCGGATCGAGACCATCCCCACAGCTGATGCCTTCATGGAC
CTGATCAGAAATATGTTTCCACCAAACCTTGTGGAGGCCTGCTTCAAACAGTTCAAGACG
CAGTACAGCACGAGGGTGGTAACCAGGACCATGGTGAGGACAGAGAACGGGTCTGAGCCG
GGTGCCTCCATGCCTCCTCCATTCTCAGTGGAGAACGGAACCAGCTTCCTGGAAAATGTC
ACTCGGGCCTTGGGTACCCTGCAGGAGATGCTGAGCTTTGAGGAGACTGTACCCGTGCCT
GGCTCCGCCAATGGCATCAACGCCCTGGGCCTCGTGGTCTTCTCTGTGGCCTTTGGGCTG
GTCATTGGTGGCATGAAACACAAGGGCAGAGTCCTCAGGGACTTCTTCGACAGCCTCAAT
GAGGCTATTATGAGGCTGGTGGGCATCATTATCTGGTATGCACCTGTGGGCATCCTGTTC
CTGATTGCTGGGAAGATTCTGGAGATGGAAGACATGGCCGTCCTGGGGGGTCAGCTGGGC
ATGTACACCCTGACCGTCATCGTGGGCCTGTTCCTCCATGCCGGCATTGTCCTTCCCCTC
ATCTACTTCCTCGTCACTCACCGGAACCCCTTCCCCTTCATTGGGGGCATGCTACAAGCC
CTCATCACCGCTATGGGCACGTCTTCCAGCTCGGCAACGCTGCCCATCACCTTCCGCTGC
CTGGAGGAGGGCCTGGGTGTGGACCGCCGCATCACCAGGTTCGTCCTGCCCGTGGGCGCC
ACGGTCAACATGGATGGCACTGCCCTCTACGAGGCCCTGGCTGCCATCTTCATTGCTCAA
GTTAACAACTACGAGCTCAACCTGGGTCAGATCACAACCATCAGCATCACGGCCACAGCA
GCCAGTGTTGGGGCTGCTGGCATCCCCCAGGCGGGTCTGGTCACCATGGTCATTGTGCTT
ACGTCGGTCGGCTTGCCCACGGAAGACATCACGCTCATCATCGCCGTGGACTGGTTCCTT
GACCGGCTTCGCACAATGACCAACGTACTGGGGGACTCAATTGGAGCGGCCGTCATCGAG
CACTTGTCTCAGCGGGAGCTGGAGCTTCAGGAAGCTGAGCTTACCCTCCCCAGCCTGGGG
AAACCCTACAAGTCCCTCATGGCACAGGAGAAGGGGGCATCCCGGGGACGGGGAGGCAAC
GAGAGTGCTATGTGA

# Drug_Target_28_General_Function:
Energy production and conversion

# Drug_Target_28_General_References:
7791878	Fairman WA, Vandenberg RJ, Arriza JL, Kavanaugh MP, Amara SG: An excitatory amino-acid transporter with properties of a ligand-gated chloride channel. Nature. 1995 Jun 15;375(6532):599-603.

# Drug_Target_28_HGNC_ID:
HGNC:10944

# Drug_Target_28_HPRD_ID:
Not Available

# Drug_Target_28_ID:
4019

# Drug_Target_28_Locus:
19p13.12

# Drug_Target_28_Molecular_Weight:
61567

# Drug_Target_28_Name:
Excitatory amino acid transporter 4

# Drug_Target_28_Number_of_Residues:
564

# Drug_Target_28_PDB_ID:
Not Available

# Drug_Target_28_Pathway:
Not Available

# Drug_Target_28_Pfam_Domain_Function:
PF00375	SDF

# Drug_Target_28_Protein_Sequence:
>Excitatory amino acid transporter 4
MSSHGNSLFLRESGQRLGRVGWLQRLQESLQQRALRTRLRLQTMTLEHVLRFLRRNAFIL
LTVSAVVIGVSLAFALRPYQLTYRQIKYFSFPGELLMRMLQMLVLPLIVSSLVTGMASLD
NKATGRMGMRAAVYYMVTTIIAVFIGILMVTIIHPGKGSKEGLHREGRIETIPTADAFMD
LIRNMFPPNLVEACFKQFKTQYSTRVVTRTMVRTENGSEPGASMPPPFSVENGTSFLENV
TRALGTLQEMLSFEETVPVPGSANGINALGLVVFSVAFGLVIGGMKHKGRVLRDFFDSLN
EAIMRLVGIIIWYAPVGILFLIAGKILEMEDMAVLGGQLGMYTLTVIVGLFLHAGIVLPL
IYFLVTHRNPFPFIGGMLQALITAMGTSSSSATLPITFRCLEEGLGVDRRITRFVLPVGA
TVNMDGTALYEALAAIFIAQVNNYELNLGQITTISITATAASVGAAGIPQAGLVTMVIVL
TSVGLPTEDITLIIAVDWFLDRLRTMTNVLGDSIGAAVIEHLSQRELELQEAELTLPSLG
KPYKSLMAQEKGASRGRGGNESAM

# Drug_Target_28_Reaction:
Not Available

# Drug_Target_28_Signals:
None

# Drug_Target_28_Specific_Function:
Transports L-glutamate and also L- and D-aspartate. Seems to act as a symport by cotransporting sodium

# Drug_Target_28_SwissProt_ID:
P48664

# Drug_Target_28_SwissProt_Name:
EAA4_HUMAN

# Drug_Target_28_Synonyms:
Sodium-dependent glutamate/aspartate transporter
Solute carrier family 1 member 6

# Drug_Target_28_Theoretical_pI:
9.54

# Drug_Target_28_Transmembrane_Regions:
56-76
99-119
133-153
265-285
306-326
345-365
370-390
418-438
460-480
481-501

# Drug_Target_29_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_29_Chromosome_Location:
Not Available

# Drug_Target_29_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_29_Essentiality:
Non-Essential

# Drug_Target_29_GenAtlas_ID:
GLUD2

# Drug_Target_29_GenBank_ID_Gene:
X66310

# Drug_Target_29_GenBank_ID_Protein:
31815

# Drug_Target_29_GeneCard_ID:
GLUD2

# Drug_Target_29_Gene_Name:
GLUD2

# Drug_Target_29_Gene_Sequence:
>1677 bp
ATGTACCGCTACCTGGCCAAAGCGCTGCTGCCGTCCCGGGCCGGGCCCGCTGCCCTGGGC
TCCGCGGCCAACCACTCGGCCGCGTTGCTGGGCCGGGGCCGCGGACAGCCCGCCGCCGCC
TCGCAGCCGGGGCTCGCATTGGCCGCCCGGCGCCACTACAGCGAGTTGGTGGCCGACCGC
GAGGACGACCCCAACTTCTTCAAGATGGTGGAGGGCTTCTTCGATCGCGGCGCCAGCATC
GTGGAGGACAAGTTGGTGAAGGACCTGAGGACCCAGGAAAGCGAGGAGCAGAAGCGGAAC
CGGGTGCGCGGCATCCTGCGGATCATCAAGCCCTGCAACCATGTGCTGAGTCTCTCCTTC
CCCATCCGGCGCGACGACGGCTCCTGGGAGGTCATCGAAGGCTACCGGGCCCAGCACAGC
CAGCACCGCACGCCCTGCAAGGGAGGTATCCGTTACAGCACTGATGTGAGTGTAGATGAA
GTAAAAGCTTTGGCTTCTCTGATGACATACAAGTGTGCAGTGGTTGATGTGCCGTTTGGG
GGTGCTAAAGCTGGTGTTAAGATCAATCCCAAGAACTATACCGAAAATGAATTGGAAAAG
ATCACAAGGAGGTTCACCATGGAGCTAGCAAAGAAGGGCTTTATTGGTCCTGGCGTTGAT
GTGCCTGCTCCAGACATGAACACAGGTGAGCGGGAGATGTCCTGGATTGCTGATACCTAT
GCCAGCACCATAGGGCACTATGATATTAATGCACACGCCTGTGTTACTGGTAAACCCATC
AGCCAAGGGGGAATCCATGGACGCATCTCTGCTACTGGCCGTGGTGTCTTCCATGGGATT
GAAAACTTCATCAATCAAGCTTCTTACATGAGCATTTTAGGAATGACACCAGGGTTTAGA
GATAAAACATTTGTTGTTCAGGGATTTGGTAATGTGGGCCTACACTCTATGAGATATTTA
CATCGTTTTGGTGCTAAATGTATTGCTGTTGGTGAGTCTGATGGGAGTATATGGAATCCA
GATGGTATTGACCCAAAGGAACTGGAAGACTTCAAATTGCAACATGGGTCCATTCTGGGC
TTCCCCAAGGCAAAGCCCTATGAAGGAAGCATCTTGGAGGTCGACTGTGACATACTGATC
CCAGCTGCCACTGAGAAGCAGTTGACCAAATCCAACGCACCCAGAGTCAAAGCCAAGATC
ATTGCTGAAGGTGCCAATGGGCCAACAACTCCAGAAGCTGATAAGATCTTCCTGGAGAGA
AACATTTTGGTTATTCCAGATCTCTACTTGAATGCTGGAGGAGTGACAGTATCTTACTTT
GAGTGGCTGAAGAATCTAAATCATGTCAGCTATGGCCGTTTGACCTTCAAATATGAAAGG
GATTCTAACTACCACTTGCTCCTGTCTGTTCAAGAGAGTTTAGAAAGAAAATTTGGAAAG
CATGGTGGAACTATTCCCATTGTACCCACGGCAGAGTTCCAAGACAGTATATCGGGTGCA
TCTGAGAAAGACATTGTGCACTCTGCCTTGGCATACACAATGGAGCGTTCTGCCAGGCAA
ATTATGCACACAGCCATGAAGTATAACCTGGGATTGGACCTGAGAACAGCTGCCTATGTC
AATGCCATTGAAAAAGTCTTCAAAGTGTACAGTGAAGCTGGTGTGACCTTCACATAG

# Drug_Target_29_General_Function:
Replication, recombination and repair

# Drug_Target_29_General_References:
8207021	Shashidharan P, Michaelidis TM, Robakis NK, Kresovali A, Papamatheakis J, Plaitakis A: Novel human glutamate dehydrogenase expressed in neural and testicular tissues and encoded by an X-linked intronless gene. J Biol Chem. 1994 Jun 17;269(24):16971-6.

# Drug_Target_29_HGNC_ID:
HGNC:4336

# Drug_Target_29_HPRD_ID:
02143

# Drug_Target_29_ID:
830

# Drug_Target_29_Locus:
Xq24-q25

# Drug_Target_29_Molecular_Weight:
61435

# Drug_Target_29_Name:
Glutamate dehydrogenase 2, mitochondrial

# Drug_Target_29_Number_of_Residues:
558

# Drug_Target_29_PDB_ID:
1L1F

# Drug_Target_29_Pathway:
Not Available

# Drug_Target_29_Pfam_Domain_Function:
PF00208	ELFV_dehydrog
PF02812	ELFV_dehydrog_N

# Drug_Target_29_Protein_Sequence:
>Glutamate dehydrogenase 2, mitochondrial precursor
MYRYLAKALLPSRAGPAALGSAANHSAALLGRGRGQPAAASQPGLALAARRHYSELVADR
EDDPNFFKMVEGFFDRGASIVEDKLVKDLRTQESEEQKRNRVRGILRIIKPCNHVLSLSF
PIRRDDGSWEVIEGYRAQHSQHRTPCKGGIRYSTDVSVDEVKALASLMTYKCAVVDVPFG
GAKAGVKINPKNYTENELEKITRRFTMELAKKGFIGPGVDVPAPDMNTGEREMSWIADTY
ASTIGHYDINAHACVTGKPISQGGIHGRISATGRGVFHGIENFINEASYMSILGMTPGFR
DKTFVVQGFGNVGLHSMRYLHRFGAKCIAVGESDGSIWNPDGIDPKELEDFKLQHGSILG
FPKAKPYEGSILEVDCDILIPAATEKQLTKSNAPRVKAKIIAEGANGPTTPEADKIFLER
NILVIPDLYLNAGGVTVSYFEWLKNLNHVSYGRLTFKYERDSNYHLLLSVQESLERKFGK
HGGTIPIVPTAEFQDSISGASEKDIVHSALAYTMERSARQIMHTAMKYNLGLDLRTAAYV
NAIEKVFKVYSEAGVTFT

# Drug_Target_29_Reaction:
L-glutamate + H2O + NAD(P)+ = 2-oxoglutarate + NH3 + NAD(P)H + H+

# Drug_Target_29_Signals:
None

# Drug_Target_29_Specific_Function:
Important for recycling the chief excitatory neurotransmitter, glutamate, during neurotransmission

# Drug_Target_29_SwissProt_ID:
P49448

# Drug_Target_29_SwissProt_Name:
DHE4_HUMAN

# Drug_Target_29_Synonyms:
EC 1.4.1.3
GDH
Glutamate dehydrogenase 2, mitochondrial precursor

# Drug_Target_29_Theoretical_pI:
8.67

# Drug_Target_29_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17360958	Suzuki G, Kimura T, Satow A, Kaneko N, Fukuda J, Hikichi H, Sakai N, Maehara S, Kawagoe-Takaki H, Hata M, Azuma T, Ito S, Kawamoto H, Ohta H: Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N- methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC). J Pharmacol Exp Ther. 2007 Jun;321(3):1144-53. Epub 2007 Mar 14.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
GRM4

# Drug_Target_2_GenBank_ID_Gene:
X80818

# Drug_Target_2_GenBank_ID_Protein:
1160183

# Drug_Target_2_GeneCard_ID:
GRM4

# Drug_Target_2_Gene_Name:
GRM4

# Drug_Target_2_Gene_Sequence:
>2739 bp
ATGCCTGGGAAGAGAGGCTTGGGCTGGTGGTGGGCCCGGCTGCCCCTTTGCCTGCTCCTC
AGCCTTTACGGCCCCTGGATGCCTTCCTCCCTGGGAAAGCCCAAAGGCCACCCTCACATG
AATTCCATCCGCATAGATGGGGACATCACACTGGGAGGCCTGTTCCCGGTGCATGGCCGG
GGCTCAGAGGGCAAGCCCTGTGGAGAACTTAAGAAGGAAAAGGGCATCCACCGGCTGGAG
GCCATGCTGTTCGCCCTGGATCGCATCAACAACGACCCGGACCTGCTGCCTAACATCACG
CTGGGCGCCCGCATTCTGGACACCTGCTCCAGGGACACCCATGCCCTCGAGCAGTCGCTG
ACCTTTGTGCAGGCGCTCATCGAGAAGGATGGCACAGAGGTCCGCTGTGGCAGTGGCGGC
CCACCCATCATCACCAAGCCTGAACGTGTGGTGGGTGTCATCGGTGCTTCAGGGAGCTCG
GTCTCCATCATGGTGGCCAACATCCTTCGCCTCTTCAAGATACCCCAGATCAGCTACGCC
TCCACAGCGCCAGACCTGAGTGACAACAGCCGCTACGACTTCTTCTCCCGCGTGGTGCCC
TCGGACACGTACCAGGCCCAGGCCATGGTGGACATCGTCCGTGCCCTCAAGTGGAACTAT
GTGTCCACAGTGGCCTCGGAGGGCAGCTATGGTGAGAGCGGTGTGGAGGCCTTCATCCAG
AAGTCCCGTGAGGACGGGGGCGTGTGCATCGCCCAGTCGGTGAAGATACCACGGGAGCCC
AAGGCAGGCGAGTTCGACAAGATCATCCGCCGCCTCCTGGAGACTTCGAACGCCAGGGCA
GTCATCATCTTTGCCAACGAGGATGACATCAGGCGTGTGCTGGAGGCAGCACGAAGGGCC
AACCAGACAGGCCATTTCTTCTGGATGGGCTCTGACAGCTGGGGCTCCAAGATTGCACCT
GTGCTGCACCTGGAGGAGGTGGCTGAGGGTGCTGTCACGATCCTCCCCAAGAGGATGTCC
GTACGAGGCTTCGACCGCTACTTCTCCAGCCGCACGCTGGACAACAACCGGCGCAACATC
TGGTTTGCCGAGTTCTGGGAGGACAACTTCCACTGCAAGCTGAGCCGCCACGCCCTCAAG
AAGGGCAGCCACGTCAAGAAGTGCACCAACCGTGAGCGAATTGGGCAGGATTCAGCTTAT
GAGCAGGAGGGGAAGGTGCAGTTTGTGATCGATGCCGTGTACGCCATGGGCCACGCGCTG
CACGCCATGCACCGTGACCTGTGTCCCGGCCGCGTGGGGCTCTGCCCGCGCATGGACCCT
GTAGATGGCACCCAGCTGCTTAAGTACATCCGAAACGTCAACTTCTCAGGCATCGCAGGG
AACCCTGTGACCTTCAATGAGAATGGAGATGCGCCTGGGCGCTATGACATCTACCAATAC
CAGCTGCGCAACGATTCTGCCGAGTACAAGGTCATTGGCTCCTGGACTGACCACCTGCAC
CTTAGAATAGAGCGGATGCACTGGCCGGGGAGCGGGCAGCAGCTGCCCCGCTCCATCTGC
AGCCTGCCCTGCCAACCGGGTGAGCGGAAGAAGACAGTGAAGGGCATGCCTTGCTGCTGG
CACTGCGAGCCTTGCACAGGGTACCAGTACCAGGTGGACCGCTACACCTGTAAGACGTGT
CCCTATGACATGCGGCCCACAGAGAACCGCACGGGCTGCCGGCCCATCCCCATCATCAAG
CTTGAGTGGGGCTCGCCCTGGGCCGTGCTGCCCCTCTTCCTGGCCGTGGTGGGCATCGCT
GCCACGTTGTTCGTGGTGATCACCTTTGTGCGCTACAACGACACGCCCATCGTCAAGGCC
TCGGGCCGTGAACTGAGCTACGTGCTGCTGGCAGGCATCTTCCTGTGCTATGCCACCACC
TTCCTCATGATCGCTGAGCCCGACCTTGGCACCTGCTCGCTGCGCCGAATCTTCCTGGGA
CTAGGGATGAGCATCAGCTATGCAGCCCTGCTCACCAAGACCAACCGCATCTACCGCATC
TTCGAGCAGGGCAAGCGCTCGGTCAGTGCCCCACGCTTCATCAGCCCCGCCTCACAGCTG
GCCATCACCTTCAGCCTCATCTCGCTGCAGCTGCTGGGCATCTGTGTGTGGTTTGTGGTG
GACCCCTCCCACTCGGTGGTGGACTTCCAGGACCAGCGGACACTCGACCCCCGCTTCGCC
AGGGGTGTGCTCAAGTGTGACATCTCGGACCTGTCGCTCATCTGCCTGCTGGGCTACAGC
ATGCTGCTCATGGTCACGTGCACCGTGTATGCCATCAAGACACGCGGCGTGCCCGAGACC
TTCAATGAGGCCAAGCCCATTGGCTTCACCATGTACACCACTTGCATCGTCTGGCTGGCC
TTCATCCCCATCTTCTTTGGCACCTCGCAGTCGGCCGACAAGCTGTACATCCAGACGACG
ACGCTGACGGTCTCGGTGAGTCTGAGCGCCTCGGTGTCCCTGGGAATGCTCTACATGCCC
AAAGTCTACATCATCCTCTTCCACCCGGAGCAGAACGTGCCCAAGCGCAAGCGCAGCCTC
AAAGCCGTCGTTACGGCGGCCACCATGTCCAACAAGTTCACGCAGAAGGGCAACTTCCGG
CCCAACGGAGAGGCCAAGTCTGAGCTCTGCGAGAACCTTGAGGCCCCAGCGCTGGCCACC
AAACAGACTTACGTCACTTACACCAACCATGCAATCTAG

# Drug_Target_2_General_Function:
Amino acid transport and metabolism

# Drug_Target_2_General_References:
11525421	Ohtsuki T, Toru M, Arinami T: Mutation screening of the metabotropic glutamate receptor mGluR4 (GRM4) gene in patients with schizophrenia. Psychiatr Genet. 2001 Jun;11(2):79-83.
14574404	Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE, Gilbert JG, Clamp ME, Bethel G, Milne S, Ainscough R, Almeida JP, Ambrose KD, Andrews TD, Ashwell RI, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beare DM, Beasley H, Beasley O, Bird CP, Blakey S, Bray-Allen S, Brook J, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Clark SY, Clark G, Clee CM, Clegg S, Cobley V, Collier RE, Collins JE, Colman LK, Corby NR, Coville GJ, Culley KM, Dhami P, Davies J, Dunn M, Earthrowl ME, Ellington AE, Evans KA, Faulkner L, Francis MD, Frankish A, Frankland J, French L, Garner P, Garnett J, Ghori MJ, Gilby LM, Gillson CJ, Glithero RJ, Grafham DV, Grant M, Gribble S, Griffiths C, Griffiths M, Hall R, Halls KS, Hammond S, Harley JL, Hart EA, Heath PD, Heathcott R, Holmes SJ, Howden PJ, Howe KL, Howell GR, Huckle E, Humphray SJ, Humphries MD, Hunt AR, Johnson CM, Joy AA, Kay M, Keenan SJ, Kimberley AM, King A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd CR, Lloyd DM, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, Maslen GL, Matthews L, McCann OT, McLaren SJ, McLay K, McMurray A, Moore MJ, Mullikin JC, Niblett D, Nickerson T, Novik KL, Oliver K, Overton-Larty EK, Parker A, Patel R, Pearce AV, Peck AI, Phillimore B, Phillips S, Plumb RW, Porter KM, Ramsey Y, Ranby SA, Rice CM, Ross MT, Searle SM, Sehra HK, Sheridan E, Skuce CD, Smith S, Smith M, Spraggon L, Squares SL, Steward CA, Sycamore N, Tamlyn-Hall G, Tester J, Theaker AJ, Thomas DW, Thorpe A, Tracey A, Tromans A, Tubby B, Wall M, Wallis JM, West AP, White SS, Whitehead SL, Whittaker H, Wild A, Willey DJ, Wilmer TE, Wood JM, Wray PW, Wyatt JC, Young L, Younger RM, Bentley DR, Coulson A, Durbin R, Hubbard T, Sulston JE, Dunham I, Rogers J, Beck S: The DNA sequence and analysis of human chromosome 6. Nature. 2003 Oct 23;425(6960):805-11.
7617140	Flor PJ, Lukic S, Ruegg D, Leonhardt T, Knopfel T, Kuhn R: Molecular cloning, functional expression and pharmacological characterization of the human metabotropic glutamate receptor type 4. Neuropharmacology. 1995 Feb;34(2):149-55.
8738157	Makoff A, Lelchuk R, Oxer M, Harrington K, Emson P: Molecular characterization and localization of human metabotropic glutamate receptor type 4. Brain Res Mol Brain Res. 1996 Apr;37(1-2):239-48.
9473604	Wu S, Wright RA, Rockey PK, Burgett SG, Arnold JS, Rosteck PR Jr, Johnson BG, Schoepp DD, Belagaje RM: Group III human metabotropic glutamate receptors 4, 7 and 8: molecular cloning, functional expression, and comparison of pharmacological properties in RGT cells. Brain Res Mol Brain Res. 1998 Jan;53(1-2):88-97.

# Drug_Target_2_HGNC_ID:
HGNC:4596

# Drug_Target_2_HPRD_ID:
04978

# Drug_Target_2_ID:
925

# Drug_Target_2_Locus:
6p21.3

# Drug_Target_2_Molecular_Weight:
101869

# Drug_Target_2_Name:
Metabotropic glutamate receptor 4

# Drug_Target_2_Number_of_Residues:
912

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00003	7tm_3
PF01094	ANF_receptor
PF07562	NCD3G

# Drug_Target_2_Protein_Sequence:
>Metabotropic glutamate receptor 4 precursor
MPGKRGLGWWWARLPLCLLLSLYGPWMPSSLGKPKGHPHMNSIRIDGDITLGGLFPVHGR
GSEGKPCGELKKEKGIHRLEAMLFALDRINNDPDLLPNITLGARILDTCSRDTHALEQSL
TFVQALIEKDGTEVRCGSGGPPIITKPERVVGVIGASGSSVSIMVANILRLFKIPQISYA
STAPDLSDNSRYDFFSRVVPSDTYQAQAMVDIVRALKWNYVSTVASEGSYGESGVEAFIQ
KSREDGGVCIAQSVKIPREPKAGEFDKIIRRLLETSNARAVIIFANEDDIRRVLEAARRA
NQTGHFFWMGSDSWGSKIAPVLHLEEVAEGAVTILPKRMSVRGFDRYFSSRTLDNNRRNI
WFAEFWEDNFHCKLSRHALKKGSHVKKCTNRERIGQDSAYEQEGKVQFVIDAVYAMGHAL
HAMHRDLCPGRVGLCPRMDPVDGTQLLKYIRNVNFSGIAGNPVTFNENGDAPGRYDIYQY
QLRNDSAEYKVIGSWTDHLHLRIERMHWPGSGQQLPRSICSLPCQPGERKKTVKGMPCCW
HCEPCTGYQYQVDRYTCKTCPYDMRPTENRTGCRPIPIIKLEWGSPWAVLPLFLAVVGIA
ATLFVVITFVRYNDTPIVKASGRELSYVLLAGIFLCYATTFLMIAEPDLGTCSLRRIFLG
LGMSISYAALLTKTNRIYRIFEQGKRSVSAPRFISPASQLAITFSLISLQLLGICVWFVV
DPSHSVVDFQDQRTLDPRFARGVLKCDISDLSLICLLGYSMLLMVTCTVYAIKTRGVPET
FNEAKPIGFTMYTTCIVWLAFIPIFFGTSQSADKLYIQTTTLTVSVSLSASVSLGMLYMP
KVYIILFHPEQNVPKRKRSLKAVVTAATMSNKFTQKGNFRPNGEAKSELCENLEAPALAT
KQTYVTYTNHAI

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
1-32

# Drug_Target_2_Specific_Function:
Receptor for glutamate. The activity of this receptor is mediated by a G-protein that inhibits adenylate cyclase activity

# Drug_Target_2_SwissProt_ID:
Q14833

# Drug_Target_2_SwissProt_Name:
GRM4_HUMAN

# Drug_Target_2_Synonyms:
Metabotropic glutamate receptor 4 precursor
mGluR4

# Drug_Target_2_Theoretical_pI:
8.98

# Drug_Target_2_Transmembrane_Regions:
588-610
625-645
657-675
700-720
751-772
786-808
822-847

# Drug_Target_30_Cellular_Location:
Cytoplasm

# Drug_Target_30_Chromosome_Location:
Not Available

# Drug_Target_30_Drug_References:
12069605	Ravasio S, Dossena L, Martin-Figueroa E, Florencio FJ, Mattevi A, Morandi P, Curti B, Vanoni MA: Properties of the recombinant ferredoxin-dependent glutamate synthase of Synechocystis PCC6803. Comparison with the Azospirillum brasilense NADPH-dependent enzyme and its isolated alpha subunit. Biochemistry. 2002 Jun 25;41(25):8120-33.
16142895	Myers RS, Amaro RE, Luthey-Schulten ZA, Davisson VJ: Reaction coupling through interdomain contacts in imidazole glycerol phosphate synthase. Biochemistry. 2005 Sep 13;44(36):11974-85.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
7907328	Boehlein SK, Richards NG, Schuster SM: Glutamine-dependent nitrogen transfer in Escherichia coli asparagine synthetase B. Searching for the catalytic triad. J Biol Chem. 1994 Mar 11;269(10):7450-7.

# Drug_Target_30_Essentiality:
Non-Essential

# Drug_Target_30_GenAtlas_ID:
GMPS

# Drug_Target_30_GenBank_ID_Gene:
U10860

# Drug_Target_30_GenBank_ID_Protein:
595410

# Drug_Target_30_GeneCard_ID:
GMPS

# Drug_Target_30_Gene_Name:
GMPS

# Drug_Target_30_Gene_Sequence:
>2082 bp
ATGGCTCTGTGCAACGGAGACTCCAAGCTGGAGAATGCTGGAGGAGACCTTAAGGATGGC
CACCACCACTATGAAGGAGCTGTTGTCATTCTGGATGCTGGTGCTCAGTACGGGAAAGTC
ATAGACCGAAGAGTGAGGGAACTGTTCGTGCAGTCTGAAATTTTCCCCTTGGAAACACCA
GCATTTGCTATAAAGGAACAAGGATTCCGTGCTATTATCATCTCTGGAGGACCTAATTCT
GTGTATGCTGAAGATGCTCCCTGGTTTGATCCAGCAATATTCACTATTGGCAAGCCTGTT
CTTGGAATTTGCTATGGTATGCAGATGATGAATAAGGTATTTGGAGGTACTGTGCACAAA
AAAAGTGTCAGAGAAGATGGAGTTTTCAACATTAGTGTGGATAATACATGTTCATTATTC
AGGGGCCTTCAGAAGGAAGAAGTTGTTTTGCTTACACATGGAGATAGTGTAGACAAAGTA
GCTGATGGATTCAAGGTTGTGGCACGTTCTGGAAACATAGTAGCAGGCATAGCAAATGAA
TCTAAAAAGTTATATGGAGCACAGTTCCACCCTGAAGTTGGCCTTACAGAAAATGGAAAA
GTAATACTGAAGAATTTCCTTTATGATATAGCTGGATGCAGTGGAACCTTCACCGTGCAG
AACAGAGAACTTGAGTGTATTCGAGAGATCAAAGAGAGAGTAGGCACGTCAAAAGTTTTG
GTTTTACTCAGTGGTGGAGTAGACTCAACAGTTTGTACAGCTTTGCTAAATCGTGCTTTG
AACCAAGAACAAGTCATTGCTGTGCACATTGATAATGGCTTTATGAGAAAACGAGAAAGC
CAGTCTGTTGAAGAGGCCCTCAAAAAGCTTGGAATTCAGGTCAAAGTGATAAATGCTGCT
CATTCTTTCTACAATGGAACAACAACCCTACCAATATCAGATGAAGATAGAACCCCACGG
AAAAGAATTAGCAAAACGTTAAATATGACCACAAGTCCTGAAGAGAAAAGAAAAATCATT
GGGGATACTTTTGTTAAGATTGCCAATGAAGTAATTGGAGAAATGAACTTGAAACCAGAG
GAGGTTTTCCTTGCCCAAGGTACTTTACGGCCTGATCTAATTGAAAGTGCATCCCTTGTT
GCAAGTGGCAAAGCTGAACTCATCAAAACCCATCACAATGACACAGAGCTCATCAGAAAG
TTGAGAGAGGAGGGAAAAGTAATAGAACCTCTGAAAGATTTTCATAAAGATGAAGTGAGA
ATTTTGGGCAGAGAACTTGGACTTCCAGAAGAGTTAGTTTCCAGGCATCCATTTCCAGGT
CCTGGCCTGGCAATCAGAGTAATATGTGCTGAAGAACCTTATATTTGTAAGGACTTTCCT
GAAACCAACAATATTTTGAAAATAGTAGCTGATTTTTCTGCAAGTGTTAAAAAGCCACAT
ACCCTATTACAGAGAGTCAAAGCCTGCACAACAGAAGAGGATCAGGAGAAGCTGATGCAA
ATTACCAGTCTGCATTCACTGAATGCCTTCTTGCTGCCAATTAAAACTGTAGGTGTGCAG
GGTGACTGTCGTTCCTACAGTTACGTGTGTGGAATCTCCAGTAAAGATGAACCTGACTGG
GAATCACTTATTTTTCTGGCTAGGCTTATACCTCGCATGTGTCACAACGTTAACAGAGTT
GTTTATATATTTGGCCCACCAGTTAAAGAACCTCCTACAGATGTTACTCCCACTTTCTTG
ACAACAGGGGTGCTCAGTACTTTACGCCAAGCTGATTTTGAGGCCCATAACATTCTCAGG
GAGTCTGGGTATGCTGGGAAAATCAGCCAGATGCCGGTGATTTTGACACCATTACATTTT
GATCGGGACCCACTTCAAAAGCAGCCTTCATGCCAGAGATCTGTGGTTATTCGAACCTTT
ATTACTAGTGACTTCATGACTGGTATACCTGCAACACCTGGCAATGAGATCCCTGTAGAG
GTGGTATTAAAGATGGTCACTGAGATTAAGAAGATTCCTGGTATTTCTCGAATTATGTAT
GACTTAACATCAAAGCCCCCAGGAACTACTGAGTGGGAGTAA

# Drug_Target_30_General_Function:
Nucleotide transport and metabolism

# Drug_Target_30_General_References:
8089153	Hirst M, Haliday E, Nakamura J, Lou L: Human GMP synthetase. Protein purification, cloning, and functional expression of cDNA. J Biol Chem. 1994 Sep 23;269(38):23830-7.

# Drug_Target_30_HGNC_ID:
HGNC:4378

# Drug_Target_30_HPRD_ID:
10927

# Drug_Target_30_ID:
355

# Drug_Target_30_Locus:
3q24

# Drug_Target_30_Molecular_Weight:
76716

# Drug_Target_30_Name:
GMP synthase [glutamine-hydrolyzing]

# Drug_Target_30_Number_of_Residues:
693

# Drug_Target_30_PDB_ID:
Not Available

# Drug_Target_30_Pathway:
Azathioprine Pathway	SMP00427
Mercaptopurine Pathway	SMP00428
Thioguanine Pathway	SMP00430

# Drug_Target_30_Pfam_Domain_Function:
PF00117	GATase
PF00958	GMP_synt_C
PF06508	ExsB

# Drug_Target_30_Protein_Sequence:
>GMP synthase [glutamine-hydrolyzing]
MALCNGDSKLENAGGDLKDGHHHYEGAVVILDAGAQYGKVIDRRVRELFVQSEIFPLETP
AFAIKEQGFRAIIISGGPNSVYAEDAPWFDPAIFTIGKPVLGICYGMQMMNKVFGGTVHK
KSVREDGVFNISVDNTCSLFRGLQKEEVVLLTHGDSVDKVADGFKVVARSGNIVAGIANE
SKKLYGAQFHPEVGLTENGKVILKNFLYDIAGCSGTFTVQNRELECIREIKERVGTSKVL
VLLSGGVDSTVCTALLNRALNQEQVIAVHIDNGFMRKRESQSVEEALKKLGIQVKVINAA
HSFYNGTTTLPISDEDRTPRKRISKTLNMTTSPEEKRKIIGDTFVKIANEVIGEMNLKPE
EVFLAQGTLRPDLIESASLVASGKAELIKTHHNDTELIRKLREEGKVIEPLKDFHKDEVR
ILGRELGLPEELVSRHPFPGPGLAIRVICAEEPYICKDFPETNNILKIVADFSASVKKPH
TLLQRVKACTTEEDQEKLMQITSLHSLNAFLLPIKTVGVQGDCRSYSYVCGISSKDEPDW
ESLIFLARLIPRMCHNVNRVVYIFGPPVKEPPTDVTPTFLTTGVLSTLRQADFEAHNILR
ESGYAGKISQMPVILTPLHFDRDPLQKQPSCQRSVVIRTFITSDFMTGIPATPGNEIPVE
VVLKMVTEIKKIPGISRIMYDLTSKPPGTTEWE

# Drug_Target_30_Reaction:
ATP + xanthosine 5'-phosphate + L-glutamine + H2O = AMP + diphosphate + GMP + L-glutamate

# Drug_Target_30_Signals:
None

# Drug_Target_30_Specific_Function:
Involved in the de novo synthesis of guanine nucleotides which are not only essential for DNA and RNA synthesis, but also provide GTP, which is involved in a number of cellular processes important for cell division

# Drug_Target_30_SwissProt_ID:
P49915

# Drug_Target_30_SwissProt_Name:
GUAA_HUMAN

# Drug_Target_30_Synonyms:
EC 6.3.5.2
GMP synthetase
Glutamine amidotransferase

# Drug_Target_30_Theoretical_pI:
6.86

# Drug_Target_30_Transmembrane_Regions:
None

# Drug_Target_31_Cellular_Location:
Cytoplasm

# Drug_Target_31_Chromosome_Location:
Not Available

# Drug_Target_31_Drug_References:
17559390	Smirnov SV, Samsonova NN, Novikova AE, Matrosov NG, Rushkevich NY, Kodera T, Ogawa J, Yamanaka H, Shimizu S: A novel strategy for enzymatic synthesis of 4-hydroxyisoleucine: identification of an enzyme possessing HMKP (4-hydroxy-3-methyl-2-keto-pentanoate) aldolase activity. FEMS Microbiol Lett. 2007 Aug;273(1):70-7. Epub 2007 Jun 6.

# Drug_Target_31_Essentiality:
Non-Essential

# Drug_Target_31_GenAtlas_ID:
BCAT1

# Drug_Target_31_GenBank_ID_Gene:
U21551

# Drug_Target_31_GenBank_ID_Protein:
1036780

# Drug_Target_31_GeneCard_ID:
BCAT1

# Drug_Target_31_Gene_Name:
BCAT1

# Drug_Target_31_Gene_Sequence:
>1155 bp
ATGGATTGCAGTAACGGATCGGCAGAGTGTACCGGAGAAGGAGGATCAAAAGAGGTGGTG
GGGACTTTTAAGGCTAAAGACCTAATAGTCACACCAGCTACCATTTTAAAGGAAAAACCA
GACCCCAATAATCTGGTTTTTGGAACTGTGTTCACGGATCATATGCTGACGGTGGAGTGG
TCCTCAGAGTTTGGATGGGAGAAACCTCATATCAAGCCTCTTCAGAACCTGTCATTGCAC
CCTGGCTCATCAGCTTTGCACTATGCAGTGGAATTATTTGAAGGATTGAAGGCATTTCGA
GGAGTAGATAATAAAATTCGACTGTTTCAGCCAAACCTCAACATGGATAGAATGTATCGC
TCTGCTGTGAGGGCAACTCTGCCGGTATTTGACAAAGAAGAGCTCTTAGAGTGTATTCAA
CAGCTTGTGAAATTGGATCAAGAATGGGTCCCATATTCAACATCTGCTAGTCTGTATATT
CGTCCTGCATTCATTGGAACTGAGCCTTCTCTTGGAGTCAAGAAGCCTACCAAAGCCCTG
CTCTTTGTACTCTTGAGCCCAGTGGGACCTTATTTTTCAAGTGGAACCTTTAATCCAGTG
TCCCTGTGGGCCAATCCCAAGTATGTAAGAGCCTGGAAAGGTGGAACTGGGGACTGCAAG
ATGGGAGGGAATTACGGCTCATCTCTTTTTGCCCAATGTGAAGACGTAGATAATGGGTGT
CAGCAGGTCCTGTGGCTCTATGGCAGAGACCATCAGATCACTGAAGTGGGAACTATGAAT
CTTTTTCTTTACTGGATAAATGAAGATGGAGAAGAAGAACTGGCAACTCCTCCACTAGAT
GGCATCATTCTTCCAGGAGTGACAAGGCGGTGCATTCTGGACCTGGCACATCAGTGGGGT
GAATTTAAGGTGTCAGAGAGATACCTCACCATGGATGACTTGACAACAGCCCTGGAGGGG
AACAGAGTGAGAGAGATGTTTAGCTCTGGTACAGCCTGTGTTGTTTGCCCAGTTTCTGAT
ATACTGTACAAAGGCGAGACAATACACATTCCAACTATGGAGAATGGTCCTAAGCTGGCA
AGCCGCATCTTGAGCAAATTAACTGATATCCAGTATGGAAGAGAAGAGAGCGACTGGACA
ATTGTGCTATCCTGA

# Drug_Target_31_General_Function:
Amino acid transport and metabolism

# Drug_Target_31_General_References:
8692959	Schuldiner O, Eden A, Ben-Yosef T, Yanuka O, Simchen G, Benvenisty N: ECA39, a conserved gene regulated by c-Myc in mice, is involved in G1/S cell cycle regulation in yeast. Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7143-8.

# Drug_Target_31_HGNC_ID:
HGNC:976

# Drug_Target_31_HPRD_ID:
00216

# Drug_Target_31_ID:
574

# Drug_Target_31_Locus:
12pter-q12

# Drug_Target_31_Molecular_Weight:
42953

# Drug_Target_31_Name:
Branched-chain-amino-acid aminotransferase, cytosolic

# Drug_Target_31_Number_of_Residues:
386

# Drug_Target_31_PDB_ID:
Not Available

# Drug_Target_31_Pathway:
Not Available

# Drug_Target_31_Pfam_Domain_Function:
PF01063	Aminotran_4

# Drug_Target_31_Protein_Sequence:
>Branched-chain-amino-acid aminotransferase, cytosolic
MKDCSNGCSAECTGEGGSKEVVGTFKAKDLIVTPATILKEKPDPNNLVFGTVFTDHMLTV
EWSSEFGWEKPHIKPLQNLSLHPGSSALHYAVELFEGLKAFRGVDNKIRLFQPNLNMDRM
YRSAVRATLPVFDKEELLECIQQLVKLDQEWVPYSTSASLYIRPTFIGTEPSLGVKKPTK
ALLFVLLSPVGPYFSSGTFNPVSLWANPKYVRAWKGGTGDCKMGGNYGSSLFAQCEAVDN
GCQQVLWLYGEDHQITEVGTMNLFLYWINEDGEEELATPPLDGIILPGVTRRCILDLAHQ
WGEFKVSERYLTMDDLSTALEGNRVREMFGSGTACVVCPVSDILYKGETIHIPTMENGPK
LASRILSKLTDIQYGREESDWTIVLS

# Drug_Target_31_Reaction:
L-leucine + 2-oxoglutarate = 4-methyl-2-oxopentanoate + L-glutamate

# Drug_Target_31_Signals:
None

# Drug_Target_31_Specific_Function:
Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine

# Drug_Target_31_SwissProt_ID:
P54687

# Drug_Target_31_SwissProt_Name:
BCAT1_HUMAN

# Drug_Target_31_Synonyms:
BCAT(c)
EC 2.6.1.42
ECA39 protein

# Drug_Target_31_Theoretical_pI:
4.95

# Drug_Target_31_Transmembrane_Regions:
None

# Drug_Target_32_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_32_Chromosome_Location:
Not Available

# Drug_Target_32_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
1983997	Imai H, Okuno T, Wu JY, Lee TJ: GABAergic innervation in cerebral blood vessels: an immunohistochemical demonstration of L-glutamic acid decarboxylase and GABA transaminase. J Cereb Blood Flow Metab. 1991 Jan;11(1):129-34.
3299141	Happola O, Paivarinta H, Soinila S, Wu JY, Panula P: Localization of L-glutamate decarboxylase and GABA transaminase immunoreactivity in the sympathetic ganglia of the rat. Neuroscience. 1987 Apr;21(1):271-81.
8979623	Far SR, Millimoria FR: Levels of glutamic acid decarboxylase (GAD), gamma amino butyric acid transaminase (GABA-T), glutamic acid dehydrogenase (GLDH) and proteins in cerebrospinal fluid of certain neurological disorders. Indian J Med Sci. 1996 Apr;50(4):99-102.

# Drug_Target_32_Essentiality:
Non-Essential

# Drug_Target_32_GenAtlas_ID:
ABAT

# Drug_Target_32_GenBank_ID_Gene:
L32961

# Drug_Target_32_GenBank_ID_Protein:
602705

# Drug_Target_32_GeneCard_ID:
ABAT

# Drug_Target_32_Gene_Name:
ABAT

# Drug_Target_32_Gene_Sequence:
>1503 bp
ATGGCCTCCATGTTGCTCGCCCAGCGGCTGGCCTGCAGCTTCCAGCACACGTACCGCCTG
CTGGTGCCTGGATCCAGACACATTAGTCAAGCTGCAGCCAAAGTCGACGTTGAATTTGAT
TATGATGGGCCTCTGATGAAGACGGAAGTCCCAGGGCCTAGATCTCAGGAGTTAATGAAA
CAGCTGAATATAATTCAGAATGCAGAGGCTGTGCATTTTTTCTGCAATTACGAAGAGAGC
CGAGGCAATTACCTGGTTGATGTGGACGGCAACCGAATGCTGGATCTTTATTCCCAGATC
TCCTCTGTTCCCATAGGTTACAGCGACCCGGCCCTCGTGAAACTCATCCAACAGCCACAA
AATGCGAGCATGTTTGTCAACAGACCCGCCCTCGAAATCCTGCCTCCGGAGAACTTTGTG
GAGAAGCTCCGGCAGTCCTTGCTCTCGGTGGCTCCCAAAGGGATGTCCCAGCTCATCACC
ATGGCCTGCGGCTCCTGCTCCAATGAAAACGCCTTAAAGACCATCTTCATGTGGTACCGG
AGCAAGGAAAGAGGGCAGAGGGGATTCTCCAAAGAGGAGCTGGAGACGTGCATGATTAAC
CAGGCCCCCTGGTGCCCCGACTACAGCATCCTCTCCTTCATGGGTTCCTTCCATGGGAGG
ACCATGGGTTGCTTAGCGACCACGCACTCTAAAGCCATTCACAAGATCGATATCCCTTCC
TTTGACTGGCCCATCGCACCGTTCCCACGGCTGAAATACCCTCTGGAAGAGTTTGTGAAA
GAGAACCAACAGGAAGAGGCCGGCTGTCTGGAAGAGGTTGAGGATCTGATTGTGAAATAT
CGAAAAAAGAAGAAGACGGTGGCCGGGATCATCGTGGAGCCCATCCAGTCCGAGGGTGGA
GACAACCATGCATCCGATGACTTCTTTCGGAAGCTGAGAGACATCGCCAGGAAGCACTGC
TGCGCCTTCTTGGTGGACGAGGTCCAGACCGGAGGAGGCTGCACGGGCAAGTTCTGGGCC
CATGAGCACTGGGGCCTGGATGACCCAGCAGACGTGATGACCTTCAGCAAGAAGATGATG
ACTGGGGGCTTCTTCCTCAAGGAGGAGTTCAGGCCTAATGCTCCCTACCGGATCTTCAAC
ACGTGGCTGGGGGACCCGTCCAAGAACCTGTTGCTGGCTGAGGTCATCAACATCATCAAG
CGGGAGGACCTGCTAAATAATGCAGCCCATGCCGGGAAGGCCCTGCTCACAGGACTGCTG
GACCTCCAGGCCCGGTACCCCCAGTTCATCAGCAGGGTGAGAGGACGAGGCACCTTTTGC
TCCTTCGATACTCCCGATGATTCCATACGGAATAAGCTCATTTTAATTGCCAGAAACAAA
GGTGTGGTGTTGGGTGGCTGTGGTGACAAATCCATTCGTTTCCGTCCCACGCTGGTGTTC
AGGGATCACCACGCTCACCTGTTCCTCAATATTTTCAGTGACATCTTAGCAGACTTCAAG
TAA

# Drug_Target_32_General_Function:
Amino acid transport and metabolism

# Drug_Target_32_General_References:
10407778	Medina-Kauwe LK, Tobin AJ, De Meirleir L, Jaeken J, Jakobs C, Nyhan WL, Gibson KM: 4-Aminobutyrate aminotransferase (GABA-transaminase) deficiency. J Inherit Metab Dis. 1999 Jun;22(4):414-27.
7721088	Osei YD, Churchich JE: Screening and sequence determination of a cDNA encoding the human brain 4-aminobutyrate aminotransferase. Gene. 1995 Apr 3;155(2):185-7.
7851425	De Biase D, Barra D, Simmaco M, John RA, Bossa F: Primary structure and tissue distribution of human 4-aminobutyrate aminotransferase. Eur J Biochem. 1995 Jan 15;227(1-2):476-80.

# Drug_Target_32_HGNC_ID:
HGNC:23

# Drug_Target_32_HPRD_ID:
00661

# Drug_Target_32_ID:
280

# Drug_Target_32_Locus:
16p13.2

# Drug_Target_32_Molecular_Weight:
56440

# Drug_Target_32_Name:
4-aminobutyrate aminotransferase, mitochondrial

# Drug_Target_32_Number_of_Residues:
500

# Drug_Target_32_PDB_ID:
1OHY

# Drug_Target_32_Pathway:
Not Available

# Drug_Target_32_Pfam_Domain_Function:
PF00202	Aminotran_3

# Drug_Target_32_Protein_Sequence:
>4-aminobutyrate aminotransferase, mitochondrial precursor
MASMLLAQRLACSFQHSYRLLVPGSRHISQAAAKVDVEFDYDGPLMKTEVPGPRSQELMK
QLNIIQNAEAVHFFCNYEESRGNYLVDVDGNRMLDLYSQISSVPIGYSHPALLKLIQQPQ
NASMFVNRPALGILPPENFVEKLRQSLLSVAPKGMSQLITMACGSCSNENALKTIFMWYR
SKERGQRGFSQEELETCMINQAPGCPDYSILSFMGAFHGRTMGCLATTHSKAIHKIDIPS
FDWPIAPFPRLKYPLEEFVKENQQEEARCLEEVEDLIVKYRKKKKTVAGIIVEPIQSEGG
DNHASDDFFRKLRDIARKHGCAFLVDEVQTGGGCTGKFWAHEHWGLDDPADVMTFSKKMM
TGGFFHKEEFRPNAPYRIFNTWLGDPSKNLLLAEVINIIKREDLLNNAAHAGKALLTGLL
DLQARYPQFISRVRGRGTFCSFDTPDDSIRNKLILIARNKGVVLGGCGDKSIRFRPTLVF
RDHHAHLFLNIFSDILADFK

# Drug_Target_32_Reaction:
4-aminobutanoate + 2-oxoglutarate = succinate semialdehyde + L-glutamate

# Drug_Target_32_Signals:
None

# Drug_Target_32_Specific_Function:
Catalyzes the conversion of gamma-aminobutyrate and L- beta-aminoisobutyrate to succinate semialdehyde and methylmalonate semialdehyde, respectively. Can also convert delta-aminovalerate and beta-alanine

# Drug_Target_32_SwissProt_ID:
P80404

# Drug_Target_32_SwissProt_Name:
GABT_HUMAN

# Drug_Target_32_Synonyms:
(S)-3-amino-2-methylpropionate transaminase
4-aminobutyrate aminotransferase, mitochondrial precursor
EC 2.6.1.19
EC 2.6.1.22
GABA aminotransferase
GABA transaminase
GABA-AT
GABA-T
Gamma-amino-N-butyrate transaminase
L-AIBAT

# Drug_Target_32_Theoretical_pI:
8.04

# Drug_Target_32_Transmembrane_Regions:
None

# Drug_Target_33_Cellular_Location:
Cell membrane
multi-pass membrane protein. Enriched in post-synaptic plasma membrane and post-synap

# Drug_Target_33_Chromosome_Location:
Not Available

# Drug_Target_33_Drug_References:
17662248	Miglio G, Dianzani C, Fallarini S, Fantozzi R, Lombardi G: Stimulation of N-methyl-D-aspartate receptors modulates Jurkat T cell growth and adhesion to fibronectin. Biochem Biophys Res Commun. 2007 Sep 21;361(2):404-9. Epub 2007 Jul 20.

# Drug_Target_33_Essentiality:
Non-Essential

# Drug_Target_33_GenAtlas_ID:
GRIN1

# Drug_Target_33_GenBank_ID_Gene:
D13515

# Drug_Target_33_GenBank_ID_Protein:
219920

# Drug_Target_33_GeneCard_ID:
GRIN1

# Drug_Target_33_Gene_Name:
GRIN1

# Drug_Target_33_Gene_Sequence:
>2817 bp
ATGAGCACCATGCGCCTGCTGACGCTCGCCCTGCTGTTCTCCTGCTCCGTCGCCCGTGCC
GCGTGCGACCCCAAGATCGTCAACATTGGCGCGGTGCTGAGCACGCGGAAGCACGAGCAG
ATGTTCCGCGAGGCCGTGAACCAGGCCAACAAGCGGCACGGCTCCTGGAAGATTCAGCTC
AATGCCACCTCCGTCACGCACAAGCCCAACGCCATCCAGATGGCTCTGTCGGTGTGCGAG
GACCTCATCTCCAGCCAGGTCTACGCCATCCTAGTTAGCCATCCACCTACCCCCAACGAC
CACTTCACTCCCACCCCTGTCTCCTACACAGCCGGCTTCTACCGCATACCCGTGCTGGGG
CTGACCACCCGCATGTCCATCTACTCGGACAAGAGCATCCACCTGAGCTTCCTGCGCACC
GTGCCGCCCTACTCCCACCAGTCCAGCGTGTGGTTTGAGATGATGCGTGTCTACAGCTGG
AACCACATCATCCTGCTGGTCAGCGACGACCACGAGGGCCGGGCGGCTCAGAAACGCCTG
GAGACGCTGCTGGAGGAGCGTGAGTCCAAGGCAGAGAAGGTGCTGCAGTTTGACCCAGGG
ACCAAGAACGTGACGGCCCTGCTGATGGAGGCGAAAGAGCTGGAGGCCCGGGTCATCATC
CTTTCTGCCAGCGAGGACGATGCTGCCACTGTATACCGCGCAGCCGCGATGCTGAACATG
ACGGGCTCCGGGTACGTGTGGCTGGTCGGCGAGCGCGAGATCTCGGGGAACGCCCTGCGC
TACGCCCCAGACGGCATCCTCGGGCTGCAGCTCATCAACGGCAAGAACGAGTCGGCCCAC
ATCAGCGACGCCGTGGGCGTGGTGGCCCAGGCCGTGCACGAGCTCCTCGAGAAGGAGAAC
ATCACCGACCCGCCGCGGGGCTGCGTGGGCAACACCAACATCTGGAAGACCGGGCCGCTC
TTCAAGAGAGTGCTGATGTCTTCCAAGTATGCGGATGGGGTGACTGGTCGCGTGGAGTTC
AATGAGGATGGGGACCGGAAGTTCGCCAACTACAGCATCATGAACCTGCAGAACCGCAAG
CTGGTGCAAGTGGGCATCTACAATGGCACCCACGTCATCCCTAATGACAGGAAGATCATC
TGGCCAGGCGGAGAGACAGAGAAGCCTCGAGGGTACCAGATGTCCACCAGACTGAAGATT
GTGACGATCCACCAGGAGCCCTTCGTGTACGTCAAGCCCACGCTGAGTGATGGGACATGC
AAGGAGGAGTTCACAGTCAACGGCGACCCAGTCAAGAAGGTGATCTGCACCGGGCCCAAC
GACACGTCGCCGGGCAGCCCCCGCCACACGGTGCCTCAGTGTTGCTACGGCTTTTGCATC
GACCTGCTCATCAAGCTGGCACGGACCATGAACTTCACCTACGAGGTGCACCTGGTGGCA
GATGGCAAGTTCGGCACACAGGAGCGGGTGAACAACAGCAACAAGAAGGAGTGGAATGGG
ATGATGGGCGAGCTGCTCAGCGGGCAGGCAGACATGATCGTGGCGCCGCTAACCATAAAC
AACGAGCGCGCGCAGTACATCGAGTTTTCCAAGCCCTTCAAGTACCAGGGCCTGACTATT
CTGGTCAAGAAGGAGATTCCCCGGAGCACGCTGGACTCGTTCATGCAGCCGTTCCAGAGC
ACACTGTGGCTGCTGGTGGGGCTGTCGGTGCACGTGGTGGCCGTGATGCTGTACCTGCTG
GACCGCTTCAGCCCCTTCGGCCGGTTCAAGGTGAACAGCGAGGAGGAGGAGGAGGACGCA
CTGACCCTGTCCTCGGCCATGTGGTTCTCCTGGGGCGTCCTGCTCAACTCCGGCATCGGG
GAAGGCGCCCCCAGAAGCTTCTCAGCGCGCATCCTGGGCATGGTGTGGGCCGGCTTTGCC
ATGATCATCGTGGCCTCCTACACCGCCAACCTGGCGGCCTTCCTGGTGCTGGACCGGCCG
GAGGAGCGCATCACGGGCATCAACGACCCTCGGCTGAGGAACCCCTCGGACAAGTTTATC
TACGCCACGGTGAAGCAGAGCTCCGTGGATATCTACTTCCGGCGCCAGGTGGAGCTGAGC
ACCATGTACCGGCATATGGAGAAGCACAACTACGAGAGTGCGGCGGAGGCCATCCAGGCC
GTGAGAGACAACAAGCTGCATGCCTTCATCTGGGACTCGGCGGTGCTGGAGTTCGAGGCC
TCGCAGAAGTGCGACCTGGTGACGACTGGAGAGCTGTTTTTCCGCTCGGGCTTCGGCATA
GGCATGCGCAAAGACAGCCCCTGGAAGCAGAACGTCTCCCTGTCCATCCTCAAGTCCCAC
GAGAATGGCTTCATGGAAGACCTGGACAAGACGTGGGTTCGGTATCAGGAATGTGACTCG
CGCAGCAACGCCCCTGCGACCCTTACTTTTGAGAACATGGCCGGGGTCTTCATGCTGGTA
GCTGGGGGCATCGTGGCCGGGATCTTCCTGATTTTCATCGAGATTGCCTACAAGCGGCAC
AAGGATGCTCGCCGGAAGCAGATGCAGCTGGCCTTTGCCGCCGTTAACGTGTGGCGGAAG
AACCTGCAGGATAGAAAGAGTGGTAGAGCAGAGCCTGACCCTAAAAAGAAAGCCACATTT
AGGGCTATCACCTCCACCCTGGCTTCCAGCTTCAAGAGGCGTAGGTCCTCCAAAGACACG
AGCACCGGGGGTGGACGCGGCGCTTTGCAAAACCAAAAAGACACAGTGCTGCCGCGACGC
GCTATTGAGAGGGAGGAGGGCCAGCTGCAGCTGTGTTCCCGTCATAGGGAGAGCTGA

# Drug_Target_33_General_Function:
Involved in ionotropic glutamate receptor activity

# Drug_Target_33_General_References:
7679115	Karp SJ, Masu M, Eki T, Ozawa K, Nakanishi S: Molecular cloning and chromosomal localization of the key subunit of the human N-methyl-D-aspartate receptor. J Biol Chem. 1993 Feb 15;268(5):3728-33.
7681588	Younkin DP, Tang CM, Hardy M, Reddy UR, Shi QY, Pleasure SJ, Lee VM, Pleasure D: Inducible expression of neuronal glutamate receptor channels in the NT2 human cell line. Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2174-8.
7685113	Planells-Cases R, Sun W, Ferrer-Montiel AV, Montal M: Molecular cloning, functional expression, and pharmacological characterization of an N-methyl-D-aspartate receptor subunit from human brain. Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5057-61.
7926821	Foldes RL, Rampersad V, Kamboj RK: Cloning and sequence analysis of additional splice variants encoding human N-methyl-D-aspartate receptor (hNR1) subunits. Gene. 1994 Sep 30;147(2):303-4.
8316301	Tingley WG, Roche KW, Thompson AK, Huganir RL: Regulation of NMDA receptor phosphorylation by alternative splicing of the C-terminal domain. Nature. 1993 Jul 1;364(6432):70-3.
8406025	Foldes RL, Rampersad V, Kamboj RK: Cloning and sequence analysis of cDNAs encoding human hippocampus N-methyl-D-aspartate receptor subunits: evidence for alternative RNA splicing. Gene. 1993 Sep 15;131(2):293-8.

# Drug_Target_33_HGNC_ID:
HGNC:4584

# Drug_Target_33_HPRD_ID:
15926

# Drug_Target_33_ID:
401

# Drug_Target_33_Locus:
9q34.3

# Drug_Target_33_Molecular_Weight:
105374

# Drug_Target_33_Name:
Glutamate [NMDA] receptor subunit zeta-1

# Drug_Target_33_Number_of_Residues:
938

# Drug_Target_33_PDB_ID:
1PB7

# Drug_Target_33_Pathway:
Methadone Pathway	SMP00408

# Drug_Target_33_Pfam_Domain_Function:
PF00060	Lig_chan
PF01094	ANF_receptor

# Drug_Target_33_Protein_Sequence:
>Glutamate [NMDA] receptor subunit zeta 1 precursor
MSTMRLLTLALLFSCSVARAACDPKIVNIGAVLSTRKHEQMFREAVNQANKRHGSWKIQL
NATSVTHKPNAIQMALSVCEDLISSQVYAILVSHPPTPNDHFTPTPVSYTAGFYRIPVLG
LTTRMSIYSDKSIHLSFLRTVPPYSHQSSVWFEMMRVYSWNHIILLVSDDHEGRAAQKRL
ETLLEERESKAEKVLQFDPGTKNVTALLMEAKELEARVIILSASEDDAATVYRAAAMLNM
TGSGYVWLVGEREISGNALRYAPDGILGLQLINGKNESAHISDAVGVVAQAVHELLEKEN
ITDPPRGCVGNTNIWKTGPLFKRVLMSSKYADGVTGRVEFNEDGDRKFANYSIMNLQNRK
LVQVGIYNGTHVIPNDRKIIWPGGETEKPRGYQMSTRLKIVTIHQEPFVYVKPTLSDGTC
KEEFTVNGDPVKKVICTGPNDTSPGSPRHTVPQCCYGFCIDLLIKLARTMNFTYEVHLVA
DGKFGTQERVNNSNKKEWNGMMGELLSGQADMIVAPLTINNERAQYIEFSKPFKYQGLTI
LVKKEIPRSTLDSFMQPFQSTLWLLVGLSVHVVAVMLYLLDRFSPFGRFKVNSEEEEEDA
LTLSSAMWFSWGVLLNSGIGEGAPRSFSARILGMVWAGFAMIIVASYTANLAAFLVLDRP
EERITGINDPRLRNPSDKFIYATVKQSSVDIYFRRQVELSTMYRHMEKHNYESAAEAIQA
VRDNKLHAFIWDSAVLEFEASQKCDLVTTGELFFRSGFGIGMRKDSPWKQNVSLSILKSH
ENGFMEDLDKTWVRYQECDSRSNAPATLTFENMAGVFMLVAGGIVAGIFLIFIEIAYKRH
KDARRKQMQLAFAAVNVWRKNLQDRKSGRAEPDPKKKATFRAITSTLASSFKRRRSSKDT
STGGGRGALQNQKDTVLPRRAIEREEGQLQLCSRHRES

# Drug_Target_33_Reaction:
Not Available

# Drug_Target_33_Signals:
1-18

# Drug_Target_33_Specific_Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. It mediates neuronal functions in glutamate neurotransmission. Is involved in the cell surface targeting of NMDA receptors

# Drug_Target_33_SwissProt_ID:
Q05586

# Drug_Target_33_SwissProt_Name:
NMDZ1_HUMAN

# Drug_Target_33_Synonyms:
Glutamate receptor subunit zeta-1 precursor
N-methyl-D- aspartate receptor subunit NR1

# Drug_Target_33_Theoretical_pI:
9.20

# Drug_Target_33_Transmembrane_Regions:
560-580
637-657
813-833

# Drug_Target_34_Cellular_Location:
Mitochondrion. Cytoplasm

# Drug_Target_34_Chromosome_Location:
Not Available

# Drug_Target_34_Drug_References:
16686541	DeMartino JK, Hwang I, Xu L, Wilson IA, Boger DL: Discovery of a potent, nonpolyglutamatable inhibitor of glycinamide ribonucleotide transformylase. J Med Chem. 2006 May 18;49(10):2998-3002.
16990006	Gangjee A, Yang J, McGuire JJ, Kisliuk RL: Synthesis and evaluation of a classical 2,4-diamino-5-substituted-furo[2,3-d]pyrimidine and a 2-amino-4-oxo-6-substituted-pyrrolo[2,3-d]pyrimidine as antifolates. Bioorg Med Chem. 2006 Dec 15;14(24):8590-8. Epub 2006 Sep 20.

# Drug_Target_34_Essentiality:
Non-Essential

# Drug_Target_34_GenAtlas_ID:
FPGS

# Drug_Target_34_GenBank_ID_Gene:
M98045

# Drug_Target_34_GenBank_ID_Protein:
292029

# Drug_Target_34_GeneCard_ID:
FPGS

# Drug_Target_34_Gene_Name:
FPGS

# Drug_Target_34_Gene_Sequence:
>1638 bp
ATGGAGTACCAGGATGCCGTGCGCATGCTCAATACCCTGCAGACCAATGCCGGCTACCTG
GAGCAGGTGAAGCGCCAGCGGGGTGACCCTCAGACACAGTTGGAAGCCATGGAACTGTAC
CTGGCACGGAGTGGGCTGCAGGTGGAGGACTTGGACCGGCTGAACATCATCCACGTCACT
GGGACGAAGGGGAAGGGCTCCACCTGTGCCTTCACGGAATGTATCCTCCGAAGCTATGGC
CTGAAGACGGGATTCTTTAGCTCTCCCCACCTGGTGCAGGTTCGGGAGCGGATCCGCATC
AATGGGCAGCCCATCAGTCCTGAGCTCTTCACCAAGTACTTCTGGCGCCTCTACCACCGG
CTGGAGGAGACCAAGGATGGCAGCTGTGTCTCCATGCCCCCCTACTTCCGCTTCCTGACA
CTCATGGCCTTCCACGTCTTCCTCCAAGAGAAGGTGGACCTGGCAGTGGTGGAGGTGGGC
ATTGGCGGGGCTTATGACTGCACCAACATCATCAGGAAGCCTGTGGTGTGCGGAGTCTCC
TCTCTTGGCATCGACCACACCAGCCTCCTGGGGGATACGGTGGAGAAGATCGCATGGCAG
AAAGGGGGCATCTTTAAGCAAGGTGTCCCTGCCTTCACTGTGCTCCAACCTGAAGGTCCC
CTGGCAGTGCTGAGGGACCGAGCCCAGCAGATCTCATGTCCTCTATACCTGTGTCCGATG
CTGGAGGCCCTCGAGGAAGGGGGGCCGCCGCTGACCCTGGGCCTGGAGGGGGAGCACCAG
CGGTCCAACGCCGCCTTGGCCTTGCAGCTGGCCCACTGCTGGCTGCAGCGGCAGGACCGC
CATGGTGCTGGGGAGCCAAAGGCATCCAGGCCAGGGCTCCTGTGGCAGCTGCCCCTGGCA
CCTGTGTTCCAGCCCACATCCCACATGCGGCTCGGGCTTCGGAACACGGAGTGGCCGGGC
CGGACGCAGGTGCTGCGGCGCGGGCCCCTCACCTGGTACCTGGACGGTGCGCACACCGCC
AGCAGCGCGCAGGCCTGCGTGCGCTGGTTCCGCCAGGCGCTGCAGGGCCGCGAGAGGCCG
AGCGGTGGCCCCGAGGTTCGAGTCTTGCTCTTCAATGCTACCGGGGACCGGGACCCGGCG
GCCCTGCTGAAGCTGCTGCAGCCCTGCCAGTTTGACTATGCCGTCTTCTGCCCTAACCTG
ACAGAGGTGTCATCCACAGGCAACGCAGACCAACAGAACTTCACAGTGACACTGGACCAG
GTCCTGCTCCGCTGCCTGGAACACCAGCAGCACTGGAACCACCTGGACGAAGAGCAGGCC
AGCCCGGACCTCTGGAGTGCCCCCAGCCCAGAGCCCGGTGGGTCCGCATCCCTGCTTCTG
GCGCCCCACCCACCCCACACCTGCAGTGCCAGCTCCCTCGTCTTCAGCTGCATTTCACAT
GCCTTGCAATGGATCAGCCAAGGCCGAGACCCCATCTTCCAGCCACCTAGTCCCCCAAAG
GGCCTCCTCACCCACCCTGTGGCTCACAGTGGGGCCAGCATACTCCGTGAGGCTGCTGCC
ATCCATGTGCTAGTCACTGGCAGCCTGCACCTGGTGGGTGGTGTCCTGAAGCTGCTGGAG
CCCGCACTGTCCCAGTAG

# Drug_Target_34_General_Function:
Coenzyme transport and metabolism

# Drug_Target_34_General_References:
1409616	Garrow TA, Admon A, Shane B: Expression cloning of a human cDNA encoding folylpoly(gamma-glutamate) synthetase and determination of its primary structure. Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9151-5.
3828320	Cichowicz DJ, Shane B: Mammalian folylpoly-gamma-glutamate synthetase. 1. Purification and general properties of the hog liver enzyme. Biochemistry. 1987 Jan 27;26(2):504-12.
7721888	Freemantle SJ, Taylor SM, Krystal G, Moran RG: Upstream organization of and multiple transcripts from the human folylpoly-gamma-glutamate synthetase gene. J Biol Chem. 1995 Apr 21;270(16):9579-84.
8521387	Taylor SM, Freemantle SJ, Moran RG: Structural organization of the human folypoly-gamma-glutamate synthetase gene: evidence for a single genomic locus. Cancer Res. 1995 Dec 15;55(24):6030-4.

# Drug_Target_34_HGNC_ID:
HGNC:3824

# Drug_Target_34_HPRD_ID:
00642

# Drug_Target_34_ID:
773

# Drug_Target_34_Locus:
9q34.1

# Drug_Target_34_Molecular_Weight:
64610

# Drug_Target_34_Name:
Folylpolyglutamate synthase, mitochondrial

# Drug_Target_34_Number_of_Residues:
587

# Drug_Target_34_PDB_ID:
Not Available

# Drug_Target_34_Pathway:
Methotrexate Pathway	SMP00432

# Drug_Target_34_Pfam_Domain_Function:
PF02875	Mur_ligase_C

# Drug_Target_34_Protein_Sequence:
>Folylpolyglutamate synthase, mitochondrial precursor
MSRARSHLRAALFLAAASARGITTQVAARRGLSAWPVPQEPSMEYQDAVRMLNTLQTNAG
YLEQVKRQRGDPQTQLEAMELYLARSGLQVEDLDRLNIIHVTGTKGKGSTCAFTECILRS
YGLKTGFFSSPHLVQVRERIRINGQPISPELFTKYFWRLYHRLEETKDGSCVSMPPYFRF
LTLMAFHVFLQEKVDLAVVEVGIGGAYDCTNIIRKPVVCGVSSLGIDHTSLLGDTVEKIA
WQKGGIFKQGVPAFTVLQPEGPLAVLRDRAQQISCPLYLCPMLEALEEGGPPLTLGLEGE
HQRSNAALALQLAHCWLQRQDRHGAGEPKASRPGLLWQLPLAPVFQPTSHMRLGLRNTEW
PGRTQVLRRGPLTWYLDGAHTASSAQACVRWFRQALQGRERPSGGPEVRVLLFNATGDRD
PAALLKLLQPCQFDYAVFCPNLTEVSSTGNADQQNFTVTLDQVLLRCLEHQQHWNHLDEE
QASPDLWSAPSPEPGGSASLLLAPHPPHTCSASSLVFSCISHALQWISQGRDPIFQPPSP
PKGLLTHPVAHSGASILREAAAIHVLVTGSLHLVGGVLKLLEPALSQ

# Drug_Target_34_Reaction:
ATP + tetrahydropteroyl-[gamma-Glu]n + L-glutamate = ADP + phosphate + tetrahydropteroyl-[gamma-Glu]n+1

# Drug_Target_34_Signals:
None

# Drug_Target_34_Specific_Function:
Conversion of folates to polyglutamate derivatives. This allows tissues to concentrate folate at higher levels than in plasma

# Drug_Target_34_SwissProt_ID:
Q05932

# Drug_Target_34_SwissProt_Name:
FOLC_HUMAN

# Drug_Target_34_Synonyms:
EC 6.3.2.17
FPGS
Folylpoly-gamma-glutamate synthetase
Folylpolyglutamate synthase, mitochondrial precursor
Tetrahydrofolate synthase
Tetrahydrofolylpolyglutamate synthase

# Drug_Target_34_Theoretical_pI:
8.00

# Drug_Target_34_Transmembrane_Regions:
None

# Drug_Target_35_Cellular_Location:
Membrane

# Drug_Target_35_Chromosome_Location:
Not Available

# Drug_Target_35_Drug_References:
11732752	Acarturk F, Parlatan ZI, Saracoglu OF: Comparison of vaginal aminopeptidase enzymatic activities in various animals and in humans. J Pharm Pharmacol. 2001 Nov;53(11):1499-504.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
7448199	Tobe H, Kojima F, Aoyagi T, Umezawa H: Purification by affinity chromatography using amastatin and properties of aminopeptidase A from pig kidney. Biochim Biophys Acta. 1980 Jun 13;613(2):459-68.
8568030	Sasaki M, Bosman BW, Tan PS: Comparison of proteolytic activities in various lactobacilli. J Dairy Res. 1995 Nov;62(4):601-10.

# Drug_Target_35_Essentiality:
Non-Essential

# Drug_Target_35_GenAtlas_ID:
ENPEP

# Drug_Target_35_GenBank_ID_Gene:
L14721

# Drug_Target_35_GenBank_ID_Protein:
291854

# Drug_Target_35_GeneCard_ID:
ENPEP

# Drug_Target_35_Gene_Name:
ENPEP

# Drug_Target_35_Gene_Sequence:
>2874 bp
ATGAACTTTGCGGAGAGAGAGGGCTCTAAGAGATACTGCATTCAAACGAAACATGTGGCC
ATTCTCTGTGCGGTGGTGGTGGGTGTAGGATTAATAGTGGGACTTGCCGTGGGCTTGACC
AGATCGTGTGACTCCAGCGGGGACGGCGGGCCGGGCACTGCGCCAGCTCCTTCCCACCTG
CCTTCTTCCACGGCCAGCCCCTCAGGTCCTCCTGCCCAGGACCAGGACATCTGCCCGGCC
AGTGAGGATGAGAGCGGACAGTGGAAAAACTTTCGACTGCCGGACTTCGTCAACCCAGTC
CACTACGACCTGCACGTGAAGCCCCTGTTGGAGGAGGACACCTACACGGGCACCGTGAGC
ATCTCCATCAACCTGAGCGCTCCCACCCGGTACCTGTGGCTGCACCTCCGGGAGACCAGG
ATCACCCGGCTCCCGGAGCTGAAGAGGCCCTCTGGGGACCAGGTGCAAGTCCGGAGGTGT
TTCGAGTACAAAAAGCAGGAGTACGTGGTGGTCGAGGCGGAGGAAGAGCTTACCCCCAGC
AGTGGAGATGGCCTGTATCTCCTGACCATGGAGTTCGCCGGCTGGCTGAACGGCTCCCTC
GTGGGATTTTATAGAACCACCTACACGGAGAACGGACGAGTCAAGAGCATAGCGGCCACC
GATCATGAACCAACAGATGCCAGGAAATCTTTTCCTTGTTTTGATGAGCCCAACAAAAAG
GCAACTTATACAATATCTATCACCCATCCCAAAGAATACGGAGCACTTTCAAATATGCCA
GTGGCGAAAGAAGAGTCAGTGGATGATAAATGGACTCGAACAACTTTTGAGAAGTCTGTC
CCCATGAGCACGTACCTGGTGTGCTTTGCTGTACATCAATTTGACTCTGTAAAGAGAATA
TCAAATAGTGGAAAACCTCTTACAATTTATGTCCAGCCAGAGCAAAAGCACACAGCCGAA
TATGCTGCAAACATAACTAAAAGTGTGTTTGATTATTTTGAAGAATACTTTGCTATGAAT
TATTCTCTTCCTAAATTAGATAAAATCGCTATTCCAGATTTTGGCACTGGTGCCATGGAG
AACTGGGGACTCATCACGTACAGAGAAACGAACCTGCTTTATGACCCTAAGGAATCAGCC
TCATCAAACCAACAGAGGGTGGCCACTGTGGTTGCCCATGAACTTGTGCATCAGTGGTTT
GGAAATATTGTGACCATGGACTGGTGGGAAGACTTGTGGCTAAATGAAGGATTTGCTTCT
TTCTTTGAGTTTCTGGGAGTAAACCATGCAGAAACAGACTGGCAAATGCGTGACCAAATG
TTACTTGAAGATGTATTACCTGTTCAAGAGGATGATTCTTTGATGTCTTCGCATCCAATT
ATTGTGACTGTGACAACCCCTGATGAAATAACATCTGTTTTTGATGGAATATCCTATAGC
AAGGGATCTTCTATTTTGAGAATGCTTGAAGACTGGATAAAACCAGAGAATTTTCAAAAA
GGATGTCAGATGTACTTGGAAAAATACCAATTCAAGAATGCAAAAACTTCTGATTTTTGG
GCAGCACTGGAAGAGGCAAGTAGGCTACCAGTGAAAGAAGTAATGGACACCTGGACCAGA
CAGATGGGTTATCCTGTGCTTAACGTGAACGGTGTCAAGAACATCACACAGAAACGCTTT
TTGTTGGACCCAAGAGCTAACCCTTCTCAGCCCCCTTCAGATCTTGGTTATACATGGAAT
ATCCCAGTTAAATGGACTGAAGATAATATAACAAGCAGTGTGTTATTTAATAGGTCAGAA
AAAGAAGGAATCACTTTGAACTCCTCTAATCCTAGTGGAAATGCTTTTCTCAAAATAAAC
CCAGATCATATTGGGTTTTATCGTGTAAATTATGAAGTAGCAACTTGGGACTCGATAGCT
ACAGCGCTCTCCTTGAACCACAAGACATTTTCTTCAGCAGATCGTGCAAGTCTTATTGAT
GATGCTTTTGCCTTGGCAAGAGCTCAACTTCTAGATTATAAGGTGGCTTTGAACTTGACC
AAGTATCTCAAAAGGGAAGAGAATTTTTTACCATGGCAGAGAGTAATTTCAGCTGTAACC
TACATCATTAGCATGTTTGAAGATGATAAAGAGCTATATCCTATGATTGAGGAATACTTC
CAAGGTCAAGTGAAGCCTATTGCAGATTCTCTGGGATGGAATGATGCTGGAGACCATGTC
ACAAAGTTACTCCGTTCCTCCGTGTTAGGGTTTGCGTGCAAGATGGGAGACAGAGAAGCC
TTGAACAATGCTTCCTCGTTATTTGAGCAGTGGCTAAATGGGACTGTAAGCCTTCCCGTA
AATCTCAGGCTTCTGGTGTATCGGTATGGGATGCAGAACTCTGGCAATGAGATTTCATGG
AACTACACTCTTGAGCAATACCAGAAAACTTCATTAGCTCAAGAAAAAGAAAAACTGCTG
TATGGATTAGCATCAGTGAAGAACGTTACTCTTTTGTCAAGGTATTTGGATTTGCTCAAG
GACACGAACCTTATTAAAACTCAGGATGTGTTTACAGTCATTCGATATATCTCATATAAC
AGCTATGGGAAGAACATGGCCTGGAATTGGATACAACTCAACTGGGACTATCTAGTCAAC
AGATATACACTCAATAACAGAAACCTTGGCCGAATTGTCACAATAGCAGAGCCATTCAAC
ACTGAACTGCAACTGTGGCAGATGGAGAGCTTTTTTGCAAAATATCCACAAGCTGGAGCA
GGAGAAAAACCTAGGGAACAAGTGCTGGAAACAGTGAAAAACAATATAGAGTGGCTAAAA
CAACATAGAAACACCATCAGAGAATGGTTTTTTAATTTACTTGAGAGTGGTTAA

# Drug_Target_35_General_Function:
Amino acid transport and metabolism

# Drug_Target_35_General_References:
8244382	Li L, Wang J, Cooper MD: cDNA cloning and expression of human glutamyl aminopeptidase (aminopeptidase A). Genomics. 1993 Sep;17(3):657-64.
8346219	Nanus DM, Engelstein D, Gastl GA, Gluck L, Vidal MJ, Morrison M, Finstad CL, Bander NH, Albino AP: Molecular cloning of the human kidney differentiation antigen gp160: human aminopeptidase A. Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7069-73.

# Drug_Target_35_HGNC_ID:
HGNC:3355

# Drug_Target_35_HPRD_ID:
Not Available

# Drug_Target_35_ID:
4020

# Drug_Target_35_Locus:
4q25

# Drug_Target_35_Molecular_Weight:
109273

# Drug_Target_35_Name:
Glutamyl aminopeptidase

# Drug_Target_35_Number_of_Residues:
957

# Drug_Target_35_PDB_ID:
Not Available

# Drug_Target_35_Pathway:
Not Available

# Drug_Target_35_Pfam_Domain_Function:
PF01433	Peptidase_M1

# Drug_Target_35_Protein_Sequence:
>Glutamyl aminopeptidase
MNFAEREGSKRYCIQTKHVAILCAVVVGVGLIVGLAVGLTRSCDSSGDGGPGTAPAPSHL
PSSTASPSGPPAQDQDICPASEDESGQWKNFRLPDFVNPVHYDLHVKPLLEEDTYTGTVS
ISINLSAPTRYLWLHLRETRITRLPELKRPSGDQVQVRRCFEYKKQEYVVVEAEEELTPS
SGDGLYLLTMEFAGWLNGSLVGFYRTTYTENGRVKSIVATDHEPTDARKSFPCFDEPNKK
ATYTISITHPKEYGALSNMPVAKEESVDDKWTRTTFEKSVPMSTYLVCFAVHQFDSVKRI
SNSGKPLTIYVQPEQKHTAEYAANITKSVFDYFEEYFAMNYSLPKLDKIAIPDFGTGAME
NWGLITYRETNLLYDPKESASSNQQRVATVVAHELVHQWFGNIVTMDWWEDLWLNEGFAS
FFEFLGVNHAETDWQMRDQMLLEDVLPVQEDDSLMSSHPIIVTVTTPDEITSVFDGISYS
KGSSILRMLEDWIKPENFQKGCQMYLEKYQFKNAKTSDFWAALEEASRLPVKEVMDTWTR
QMGYPVLNVNGVKNITQKRFLLDPRANPSQPPSDLGYTWNIPVKWTEDNITSSVLFNRSE
KEGITLNSSNPSGNAFLKINPDHIGFYRVNYEVATWDSIATALSLNHKTFSSADRASLID
DAFALARAQLLDYKVALNLTKYLKREENFLPWQRVISAVTYIISMFEDDKELYPMIEEYF
QGQVKPIADSLGWNDAGDHVTKLLRSSVLGFACKMGDREALNNASSLFEQWLNGTVSLPV
NLRLLVYRYGMQNSGNEISWNYTLEQYQKTSLAQEKEKLLYGLASVKNVTLLSRYLDLLK
DTNLIKTQDVFTVIRYISYNSYGKNMAWNWIQLNWDYLVNRYTLNNRNLGRIVTIAEPFN
TELQLWQMESFFAKYPQAGAGEKPREQVLETVKNNIEWLKQHRNTIREWFFNLLESG

# Drug_Target_35_Reaction:
Release of N-terminal glutamate (and to a lesser extent aspartate) from a peptide COFACTOR Zinc; Calcium

# Drug_Target_35_Signals:
None

# Drug_Target_35_Specific_Function:
Appears to have a role in the catabolic pathway of the renin-angiotensin system. Probably plays a role in regulating growth and differentiation of early B-lineage cells

# Drug_Target_35_SwissProt_ID:
Q07075

# Drug_Target_35_SwissProt_Name:
AMPE_HUMAN

# Drug_Target_35_Synonyms:
APA
Aminopeptidase A
CD249 antigen
Differentiation antigen gp160
EAP
EC 3.4.11.7

# Drug_Target_35_Theoretical_pI:
5.18

# Drug_Target_35_Transmembrane_Regions:
19-39

# Drug_Target_36_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_36_Chromosome_Location:
Not Available

# Drug_Target_36_Drug_References:
11080203	Rutter AR, Stephenson FA: Coexpression of postsynaptic density-95 protein with NMDA receptors results in enhanced receptor expression together with a decreased sensitivity to L-glutamate. J Neurochem. 2000 Dec;75(6):2501-10.
12068077	Rutter AR, Freeman FM, Stephenson FA: Further characterization of the molecular interaction between PSD-95 and NMDA receptors: the effect of the NR1 splice variant and evidence for modulation of channel gating. J Neurochem. 2002 Jun;81(6):1298-307.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
8886398	Bresink I, Benke TA, Collett VJ, Seal AJ, Parsons CG, Henley JM, Collingridge GL: Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells. Br J Pharmacol. 1996 Sep;119(2):195-204.

# Drug_Target_36_Essentiality:
Non-Essential

# Drug_Target_36_GenAtlas_ID:
GRIN2A

# Drug_Target_36_GenBank_ID_Gene:
U09002

# Drug_Target_36_GenBank_ID_Protein:
558749

# Drug_Target_36_GeneCard_ID:
GRIN2A

# Drug_Target_36_Gene_Name:
GRIN2A

# Drug_Target_36_Gene_Sequence:
>4395 bp
ATGGGCAGAGTGGGCTATTGGACCCTGCTGGTGCTGCCGGCCCTTCTGGTCTGGCGCGGT
CCGGCGCCGAGCGCGGCGGCGGAGAAGGGTCCCCCCGCGCTAAATATTGCGGTGATGCTG
GGTCACAGCCACGACGTGACAGAGCGCGAACTTCGAACACTGTGGGGCCCCGAGCAGGCG
GCGGGGCTGCCCCTGGACGTGAACGTGGTAGCTCTGCTGATGAACCGCACCGACCCCAAG
AGCCTCATCACGCACGTGTGCGACCTCATGTCCGGGGCACGCATCCACGGCCTCGTGTTT
GGGGACGACACGGACCAGGAGGCCGTAGCCCAGATGCTGGATTTTATCTCCTCCCACACC
TTCGTCCCCATCTTGGGCATTCATGGGGGCGCATCTATGATCATGGCTGACAAGGATCCG
ACGTCTACCTTCTTCCAGTTTGGAGCGTCCATCCAGCAGCAAGCCACGGTCATGCTGAAG
ATCATGCAGGATTATGACTGGCATGTCTTCTCCCTGGTGACCACTATCTTCCCTGGCTAC
AGGGAATTCATCAGCTTCGTCAAGACCACAGTGGACAACAGCTTTGTGGGCTGGGACATG
CAGAATGTGATCACACTGGACACTTCCTTTGAGGATGCAAAGACACAAGTCCAGCTGAAG
AAGATCCACTCTTCTGTCATCTTGCTCTACTGTTCCAAAGACGAGGCTGTTCTCATTCTG
AGTGAGGCCCGCTCCCTTGGCCTCACCGGGTATGATTTCTTCTGGATTGTCCCCAGCTTG
GTCTCTGGGAACACGGAGCTCATCCCAAAAGAGTTTCCATCGGGACTCATTTCTGTCTCC
TACGATGACTGGGACTACAGCCTGGAGGCGAGAGTGAGGGACGGCATTGGCATCCTAACC
ACCGCTGCATCTTCTATGCTGGAGAAGTTCTCCTACATCCCCGAGGCCAAGGCCAGCTGC
TACGGGCAGATGGAGAGGCCAGAGGTCCCGATGCACACCTTGCACCCATTTATGGTCAAT
GTTACATGGGATGGCAAAGACTTATCCTTCACTGAGGAAGGCTACCAGGTGCACCCCAGG
CTGGTGGTGATTGTGCTGAACAAAGACCGGGAATGGGAAAAGGTGGGCAAGTGGGAGAAC
CATACGCTGAGCCTGAGGCACGCCGTGTGGCCCAGGTACAAGTCCTTCTCCGACTGTGAG
CCGGATGACAACCATCTCAGCATCGTCACCCTGGAGGAGGCCCCATTCGTCATCGTGGAA
GACATAGACCCCCTAACCGAGACGTGTGTGAGGAACACCGTGCCATGTCGGAAGTTCGTC
AAAATCAACAATTCAACCAATGAGGGGATGAATGTGAAGAAATGCTGCAAGGGGTTCTGC
ATTGATATTCTGAAGAAGCTTTCCAGAACTGTGAAGTTTACTTACGACCTCTATCTGGTG
ACCAATGGGAAGCATGGCAAGAAAGTTAACAATGTGTGGAATGGAATGATCGGTGAAGTG
GTCTATCAACGGGCAGTCATGGCAGTTGGCTCGCTCACCATCAATGAGGAACGTTCTGAA
GTGGTGGACTTCTCTGTGCCCTTTGTGGAAACGGGAATCAGTGTCATGGTTTCAAGAAGT
AATGGCACCGTCTCACCTTCTGCTTTTCTAGAACCATTCAGCGCCTCTGTCTGGGTGATG
ATGTTTGTGATGCTGCTCATTGTTTCTGCCATAGCTGTTTTTGTCTTTGAATACTTCAGC
CCTGTTGGATACAACAGAAACTTAGCCAAAGGGAAAGCACCCCATGGGCCTTCTTTTACA
ATTGGAAAAGCTATATGGCTTCTTTGGGGCCTGGTGTTCAATAACTCCGTGCCTGTCCAG
AATCCTAAAGGGACCACCAGCAAGATCATGGTATCTGTATGGGCCTTCTTCGCTGTCATA
TTCCTGGCTAGCTACACAGCCAATCTGGCTGCCTTCATGATCCAAGAGGAATTTGTGGAC
CAAGTGACCGGCCTCAGTGACAAAAAGTTTCAGAGACCTCATGACTATTCCCCACCTTTT
CGATTTGGGACAGTGCCTAATGGAAGCACGGAGAGAAACATTCGGAATAACTATCCCTAC
ATGCATCAGTACATGACCAAATTTAATCAGAAAGGAGTAGAGGACGCCTTGGTCAGCCTG
AAAACGGGGAAGCTGGACGCTTTCATCTACGATGCCGCAGTCTTGAATTACAAGGCTGGG
AGGGATGAAGGCTGCAAGCTGGTGACCATCGGGAGTGGGTACATCTTTGCCACCACCGGT
TATGGAATTGCCCTTCAGAAAGGCTCTCCTTGGAAGAGGCAGATCGACCTGGCCTTGCTT
CAGTTTGTGGGTGATGGTGAGATGGAGGAGCTGGAGACCCTGTGGCTCACTGGGATCTGC
CACAACGAGAAGAACGAGGTGATGAGCAGCCAGCTGGACATTGACAACATGGCGGGCGTA
TTCTACATGCTGGCTGCCGCCATGGCCCTTAGCCTCATCACCTTCATCTGGGAGCACCTC
TTCTACTGGAAGCTGCGCTTCTGTTTCACGGGCGTGTGCTCCGACCGGCCTGGGTTGCTC
TTCTCCATCAGCAGGGGCATCTACAGCTGCATTCATGGAGTGCACATTGAAGAAAAGAAG
AAGTCTCCAGACTTCAATCTGACGGGATCCCAGAGCAACATGTTAAAACTCCTCCGGTCA
GCCAAAAACATTTCCAGCATGTCCAACATGAACTCCTCAAGAATGGACTCACCCAAAAGA
GCTGCTGACTTCATCCAAAGAGGTTCCCTCATCATGGACATGGTTTCAGATAAGGGGAAT
TTGATGTACTCAGACAACAGGTCCTTTCAGGGGAAAGAGAGCATTTTTGGAGACAACATG
AACGAACTCCAAACATTTGTGGCCAACCGGCAGAAGGATAACCTCAATAACTATGTATTC
CAGGGACAACATCCTCTTACTCTCAATGAGTCCAACCCTAACACGGTGGAGGTGGCCGTG
AGCACAGAATCCAAAGCGAACTCTAGACCCCGGCAGCTGTGGAAGAAATCCGTAGATTCC
ATACGCCAGGATTCACTATCCCAGAATCCAGTCTCCCAGAGGGATGAGGCAACAGCAGAG
AATAGGACCCACTCCCTAAAGAGCCCTAGGTATCTTCCAGAAGAGATGGCCCACTCTGAC
ATTTCAGAAACGTCAAATCGGGCCACGTGCCACAGGGAACCTGACAACAGTAAGAACCAC
AAAACCAAGGACAACTTTAAAAGGTCAGTGGCCTCCAAATACCCCAAGGACTGTAGTGAG
GTCGAGCGCACCTACCTGAAAACCAAATCAAGCTCCCCTAGAGACAAGATCTACACTATA
GATGGTGAGAAGGAGCCTGGTTTCCACTTAGATCCACCCCAGTTTGTTGAAAATGTGACC
CTGCCCGAGAACGTGGACTTCCCGGACCCCTACCAGGATCCCAGTGAAAACTTCCGCAAG
GGGGACTCCACGCTGCCAATGAACCGGAACCCCTTGCATAATGAAGAGGGGCTTTCCAAC
AACGACCAGTATAAACTCTACTCCAAGCACTTCACCTTGAAAGACAAGGGTTCCCCGCAC
AGTGAGACCAGCGAGCGATACCGGCAGAACTCCACGCACTGCAGAAGCTGCCTTTCCAAC
ATGCCCACCTATTCAGGCCACTTCACCATGAGGTCCCCCTTCAAGTGCGATGCCTGCCTG
CGGATGGGGAATCTCTATGACATCGATGAAGACCAGATGCTTCAGGAGACAGGTAACCCA
GCCACCGGGGAGCAGGTCTACCAGCAGGACTGGGCACAGAACAATGCCCTTCAATTACAA
AAGAACAAGCTAAGGATTAGCCGTCAGCATTCCTACGATAACATTGTCGACAAACCTAGG
GAGCTAGACCTTAGCAGGCCCTCCCGGAGCATAAGCCTCAAGGACAGGGAACGGCTTCTG
GAGGGAAATTTTTACGGCAGCCTGTTTAGTGTCCCCTCAAGCAAACTCTCGGGGAAAAAA
AGCTCCCTTTTCCCCCAAGGTCTGGAGGACAGCAAGAGGAGCAAGTCTCTCTTGCCAGAC
CACACCTCCGATAACCCTTTCCTCCACTCCCACAGGGATGACCAACGCTTGGTTATTGGG
AGATGCCCCTCGGACCCTTACAAACACTCGTTGCCATCCCAGGCGGTGAATGACAGCTAT
CTTCGGTCGTCCTTGAGGTCAACGGCATCGTACTGTTCCAGGGACAGTCGGGGCCACAAT
GATGTGTATATTTCGGAGCATGTTATGCCTTATGCTGCAAATAAGAATAATATGTACTCT
ACCCCCAGGGTTTTAAATTCCTGCAGCAATAGACGCGTGTACAAGAAAATGCCTAGTATC
GAATCTGATGTTTAA

# Drug_Target_36_General_Function:
Involved in ionotropic glutamate receptor activity

# Drug_Target_36_General_References:
8061049	Foldes RL, Adams SL, Fantaske RP, Kamboj RK: Human N-methyl-D-aspartate receptor modulatory subunit hNR2A: cloning and sequencing of the cDNA and primary structure of the protein. Biochim Biophys Acta. 1994 Aug 11;1223(1):155-9.
8768735	Hess SD, Daggett LP, Crona J, Deal C, Lu CC, Urrutia A, Chavez-Noriega L, Ellis SB, Johnson EC, Velicelebi G: Cloning and functional characterization of human heteromeric N-methyl-D-aspartate receptors. J Pharmacol Exp Ther. 1996 Aug;278(2):808-16.

# Drug_Target_36_HGNC_ID:
HGNC:4585

# Drug_Target_36_HPRD_ID:
00698

# Drug_Target_36_ID:
837

# Drug_Target_36_Locus:
16p13.2

# Drug_Target_36_Molecular_Weight:
165284

# Drug_Target_36_Name:
Glutamate [NMDA] receptor subunit epsilon-1

# Drug_Target_36_Number_of_Residues:
1464

# Drug_Target_36_PDB_ID:
Not Available

# Drug_Target_36_Pathway:
Methadone Pathway	SMP00408

# Drug_Target_36_Pfam_Domain_Function:
PF00060	Lig_chan

# Drug_Target_36_Protein_Sequence:
>Glutamate [NMDA] receptor subunit epsilon 1 precursor
MGRVGYWTLLVLPALLVWRGPAPSAAAEKGPPALNIAVMLGHSHDVTERELRTLWGPEQA
AGLPLDVNVVALLMNRTDPKSLITHVCDLMSGARIHGLVFGDDTDQEAVAQMLDFISSHT
FVPILGIHGGASMIMADKDPTSTFFQFGASIQQQATVMLKIMQDYDWHVFSLVTTIFPGY
REFISFVKTTVDNSFVGWDMQNVITLDTSFEDAKTQVQLKKIHSSVILLYCSKDEAVLIL
SEARSLGLTGYDFFWIVPSLVSGNTELIPKEFPSGLISVSYDDWDYSLEARVRDGIGILT
TAASSMLEKFSYIPEAKASCYGQMERPEVPMHTLHPFMVNVTWDGKDLSFTEEGYQVHPR
LVVIVLNKDREWEKVGKWENHTLSLRHAVWPRYKSFSDCEPDDNHLSIVTLEEAPFVIVE
DIDPLTETCVRNTVPCRKFVKINNSTNEGMNVKKCCKGFCIDILKKLSRTVKFTYDLYLV
TNGKHGKKVNNVWNGMIGEVVYQRAVMAVGSLTINEERSEVVDFSVPFVETGISVMVSRS
NGTVSPSAFLEPFSASVWVMMFVMLLIVSAIAVFVFEYFSPVGYNRNLAKGKAPHGPSFT
IGKAIWLLWGLVFNNSVPVQNPKGTTSKIMVSVWAFFAVIFLASYTANLAAFMIQEEFVD
QVTGLSDKKFQRPHDYSPPFRFGTVPNGSTERNIRNNYPYMHQYMTKFNQKGVEDALVSL
KTGKLDAFIYDAAVLNYKAGRDEGCKLVTIGSGYIFATTGYGIALQKGSPWKRQIDLALL
QFVGDGEMEELETLWLTGICHNEKNEVMSSQLDIDNMAGVFYMLAAAMALSLITFIWEHL
FYWKLRFCFTGVCSDRPGLLFSISRGIYSCIHGVHIEEKKKSPDFNLTGSQSNMLKLLRS
AKNISSMSNMNSSRMDSPKRAADFIQRGSLIMDMVSDKGNLMYSDNRSFQGKESIFGDNM
NELQTFVANRQKDNLNNYVFQGQHPLTLNESNPNTVEVAVSTESKANSRPRQLWKKSVDS
IRQDSLSQNPVSQRDEATAENRTHSLKSPRYLPEEMAHSDISETSNRATCHREPDNSKNH
KTKDNFKRSVASKYPKDCSEVERTYLKTKSSSPRDKIYTIDGEKEPGFHLDPPQFVENVT
LPENVDFPDPYQDPSENFRKGDSTLPMNRNPLHNEEGLSNNDQYKLYSKHFTLKDKGSPH
SETSERYRQNSTHCRSCLSNMPTYSGHFTMRSPFKCDACLRMGNLYDIDEDQMLQETGNP
ATGEQVYQQDWAQNNALQLQKNKLRISRQHSYDNIVDKPRELDLSRPSRSISLKDRERLL
EGNFYGSLFSVPSSKLSGKKSSLFPQGLEDSKRSKSLLPDHTSDNPFLHSHRDDQRLVIG
RCPSDPYKHSLPSQAVNDSYLRSSLRSTASYCSRDSRGHNDVYISEHVMPYAANKNNMYS
TPRVLNSCSNRRVYKKMPSIESDV

# Drug_Target_36_Reaction:
Not Available

# Drug_Target_36_Signals:
1-22

# Drug_Target_36_Specific_Function:
NMDA receptor subtype of glutamate-gated ion channels possesses high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine

# Drug_Target_36_SwissProt_ID:
Q12879

# Drug_Target_36_SwissProt_Name:
NMDE1_HUMAN

# Drug_Target_36_Synonyms:
Glutamate receptor subunit epsilon-1 precursor
N-methyl D- aspartate receptor subtype 2A
NMDAR2A
NR2A
hNR2A

# Drug_Target_36_Theoretical_pI:
7.11

# Drug_Target_36_Transmembrane_Regions:
556-576
593-613
634-654
817-837

# Drug_Target_37_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_37_Chromosome_Location:
Not Available

# Drug_Target_37_Drug_References:
17229973	Verkhratsky A, Kirchhoff F: NMDA Receptors in glia. Neuroscientist. 2007 Feb;13(1):28-37.
17662248	Miglio G, Dianzani C, Fallarini S, Fantozzi R, Lombardi G: Stimulation of N-methyl-D-aspartate receptors modulates Jurkat T cell growth and adhesion to fibronectin. Biochem Biophys Res Commun. 2007 Sep 21;361(2):404-9. Epub 2007 Jul 20.

# Drug_Target_37_Essentiality:
Non-Essential

# Drug_Target_37_GenAtlas_ID:
GRIN2B

# Drug_Target_37_GenBank_ID_Gene:
U90278

# Drug_Target_37_GenBank_ID_Protein:
1899202

# Drug_Target_37_GeneCard_ID:
GRIN2B

# Drug_Target_37_Gene_Name:
GRIN2B

# Drug_Target_37_Gene_Sequence:
>4455 bp
ATGAAGCCCAGAGCGGAGTGCTGTTCTCCCAAGTTCTGGTTGGTGTTGGCCGTCCTGGCC
GTGTCAGGCAGCAGAGCTCGTTCTCAGAAGAGCCCCCCCAGCATTGGCATTGCTGTCATC
CTCGTGGGCACTTCCGACGAGGTGGCCATCAAGGATGCCCACGAGAAAGATGATTTCCAC
CATCTCTCCGTGGTACCCCGGGTGGAACTGGTAGCCATGAATGAGACCGACCCAAAGAGC
ATCATCACCCGCATCTGTGATCTCATGTCTGACCGGAAGATCCAGGGGGTGGTGTTTGCT
GATGACACAGACCAGGAAGCCATCGCCCAGATCCTCGATTTCATTTCAGCACAGACTCTC
ACCCCGATCCTGGGCATCCACGGGGGCTCCTCTATGATAATGGCAGATAAGGATGAATCC
TCCATGTTCTTCCAGTTTGGCCCATCAATTGAACAGCAAGCTTCCGTAATGCTCAACATC
ATGGAAGAATATGACTGGTACATCTTTTCTATCGTCACCACCTATTTCCCTGGCTACCAG
GACTTTGTAAACAAGATCCGCAGCACCATTGAGAATAGCTTTGTGGGCTGGGAGCTAGAG
GAGGTCCTCCTACTGGACATGTCCCTGGACGATGGAGATTCTAAGATCCAGAATCAGCTC
AAGAAACTTCAAAGCCCCATCATTCTTCTTTACTGTACCAAGGAAGAAGCCACCTACATC
TTTGAAGTGGCCAACTCAGTAGGGCTGACTGGCTATGGCTACACGTGGATCGTGCCCAGT
CTGGTGGCAGGGGATACAGACACAGTGCCTGCGGAGTTCCCCACTGGGCTCATCTCTGTA
TCATATGATGAATGGGACTATGGCCTCCCCGCCAGAGTGAGAGATGGAATTGCCATAATC
ACCACTGCTGCTTCTGACATGCTGTCTGAGCACAGCTTCATCCCTGAGCCCAAAAGCAGT
TGTTACAACACCCACGAGAAGAGAATCTACCAGTCCAATATGCTAAATAGGTATCTGATC
AATGTCACTTTTGAGGGGAGGAATTTGTCCTTCAGTGAAGATGGCTACCAGATGCACCCG
AAACTGGTGATAATTCTTCTGAACAAGGAGAGGAAGTGGGAAAGGGTGGGGAAGTGGAAA
GACAAGTCCCTGCAGATGAAGTACTATGTGTGGCCCCGAATGTGTCCAGAGACTGAAGAG
CAGGAGGATGACCATCTGAGCATTGTGACCCTGGAGGAGGCACCATTTGTCATTGTGGAA
AGTGTGGACCCTCTGAGTGGAACCTGCATGAGGAACACAGTCCCCTGCCAAAAACGCATA
GTCACTGAGAATAAAACAGACGAGGAGCCGGGTTACATCAAAAAATGCTGCAAGGGGTTC
TGTATTGACATCCTTAAGAAAATTTCTAAATCTGTGAAGTTCACCTATGACCTTTACCTG
GTTACCAATGGCAAGCATGGGAAGAAAATCAATGGAACCTGGAATGGTATGATTGGAGAG
GTGGTCATGAAGAGGGCCTACATGGCAGTGGGCTCACTCACCATCAATGAGGAACGATCG
GAGGTGGTCGACTTCTCTGTGCCCTTCATAGAGACAGGCATCAGTGTCATGGTGTCACGC
AGCAATGGGACTGTCTCACCTTCTGCCTTCTTAGAGCCATTCAGCGCTGACGTATGGGTG
ATGATGTTTGTGATGCTGCTCATCGTCTCAGCCGTGGCTGTCTTTGTCTTTGAGTACTTC
AGCCCTGTGGGTTATAACAGGTGCCTCGCTGATGGCAGAGAGCCTGGTGGACCCTCTTTC
ACCATCGGCAAAGCTATTTGGTTGCTCTGGGGTCTGGTGTTTAACAACTCCGTACCTGTG
CAGAACCCAAAGGGGACCACCTCCAAGATCATGGTGTCAGTGTGGGCCTTCTTTGCTGTC
ATCTTCCTGGCCAGCTACACTGCCAACTTAGCTGCCTTCATGATCCAAGAGGAATATGTG
GACCAGGTTTCTGGCCTGAGCGACAAAAAGTTCCAGAGACCTAATGACTTCTCACCCCCT
TTCCGCTTTGGGACCGTGCCCAACGGCAGCACAGAGAGAAATATTCGCAATAACTATGCA
GAAATGCATGCCTACATGGGAAAGTTCAACCAGAGGGGTGTAGATGATGCATTGCTCTCC
CTGAAAACAGGGAAACTGGATGCCTTCATCTATGATGCAGCAGTGCTGAACTATATGGCA
GGCAGAGATGAAGGCTGCAAGCTGGTGACCATTGGCAGTGGGAAGGTCTTTGCTTCCACT
GGCTATGGCATTGCCATCCAAAAAGATTCTGGGTGGAAGCGCCAGGTGGACCTTGCTATC
CTGCAGCTCTTTGGAGATGGGGAGATGGAAGAACTGGAAGCTCTCTGGCTCACTGGCATT
TGTCACAATGAGAAGAATGAGGTCATGAGCAGCCAGCTGGACATTGACAACATGGCAGGG
GTCTTCTACATGTTGGGGGCGGCCATGGCTCTCAGCCTCATCACCTTCATCTGCGAACAC
CTTTTCTATTGGCAGTTCCGACATTGCTTTATGGGTGTCTGTTCTGGCAAGCCTGGCATG
GTCTTCTCCATCAGCAGAGGTATCTACAGCTGCATCCATGGGGTGGCGATCGAGGAGCGC
CAGTCTGTAATGAACTCCCCCACCGCAACCATGAACAACACACACTCCAACATCCTGCGC
CTGCTGCGCACGGCCAAGAACATGGCTAACCTGTCTGGTGTGAATGGCTCACCGCAGAGC
GCCCTGGACTTCATCCGACGGGAGTCATCCGTCTATGACATCTCAGAGCACCGCCGCAGC
TTCACGCATTCTGACTGCAAATCCTACAACAACCCGCCCTGTGAGGAGAACCTCTTCAGT
GACTACATCAGTGAGGTAGAGAGAACGTTCGGGAACCTGCAGCTGAAGGACAGCAACGTG
TACCAAGATCACTACCACCATCACCACCGGCCCCATAGTATTGGCAGTGCCAGCTCCATC
GATGGGCTCTACGACTGTGACAACCCACCCTTCACCACCCAGTCCAGGTCCATCAGCAAG
AAGCCCCTGGACATCGGCCTCCCCTCCTCCAAGCACAGCCAGCTCAGTGACCTGTACGGC
AAATTCTCCTTCAAGAGCGACCGCTACAGTGGCCACGACGACTTGATCCGCTCCGATGTC
TCTGACATCTCAACCCACACCGTCACCTATGGGAACATCGAGGGCAATGCCGCCAAGAGG
CGTAAGCAGCAATATAAGGACAGCCTGAAGAAGCGGCCTGCCTCGGCCAAGTCCCGCAGG
GAGTTTGACGAGATCGAGCTGGCCTACCGTCGCCGACCGCCCCGCTCCCCTGACCACAAG
CGCTACTTCAGGGACAAGGAAGGGCTACGGGACTTCTACCTGGACCAGTTCCGAACAAAG
GAGAACTCACCCCACTGGGAGCACGTAGACCTGACCGACATCTACAAGGAGCGGAGTGAT
GACTTTAAGCGCGACTCCATCAGCGGAGGAGGGCCCTGTACCAACAGGTCTCACATCAAG
CACGGGACGGGCGACAAACACGGCGTGGTCAGCGGGGTACCTGCACCTTGGGAGAAGAAC
CTGACCAACGTGGAGTGGGAGGACCGGTCCGGGGGCAACTTCTGCCGCAGCTGTCCCTCC
AAGCTGCACAACTACTCCACGACGGTGACGGGTCAGAACTCGGGCAGGCAGGCGTGCATC
CGGTGTGAGGCTTGCAAGAAAGCAGGCAACCTGTATGACATCAGTGAGGACAACTCCCTG
CAGGAACTGGACCAGCCGGCTGCCCCAGTGGCGGTGACGTCAAACGCCTCCACCACTAAG
TACCCTCAGAGCCCGACTAATTCCAAGGCCCAGAAGAAGAACCGGAACAAACTGCGCCGG
CAGCACTCCTACGACACCTTCGTGGACCTGCAGAAGGAAGAAGCCGCCCTGGCCCCGCGC
AGCGTAAGCCTGAAAGACAAGGGCCGATTCATGGATGGGAGCCCCTACGCCCACATGTTT
GAGATGTCAGCTGGCGAGAGCACCTTTGCCAACAACAAGTCCTCAGTGCCCACTGCCGGA
CATCACCACCACAACAACCCCGGCGGCGGGTACATGCTCAGCAAGTCGCTCTACCCTGAC
CGGGTCACGCAAAACCCTTTCATCCCCACTTTTGGGGACGACCAGTGCTTGCTCCATGGC
AGCAAATCCTACTTCTTCAGGCAGCCCACGGTGGCGGGGGCGTCGAAAGCCAGGCCGGAC
TTCCGGGCCCTTGTCACCAACAAGCCGGTGGTCTCGGCCCTTCATGGGGCCGTGCCAGCC
CGTTTCCAGAAGGACATCTGTATAGGGAACCAGTCCAACCCCTGTGTGCCTAACAACAAA
AACCCCAGGGCTTTCAATGGCTCCAGCAATGGGCATGTTTATGAGAAACTTTCTAGTATT
GAGTCTGATGTCTGA

# Drug_Target_37_General_Function:
Involved in ionotropic glutamate receptor activity

# Drug_Target_37_General_References:
7959773	Mandich P, Schito AM, Bellone E, Antonacci R, Finelli P, Rocchi M, Ajmar F: Mapping of the human NMDAR2B receptor subunit gene (GRIN2B) to chromosome 12p12. Genomics. 1994 Jul 1;22(1):216-8.
7999784	Adams SL, Foldes RL, Kamboj RK: Human N-methyl-D-aspartate receptor modulatory subunit hNR3: cloning and sequencing of the cDNA and primary structure of the protein. Biochim Biophys Acta. 1995 Jan 2;1260(1):105-8.
8768735	Hess SD, Daggett LP, Crona J, Deal C, Lu CC, Urrutia A, Chavez-Noriega L, Ellis SB, Johnson EC, Velicelebi G: Cloning and functional characterization of human heteromeric N-methyl-D-aspartate receptors. J Pharmacol Exp Ther. 1996 Aug;278(2):808-16.
9547169	Schito AM, Pizzuti A, Di Maria E, Schenone A, Ratti A, Defferrari R, Bellone E, Mancardi GL, Ajmar F, Mandich P: mRNA distribution in adult human brain of GRIN2B, a N-methyl-D-aspartate (NMDA) receptor subunit. Neurosci Lett. 1997 Dec 12;239(1):49-53.

# Drug_Target_37_HGNC_ID:
HGNC:4586

# Drug_Target_37_HPRD_ID:
00697

# Drug_Target_37_ID:
464

# Drug_Target_37_Locus:
12p12

# Drug_Target_37_Molecular_Weight:
166369

# Drug_Target_37_Name:
Glutamate [NMDA] receptor subunit epsilon-2

# Drug_Target_37_Number_of_Residues:
1484

# Drug_Target_37_PDB_ID:
Not Available

# Drug_Target_37_Pathway:
Not Available

# Drug_Target_37_Pfam_Domain_Function:
PF00060	Lig_chan

# Drug_Target_37_Protein_Sequence:
>Glutamate [NMDA] receptor subunit epsilon 2 precursor
MKPRAECCSPKFWLVLAVLAVSGSRARSQKSPPSIGIAVILVGTSDEVAIKDAHEKDDFH
HLSVVPRVELVAMNETDPKSIITRICDLMSDRKIQGVVFADDTDQEAIAQILDFISAQTL
TPILGIHGGSSMIMADKDESSMFFQFGPSIEQQASVMLNIMEEYDWYIFSIVTTYFPGYQ
DFVNKIRSTIENSFVGWELEEVLLLDMSLDDGDSKIQNQLKKLQSPIILLYCTKEEATYI
FEVANSVGLTGYGYTWIVPSLVAGDTDTVPAEFPTGLISVSYDEWDYGLPARVRDGIAII
TTAASDMLSEHSFIPEPKSSCYNTHEKRIYQSNMLNRYLINVTFEGRNLSFSEDGYQMHP
KLVIILLNKERKWERVGKWKDKSLQMKYYVWPRMCPETEEQEDDHLSIVTLEEAPFVIVE
SVDPLSGTCMRNTVPCQKRIVTENKTDEEPGYIKKCCKGFCIDILKKISKSVKFTYDLYL
VTNGKHGKKINGTWNGMIGEVVMKRAYMAVGSLTINEERSEVVDFSVPFIETGISVMVSR
SNGTVSPSAFLEPFSADVWVMMFVMLLIVSAVAVFVFEYFSPVGYNRCLADGREPGGPSF
TIGKAIWLLWGLVFNNSVPVQNPKGTTSKIMVSVWAFFAVIFLASYTANLAAFMIQEEYV
DQVSGLSDKKFQRPNDFSPPFRFGTVPNGSTERNIRNNYAEMHAYMGKFNQRGVDDALLS
LKTGKLDAFIYDAAVLNYMAGRDEGCKLVTIGSGKVFASTGYGIAIQKDSGWKRQVDLAI
LQLFGDGEMEELEALWLTGICHNEKNEVMSSQLDIDNMAGVFYMLGAAMALSLITFICEH
LFYWQFRHCFMGVCSGKPGMVFSISRGIYSCIHGVAIEERQSVMNSPTATMNNTHSNILR
LLRTAKNMANLSGVNGSPQSALDFIRRESSVYDISEHRRSFTHSDCKSYNNPPCEENLFS
DYISEVERTFGNLQLKDSNVYQDHYHHHHRPHSIGSASSIDGLYDCDNPPFTTQSRSISK
KPLDIGLPSSKHSQLSDLYGKFSFKSDRYSGHDDLIRSDVSDISTHTVTYGNIEGNAAKR
RKQQYKDSLKKRPASAKSRREFDEIELAYRRRPPRSPDHKRYFRDKEGLRDFYLDQFRTK
ENSPHWEHVDLTDIYKERSDDFKRDSVSGGGPCTNRSHIKHGTGDKHGVVSGVPAPWEKN
LTNVEWEDRSGGNFCRSCPSKLHNYSTTVTGQNSGRQACIRCEACKKAGNLYDISEDNSL
QELDQPAAPVAVTSNASTTKYPQSPTNSKAQKKNRNKLRRQHSYDTFVDLQKEEAALAPR
SVSLKDKGRFMDGSPYAHMFEMSAGESTFANNKSSVPTAGHHHHNNPGGGYMLSKSLYPD
RVTQNPFIPTFGDDQCLLHGSKSYFFRQPTVAGASKARPDFRALVTNKPVVSALHGAVPA
RFQKDICIGNQSNPCVPNNKNPRAFNGSSNGHVYEKLSSIESDV

# Drug_Target_37_Reaction:
Not Available

# Drug_Target_37_Signals:
1-26

# Drug_Target_37_Specific_Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine

# Drug_Target_37_SwissProt_ID:
Q13224

# Drug_Target_37_SwissProt_Name:
NMDE2_HUMAN

# Drug_Target_37_Synonyms:
Glutamate receptor subunit epsilon-2 precursor
N-methyl D- aspartate receptor subtype 2B
N-methyl-D-aspartate receptor subunit 3
NMDAR2B
NR2B
NR3
hNR3

# Drug_Target_37_Theoretical_pI:
6.92

# Drug_Target_37_Transmembrane_Regions:
558-578
635-655
818-838

# Drug_Target_38_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_38_Chromosome_Location:
Not Available

# Drug_Target_38_Drug_References:
10455281	Olmos G, DeGregorio-Rocasolano N, Paz Regalado M, Gasull T, Assumpcio Boronat M, Trullas R, Villarroel A, Lerma J, Garcia-Sevilla JA: Protection by imidazol(ine) drugs and agmatine of glutamate-induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor. Br J Pharmacol. 1999 Jul;127(6):1317-26.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
7905294	Kuner T, Schoepfer R, Korpi ER: Ethanol inhibits glutamate-induced currents in heteromeric NMDA receptor subtypes. Neuroreport. 1993 Dec 13;5(3):297-300.
9417820	Sundstrom E, Whittemore S, Mo LL, Seiger A: Analysis of NMDA receptors in the human spinal cord. Exp Neurol. 1997 Dec;148(2):407-13.

# Drug_Target_38_Essentiality:
Non-Essential

# Drug_Target_38_GenAtlas_ID:
GRIN2C

# Drug_Target_38_GenBank_ID_Gene:
L76224

# Drug_Target_38_GenBank_ID_Protein:
1196449

# Drug_Target_38_GeneCard_ID:
GRIN2C

# Drug_Target_38_Gene_Name:
GRIN2C

# Drug_Target_38_Gene_Sequence:
>3702 bp
ATGGGTGGGGCCCTGGGGCCGGCCCTGTTGCTCACCTCGCTCTTCGGTGCCTGGGCAGGG
CTGGGTCCGGGGCAGGGCGAGCAGGGCATGACGGTGGCCGTGGTGTTTAGCAGCTCAGGG
CCGCCCCAGGCCCAGTTCCGTGCCCGCCTCACCCCCCAGAGCTTCCTGGACCTACCCCTG
GAGATCCAGCCGCTCACAGTTGGGGTCAACACCACCAACCCCAGCAGCCTCCTCACCCAG
ATCTGCGGCCTCCTGGGTGCTGCCCACGTCCACGGCATTGTCTTTGAGGACAACGTGGAC
ACCGAGGCGGTGGCCCAGATCCTTGACTTCATCTCCTCCCAGACCCATGTGCCCATCCTC
AGCATCAGCGGAGGCTCTGCTGTGGTCCTCACCCCCAAGGAGCCGGGCTCCGCCTTCCTG
CAGCTGGGCGTGTCCCTGGAGCAGCAGCTGCAGGTGCTGTTCAAGGTGCTGGAAGAGTAC
GACTGGAGCGCCTTCGCCGTCATCACCAGCCTGCACCCGGGCCACGCGCTCTTCCTGGAG
GGCGTGCGCGCCGTCGCCGACGCCAGCCACGTGAGTTGGCGGCTGCTGGACGTGGTCACG
CTGGAGCTGGGCCCGGGAGGGCCGCGCGCGCGCACGCAGCGCCTGCTGCGCCAGCTCGAC
GCGCCCGTGTTTGTGGCCTACTGCTCGCGCGAGGAGGCCGAGGTGCTCTTCGCCGAGGCG
GCGCAGGCCGGTCTGGTGGGGCCCGGCCACGTGTGGTTGGTGCCCAACCTGGCGCTGGGC
AGCACCGATGCGCCCCCCGCCACCTTCCCCGTGGGCCTCATCAGCGTCGTCACCGAGAGC
TGGCGCCTCAGCCTGCGCCAGAAGGTGCGCGACGGCGTGGCCATTCTGGCCCTGGGCGCC
CACAGCTACTGGCGCCAGCATGGAACCCTGCCAGCCCCGGCCGGGGACTGCCGTGTTCAC
CCTGGGCCCGTCAGCCCTGCCCGGGAGGCCTTCTACAGGCACCTACTGAATGTCACCTGG
GAGGGCCGAGACTTCTCCTTCAGCCCTGGTGGGTACCTGGTCCAGCCCACCATGGTGGTG
ATCGCCCTCAACCGGCACCGCCTCTGGGAGATGGTGGGGCGCTGGGAGCATGGCGTCCTA
TACATGAAGTACCCCGTGTGGCCTCGCTACAGTGCCTCTCTGCAGCCTGTGGTGGACAGT
CGGCACCTGACGGTGGCCACGCTGGAAGAGCGGCCCTTTGTCATCGTGGAGAGCCCTGAC
CCTGGCACAGGAGGCTGTGTCCCCAACACCGTGCCCTGCCGCAGGCAGAGCAACCACACC
TTCAGCAGCGGGGACGTGGCCCCCTACACCAAGCTCTGCTGTAAGGGATTCTGCATCGAC
ATCCTCAAGAAGCTGGCCAGAGTGGTCAAATTCTCCTACGACCTGTACCTGGTGACCAAC
GGCAAGCATGGCAAGCGGGTGCGCGGCGTATGGAACGGCATGATTGGGGAGGTGTACTAC
AAGCGGGCAGACATGGCCATCGGCTCCCTCACCATCAATGAGGAACGCTCCGAGATCGTA
GACTTCTCTGTACCCTTTGTGGAGACGGGCATCAGTGTGATGGTGGCTCGCAGCAATGGC
ACCGTCTCCCCCTCGGCCTTCTTGGAGCCATATAGCCCTGCAGTGTGGGTGATGATGTTT
GTCATGTGCCTCACTGTGGTGGCCATCACCGTCTTCATGTTCGAGTACTTCAGCCCTGTC
AGCTACAACCAGAACCTCACCAGAGGCAAGAAGTCCGGGGGCCCAGCTTTCACTATCGGC
AAGTCCGTGTGGCTGCTGTGGGCGCTGGTCTTCAACAACTCAGTGCCCATCGAGAACCCG
CGGGGCACCACCAGCAAGATCATGGTTCTGGTCTGGGCCTTCTTTGCTGTCATCTTCCTC
GCCAGCTACACGGCCAACCTGGCCGCCTTCATGATCCAAGAGCAATACATCGACACTGTG
TCGGGCCTCAGTGACAAGAAGTTTCAGCGGCCTCAAGATCAGTACCCACCTTTCCGCTTC
GGCACGGTGCCCAACGGCAGCACGGAGCGGAACATCCGCAGTAACTACCGTGACATGCAC
ACCCACATGGTCAAGTTCAACCAGCGCTCGGTGGAGGACGCGCTCACCAGCCTCAAGATG
GGGAAGCTGGATGCCTTCATCTATGATGCTGCTGTCCTCAACTACATGGCAGGCAAGGAC
GAGGGCTGCAAGCTGGTCACCATTGGGTCTGGCAAGGTCTTTGCTACCACTGGCTACGGC
ATCGCCATGCAGAAGGACTCCCACTGGAAGCGGGCCATAGACCTGGCGCTCTTGCAGTTC
CTGGGGGACGGAGAGACACAGAAACTGGAGACAGTGTGGCTCTCAGGGATCTGCCAGAAT
GAGAAGAACGAGGTGATGAGCAGCAAGCTGGACATCGACAACATGGCAGGCGTCTTCTAC
ATGCTGCTGGTGGCCATGGGGCTGGCCCTGCTGGTCTTCGCCTGGGAGCACCTGGTCTAC
TGGAAGCTGCGCCACTCGGTGCCCAACTCATCCCAGCTGGACTTCCTGCTGGCTTTCAGC
AGGGGCATCTACAGCTGCTTCAGCGGGGTGCAGAGCCTCGCCAGCCCACCGCGGCAGGCC
AGCCCGGACCTCACGGCCAGCTCGGCCCAGGCCAGCGTGCTCAAGATGCTGCAGGCAGCC
CGCGACATGGTGACCACGGCGGGCGTAAGCAGCTCCCTGGACCGCGCCACTCGCACCATC
GAGAATTGGGGTGGCGGCCGCCGTGCGCCCCCACCGTCCCCCTGCCCGACCCCGCGGTCT
GGCCCCAGCCCATGCCTGCCCACCCCCGACCCGCCCCCAGAGCCGAGCCCCACGGGCTGG
GGACCGCCAGACGGGGGTCGCGCGGCGCTTGTGCGCAGGGCTCCGCAGCCCCCGGGCCGC
CCCCCGACGCCGGGGCCGCCCCTGTCCGACGTCTCCCGAGTGTCGCGCCGCCCAGCCTGG
GAGGCGCGGTGGCCGGTGCGGACCGGGCACTGCGGGAGGCACCTCTCGGCCTCCGAGCGG
CCCCTGTCGCCCGCGCGCTGTCACTACAGCTCCTTTCCTCGAGCCGACCGATCCGGCCGC
CCCTTCCTCCCGCTCTTCCCGGAGCTGGAGGACCTGCCGCTGCTCGGTAAGGAGCAGCTG
GCCCGGCGGGAGGCCCTGCTGCACGCGGCCTGGGCCCGGGGCTCGCGCCCGCGTCACGCT
TCCCTGCCCAGCTCCGTGGCCGAGGCCTTCGCTCGGCCCAGCTCGCTGCCCGCTGGGTGC
ACCGGCCCCGCCTGCGCCCGCCCCGACGGCCACTCGGCCTGCAGGCGCTTGGCGCAGGCG
CAGTCGATGTGCTTGCCGATCTACCGGGAGGCCTGCCAGGAGGGCGAGCAGGCAGGGGCC
CCCGCCTGGCAGCACAGACAGCACGTCTGCCTGCACGCCCACGCCCACCTGCCATTTTGC
TGGGGGGCTGTCTGTCCTCACCTTCCACCCTGTGCCAGCCACGGCTCCTGGCTCTCCGGG
GCCTGGGGGCCTCTGGGGCACAGGGGCAGGACTCTGGGGCTGGGCACAGGCTACAGAGAC
AGTGGGGGACTGGACGAGATCAGCAGGGTAGCCCGTGGGACGCAAGGCTTCCCGGGACCC
TGCACCTGGAGACGGATCTCCAGTCTGGAGTCAGAAGTGTGA

# Drug_Target_38_General_Function:
Involved in ionotropic glutamate receptor activity

# Drug_Target_38_General_References:
9037519	Lin YJ, Bovetto S, Carver JM, Giordano T: Cloning of the cDNA for the human NMDA receptor NR2C subunit and its expression in the central nervous system and periphery. Brain Res Mol Brain Res. 1996 Dec 31;43(1-2):57-64.

# Drug_Target_38_HGNC_ID:
HGNC:4587

# Drug_Target_38_HPRD_ID:
00699

# Drug_Target_38_ID:
505

# Drug_Target_38_Locus:
17q25

# Drug_Target_38_Molecular_Weight:
134241

# Drug_Target_38_Name:
Glutamate [NMDA] receptor subunit epsilon-3

# Drug_Target_38_Number_of_Residues:
1233

# Drug_Target_38_PDB_ID:
Not Available

# Drug_Target_38_Pathway:
Not Available

# Drug_Target_38_Pfam_Domain_Function:
PF00060	Lig_chan
PF01094	ANF_receptor

# Drug_Target_38_Protein_Sequence:
>Glutamate [NMDA] receptor subunit epsilon 3 precursor
MGGALGPALLLTSLFGAWAGLGPGQGEQGMTVAVVFSSSGPPQAQFRARLTPQSFLDLPL
EIQPLTVGVNTTNPSSLLTQICGLLGAAHVHGIVFEDNVDTEAVAQILDFISSQTHVPIL
SISGGSAVVLTPKEPGSAFLQLGVSLEQQLQVLFKVLEEYDWSAFAVITSLHPGHALFLE
GVRAVADASHVSWRLLDVVTLELGPGGPRARTQRLLRQLDAPVFVAYCSREEAEVLFAEA
AQAGLVGPGHVWLVPNLALGSTDAPPATFPVGLISVVTESWRLSLRQKVRDGVAILALGA
HSYWRQHGTLPAPAGDCRVHPGPVSPAREAFYRHLLNVTWEGRDFSFSPGGYLVQPTMVV
IALNRHRLWEMVGRWEHGVLYMKYPVWPRYSASLQPVVDSRHLTVATLEERPFVIVESPD
PGTGGCVPNTVPCRRQSNHTFSSGDVAPYTKLCCKGFCIDILKKLARVVKFSYDLYLVTN
GKHGKRVRGVWNGMIGEVYYKRADMAIGSLTINEERSEIVDFSVPFVETGISVMVARSNG
TVSPSAFLEPYSPAVWVMMFVMCLTVVAITVFMFEYFSPVSYNQNLTRGKKSGGPAFTIG
KSVWLLWALVFNNSVPIENPRGTTSKIMVLVWAFFAVIFLASYTANLAAFMIQEQYIDTV
SGLSDKKFQRPQDQYPPFRFGTVPNGSTERNIRSNYRDMHTHMVKFNQRSVEDALTSLKM
GKLDAFIYDAAVLNYMAGKDEGCKLVTIGSGKVFATTGYGIAMQKDSHWKRAIDLALLQF
LGDGETQKLETVWLSGICQNEKNEVMSSKLDIDNMAGVFYMLLVAMGLALLVFAWEHLVY
WKLRHSVPNSSQLDFLLAFSRGIYSCFSGVQSLASPPRQASPDLTASSAQASVLKMLQAA
RDMVTTAGVSSSLDRATRTIENWGGGRRAPPPSPCPTPRSGPSPCLPTPDPPPEPSPTGW
GPPDGGRAALVRRAPQPPGRPPTPGPPLSDVSRVSRRPAWEARWPVRTGHCGRHLSASER
PLSPARCHYSSFPRADRSGRPFLPLFPELEDLPLLGKEQLARREALLHAAWARGSRPRHA
SLPSSVAEAFARPSSLPAGCTGPACARPDGHSACRRLAQAQSMCLPIYREACQEGEQAGA
PAWQHRQHVCLHAHAHLPFCWGAVCPHLPPCASHGSWLSGAWGPLGHRGRTLGLGTGYRD
SGGLDEISRVARGTQGFPGPCTWRRISSLESEV

# Drug_Target_38_Reaction:
Not Available

# Drug_Target_38_Signals:
1-19

# Drug_Target_38_Specific_Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine

# Drug_Target_38_SwissProt_ID:
Q14957

# Drug_Target_38_SwissProt_Name:
NMDE3_HUMAN

# Drug_Target_38_Synonyms:
Glutamate receptor subunit epsilon-3 precursor
N-methyl D- aspartate receptor subtype 2C
NMDAR2C
NR2C

# Drug_Target_38_Theoretical_pI:
8.61

# Drug_Target_38_Transmembrane_Regions:
554-574
597-617
627-647
815-835

# Drug_Target_39_Cellular_Location:
Not Available

# Drug_Target_39_Chromosome_Location:
Not Available

# Drug_Target_39_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_39_Essentiality:
Non-Essential

# Drug_Target_39_GenAtlas_ID:
GIG18

# Drug_Target_39_GenBank_ID_Gene:
AY513279

# Drug_Target_39_GenBank_ID_Protein:
46981967

# Drug_Target_39_GeneCard_ID:
GIG18

# Drug_Target_39_Gene_Name:
GIG18

# Drug_Target_39_Gene_Sequence:
>1242 bp
ATGGCACCTCCGTCAGTCTTTGCCGAGGTTCCGCAGGCCCAGCCTGTCCTGGTCTTCAAG
CTCACTGCCGACTTCAGGGAGGATCCGGACCCCCGCAAGGTCAACCTGGGAGTGGGAGCA
TATCGCACGGATGACTGCCATCCCTGGGTTTTGCCAGTAGTGAAGAAAGTGGAGCAGAAG
ATTGCTAATGACAATAGCCTAAATCACGAGTATCTGCCAATCCTGGGCCTGGCTGAGTTC
CGGAGCTGTGCTTCTCGTCTTGCCCTTGAGGATGACAGCCCAGCACTCAAGGAGAAGCGG
GTAGGAGGTGTGCAATCTTTGGGGGGAACAGGTGCACTTCGAATTGGAGCTGATTTCTTA
GCGCGTTGGTACAATGGAACAAACAACAAGAACACACCTGTCTATGTGTCCTCACCAACC
TGGGAGAATCACAATGCTGTGTTTTCCGCTGCTGGTTTTAAAGACATTCGGTCCTATCGC
TACTGGGATGCAGAGAAGAGAGGATTGGACCTCCAGGGCTTCCTGAATGATCTGGAGAAT
GCTCCTGAGTTCTCCATTGTTGTCCTCCACGCCTGTGCACACAACCCAACTGGGATTGAC
CCAACTCCGGAGCAGTGGAAGCAGATTGCTTCTGTCATGAAGCACCGGTTTCTGTTCCCC
TTCTTTGACTCAGCCTATCAGGGCTTCGCATCTGGAAACCTGGAGAGAGATGCCTGGGCC
ATTCGCTATTTTGTGTCTGAAGGCTTCGAGTTCTTCTGTGCCCAGTCCTTCTCCAAGAAC
TTCGGGCTCTACAATGAGAGAGTCGGGAATCTGACTGTGGTTGGAAAAGAACCTGAGAGC
ATCCTGCAAGTCCTTTCCCAGATGGAGAAGATCGTGCGGATTACTTGGTCCAATCCCCCC
GCCCAGGGAGCACGAATTGTGGCCAGCACCCTCTCTAACCCTGAGCTCTTTGAGGAATGG
ACAGGTAATGTGAAGACAATGGCTGACCGGATTCTGACCATGAGATCTGAACTCAGGGCA
CGACTAGAAGCCCTCAAAACCCCTGGGACCTGGAACCACATCACTGATCAAATTGGCATG
TTCAGCTTCACTGGGTTGAACCCCAAGCAGGTTGAGTATCTGGTCAATGAAAAGCACATC
TACCTGCTGCCAAGTGGTCGAATCAACGTGAGTGGCTTAACCACCAAAAATCTAGATTAC
GTGGCCACCTCCATCCATGAAGCAGTCACCAAAATCCAGTGA

# Drug_Target_39_General_Function:
Amino acid transport and metabolism

# Drug_Target_39_General_References:
Not Available

# Drug_Target_39_HGNC_ID:
HGNC:4432

# Drug_Target_39_HPRD_ID:
Not Available

# Drug_Target_39_ID:
3877

# Drug_Target_39_Locus:
Not Available

# Drug_Target_39_Molecular_Weight:
46320

# Drug_Target_39_Name:
Growth-inhibiting protein 18

# Drug_Target_39_Number_of_Residues:
413

# Drug_Target_39_PDB_ID:
1AJS

# Drug_Target_39_Pathway:
Not Available

# Drug_Target_39_Pfam_Domain_Function:
PF00155	Aminotran_1_2

# Drug_Target_39_Protein_Sequence:
>Growth-inhibiting protein 18
MAPPSVFAEVPQAQPVLVFKLTADFREDPDPRKVNLGVGAYRTDDCHPWVLPVVKKVEQK
IANDNSLNHEYLPILGLAEFRSCASRLALEDDSPALKEKRVGGVQSLGGTGALRIGADFL
ARWYNGTNNKNTPVYVSSPTWENHNAVFSAAGFKDIRSYRYWDAEKRGLDLQGFLNDLEN
APEFSIVVLHACAHNPTGIDPTPEQWKQIASVMKHRFLFPFFDSAYQGFASGNLERDAWA
IRYFVSEGFEFFCAQSFSKNFGLYNERVGNLTVVGKEPESILQVLSQMEKIVRITWSNPP
AQGARIVASTLSNPELFEEWTGNVKTMADRILTMRSELRARLEALKTPGTWNHITDQIGM
FSFTGLNPKQVEYLVNEKHIYLLPSGRINVSGLTTKNLDYVATSIHEAVTKIQ

# Drug_Target_39_Reaction:
Not Available

# Drug_Target_39_Signals:
None

# Drug_Target_39_Specific_Function:
L-aspartate + 2-oxoglutarate = oxaloacetate + L-glutamate

# Drug_Target_39_SwissProt_ID:
Q2TU84

# Drug_Target_39_SwissProt_Name:
Q2TU84_HUMAN

# Drug_Target_39_Synonyms:
Not Available

# Drug_Target_39_Theoretical_pI:
6.80

# Drug_Target_39_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
8589992	Korczak B, Nutt SL, Fletcher EJ, Hoo KH, Elliott CE, Rampersad V, McWhinnie EA, Kamboj RK: cDNA cloning and functional properties of human glutamate receptor EAA3 (GluR5) in homomeric and heteromeric configuration. Receptors Channels. 1995;3(1):41-9.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
GRIK4

# Drug_Target_3_GenBank_ID_Gene:
S67803

# Drug_Target_3_GenBank_ID_Protein:
544590

# Drug_Target_3_GeneCard_ID:
GRIK4

# Drug_Target_3_Gene_Name:
GRIK4

# Drug_Target_3_Gene_Sequence:
>2871 bp
ATGCCCCGCGTCTCGGCGCCTTTGGTGCTGCTTCCTGCGTGGCTCGTGATGGTCGCCTGC
AGCCCGCACTCCTTGAGGATCGCTGCTATCTTGGACGACCCCATGGAGTGCAGCAGAGGG
GAGCGGCTCTCCATCACCCTGGCCAAGAACCGCATCAACCGCGCTCCTGAGAGGCTGGGC
AAGGCCAAGGTCGAAGTGGACATCTTTGAGCTTCTCAGAGACAGCGAGTACGAGACTGCA
GAAACCATGTGTCAGATCCTCCCCAAGGGGGTGGTCGCTGTCCTCGGACCATCGTCCAGC
CCAGCCTCCAGCTCCATCATCAGCAACATCTGTGGAGAGAAGGAGGTCCCTCACTTCAAA
GTGGCCCCAGAGGAGTTCGTCAAGTTCCAGTTCCAGAGATTCACAACCCTGAACCTCCAC
CCCAGCAACACTGACATCAGCGTGGCTGTAGCTGGGATCCTGAACTTCTTCAACTGCACC
ACCGCCTGCCTCATCTGTGCCAAAGCAGAATGCCTTTTAAACCTAGAGAAGCTGCTCCGG
CAATTCCTTATCTCCAAGGACACGCTGTCCGTCCGCATGCTGGATGACACCCGGGACCCC
ACCCCGCTCCTCAAGGAGATCCGGGACGACAAGACCGCCACCATCATCATCCACGCCAAC
GCCTCCATGTCCCACACCATCCTCCTGAAGGCAGCCGAACTTGGGATGGTGTCAGCCTAT
TACACATACATCTTCACTAATCTGGAGTTCTCACTCCAGAGAACGGACAGCCTTGTGGAT
GATCGTGTCAACATCCTGGGATTTTCCATTTTCAACCAATCCCATGCTTTCTTCCAAGAG
TTTGCCCAGAGCCTCAACCAGTCCTGGCAGGAGAACTGTGACCATGTGCCCTTCACTGGG
CCTGCGCTCTCCTCGGCCCTGCTGTTTGATGCTGTCTATGCTGTGGTGACTGCGGTGCAG
GAACTGAACCGGAGCCAAGAGATCGGCGTGAAGCCCTTGTCCTGCGGCTCGGCCCAGATC
TGGCAGCACGGCACCAGCCTCATGAACTACCTGCGCATGGTAGAATTGGAAGGTCTTACC
GGCCACATTGAATTCAACAGCAAAGGCCAGAGGTCCAACTACGCTTTGAAAATCTTACAG
TTCACAAGGAATGGTTTTCGGCAGATCGGCCAGTGGCACGTGGCAGAGGGCCTCAGCATG
GACAGCCACCTCTATGCCTCCAACATCTCGGACACTCTCTTCAACACCACCCTGGTCGTC
ACCACCATCCTGGAAAACCCATATTTAATGCTGAAGGGGAACCACCAGGAGATGGAAGGC
AATGACCGCTACGAGGGCTTCTGTGTGGACATGCTCAAGGAGCTGGCAGAGATCCTCCGA
TTCAACTACAAGATCCGCCTGGTTGGGGATGGCGTGTACGGCGTTCCCGAGGCCAACGGC
ACCTGGACGGGAATGGTCGGGGAGCTGATCGCTAGGAAAGCAGATCTGGCTGTGGCAGGC
CTCACCATTACAGCTGAACGGGAGAAGGTGATTGATTTCTCTAAGCCATTCATGACTCTG
GGAATTAGCATTCTTTACCGCATTCATATGGGACGCAAACCCGGCTATTTCTCCTTCCTG
GACCCATTTTCTCCGGGCGTCTGGCTCTTCATGCTTCTAGCCTATCTGGCCGTCAGCTGT
GTCCTCTTCCTGGTGGCTCGGTTGACGCCCTACGAGTGGTACAGCCCACACCCATGTGCC
CAGGGCCGGTGCAACCTCCTGGTGAACCAGTACTCCCTGGGCAACAGCCTCTGGTTTCCG
GTCGGGGGGTTCATGCAGCAGGGCTCCACCATCGCCCCTCGCGCCTTATCCACCCGCTGT
GTCAGTGGCGTCTGGTGGGCATTCACGCTGATCATCATCTCATCCTACACGGCCAACCTG
GCAGCCTTCCTGACCGTGCAGCGCATGGATGTGCCCATTGAGTCAGTGGATGACCTGGCT
GACCAGACCGCCATTGAATATGGCACAATTCACGGAGGCTCCAGCATGACCTTCTTCCAA
AATTCCCGCTACCAGACCTACCAACGCATGTGGAATTACATGTATTCCAAGCAGCCCAGC
GTGTTCGTGAAGAGCACAGAGGAGGGAATCGCCAGGGTGTTGAATTCCAACTACGCCTTC
CTCCTGGAATCCACCATGAACGAGTACTATCGGCAGCGAAACTGCAACCTCACTCAGATT
GGGGGCCTGCTGGACACCAAGGGCTATGGGATTGGCATGCCAGTCGGCTCGGTTTTCCGG
GACGAGTTTGATCTGGCCATTCTCCAGCTGCAGGAGAACAACCGCCTGGAGATCCTGAAG
CGCAAATGGTGGGAAGGAGGGAAGTGCCCCAAGGAGGAAGATCACAGAGCTAAAGGCCTG
GGAATGGAGAATATTGGTGGAATCTTTGTGGTTCTTATTTGTGGCTTAATCGTGGCCATT
TTTATGGCTATGTTGGAGTTTTTATGGACTCTCAGACACTCAGAAGCAACTGAGGTGTCC
GTCTGCCAGGAGATGGTGACCGAGCTGCGCAGCATTATCCTGTGTCAGGACAGTATCCAC
CCCCGCCGGCGGCGCGCCGCAGTCCCGCCGCCCCGGCCCCCCATCCCCGAGGAGCGCCGA
CCGCGGGGCACGGCGACGCTCAGCAACGGGAAGCTGTGCGGGGCAGGGGAGCCCGACCAG
CTCGCGCAGAGACTGGCGCAGGAGGCCGCCCTGGTGGCCCGCGGCTGCACGCACATCCGC
GTCTGCCCCGAGTGCCGCCGCTTCCAGGGCCTGCGGGCACGGCCGTCGCCCGCCCGCAGC
GAGGAGAGCCTGGAGTGGGAGAAAACCACCAACAGCAGCGAGCCCGAGTAG

# Drug_Target_3_General_Function:
Amino acid transport and metabolism

# Drug_Target_3_General_References:
8263508	Kamboj RK, Schoepp DD, Nutt S, Shekter L, Korczak B, True RA, Rampersad V, Zimmerman DM, Wosnick MA: Molecular cloning, expression, and pharmacological characterization of humEAA1, a human kainate receptor subunit. J Neurochem. 1994 Jan;62(1):1-9.

# Drug_Target_3_HGNC_ID:
HGNC:4582

# Drug_Target_3_HPRD_ID:
02613

# Drug_Target_3_ID:
919

# Drug_Target_3_Locus:
11q22.3

# Drug_Target_3_Molecular_Weight:
107231

# Drug_Target_3_Name:
Glutamate receptor, ionotropic kainate 4

# Drug_Target_3_Number_of_Residues:
956

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00060	Lig_chan
PF01094	ANF_receptor

# Drug_Target_3_Protein_Sequence:
>Glutamate receptor, ionotropic kainate 4 precursor
MPRVSAPLVLLPAWLVMVACSPHSLRIAAILDDPMECSRGERLSITLAKNRINRAPERLG
KAKVEVDIFELLRDSEYETAETMCQILPKGVVAVLGPSSSPASSSIISNICGEKEVPHFK
VAPEEFVKFQFQRFTTLNLHPSNTDISVAVAGILNFFNCTTACLICAKAECLLNLEKLLR
QFLISKDTLSVRMLDDTRDPTPLLKEIRDDKTATIIIHANASMSHTILLKAAELGMVSAY
YTYIFTNLEFSLQRTDSLVDDRVNILGFSIFNQSHAFFQEFAQSLNQSWQENCDHVPFTG
PALSSALLFDAVYAVVTAVQELNRSQEIGVKPLSCGSAQIWQHGTSLMNYLRMVELEGLT
GHIEFNSKGQRSNYALKILQFTRNGFRQIGQWHVAEGLSMDSHLYASNISDTLFNTTLVV
TTILENPYLMLKGNHQEMEGNDRYEGFCVDMLKELAEILRFNYKIRLVGDGVYGVPEANG
TWTGMVGELIARKADLAVAGLTITAEREKVIDFSKPFMTLGISILYRIHMGRKPGYFSFL
DPFSPGVWLFMLLAYLAVSCVLFLVARLTPYEWYSPHPCAQGRCNLLVNQYSLGNSLWFP
VGGFMQQGSTIAPRALSTRCVSGVWWAFTLIIISSYTANLAAFLTVQRMDVPIESVDDLA
DQTAIEYGTIHGGSSMTFFQNSRYQTYQRMWNYMYSKQPSVFVKSTEEGIARVLNSNYAF
LLESTMNEYYRQRNCNLTQIGGLLDTKGYGIGMPVGSVFRDEFDLAILQLQENNRLEILK
RKWWEGGKCPKEEDHRAKGLGMENIGGIFVVLICGLIVAIFMAMLEFLWTLRHSEATEVS
VCQEMVTELRSIILCQDSIHPRRRRAAVPPPRPPIPEERRPRGTATLSNGKLCGAGEPDQ
LAQRLAQEAALVARGCTHIRVCPECRRFQGLRARPSPARSEESLEWEKTTNSSEPE

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
1-20

# Drug_Target_3_Specific_Function:
L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists

# Drug_Target_3_SwissProt_ID:
Q16099

# Drug_Target_3_SwissProt_Name:
GRIK4_HUMAN

# Drug_Target_3_Synonyms:
EAA1
Excitatory amino acid receptor 1
Glutamate receptor KA-1
Glutamate receptor, ionotropic kainate 4 precursor
KA1

# Drug_Target_3_Theoretical_pI:
6.71

# Drug_Target_3_Transmembrane_Regions:
546-566
624-644
805-825

# Drug_Target_40_Cellular_Location:
Mitochondrion

# Drug_Target_40_Chromosome_Location:
Not Available

# Drug_Target_40_Drug_References:
17161369	Sekine S, Shichiri M, Bernier S, Chenevert R, Lapointe J, Yokoyama S: Structural bases of transfer RNA-dependent amino acid recognition and activation by glutamyl-tRNA synthetase. Structure. 2006 Dec;14(12):1791-9.

# Drug_Target_40_Essentiality:
Non-Essential

# Drug_Target_40_GenAtlas_ID:
EARS2

# Drug_Target_40_GenBank_ID_Gene:
AL832489

# Drug_Target_40_GenBank_ID_Protein:
57997136

# Drug_Target_40_GeneCard_ID:
EARS2

# Drug_Target_40_Gene_Name:
EARS2

# Drug_Target_40_Gene_Sequence:
>1572 bp
ATGGCGGCGCTCCTGAGGAGACTGCTGCAGCGCGAGAGGCCTTCGGCGGCCTCTGGCCGC
CCCGTAGGACGGCGCGAGGCCAACCTGGGCACTGATGCCGGGGTTGCGGTGCGAGTGCGG
TTCGCTCCCAGCCCCACAGGCTTCTTGCACCTGGGTGGCCTCCGCACTGCCTTGTACAAC
TACATCTTTGCTAAGAAGTACCAGGGGAGCTTCATCCTGAGGCTAGAGGACACAGATCAG
ACTCGCGTTGTGCCTGGGGCAGCAGAGAATATTGAGGACATGCTGGAGTGGGCAGGCATC
CCGCCTGATGAGAGCCCCCGCCGGGGCGGTCCTGCTGGGCCCTACCAGCAATCTCAGCGG
TTGGAGCTGTATGCCCAGGCCACAGAAGCGCTGCTGAAGACCGGAGCTGCTTACCCCTGT
TTCTGCTCACCCCAGCGGCTGGAGCTCCTGAAGAAGGAGGCCTTGCGGAACCACCAGACG
CCCCGGTATGACAATCGGTGCAGGAACATGAGCCAGGAGCAGGTGGCCCAGAAGCTGGCC
AAGGACCCCAAGCCTGCGATCCGCTTCCGCCTGGAGCAGGTGGTGCCAGCCTTCCAGGAC
CTGGTGTATGGCTGGAATAGGCATGAAGTGGCCAGCGTGGAGGGAGACCCAGTCATCATG
AAGAGCGACGGCTTCCCCACATACCACCTGGCCTGCGTGGTGGACGACCACCACATGGGC
ATCAGCCACGTGCTGCGAGGCTCTGAGTGGCTCGTCTCCACTGCCAAGCACCTGCTCCTC
TACCAGGCCCTGGGCTGGCAGCCACCCCACTTCGCCCACCTGCCCCTGCTCCTCAACAGG
GATGGCAGCAAGCTCTCCAAGAGGCAAGGGGACGTTTTCCTGGAGCACTTTGCTGCTGAT
GGCTTCCTGCCCGATTCCTTGTTGGACATCATCACCAACTGTGGCTCAGGTTTTGCAGAG
AACCAAATGGGCAGGACCCTGCCGGAGCTGATCACACAGTTCAACCTGACACAGGTCACC
TGTCACTCAGCCCTGCTGGACCTGGAGAAGCTCCCAGAATTCAACAGACTGCACCTCCAG
CGGCTGGTGAGCAATGAGAGCCAGAGGCGCCAGCTGGTGGGGAAGCTGCAGGTCCTTGTG
GAGGAGGCCTTTGGTTGCCAGCTGCAAAACAGGGATGTCCTCAACCCAGTCTACGTGGAG
AGGATCCTCCTGCTGAGACAGGGTCACATTTGCCGCCTGCAGGACTTGGTGTCCCCAGTA
TACTCTTACCTGTGGACTCGCCCTGCAGTAGGTCGAGCACAGCTGGACGCCATCTCGGAG
AAGGTGGATGTGATTGCCAAGCGTGTGCTGGGGCTTCTAGAAAGATCTGGTATGAGCTTA
ACTCAGGATATGCTGAATGGAGAACTGAAGAAGCTATCAGAAGGTCTGGAAGGCACCAAG
TACAGTAATGTGATGAAACTCCTTCGGATGGCCCTCAGTGGACAGCAGCAAGGACCTCCT
GTAGCTGAGATGATGTTGGCCTTGGGACCAAAGGAAGTACGGGAACGGATCCAGAAGGTG
GTTTCCAGCTAG

# Drug_Target_40_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_40_General_References:
11853319	Nagase T, Kikuno R, Ohara O: Prediction of the coding sequences of unidentified human genes. XXII. The complete sequences of 50 new cDNA clones which code for large proteins. DNA Res. 2001 Dec 31;8(6):319-27.

# Drug_Target_40_HGNC_ID:
HGNC:29419

# Drug_Target_40_HPRD_ID:
Not Available

# Drug_Target_40_ID:
4021

# Drug_Target_40_Locus:
16p12.1

# Drug_Target_40_Molecular_Weight:
58689

# Drug_Target_40_Name:
Probable glutamyl-tRNA synthetase, mitochondrial

# Drug_Target_40_Number_of_Residues:
523

# Drug_Target_40_PDB_ID:
Not Available

# Drug_Target_40_Pathway:
Not Available

# Drug_Target_40_Pfam_Domain_Function:
PF00749	tRNA-synt_1c

# Drug_Target_40_Protein_Sequence:
>Probable glutamyl-tRNA synthetase, mitochondrial
MAALLRRLLQRERPSAASGRPVGRREANLGTDAGVAVRVRFAPSPTGFLHLGGLRTALYN
YIFAKKYQGSFILRLEDTDQTRVVPGAAENIEDMLEWAGIPPDESPRRGGPAGPYQQSQR
LELYAQATEALLKTGAAYPCFCSPQRLELLKKEALRNHQTPRYDNRCRNMSQEQVAQKLA
KDPKPAIRFRLEQVVPAFQDLVYGWNRHEVASVEGDPVIMKSDGFPTYHLACVVDDHHMG
ISHVLRGSEWLVSTAKHLLLYQALGWQPPHFAHLPLLLNRDGSKLSKRQGDVFLEHFAAD
GFLPDSLLDIITNCGSGFAENQMGRTLPELITQFNLTQVTCHSALLDLEKLPEFNRLHLQ
RLVSNESQRRQLVGKLQVLVEEAFGCQLQNRDVLNPVYVERILLLRQGHICRLQDLVSPV
YSYLWTRPAVGRAQLDAISEKVDVIAKRVLGLLERSSMSLTQDMLNGELKKLSEGLEGTK
YSNVMKLLRMALSGQQQGPPVAEMMLALGPKEVRERIQKVVSS

# Drug_Target_40_Reaction:
ATP + L-glutamate + tRNAGlu = AMP + diphosphate + L-glutamyl-tRNAGlu

# Drug_Target_40_Signals:
None

# Drug_Target_40_Specific_Function:
ATP + L-glutamate + tRNA(Glu) = AMP + diphosphate + L-glutamyl-tRNA(Glu)

# Drug_Target_40_SwissProt_ID:
Q5JPH6

# Drug_Target_40_SwissProt_Name:
SYEM_HUMAN

# Drug_Target_40_Synonyms:
EC 6.1.1.17
GluRS
Glutamate--tRNA ligase
Probable glutamyl-tRNA synthetase, mitochondrial precursor

# Drug_Target_40_Theoretical_pI:
8.98

# Drug_Target_40_Transmembrane_Regions:
None

# Drug_Target_41_Cellular_Location:
Not Available

# Drug_Target_41_Chromosome_Location:
Not Available

# Drug_Target_41_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_41_Essentiality:
Non-Essential

# Drug_Target_41_GenAtlas_ID:
GLULD1

# Drug_Target_41_GenBank_ID_Gene:
AF242388

# Drug_Target_41_GenBank_ID_Protein:
7341339

# Drug_Target_41_GeneCard_ID:
GLULD1

# Drug_Target_41_Gene_Name:
LGSN

# Drug_Target_41_Gene_Sequence:
>1530 bp
ATGAATAATGAAGAGGACCTTCTGCAGGAGGACTCAACAAGAGATGAAGGCAATGAGACT
GAAGCCAACAGCATGAACACATTAAGAAGGACAAGGAAGAAAGTCACTAAACCATATGTT
TGTTCAACTGAAGTGGGAGAAACGGATATGTCCAATTCAAATGATTGCATGAGGGACAGC
AGTCAAATTTTGACCCCACCTCAACTCTCTTCTAGAATGAAACACATTAGACAAGCCATG
GCCAAAAATCGCCTCCAGTTTGTACGATTTGAAGCAACAGACCTCCACGGCGTGTCCAGG
TCTAAGACTATCCCTGCACACTTTTTTCAAGAGAAAGTGAGCCATGGTGTTTGCATGCCC
CGAGGTTATCTTGAAGTGATACCAAATCCAAAGGACAATGAAATGAATAACATAAGAGCC
ACATGTTTTAATAGCGACATAGTCCTAATGCCAGAGTTATCAACCTTTAGAGTTTTGCCA
TGGGCTGACAGAACTGCAAGAGTGATATGTGATACCTTCACTGTGACTGGTGAGCCTCTT
TTGACTTCCCCAAGGTACATTGCAAAGAGGCAGCTGAGCCATCTGCAGGCCTCTGGCTTT
TCCCTGCTTTCTGCTTTCATCTATGATTTTTGCATTTTTGGTGTGCCCGAAATTTTAAAT
TCAAAGATTATATCTTTTCCTGCTTTAACATTTTTAAATAACCATGATCAGCCCTTCATG
CAGGAACTTGTTGATGGCTTGTATCACACTGGAGCCAATGTCGAGAGTTTTTCCTCCTCT
ACCAGGCCTGGTCAGATGGAAATCTCTTTCCTGCCTGAATTTGGCATTAGCTCAGCTGAT
AATGCATTTACCCTCAGAACAGGTGTCAAAGAAGTGGCAAGGAAATATAATTACATTGCC
AGCTTCTTCATTGAGACTGGATTTTGTGATTCAGGGATTTTGTCTCATAGTCTCTGGGAT
GTCGATAGGAAGAAAAACATGTTCTGCAGCACTTCTGGAACTGAGCAGCTCACGATCACT
GGGAAAAAATGGTTGGCAGGACTCTTGAAGCACTCTGCTGCGCTCAGCTGCCTGATGGCG
CCTTCTGTTAGCTGCCGAAAGCGTTATTCCAAGGACAGGAAAGACCTGAAGAAGAGTGTG
CCTACAACATGGGGATACAATGACAACAGCTGTATATTTAATATCAAATGTCATGGAGAG
AAAGGCACCCGGATAGAAAATAAACTAGGCTCAGCAACAGCAAACCCTTACTTGGTGCTG
GCTGCAACTGTTGCTGCCGGCTTAGATGGACTTCATAGCAGTAATGAGGTCTTGGCTGGT
CCAGATGAGAGCACAGACTTTTACCAAGTGGAACCTTCTGAGATCCCTTTAAAACTAGAA
GATGCCCTTGTGGCACTGGAAGAAGATCAATGCCAGAGACAGGCTCTAGGAGAAACCTTT
ATTCGATATTTTGTTGCCATGAAGAAATATGAGTTGGAGAATGAAGAAATAGCTGCAGAG
AGAAATAAATTCTTAGAGTATTTTATTTAG

# Drug_Target_41_General_Function:
Amino acid transport and metabolism

# Drug_Target_41_General_References:
14574404	Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE, Gilbert JG, Clamp ME, Bethel G, Milne S, Ainscough R, Almeida JP, Ambrose KD, Andrews TD, Ashwell RI, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beare DM, Beasley H, Beasley O, Bird CP, Blakey S, Bray-Allen S, Brook J, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Clark SY, Clark G, Clee CM, Clegg S, Cobley V, Collier RE, Collins JE, Colman LK, Corby NR, Coville GJ, Culley KM, Dhami P, Davies J, Dunn M, Earthrowl ME, Ellington AE, Evans KA, Faulkner L, Francis MD, Frankish A, Frankland J, French L, Garner P, Garnett J, Ghori MJ, Gilby LM, Gillson CJ, Glithero RJ, Grafham DV, Grant M, Gribble S, Griffiths C, Griffiths M, Hall R, Halls KS, Hammond S, Harley JL, Hart EA, Heath PD, Heathcott R, Holmes SJ, Howden PJ, Howe KL, Howell GR, Huckle E, Humphray SJ, Humphries MD, Hunt AR, Johnson CM, Joy AA, Kay M, Keenan SJ, Kimberley AM, King A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd CR, Lloyd DM, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, Maslen GL, Matthews L, McCann OT, McLaren SJ, McLay K, McMurray A, Moore MJ, Mullikin JC, Niblett D, Nickerson T, Novik KL, Oliver K, Overton-Larty EK, Parker A, Patel R, Pearce AV, Peck AI, Phillimore B, Phillips S, Plumb RW, Porter KM, Ramsey Y, Ranby SA, Rice CM, Ross MT, Searle SM, Sehra HK, Sheridan E, Skuce CD, Smith S, Smith M, Spraggon L, Squares SL, Steward CA, Sycamore N, Tamlyn-Hall G, Tester J, Theaker AJ, Thomas DW, Thorpe A, Tracey A, Tromans A, Tubby B, Wall M, Wallis JM, West AP, White SS, Whitehead SL, Whittaker H, Wild A, Willey DJ, Wilmer TE, Wood JM, Wray PW, Wyatt JC, Young L, Younger RM, Bentley DR, Coulson A, Durbin R, Hubbard T, Sulston JE, Dunham I, Rogers J, Beck S: The DNA sequence and analysis of human chromosome 6. Nature. 2003 Oct 23;425(6960):805-11.

# Drug_Target_41_HGNC_ID:
HGNC:21016

# Drug_Target_41_HPRD_ID:
Not Available

# Drug_Target_41_ID:
4022

# Drug_Target_41_Locus:
6pter-q22.33

# Drug_Target_41_Molecular_Weight:
57279

# Drug_Target_41_Name:
Glutamate--ammonia ligase domain-containing protein 1

# Drug_Target_41_Number_of_Residues:
509

# Drug_Target_41_PDB_ID:
Not Available

# Drug_Target_41_Pathway:
Not Available

# Drug_Target_41_Pfam_Domain_Function:
PF00120	Gln-synt_C
PF03951	Gln-synt_N

# Drug_Target_41_Protein_Sequence:
>Glutamate--ammonia ligase domain-containing protein 1
MNNEEDLLQEDSTRDEGNETEANSMNTLRRTRKKVTKPYVCSTEVGETDMSNSNDCMRDS
SQILTPPQLSSRMKHIRQAMAKNRLQFVRFEATDLHGVSRSKTIPAHFFQEKVSHGVCMP
RGYLEVIPNPKDNEMNNIRATCFNSDIVLMPELSTFRVLPWADRTARVICDTFTVTGEPL
LTSPRYIAKRQLSHLQASGFSLLSAFIYDFCIFGVPEILNSKIISFPALTFLNNHDQPFM
QELVDGLYHTGANVESFSSSTRPGQMEISFLPEFGISSADNAFTLRTGVKEVARKYNYIA
SFFIETGFCDSGILSHSLWDVDRKKNMFCSTSGTEQLTITGKKWLAGLLKHSAALSCLMA
PSVSCRKRYSKDRKDLKKSVPTTWGYNDNSCIFNIKCHGEKGTRIENKLGSATANPYLVL
AATVAAGLDGLHSSNEVLAGPDESTDFYQVEPSEIPLKLEDALVALEEDQCLRQALGETF
IRYFVAMKKYELENEEIAAERNKFLEYFI

# Drug_Target_41_Reaction:
Not Available

# Drug_Target_41_Signals:
None

# Drug_Target_41_Specific_Function:
Not known

# Drug_Target_41_SwissProt_ID:
Q5TDP6

# Drug_Target_41_SwissProt_Name:
LGSN_HUMAN

# Drug_Target_41_Synonyms:
Lengsin
Lens glutamine synthase-like

# Drug_Target_41_Theoretical_pI:
6.30

# Drug_Target_41_Transmembrane_Regions:
None

# Drug_Target_42_Cellular_Location:
Cytoplasmic

# Drug_Target_42_Chromosome_Location:
Not Available

# Drug_Target_42_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_42_Essentiality:
Non-Essential

# Drug_Target_42_GenAtlas_ID:
NADSYN1

# Drug_Target_42_GenBank_ID_Gene:
AB091316

# Drug_Target_42_GenBank_ID_Protein:
28849201

# Drug_Target_42_GeneCard_ID:
NADSYN1

# Drug_Target_42_Gene_Name:
NADSYN1

# Drug_Target_42_Gene_Sequence:
>2121 bp
ATGGGCCGGAAGGTGACCGTGGCCACCTGCGCACTCAACCAGTGGGCCCTGGACTTCGAG
GGCAATTTGCAAAGAATTTTAAAGAGTATTGAAATTGCCAAAAACAGAGGAGCAAGATAC
AGGCTTGGACCAGAGCTGGAAATATGCGGCTACGGATGTTGGGATCATTATTACGAGTCG
GACACCCTCTTGCACTCGTTTCAAGTCCTAGCGGCCCTTGTGGAGTCTCCCGTCACTCAG
GACATCATCTGCGACGTGGGGATGCCTGTAATGCACCGAAACGTCCGCTACAACTGCAGA
GTGGTATTCCTCAACAGGAAGATCCTGCTCATCAGACCCAAGATGGCCTTGGCCAATGAA
GGCAACTACCGCGAGCTGCGCTGGTTCACCCCGTGGTCGAGGAGTCGGCACACAGAGGAG
TACTTTCTGCCTCGGATGATACAGGACCTGACAAAGCAGGAAACCGTACCCTTCGGAGAT
GCGGTGCTGGTGACATGGGACACCTGCATTGGAAGTGAGATCTGTGAGGAGCTCTGGACA
CCCCACAGCCCGCACATCGACATGGGCCTGGATGGCGTGGAGATCATCACCAACGCCTCG
GGCAGCCACCACGTGCTGCGCAAAGCCAACACCAGGGTGGATCTCGTGACTATGGTCACC
AGCAAGAACGGTGGGATTTACTTGCTGGCCAACCAGAAGGGTTGCGACGGGGACCGCCTG
TACTACGACGGCTGTGCCATGATCGCCATGAACGGAAGCGTCTTTGCTCAAGGATCCCAG
TTTTCTCTGGATGACGTGGAAGTCCTGACGGCCACGCTGGATCTGGAGGACGTCCGGAGC
TACAGGGCGGAGATTTCATCTCGAAACCTGGCGGCCAGCAGGGCGAGCCCCTACCCCAGA
GTGAAGGTGGACTTTGCCCTCTCGTGCCACGAGGACTTGCTGGCACCCATCTCTGAGCCC
ATCGAGTGGAAATACCACAGCCCTGAGGAGGAGATAAGCCTTGGACCTGCCTGCTGGCTC
TGGGATTTTTTAAGACGAAGTCAACAGGCAGGGTTTTTGCTGCCCTTGAGTGGCGGGGTG
GACAGCGCAGCCACCGCCTGCCTCATCTACTCCATGTGCTGCCAGGTCTGCGAGGCCGTG
AGGAGTGGAAATGAGGAAGTGCTGGCTGATGTCCGCACCATCGTGAACCAGATCAGCTAC
ACCCCCCAGGATCCCCGAGACCTCTGTGGACGCATACTGACCACCTGCTACATGGCCAGC
AAGAACTCCTCCCAGGAGACGTGCACCCGGGCCAGAGAGTTGGCCCAGCAGATTGGAAGC
CACCACATCAGTCTCAACATCGATCCAGCCGTGAAGGCCGTCATGGGCATCTTCAGCCTG
GTGACGGGGAAGAGCCCTCTGTTTGCAGCTCATGGAGGAAGCAGCAGGGAAAACCTGGCG
CTGCAAAATGTGCAGGCTCGAATACGGATGGTCCTCGCCTATCTGTTTGCTCAGTTGAGC
CTCTGGTCTCGGGGTGTCCACGGTGGGCTCCTCGTGCTGGGATCCGCCAACGTGGATGAG
AGTCTCCTGGGCTACCTGACCAAGTACGACTGCTCCAGTGCGGACATCAACCCCATAGGC
GGGATCAGCAAGACGGACCTCAGGGCCTTCGTCCAGTTCTGCATCCAGCGCTTCCAGCTT
CCTGCCCTGCAGAGCATCCTGTTGGCGCCGGCCACCGCAGAGCTGGAGCCCTTGGCTGAT
GGACAGGTGTCCCAGACCGACGAGGAAGATATGGGGATGACATATGCGGAGCTCTCGGTC
TATGGGAAACTCAGGAAGGTGGCCAAGATGGGGCCCTACAGCATGTTCTGCAAACTCCTC
GGCATGCGGAGACACATCTGCACCCCGAGACAGGTCGCTGACAAAGTGAAGCGGTTTTTC
TCCAAGTACTCCATGAACAGACACAAGATGACCACGCTCACACCCGCGTACCACGCCGAG
AACTACAGCCCTGAGGACAACAGGTTTGATCTGCGACCATTTCTGTACAACACAAGCTGG
CCTTGGCAGTTTCGGTGCATAGAAAATCAGGTGCTACAGCTCGAGAGGGCAGAGCCACAG
TCCCTGGACGGCGTGGACTGA

# Drug_Target_42_General_Function:
Coenzyme transport and metabolism

# Drug_Target_42_General_References:
12547821	Hara N, Yamada K, Terashima M, Osago H, Shimoyama M, Tsuchiya M: Molecular identification of human glutamine- and ammonia-dependent NAD synthetases. Carbon-nitrogen hydrolase domain confers glutamine dependency. J Biol Chem. 2003 Mar 28;278(13):10914-21. Epub 2003 Jan 23.

# Drug_Target_42_HGNC_ID:
HGNC:29832

# Drug_Target_42_HPRD_ID:
Not Available

# Drug_Target_42_ID:
3991

# Drug_Target_42_Locus:
11q13.4

# Drug_Target_42_Molecular_Weight:
79295

# Drug_Target_42_Name:
Glutamine-dependent NAD(+) synthetase

# Drug_Target_42_Number_of_Residues:
706

# Drug_Target_42_PDB_ID:
Not Available

# Drug_Target_42_Pathway:
Not Available

# Drug_Target_42_Pfam_Domain_Function:
PF00795	CN_hydrolase
PF02540	NAD_synthase

# Drug_Target_42_Protein_Sequence:
>Glutamine-dependent NAD(+) synthetase
MGRKVTVATCALNQWALDFEGNLQRILKSIEIAKNRGARYRLGPELEICGYGCWDHYYES
DTLLHSFQVLAALVESPVTQDIICDVGMPVMHRNVRYNCRVIFLNRKILLIRPKMALANE
GNYRELRWFTPWSRSRHTEEYFLPRMIQDLTKQETVPFGDAVLVTWDTCIGSEICEELWT
PHSPHIDMGLDGVEIITNASGSHHVLRKANTRVDLVTMVTSKNGGIYLLANQKGCDGDRL
YYDGCAMIAMNGSVFAQGSQFSLDDVEVLTATLDLEDVRSYRAEISSRNLAASRASPYPR
VKVDFALSCHEDLLAPISEPIEWKYHSPEEEISLGPACWLWDFLRRSQQAGFLLPLSGGV
DSAATACLIYSMCCQVCEAVRSGNEEVLADVRTIVNQISYTPQDPRDLCGRILTTCYMAS
KNSSQETCTRARELAQQIGSHHISLNIDPAVKAVMGIFSLVTGKSPLFAAHGGSSRENLA
LQNVQARIRMVLAYLFAQLSLWSRGVHGGLLVLGSANVDESLLGYLTKYDCSSADINPIG
GISKTDLRAFVQFCIQRFQLPALQSILLAPATAELEPLADGQVSQTDEEDMGMTYAELSV
YGKLRKVAKMGPYSMFCKLLGMWRHICTPRQVADKVKRFFSKYSMNRHKMTTLTPAYHAE
NYSPEDNRFDLRPFLYNTSWPWQFRCIENQVLQLERAEPQSLDGVD

# Drug_Target_42_Reaction:
ATP + deamido-NAD+ + L-glutamine + H2O = AMP + diphosphate + NAD+ + L-glutamate

# Drug_Target_42_Signals:
None

# Drug_Target_42_Specific_Function:
ATP + deamido-NAD(+) + L-glutamine + H(2)O = AMP + diphosphate + NAD(+) + L-glutamate

# Drug_Target_42_SwissProt_ID:
Q6IA69

# Drug_Target_42_SwissProt_Name:
NADE_HUMAN

# Drug_Target_42_Synonyms:
+
EC 6.3.5.1
NAD(+

# Drug_Target_42_Theoretical_pI:
6.46

# Drug_Target_42_Transmembrane_Regions:
None

# Drug_Target_43_Cellular_Location:
Not Available

# Drug_Target_43_Chromosome_Location:
Not Available

# Drug_Target_43_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_43_Essentiality:
Non-Essential

# Drug_Target_43_GenAtlas_ID:
CCBL2

# Drug_Target_43_GenBank_ID_Gene:
AY028624

# Drug_Target_43_GenBank_ID_Protein:
37542047

# Drug_Target_43_GeneCard_ID:
CCBL2

# Drug_Target_43_Gene_Name:
CCBL2

# Drug_Target_43_Gene_Sequence:
>1365 bp
ATGTTTTTGGCCCAGAGGAGCCTCTGCTCTCTTAGCGGTAGAGCAAAATTCCTGAAGACA
ATTTCTTCTTCCAAAATCCTCGGATTCTCTACTTCTGCTAAAATGTCACTGAAATTCACA
AATGCAAAACGGATTGAAGGACTTGATAGTAATGTGTGGATTGAATTTACCAAATTGGCT
GCAGACCCTTCTGTTGTGAATCTTGGCCAAGGCTTTCCAGATATATCCCCTCCTACATAT
GTAAAAGAAGAATTATCAAAGATTGCAGCAATCGATAGCCTGAATCAGTATACACGAGGC
TTTGGCCATCCATCACTTGTGAAAGCTCTGTCCTATCTGTATGAAAAGCTTTATCAAAAG
CAAATTGATTCAAATAAAGAAATCCTTGTGACAGTAGGAGCATATGGATCTCTTTTTAAC
ACCATTCAAGCATTAATTGATGAGGGAGATGAAGTCATACTAATAGTGCCTTTCTATGAC
TGCTATGAGCCCATGGTGAGAATGGCTGGAGCAACACCTGTTTTTATTCCCCTGAGATCT
AAACCTGTTTATGGAAAAAGATGGTCTAGTTCTGACTGGACATTAGATCCTCAAGAACTG
GAAAGTAAATTTAATTCCAAAACCAAAGCTATTATACTAAATACTCCACATAACCCACTT
GGCAAGGTGTATAACAGAGAGGAACTGCAAGTAATTGCTGACCTTTGCATCAAATATGAC
ACACTCTGCATCAGCGATGAGGTTTATGAATGGCTTGTATATTCTGGAAATAAGCACTTA
AAAATAGCTACTTTTCCAGGTATGTGGGAGAGAACAATAACAATAGGAAGTGCTGGAAAG
ACTTTCAGTGTAACTGGCTGGAAGCTTGGCTGGTCCATTGGTCCAAATCATTTGATAAAA
CATTTACAGACAGTTCAACAAAACACGATTTATACTTGTGCAACTCCTTTACAGGAAGCC
TTGGCTCAAGCTTTCTGGATTGACATCAAGCGCATGGATGACCCAGAATGTTACTTTAAT
TCTTTGCCAAAAGAGTTAGAAGTAAAAAGAGATCGGATGGTACGTTTACTTGAAAGTGTT
GGCCTAAAACCCATAGTTCCTGATGGAGGATACTTCATCATCGCTGATGTGTCTTTGCTA
GATCCAGACCTCTCTGATATGAAGAATAATGAGCCTTATGACTATAAGTTTGTGAAATGG
ATGACTAAACATAAGAAACTATCAGCCATCCCCGTTTCAGCATTCTGTAACTCAGAGACT
AAATCACAGTTTGAGAAGTTTGTGCGTTTTTGCTTCATTAAAAAAGACAGCACACTGGAT
GCTGCTGAAGAAATCATCAAGGCATGGAGTGTACAGAAGTCTTGA

# Drug_Target_43_General_Function:
Amino acid transport and metabolism

# Drug_Target_43_General_References:
Not Available

# Drug_Target_43_HGNC_ID:
HGNC:33238

# Drug_Target_43_HPRD_ID:
Not Available

# Drug_Target_43_ID:
3895

# Drug_Target_43_Locus:
1p22.2

# Drug_Target_43_Molecular_Weight:
51401

# Drug_Target_43_Name:
Kynurenine--oxoglutarate transaminase 3

# Drug_Target_43_Number_of_Residues:
454

# Drug_Target_43_PDB_ID:
Not Available

# Drug_Target_43_Pathway:
Not Available

# Drug_Target_43_Pfam_Domain_Function:
PF00155	Aminotran_1_2

# Drug_Target_43_Protein_Sequence:
>Kynurenine--oxoglutarate transaminase 3
MFLAQRSLCSLSGRAKFLKTISSSKILGFSTSAKMSLKFTNAKRIEGLDSNVWIEFTKLA
ADPSVVNLGQGFPDISPPTYVKEELSKIAAIDSLNQYTRGFGHPSLVKALSYLYEKLYQK
QIDSNKEILVTVGAYGSLFNTIQALIDEGDEVILIVPFYDCYEPMVRMAGATPVFIPLRS
KPVYGKRWSSSDWTLDPQELESKFNSKTKAIILNTPHNPLGKVYNREELQVIADLCIKYD
TLCISDEVYEWLVYSGNKHLKIATFPGMWERTITIGSAGKTFSVTGWKLGWSIGPNHLIK
HLQTVQQNTIYTCATPLQEALAQAFWIDIKRMDDPECYFNSLPKELEVKRDRMVRLLESV
GLKPIVPDGGYFIIADVSLLDPDLSDMKNNEPYDYKFVKWMTKHKKLSAIPVSAFCNSET
KSQFEKFVRFCFIKKDSTLDAAEEIIKAWSVQKS

# Drug_Target_43_Reaction:
RS-CH2-CH(NH3+)COO- = RSH + NH3 + pyruvate

# Drug_Target_43_Signals:
None

# Drug_Target_43_Specific_Function:
Catalyzes the irreversible transamination of the L- tryptophan metabolite L-kinurenine to form kynurenic acid (KA). May catalyze the beta-elimination of S-conjugates and Se- conjugates of L-(seleno)cysteine, resulting in the cleavage of the C-S or C-Se bond

# Drug_Target_43_SwissProt_ID:
Q6YP21

# Drug_Target_43_SwissProt_Name:
KAT3_HUMAN

# Drug_Target_43_Synonyms:
Cysteine-S-conjugate beta-lyase 2
EC 2.6.1.7
EC 4.4.1.13
KATIII
Kynurenine aminotransferase III
Kynurenine-- oxoglutarate transaminase III

# Drug_Target_43_Theoretical_pI:
8.34

# Drug_Target_43_Transmembrane_Regions:
None

# Drug_Target_44_Cellular_Location:
Mitochondrion

# Drug_Target_44_Chromosome_Location:
Not Available

# Drug_Target_44_Drug_References:
17347518	Xu Y, Labedan B, Glansdorff N: Surprising arginine biosynthesis: a reappraisal of the enzymology and evolution of the pathway in microorganisms. Microbiol Mol Biol Rev. 2007 Mar;71(1):36-47.

# Drug_Target_44_Essentiality:
Non-Essential

# Drug_Target_44_GenAtlas_ID:
NAGS

# Drug_Target_44_GenBank_ID_Gene:
AY116537

# Drug_Target_44_GenBank_ID_Protein:
22651769

# Drug_Target_44_GeneCard_ID:
NAGS

# Drug_Target_44_Gene_Name:
NAGS

# Drug_Target_44_Gene_Sequence:
>1605 bp
ATGGCGACGGCGCTGATGGCTGTGGTTCTGCGGGCAGCTGCTGTAGCCCCGAGGCTGAGA
GGCCGGGGAGGCACTGGGGGCGCCCGAAGGCTGAGCTGTGGCGCGCGGCGGCGGGCGGCG
AGGGGCACCAGCCCGGGGCGCCGGCTCAGCACCGCCTGGTCGCAGCCCCAGCCCCCGCCC
GAGGAGTACGCGGGCGCGGACGACGTCTCCCAGTCGCCCGTCGCCGAGGAGCCGTCGTGG
GTGCCGAGTCCCAGGCCCCCGGTGCCCCACGAGTCCCCAGAGCCTCCTTCGGGCCGCTCG
CTGGTGCAGCGGGACATCCAGGCCTTCCTGAACCAGTGCGGGGCCAGCCCTGGGGAGGCG
CGCCACTGGCTCACGCAGTTCCAGACCTGCCATCACTCCGCGGACAAGCCCTTCGCCGTC
ATCGAGGTGGACGAGGAGGTGCTCAAGTGCCAGCAGGGCGTATCCAGTCTGGCCTTTGCC
CTGGCCTTCTTGCAGCGCATGGACATGAAGCCGCTGGTGGTCCTGGGGCTGCCGGCCCCT
ACGGCTCCCTCGGGCTGTCTTTCCTTCTGGGAGGCCAAGGCGCAGCTGGCCAAGAGCTGC
AAGGTGCTGGTAGACGCGCTTCGACACAACGCCGCCGCTGCTGTGCCATTTTTTGGCGGC
GGGTCTGTGCTACGCGCTGCCGAGCCGGCTCCCCATGCCAGCTACGGCGGCATCGTCTCG
GTGGAGACAGACCTGCTGCAGTGGTGCCTGGAGTCGGGCAGCATCCCCATCCTGTGCCCC
ATCGGGGAGACGGCCGCGCGCCGCTCCGTGCTTCTCGACTCCCTGGAGGTGACCGCGTCG
CTGGCCAAGGCGCTGCGGCCCACCAAAATCATCTTCCTCAATAACACAGGCGGCCTGCGC
GACAGCAGTCATAAGGTCCTGAGTAACGTGAACCTGCCCGCCGACCTGGACCTGGTGTGC
AACGCCGAGTGGGTGAGCACAAAAGAACGGCAGCAGATGCGGCTCATCGTGGACGTGCTC
AGCCGCCTGCCCCACCACTCCTCGGCCGTCATCACCGCCGCTAGCACGCTGCTCACTGAG
CTCTTTAGCAACAAGGGGTCCGGGACCCTGTTCAAGAACGCCGAGCGAATGCTACGGGTG
CGCAGCCTGGACAAGCTGGACCAGGGCCGTCTAGTGGACCTGGTCAACGCCAGCTTCGGC
AAGAAGCTCAGGGACGACTACCTGGCCTCGCTGCGCCCGCGGCTGCACTCCATCTACGTC
TCCGAGGGGTACAACGCCGCCGCCATTCTGACCATGGAGCCCGTCCTGGGGGGCACCCCG
TACCTGGACAAATTTGTGGTGAGCTCCAGCCGCCAGGGCCAAGGCTCCGGCCAGATGCTG
TGGGAGTGCCTGCGGCGGGACCTTCAGACACTTTTCTGGCGCTCCCGGGTCACCAACCCC
ATCAATCCCTGGTACTTCAAACACAGTGATGGCAGCTTCTCCAACAAGCAGTGGATCTTC
TTCTGGTTTGGCCTGGCTGATATCCGGGACTCCTATGAGTTGGTCAACCACGCCAAGGGA
CTGCCAGACTCCTTTCACAAGCCAGCTTCTGACCCAGGCAGCTGA

# Drug_Target_44_General_Function:
Amino acid transport and metabolism

# Drug_Target_44_General_References:
12459178	Caldovic L, Morizono H, Gracia Panglao M, Gallegos R, Yu X, Shi D, Malamy MH, Allewell NM, Tuchman M: Cloning and expression of the human N-acetylglutamate synthase gene. Biochem Biophys Res Commun. 2002 Dec 13;299(4):581-6.
12754705	Haberle J, Schmidt E, Pauli S, Kreuder JG, Plecko B, Galler A, Wermuth B, Harms E, Koch HG: Mutation analysis in patients with N-acetylglutamate synthase deficiency. Hum Mutat. 2003 Jun;21(6):593-7.

# Drug_Target_44_HGNC_ID:
HGNC:17996

# Drug_Target_44_HPRD_ID:
Not Available

# Drug_Target_44_ID:
4023

# Drug_Target_44_Locus:
17q21.31

# Drug_Target_44_Molecular_Weight:
58157

# Drug_Target_44_Name:
N-acetylglutamate synthase, mitochondrial

# Drug_Target_44_Number_of_Residues:
534

# Drug_Target_44_PDB_ID:
Not Available

# Drug_Target_44_Pathway:
Not Available

# Drug_Target_44_Pfam_Domain_Function:
PF04768	DUF619

# Drug_Target_44_Protein_Sequence:
>N-acetylglutamate synthase, mitochondrial
MATALMAVVLRAAAVAPRLRGRGGTGGARRLSCGARRRAARGTSPGRRLSTAWSQPQPPP
EEYAGADDVSQSPVAEEPSWVPSPRPPVPHESPEPPSGRSLVQRDIQAFLNQCGASPGEA
RHWLTQFQTCHHSADKPFAVIEVDEEVLKCQQGVSSLAFALAFLQRMDMKPLVVLGLPAP
TAPSGCLSFWEAKAQLAKSCKVLVDALRHNAAAAVPFFGGGSVLRAAEPAPHASYGGIVS
VETDLLQWCLESGSIPILCPIGETAARRSVLLDSLEVTASLAKALRPTKIIFLNNTGGLR
DSSHKVLSNVNLPADLDLVCNAEWVSTKERQQMRLIVDVLSRLPHHSSAVITAASTLLTE
LFSNKGSGTLFKNAERMLRVRSLDKLDQGRLVDLVNASFGKKLRDDYLASLRPRLHSIYV
SEGYNAAAILTMEPVLGGTPYLDKFVVSSSRQGQGSGQMLWECLRRDLQTLFWRSRVTNP
INPWYFKHSDGSFSNKQWIFFWFGLADIRDSYELVNHAKGLPDSFHKPASDPGS

# Drug_Target_44_Reaction:
acetyl-CoA + L-glutamate = CoA + N-acetyl-L-glutamate

# Drug_Target_44_Signals:
None

# Drug_Target_44_Specific_Function:
Plays a role in the regulation of ureagenesis by producing variable amounts of N-acetylglutamate (NAG), thus modulating carbamoylphosphate synthase I (CPSI) activity

# Drug_Target_44_SwissProt_ID:
Q8N159

# Drug_Target_44_SwissProt_Name:
NAGS_HUMAN

# Drug_Target_44_Synonyms:
Amino-acid acetyltransferase
EC 2.3.1.1
N-acetylglutamate synthase, mitochondrial precursor

# Drug_Target_44_Theoretical_pI:
9.12

# Drug_Target_44_Transmembrane_Regions:
None

# Drug_Target_45_Cellular_Location:
Mitochondrion (Potential)

# Drug_Target_45_Chromosome_Location:
Not Available

# Drug_Target_45_Drug_References:
12850557	Kocki T, Luchowski P, Luchowska E, Wielosz M, Turski WA, Urbanska EM: L-cysteine sulphinate, endogenous sulphur-containing amino acid, inhibits rat brain kynurenic acid production via selective interference with kynurenine aminotransferase II. Neurosci Lett. 2003 Jul 31;346(1-2):97-100.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_45_Essentiality:
Non-Essential

# Drug_Target_45_GenAtlas_ID:
AADAT

# Drug_Target_45_GenBank_ID_Gene:
AF097994

# Drug_Target_45_GenBank_ID_Protein:
6165634

# Drug_Target_45_GeneCard_ID:
AADAT

# Drug_Target_45_Gene_Name:
AADAT

# Drug_Target_45_Gene_Sequence:
>1278 bp
ATGAATTACGCACGGTTCATCACGGCAGCGAGCGCAGCCAGAAACCCTTCTCCCATCCGG
ACCATGACTGACATATTGAGCAGAGGACCAAAATCGATGATCTCCTTGGCTGGTGGCTTA
CCAAATCCAAACATGTTTCCTTTTAAGACTGCCGTAATCACTGTAGAAAATGGAAAGACC
ATCCAATTTGGAGAAGAGATGATGAAGAGAGCACTTCAGTATTCTCCGAGTGCTGGAATT
CCAGAGCTTTTGTCCTGGCTAAAACAGTTACAAATAAAATTGCATAATCCTCCTACCATC
CATTACCCACCCAGTCAAGGACAAATGGATCTATGTGTCACATCTGGCAGCCAACAAGGT
CTTTGTAAGGTGTTTGAAATGATCATTAATCCTGGAGATAATGTCCTCCTAGATGAACCT
GCTTATTCAGGAACTCTTCAAAGTCTGCACCCACTGGGCTGCAACATTATTAATGTTGCC
AGTGATGAAAGTGGGATTGTTCCAGATTCCCTAAGAGACATACTTTCCAGATGGAAACCA
GAAGATGCAAAGAATCCCCAGAAAAACACCCCCAAATTTCTTTATACTGTTCCAAATGGC
AACAACCCTACTGGAAACTCATTAACCAGTGAACGCAAAAAGGAAATCTATGAGCTTGCA
AGAAAATATGATTTCCTCATAATAGAAGATGATCCTTACTATTTTCTCCAGTTTAACAAG
TTCAGGGTACCAACATTTCTTTCCATGGATGTTGATGGACGTGTCATCAGAGCTGACTCT
TTTTCAAAAATCATTTCCTCTGGGTTGAGAATAGGATTTTTAACTGGTCCAAAACCCTTA
ATAGAGAGAGTTATTTTACACATACAAGTTTCAACATTGCACCCCAGCACTTTTAACCAG
CTCATGATATCACAGCTTCTACACGAATGGGGAGAAGAAGGTTTCATGGCTCATGTAGAC
AGGGTTATTGATTTCTATAGTAACCAGAAGGATGCAATACTGGCAGCTGCAGACAAGTGG
TTAACTGGTTTGGCAGAATGGCATGTTCCTGCTGCTGGAATGTTTTTATGGATTAAAGTT
AAAGGCATTAATGATGTAAAAGAACTGATTGAAGAAAAGGCCGTTAAGATGGGGGTATTA
ATGCTCCCTGGAAATGCTTTCTACGTCGATAGCTCAGCTCCTAGCCCTTACTTGAGAGCA
TCCTTCTCTTCAGCTTCTCCAGAACAGATGGATGTGGCCTTCCAGGTATTAGCACAACTT
ATAAAAGAATCTTTATGA

# Drug_Target_45_General_Function:
Transcription

# Drug_Target_45_General_References:
Not Available

# Drug_Target_45_HGNC_ID:
HGNC:17929

# Drug_Target_45_HPRD_ID:
12392

# Drug_Target_45_ID:
801

# Drug_Target_45_Locus:
4q33

# Drug_Target_45_Molecular_Weight:
47352

# Drug_Target_45_Name:
Kynurenine/alpha-aminoadipate aminotransferase mitochondrial

# Drug_Target_45_Number_of_Residues:
425

# Drug_Target_45_PDB_ID:
Not Available

# Drug_Target_45_Pathway:
Not Available

# Drug_Target_45_Pfam_Domain_Function:
PF00155	Aminotran_1_2

# Drug_Target_45_Protein_Sequence:
>Kynurenine/alpha-aminoadipate aminotransferase mitochondrial precursor
MNYARFITAASAARNPSPIRTMTDILSRGPKSMISLAGGLPNPNMFPFKTAVITVENGKT
IQFGEEMMKRALQYSPSAGIPELLSWLKQLQIKLHNPPTIHYPPSQGQMDLCVTSGSQQG
LCKVFEMIINPGDNVLLDEPAYSGTLQSLHPLGCNIINVASDESGIVPDSLRDILSRWKP
EDAKNPQKNTPKFLYTVPNGNNPTGNSLTSERKKEIYELARKYDFLIIEDDPYYFLQFNK
FRVPTFLSMDVDGRVIRADSFSKIISSGLRIGFLTGPKPLIERVILHIQVSTLHPSTFNQ
LMISQLLHEWGEEGFMAHVDRVIDFYSNQKDAILAAADKWLTGLAEWHVPAAGMFLWIKV
KGINDVKELIEEKAVKMGVLMLPGNAFYVDSSAPSPYLRASFSSASPEQMDVAFQVLAQL
IKESL

# Drug_Target_45_Reaction:
L-kynurenine + 2-oxoglutarate = 4-(2-aminophenyl)-2,4-dioxobutanoate + L-glutamate

# Drug_Target_45_Signals:
None

# Drug_Target_45_Specific_Function:
Shows activity also towards tryptophan, aspartate and hydroxykinurenine

# Drug_Target_45_SwissProt_ID:
Q8N5Z0

# Drug_Target_45_SwissProt_Name:
AADAT_HUMAN

# Drug_Target_45_Synonyms:
2- aminoadipate aminotransferase
2-aminoadipate transaminase
AadAT
Alpha-aminoadipate aminotransferase
EC 2.6.1.39
EC 2.6.1.7
KAT/AadAT
Kynurenine aminotransferase II
Kynurenine--oxoglutarate aminotransferase II
Kynurenine--oxoglutarate transaminase II
Kynurenine/alpha-aminoadipate aminotransferase mitochondrial precursor

# Drug_Target_45_Theoretical_pI:
6.96

# Drug_Target_45_Transmembrane_Regions:
None

# Drug_Target_46_Cellular_Location:
Cell membrane
multi-pass membrane protein. Enriched in post-synaptic plasma membrane and post-synap

# Drug_Target_46_Chromosome_Location:
Not Available

# Drug_Target_46_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_46_Essentiality:
Non-Essential

# Drug_Target_46_GenAtlas_ID:
GRIN3A

# Drug_Target_46_GenBank_ID_Gene:
AJ416950

# Drug_Target_46_GenBank_ID_Protein:
20372905

# Drug_Target_46_GeneCard_ID:
GRIN3A

# Drug_Target_46_Gene_Name:
GRIN3A

# Drug_Target_46_Gene_Sequence:
>3348 bp
ATGAGGAGACTGAGTTTGTGGTGGCTGCTGAGCAGGGTCTGTCTGCTGTTGCCGCCGCCC
TGCGCACTGGTGCTGGCCGGGGTGCCCAGCTCCTCCTCGCACCCGCAGCCCTGCCAGATC
CTCAAGCGCATCGGGCACGCGGTGAGGGTGGGCGCGGTGCACTTGCAGCCCTGGACCACC
GCCCCCCGCGCGGCCAGCCGCGCTCCGGACGACAGCCGAGCAGGAGCCCAGAGGGATGAG
CCGGAGCCAGGGACTAGGCGGTCCCCGGCGCCCTCGCCGGGCGCACGCTGGTTGGGGAGC
ACCCTGCATGGCCGGGGGCCGCCGGGCTCCCGTAAGCCCGGGGAGGGCGCCAGGGCGGAG
GCCCTGTGGCCACGGGACGCCCTCCTATTTGCCGTGGACAACCTGAACCGCGTGGAAGGG
CTGCTACCCTACAACCTGTCTTTGGAAGTAGTGATGGCCATCGAGGCAGGCCTGGGCGAT
CTGCCACTTTTGCCCTTCTCCTCCCCTAGTTCGCCATGGAGCAGTGACCCTTTCTCCTTC
CTGCAAAGTGTGTGCCATACCGTGGTGGTGCAAGGGGTGTCGGCGCTGCTCGCCTTCCCC
CAGAGCCAGGGCGAAATGATGGAGCTCGACTTGGTCAGCTTAGTCCTGCACATTCCAGTG
ATCAGCATCGTGCGCCACGAGTTTCCGCGGGAGAGTCAGAATCCCCTTCACCTACAACTG
AGTTTAGAAAATTCATTAAGTTCTGATGCTGATGTCACTGTCTCAATCCTGACCATGAAC
AACTGGTACAATTTTAGCTTGTTGCTGTGCCAGGAAGACTGGAACATCACCGACTTCCTC
CTCCTTACCCAGAATAATTCCAAGTTCCACCTTGGTTCTATCATCAACATCACCGCTAAC
CTCCCCTCCACCCAGGACCTCTTGAGCTTCCTACAGATCCAGCTTGAGAGTATTAAGAAC
AGCACACCCACAGTGGTGATGTTTGGCTGCGACATGGAAAGTATCCGGCGGATTTTCGAA
ATTACAACCCAGTTTGGGGTCATGCCCCCTGAACTTCGTTGGGTGCTGGGAGATTCCCAG
AATATGGAGGAACTGAGGACAGAGGGTCTGCCCTTAGGACTCATTGCTCATGGAAAAACA
ACACAGTCTGTCTTTGAGCACTACGTACAAGATGCTATGGAGCTGGTCGCAAGAGCTGTA
GCCACAGCCACCATGATCCAACCAGAACTTGCTCTCATTCCCAGCACGATGAACTGCATG
GAGGTGGAAACTACAAATCTCACTTCAGGACAATATTTATCAAGGTTTCTAGCCAATACC
ACTTTCAGAGGCCTCAGTGGTTCCATCAGAGTAAAAGGTTCCACCATCGTCAGCTCAGAA
AACAACTTTTTCATCTGGAATCTTCAACATGACCCCATGGGAAAGCCAATGTGGACCCGC
TTGGGCAGCTGGCAGGGGAGAAAGATTGTCATGGACTATGGAATATGGCCAGAGCAGGCC
CAGAGACACAAAACCCACTTCCAACATCCAAGTAAGCTACACTTGAGAGTGGTTACCCTG
ATTGAGCATCCTTTTGTCTTCACAAGGGAGGTAGATGATGAAGGCTTGTGCCCTGCTGGC
CAACTCTGTCTAGACCCCATGACTAATGACTCTTCCACACTGGACAGCCTTTTTAGCAGC
CTCCATAGCAGTAATGATACAGTGCCCATTAAATTCAAGAAGTGCTGCTATGGATATTGC
ATTGATCTGCTGGAAAAGATAGCAGAAGACATGAACTTTGACTTCGACCTCTATATTGTA
GGGGATGGAAAGTATGGAGCCTGGAAAAATGGGCACTGGACTGGGCTAGTGGGTGATCTC
CTGAGAGGGACTGCCCACATGGCAGTCACTTCCTTTAGCATCAATACTGCACGGAGCCAG
GTGATAGATTTCACCAGCCCTTTCTTCTCCACCAGCTTGGGCATCTTAGTGAGGACCCGA
GATACAGCAGCTCCCATTGGAGCCTTCATGTGGCCACTCCACTGGACAATGTGGCTGGGG
ATTTTTGTGGCTCTGCACATCACTGCCGTCTTCCTCACTCTGTATGAATGGAAGAGTCCA
TTTGGTTTGACTCCCAAGGGGCGAAATAGAAGTAAAGTCTTCTCCTTTTCTTCAGCCTTG
AACATCTGTTATGCCCTCTTGTTTGGCAGAACAGTGGCCATCAAACCTCCAAAATGTTGG
ACTGGAAGGTTTCTAATGAACCTTTGGGCCATTTTCTGTATGTTTTGCCTTTCCACATAC
ACGGCAAACTTGGCTGCTGTCATGGTAGGTGAGAAGATCTATGAAGAGCTTTCTGGAATA
CATGACCCCAAGTTACATCATCCTTCCCAAGGATTCCGCTTTGGAACTGTCCGAGAAAGC
AGTGCTGAAGATTATGTGAGACAAAGTTTCCCAGAGATGCATGAATATATGAGAAGGTAC
AATGTTCCAGCCACCCCTGATGGAGTGGAGTATCTGAAGAACAATCCAGAGAAACTAGAC
GCCTTCATCATGGACAAAGCCCTTCTGGATTATGAAGTGTCAATAGATGCTGACTGCAAA
CTTCTCACTGTGGGGAAGCCATTTGCCATAGAAGGATACGGCATTGGCCTCCCACCCAAC
TCTCCATTGACCGCCAACATATCCGAGCTAATCAGTCAATACAAGTCACATGGGTTTATG
GATATGCTCCATGACAAGTGGTACAGGGTGGTTCCCTGTGGCAAGAGAAGTTTTGCTGTC
ACGGAGACTTTGCAAATGGGCATCAAACACTTCTCTGGGCTCTTTGTGCTGCTGTGCATT
GGATTTGGTCTGTCCATTTTGACCACCATTGGTGAGCACATAGTATACAGGCTGCTGCTA
CCACGAATCAAAAACAAATCCAAGCTGCAATACTGGCTCCACACCAGCCAGAGATTACAC
AGAGCAATAAATACATCATTTATAGAGGAAAAGCAGCAGCATTTCAAGACCAAACGTGTG
GAAAAGAGGTCTAATGTGGGACCCCGTCAGCTTACCGTATGGAATACTTCCAATCTGAGT
CATGACAACCGACGGAAATACATCTTTAGTGATGAGGAAGGACAAAACCAGCTGGGCATC
CGGATCCACCAGGACATCCCCCTCCCTCCAAGGAGAAGAGAGCTCCCTGCCTTGCGGACC
ACCAATGGGAAAGCAGACTCCCTAAATGTATCTCGGAACTCAGTGATGCAGGAACTCTCA
GAGCTCGAGAAGCAGATTCAGGTGATCCGTCAGGAGCTGCAGCTGGCTGTGAGCAGGAAA
ACGGAGCTGGAGGAGTATCAAAGGACAAGTCGGACTTGTGAGTCCTAG

# Drug_Target_46_General_Function:
Involved in ionotropic glutamate receptor activity

# Drug_Target_46_General_References:
11735224	Andersson O, Stenqvist A, Attersand A, von Euler G: Nucleotide sequence, genomic organization, and chromosomal localization of genes encoding the human NMDA receptor subunits NR3A and NR3B. Genomics. 2001 Dec;78(3):178-84.
11853319	Nagase T, Kikuno R, Ohara O: Prediction of the coding sequences of unidentified human genes. XXII. The complete sequences of 50 new cDNA clones which code for large proteins. DNA Res. 2001 Dec 31;8(6):319-27.
11880201	Eriksson M, Nilsson A, Froelich-Fabre S, Akesson E, Dunker J, Seiger A, Folkesson R, Benedikz E, Sundstrom E: Cloning and expression of the human N-methyl-D-aspartate receptor subunit NR3A. Neurosci Lett. 2002 Mar 22;321(3):177-81.

# Drug_Target_46_HGNC_ID:
HGNC:16767

# Drug_Target_46_HPRD_ID:
09443

# Drug_Target_46_ID:
706

# Drug_Target_46_Locus:
9q31.1

# Drug_Target_46_Molecular_Weight:
125597

# Drug_Target_46_Name:
Glutamate [NMDA] receptor subunit 3A

# Drug_Target_46_Number_of_Residues:
1115

# Drug_Target_46_PDB_ID:
Not Available

# Drug_Target_46_Pathway:
Methadone Pathway	SMP00408

# Drug_Target_46_Pfam_Domain_Function:
PF00060	Lig_chan

# Drug_Target_46_Protein_Sequence:
>Glutamate [NMDA] receptor subunit 3A precursor
MRRLSLWWLLSRVCLLLPPPCALVLAGVPSSSSHPQPCQILKRIGHAVRVGAVHLQPWTT
APRAASRAPDDSRAGAQRDEPEPGTRRSPAPSPGARWLGSTLHGRGPPGSRKPGEGARAE
ALWPRDALLFAVDNLNRVEGLLPYNLSLEVVMAIEAGLGDLPLLPFSSPSSPWSSDPFSF
LQSVCHTVVVQGVSALLAFPQSQGEMMELDLVSLVLHIPVISIVRHEFPRESQNPLHLQL
SLENSLSSDADVTVSILTMNNWYNFSLLLCQEDWNITDFLLLTQNNSKFHLGSIINITAN
LPSTQDLLSFLQIQLESIKNSTPTVVMFGCDMESIRRIFEITTQFGVMPPELRWVLGDSQ
NMEELRTEGLPLGLIAHGKTTQSVFEHYVQDAMELVARAVATATMIQPELALIPSTMNCM
EVETTNLTSGQYLSRFLANTTFRGLSGSIRVKGSTIVSSENNFFIWNLQHDPMGKPMWTR
LGSWQGRKIVMDYGIWPEQAQRHKTHFQHPSKLHLRVVTLIEHPFVFTREVDDEGLCPAG
QLCLDPMTNDSSTLDSLFSSLHSSNDTVPIKFKKCCYGYCIDLLEKIAEDMNFDFDLYIV
GDGKYGAWKNGHWTGLVGDLLRGTAHMAVTSFSINTARSQVIDFTSPFFSTSLGILVRTR
DTAAPIGAFMWPLHWTMWLGIFVALHITAVFLTLYEWKSPFGLTPKGRNRSKVFSFSSAL
NICYALLFGRTVAIKPPKCWTGRFLMNLWAIFCMFCLSTYTANLAAVMVGEKIYEELSGI
HDPKLHHPSQGFRFGTVRESSAEDYVRQSFPEMHEYMRRYNVPATPDGVEYLKNNPEKLD
AFIMDKALLDYEVSIDADCKLLTVGKPFAIEGYGIGLPPNSPLTANISELISQYKSHGFM
DMLHDKWYRVVPCGKRSFAVTETLQMGIKHFSGLFVLLCIGFGLSILTTIGEHIVYRLLL
PRIKNKSKLQYWLHTSQRLHRAINTSFIEEKQQHFKTKRVEKRSNVGPRQLTVWNTSNLS
HDNRRKYIFSDEEGQNQLGIRIHQDIPLPPRRRELPALRTTNGKADSLNVSRNSVMQELS
ELEKQIQVIRQELQLAVSRKTELEEYQRTSRTCES

# Drug_Target_46_Reaction:
Not Available

# Drug_Target_46_Signals:
1-23

# Drug_Target_46_Specific_Function:
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May play a role in the development of dendritic spines. May play a role in PPP2CB-NMDAR mediated signaling mechanism

# Drug_Target_46_SwissProt_ID:
Q8TCU5

# Drug_Target_46_SwissProt_Name:
NMD3A_HUMAN

# Drug_Target_46_Synonyms:
Glutamate receptor subunit 3A precursor
N-methyl-D-aspartate receptor subtype NR3A
NMDAR-L

# Drug_Target_46_Theoretical_pI:
7.81

# Drug_Target_46_Transmembrane_Regions:
675-695
749-769
931-951

# Drug_Target_47_Cellular_Location:
Not Available

# Drug_Target_47_Chromosome_Location:
Not Available

# Drug_Target_47_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_47_Essentiality:
Non-Essential

# Drug_Target_47_GenAtlas_ID:
GPT2

# Drug_Target_47_GenBank_ID_Gene:
AY029173

# Drug_Target_47_GenBank_ID_Protein:
19046894

# Drug_Target_47_GeneCard_ID:
GPT2

# Drug_Target_47_Gene_Name:
GPT2

# Drug_Target_47_Gene_Sequence:
>1572 bp
ATGCAGCGGGCGGCGGCGCTGGTCCGGCGGGGCTGTGGTCCCCGGACCCCCAGCTCCTGG
GGCCGCAGCCAGAGCAGCGCGGCCGCCGAGGCCTCGGCGGTGCTCAAGGTGCGGCCCGAG
CGCAGCCGGCGCGAGCGCATCCTCACGCTGGAGTCCATGAACCCGCAGGTGAAGGCGGTG
GAGTACGCCGTGCGGGGACCCATCGTGCTCAAGGCCGGCGAGATCGAGCTCGAGCTGCAG
CGGGGTATCAAAAAGCCATTCACAGAGGTCATCCGAGCCAACATCGGGGACGCCCAGGCT
ATGGGGCAGCAGCCAATCACCTTCCTCCGGCAGGTGATGGCACTATGCACCTACCCAAAC
CTGCTGGACAGCCCCAGCTTCCCAGAAGATGCTAAGAAACGTGCCCGGCGGATCCTGCAG
GCTTGTGGCGGGAACAGCCTGGGGTCCTACAGTGCTAGCCAGGGTGTCAACTGCATCCGT
GAAGATGTGGCTGCCTACATCACCAGGAGGGATGGCGGTGTGCCTGCGGACCCCGACAAC
ATCTACCTGACCACGGGAGCTAGTGACGGCATTTCTACGATCCTGAAGATCCTCGTCTCC
GGGGGCGGCAAGTCACGGACAGGTGTGATGATCCCCATCCCACAATATCCCCTCTATTCA
GCTGTCATCTCTGAGCTCGACGCCATCCAGGTGAATTACTACCTGGACGAGGAGAACTGC
TGGGCGCTGAATGTGAATGAGCTCCGGCGGGCGGTGCAGGAGGCCAAAGACCACTGTGAT
CCTAAGGTGCTCTGCATAATCAACCCTGGGAACCCCACAGGCCAGGTACAAAGCAGAAAG
TGCATAGAAGATGTGATCCACTTTGCCTGGGAAGAGAAGCTCTTTCTCCTGGCTGATGAG
GTGTACCAGGACAACGTGTACTCTCCAGATTGCAGATTCCACTCCTTCAAGAAGGTGCTG
TACGAGATGGGGCCCGAGTACTCCAGCAACGTGGAGCTCGCCTCCTTCCACTCCACCTCC
AAGGGCTACATGGGCGAGTGTGGTTACAGAGGAGGCTACATGGAGGTGATCAACCTGCAC
CCTGAGATCAAGGGCCAGCTGGTGAAGCTGCTGTCGGTGCGCCTGTGCCCCCCAGTGTCT
GGGCAGGCCGCCATGGACATTGTCGTGAACCCCCCGGTGGCAGGAGAGGAGTCCTTTGAG
CAATTCAGCCGAGAGAAGGAGTCGGTCCTGGGTAATCTGGCCAAAAAAGCAAAGCTGACG
GAAGACCTGTTTAACCAAGTCCCAGGAATTCACTGCAACCCCTTGCAGGGGGCCATGTAC
GCCTTCCCTCGGATCTTCATTCCTGCCAAAGCTGTGGAGGCTGCTCAGGCCCATCAAATG
GCTCCAGACATGTTCTACTGCATGAAGCTCCTGGAGGAGACTGGCATCTGTGTCGTGCCC
GGCAGTGGCTTTGGGCAGAGGGAAGGCACTTACCACTTCAGGATGACTATCCTCCCTCCA
GTGGAGAAGCTGAAAACGGTGCTGCAGAAGGTGAAAGACTTCCACATCAACTTCCTGGAG
AAGTACGCGTGA

# Drug_Target_47_General_Function:
Amino acid transport and metabolism

# Drug_Target_47_General_References:
11863375	Yang RZ, Blaileanu G, Hansen BC, Shuldiner AR, Gong DW: cDNA cloning, genomic structure, chromosomal mapping, and functional expression of a novel human alanine aminotransferase. Genomics. 2002 Mar;79(3):445-50.

# Drug_Target_47_HGNC_ID:
HGNC:18062

# Drug_Target_47_HPRD_ID:
Not Available

# Drug_Target_47_ID:
3904

# Drug_Target_47_Locus:
16q12.1

# Drug_Target_47_Molecular_Weight:
57904

# Drug_Target_47_Name:
Alanine aminotransferase 2

# Drug_Target_47_Number_of_Residues:
523

# Drug_Target_47_PDB_ID:
Not Available

# Drug_Target_47_Pathway:
Not Available

# Drug_Target_47_Pfam_Domain_Function:
PF00155	Aminotran_1_2

# Drug_Target_47_Protein_Sequence:
>Alanine aminotransferase 2
MQRAAALVRRGCGPRTPSSWGRSQSSAAAEASAVLKVRPERSRRERILTLESMNPQVKAV
EYAVRGPIVLKAGEIELELQRGIKKPFTEVIRANIGDAQAMGQQPITFLRQVMALCTYPN
LLDSPSFPEDAKKRARRILQACGGNSLGSYSASQGVNCIREDVAAYITRRDGGVPADPDN
IYLTTGASDGISTILKILVSGGGKSRTGVMIPIPQYPLYSAVISELDAIQVNYYLDEENC
WALNVNELRRAVQEAKDHCDPKVLCIINPGNPTGQVQSRKCIEDVIHFAWEEKLFLLADE
VYQDNVYSPDCRFHSFKKVLYEMGPEYSSNVELASFHSTSKGYMGECGYRGGYMEVINLH
PEIKGQLVKLLSVRLCPPVSGQAAMDIVVNPPVAGEESFEQFSREKESVLGNLAKKAKLT
EDLFNQVPGIHCNPLQGAMYAFPRIFIPAKAVEAAQAHQMAPDMFYCMKLLEETGICVVP
GSGFGQREGTYHFRMTILPPVEKLKTVLQKVKDFHINFLEKYA

# Drug_Target_47_Reaction:
L-alanine + 2-oxoglutarate = pyruvate + L-glutamate

# Drug_Target_47_Signals:
None

# Drug_Target_47_Specific_Function:
L-alanine + 2-oxoglutarate = pyruvate + L- glutamate

# Drug_Target_47_SwissProt_ID:
Q8TD30

# Drug_Target_47_SwissProt_Name:
ALAT2_HUMAN

# Drug_Target_47_Synonyms:
ALT2
EC 2.6.1.2
GPT 2
Glutamic--alanine transaminase 2
Glutamic--pyruvic transaminase 2

# Drug_Target_47_Theoretical_pI:
7.77

# Drug_Target_47_Transmembrane_Regions:
None

# Drug_Target_48_Cellular_Location:
Mitochondrion

# Drug_Target_48_Chromosome_Location:
Not Available

# Drug_Target_48_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_48_Essentiality:
Non-Essential

# Drug_Target_48_GenAtlas_ID:
SLC25A18

# Drug_Target_48_GenBank_ID_Gene:
AJ428203

# Drug_Target_48_GenBank_ID_Protein:
21322707

# Drug_Target_48_GeneCard_ID:
SLC25A18

# Drug_Target_48_Gene_Name:
SLC25A18

# Drug_Target_48_Gene_Sequence:
>948 bp
ATGACCCACCAGGATCTGAGCATCACAGCCAAACTCATCAATGGAGGTGTAGCAGGGCTC
GTGGGGGTGACCTGCGTGTTCCCCATCGACTTGGCCAAGACTCGCCTGCAGAACCAGCAT
GGGAAAGCCATGTACAAAGGAATGATCGACTGCCTGATGAAGACGGCTCGGGCGGAGGGC
TTCTTCGGCATGTACCGAGGGGCTGCAGTGAACCTCACTCTGGTCACTCCAGAGAAGGCC
ATCAAGCTGGCGGCCAACGACTTTTTCCGGCGGCTGCTCATGGAAGATGGGATGCAGCGG
AACCTGAAGATGGAGATGCTTGCCGGGTGTGGGGCTGGGATGTGCCAGGTCGTGGTGACC
TGTCCCATGGAAATGCTCAAGATTCAGCTGCAGGATGCTGGACGCCTGGCCGTCCATCAT
CAGGGCTCGGCCTCAGCACCCTCCACCTCCAGGTCCTACACAACTGGTTCGGCTTCCACC
CACAGGCGCCCCTCTGCCACCCTCATTGCCTGGGAGCTGCTCCGCACTCAGGGCCTGGCT
GGGCTCTACAGGGGCCTGGGTGCCACTCTCCTCAGAGACATTCCTTTCTCCATCATCTAC
TTCCCACTGTTTGCCAACCTTAACAACCTGGGGTTCAACGAGCTCGCCGGTAAGGCGTCC
TTTGCACATTCCTTCGTGTCAGGCTGTGTGGCAGGTTCCATAGCTGCGGTCGCAGTGACG
CCTCTAGATGTTCTGAAAACTCGAATCCAAACCCTCAAGAAAGGCCTGGGCGAGGACATG
TACAGTGGGATCACCGACTGTGCCAGGAAACTCTGGATTCAGGAGGGACCATCTGCCTTC
ATGAAAGGCGCTGGCTGCCGGGCACTGGTCATAGCACCTCTCTTTGGGATTGCTCAAGGG
GTCTATTTTATTGGGATTGGAGAGCGCATCTTAAAGTGTTTTGACTAG

# Drug_Target_48_General_Function:
Not Available

# Drug_Target_48_General_References:
11381032	Footz TK, Brinkman-Mills P, Banting GS, Maier SA, Riazi MA, Bridgland L, Hu S, Birren B, Minoshima S, Shimizu N, Pan H, Nguyen T, Fang F, Fu Y, Ray L, Wu H, Shaull S, Phan S, Yao Z, Chen F, Huan A, Hu P, Wang Q, Loh P, Qi S, Roe BA, McDermid HE: Analysis of the cat eye syndrome critical region in humans and the region of conserved synteny in mice: a search for candidate genes at or near the human chromosome 22 pericentromere. Genome Res. 2001 Jun;11(6):1053-70.
11897791	Fiermonte G, Palmieri L, Todisco S, Agrimi G, Palmieri F, Walker JE: Identification of the mitochondrial glutamate transporter. Bacterial expression, reconstitution, functional characterization, and tissue distribution of two human isoforms. J Biol Chem. 2002 May 31;277(22):19289-94. Epub 2002 Mar 15.

# Drug_Target_48_HGNC_ID:
HGNC:10988

# Drug_Target_48_HPRD_ID:
Not Available

# Drug_Target_48_ID:
4024

# Drug_Target_48_Locus:
22q11.2

# Drug_Target_48_Molecular_Weight:
33849

# Drug_Target_48_Name:
Mitochondrial glutamate carrier 2

# Drug_Target_48_Number_of_Residues:
315

# Drug_Target_48_PDB_ID:
Not Available

# Drug_Target_48_Pathway:
Not Available

# Drug_Target_48_Pfam_Domain_Function:
PF00153	Mito_carr

# Drug_Target_48_Protein_Sequence:
>Mitochondrial glutamate carrier 2
MTHQDLSITAKLINGGVAGLVGVTCVFPIDLAKTRLQNQHGKAMYKGMIDCLMKTARAEG
FFGMYRGAAVNLTLVTPEKAIKLAANDFFRRLLMEDGMQRNLKMEMLAGCGAGMCQVVVT
CPMEMLKIQLQDAGRLAVHHQGSASAPSTSRSYTTGSASTHRRPSATLIAWELLRTQGLA
GLYRGLGATLLRDIPFSIIYFPLFANLNNLGFNELAGKASFAHSFVSGCVAGSIAAVAVT
PLDVLKTRIQTLKKGLGEDMYSGITDCARKLWIQEGPSAFMKGAGCRALVIAPLFGIAQG
VYFIGIGERILKCFD

# Drug_Target_48_Reaction:
Not Available

# Drug_Target_48_Signals:
None

# Drug_Target_48_Specific_Function:
Involved in the transport of glutamate across the inner mitochondrial membrane. Glutamate is cotransported with H(+)

# Drug_Target_48_SwissProt_ID:
Q9H1K4

# Drug_Target_48_SwissProt_Name:
GHC2_HUMAN

# Drug_Target_48_Synonyms:
GC-2
Glutamate/H(+
Solute carrier family 25 member 18

# Drug_Target_48_Theoretical_pI:
9.62

# Drug_Target_48_Transmembrane_Regions:
12-32
106-126
185-205
225-245
288-308

# Drug_Target_49_Cellular_Location:
Mitochondrion

# Drug_Target_49_Chromosome_Location:
Not Available

# Drug_Target_49_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_49_Essentiality:
Non-Essential

# Drug_Target_49_GenAtlas_ID:
SLC25A22

# Drug_Target_49_GenBank_ID_Gene:
AJ428202

# Drug_Target_49_GenBank_ID_Protein:
21322705

# Drug_Target_49_GeneCard_ID:
SLC25A22

# Drug_Target_49_Gene_Name:
SLC25A22

# Drug_Target_49_Gene_Sequence:
>972 bp
ATGGCTGATAAGCAGATCAGCCTGCCAGCCAAGCTCATCAATGGCGGCATCGCCGGGCTG
ATCGGTGTCACCTGCGTGTTTCCCATCGACCTGGCCAAGACCAGGCTGCAGAACCAGCAG
AACGGCCAGCGCGTGTACACGAGCATGTCCGACTGCCTCATCAAGACCGTCCGCTCCGAG
GGCTACTTCGGCATGTACCGGGGAGCTGCTGTGAACTTGACCCTCGTCACCCCCGAGAAG
GCCATCAAGCTGGCAGCCAACGACTTCTTCCGACATCAGCTCTCTAAGGACGGGCAGAAG
CTGACCCTGCTTAAAGAGATGCTGGCGGGCTGTGGGGCTGGCACCTGCCAGGTGATCGTG
ACCACGCCCATGGAGATGCTGAAGATCCAGCTGCAGGATGCAGGGCGCATTGCCGCCCAG
AGGAAGATCCTGGCTGCCCAGGGCCAGCTCTCGGCCCAGGGGGGTGCCCAGCCCTCAGTG
GAGGCTCCAGCTGCCCCTCGGCCCACGGCCACCCAGCTGACCCGCGACCTGCTGCGGAGC
CGTGGCATTGCCGGTCTCTACAAGGGACTCGGGGCCACGCTGCTCAGGGATGTCCCCTTC
TCTGTGGTGTACTTCCCGCTCTTTGCCAACCTGAACCAGCTGGGCCGCCCGGCGTCCGAG
GAGAAGTCGCCTTTCTACGTGTCCTTCCTGGCCGGCTGTGTGGCTGGGAGTGCCGCCGCT
GTGGCCGTCAACCCCTGTGATGTGGTGAAGACGCGGCTCCAGTCACTTCAGCGAGGCGTC
AACGAGGACACCTACTCTGGGATCCTGGACTGTGCCAGGAAGATCCTGCGGCACGAGGGC
CCCTCGGCCTTCCTGAAGGGCGCCTACTGCCGCGCGCTGGTCATCGCGCCCCTTTTCGGC
ATCGCACAGGTGGTCTACTTCCTGGGCATCGCGGAGTCCCTGCTGGGGCTGCTGCAGGAC
CCCCAGGCCTGA

# Drug_Target_49_General_Function:
Not Available

# Drug_Target_49_General_References:
11897791	Fiermonte G, Palmieri L, Todisco S, Agrimi G, Palmieri F, Walker JE: Identification of the mitochondrial glutamate transporter. Bacterial expression, reconstitution, functional characterization, and tissue distribution of two human isoforms. J Biol Chem. 2002 May 31;277(22):19289-94. Epub 2002 Mar 15.

# Drug_Target_49_HGNC_ID:
HGNC:19954

# Drug_Target_49_HPRD_ID:
Not Available

# Drug_Target_49_ID:
4025

# Drug_Target_49_Locus:
11p15.5

# Drug_Target_49_Molecular_Weight:
34471

# Drug_Target_49_Name:
Mitochondrial glutamate carrier 1

# Drug_Target_49_Number_of_Residues:
323

# Drug_Target_49_PDB_ID:
Not Available

# Drug_Target_49_Pathway:
Not Available

# Drug_Target_49_Pfam_Domain_Function:
PF00153	Mito_carr

# Drug_Target_49_Protein_Sequence:
>Mitochondrial glutamate carrier 1
MADKQISLPAKLINGGIAGLIGVTCVFPIDLAKTRLQNQQNGQRVYTSMSDCLIKTVRSE
GYFGMYRGAAVNLTLVTPEKAIKLAANDFFRHQLSKDGQKLTLLKEMLAGCGAGTCQVIV
TTPMEMLKIQLQDAGRIAAQRKILAAQGQLSAQGGAQPSVEAPAAPRPTATQLTRDLLRS
RGIAGLYKGLGATLLRDVPFSVVYFPLFANLNQLGRPASEEKSPFYVSFLAGCVAGSAAA
VAVNPCDVVKTRLQSLQRGVNEDTYSGILDCARKILRHEGPSAFLKGAYCRALVIAPLFG
IAQVVYFLGIAESLLGLLQDPQA

# Drug_Target_49_Reaction:
Not Available

# Drug_Target_49_Signals:
None

# Drug_Target_49_Specific_Function:
Involved in the transport of glutamate across the inner mitochondrial membrane. Glutamate is cotransported with H(+)

# Drug_Target_49_SwissProt_ID:
Q9H936

# Drug_Target_49_SwissProt_Name:
GHC1_HUMAN

# Drug_Target_49_Synonyms:
GC-1
Glutamate/H(+
Solute carrier family 25 member 22

# Drug_Target_49_Theoretical_pI:
9.67

# Drug_Target_49_Transmembrane_Regions:
12-32
107-127
189-209
223-243
292-312

# Drug_Target_4_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
11058796	Takeda M, Haga M, Yamada H, Kinoshita M, Otsuka M, Tsuboi S, Moriyama Y: Ionotropic glutamate receptors expressed in human retinoblastoma Y79 cells. Neurosci Lett. 2000 Nov 17;294(2):97-100.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2850065	Murphy DE, Hutchison AJ, Hurt SD, Williams M, Sills MA: Characterization of the binding of [3H]-CGS 19755: a novel N-methyl-D-aspartate antagonist with nanomolar affinity in rat brain. Br J Pharmacol. 1988 Nov;95(3):932-8.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
GRIK5

# Drug_Target_4_GenBank_ID_Gene:
S40369

# Drug_Target_4_GenBank_ID_Protein:
251840

# Drug_Target_4_GeneCard_ID:
GRIK5

# Drug_Target_4_Gene_Name:
GRIK5

# Drug_Target_4_Gene_Sequence:
>2943 bp
ATGCCGGCTGAGCTGCTGCTGCTGCTGATTGTTGCCTTCGCCAGCCCCAGCTGCCAGGTG
CTCTCATCACTGCGCATGGCTGCAATCCTGGATGATCAGACAGTGTGTGGCCGCGGTGAG
CGTCTGGCCTTGGCCTTGGCCCGGGAGCAGATCAACGGGATCATCGAGGTCCCAGCCAAG
GCCCGAGTGGAAGTAGACATCTTTGAGCTGCAGCGGGACAGCCAGTACGAGACCACGGAC
ACCATGTGTCAGATCTTACCCAAAGGGGTTGTGTCTGTCCTTGGGCCCTCCTCTAGCCCA
GCATCTGCCTCCACCGTGAGCCATATCTGTGGAGAGAAGGAGATCCCCCACATCAAGGTG
GGTCCCGAGGAGACACCCCGCCTTCAGTACCTTCGCTTCGCGTCTGTCAGCCTGTACCCC
AGTAACGAGGACGTCAGCTTGGCGGTCTCCCGAATCCTCAAGTCCTTCAACTACCCCTCG
GCCAGCCTCATCTGCGCCAAGGCTGAGTGCCTGCTGCGATTGGAGGAACTGGTGCGTGGC
TTCCTCATCTCCAAGGAGACGCTGTCAGTGAGGATGTTGGACGACAGCCGGGACCCCACA
CCACTGCTCAAGGAGATCCGTGATGACAAGGTGTCCACCATCATCATCGACGCCAACGCC
TCCATCTCCCACCTCATCCTCCGTAAGGCCTCGGAACTGGGAATGACCTCAGCGTTTTAC
AAGTACATCCTCACCACCATGGACTTCCCCATCCTGCATCTGGACGGTATTGTGGAGGAC
TCCTCCAACATCCTGGGCTTCTCCATGTTCAACACGTCCCACCCCTTCTACCCTGAGTTT
GTCCGCAGCCTCAACATGTCCTGGAGGGAGAACTGTGAAGCCAGCACCTACCTGGGCCCT
GCGCTGTCAGCCGCCCTGATGTTTGACGCCGTGCACGTGGTGGTGAGCGCTGTCCGAGAG
CTGAACCGCAGCCAGGAGATCGGTGTGAAGCCTCTGGCCTGTACATCGGCCAACATTTGG
CCCCACGGGACCAGCCTCATGAACTACCTGCGCATGGTAGAGTATGATGGGCTGACCGGG
CGGGTCGAGTTCAACAGCAAAGGGCAGAGAACCAACTACACCCTGCGCATCCTAGAAAAG
TCCCGGCAGGGCCACCGTGAGATTGGGGTGTGGTACTCTAACCGCACCCTGGCCATGAAT
GCCACCACCCTGGACATCAACCTGTCGCAGACACTGGCCAACAAGACCCTGGTGGTCACA
ACCATCCTGGAGAACCCATACGTCATGCGCCGGCCCAACTTCCAGGGCCTGTCGGGGAAC
GAACGCTTCGAGGGCTTCTGCGTGGACATGCTGCGGGAGCTGGCCGAGCTGCTGCCGTTC
CCGTACCGCCTGCGGTTGGTGGAGGATGGGCTGTACGGGGCGCCCGAGCCCAACGGCTCC
TGGACGGGCATGGTTGGCGAGCTCATCAACCGGAAGGCAGACCTGGCTGTGGCCGCCTTC
ACCATCACAGCTGAGCGGGAGAAGGTCATCGACTTTTCCAAGCCCTTTATGACCCTGGGG
ATCAGCATCCTCTACCGAGTGCACATGGGCCGCAAGCCTGGCTACTTCTCCTTCCTGGAC
CCCTTCTCCCCTGCTGTGTGGCTCTTCATGCTTCTTGCCTACCTGGCTGTCAGCTGCGTC
CTGTTTCTGGCTGCCAGGCTGAGCCCCTATGAGTGGTATAACCCACACCCATGCCTGCGG
GCACGCCCCCACATCCTGGAGAACCAGTACACGCTGGGCAACAGCCTGTGGTTTCCCGTG
GGGGGCTTCATGCAGCAGGGCTCGGAGATCATGCCCCGGGCGCTGTCCACGCGCTGTGTC
AGCGGAGTCTGGTGGGCCTTCACCTTGATCATCATCTCCTCCTACACGGCCAACCTGGCC
GCCTTCCTCACCGTGCAGCGCATGGAGGTGCCTGTGGAGTCGGCCGATGACCTGGCAGAT
CAGACCAACATCGAGTATGGCACCATCCACGCCGGCTCCACCATGACCTTCTTCCAGAAT
TCACGGTACCAAACGTACCAGCGCATGTGGAACTACATGCAGTCGAAGCAGCCCAGCGTG
TTCGTCAAGAGCACAGAAGAGGGCATTGCCGCCGTCCTCAACTCCCGCTACGCCTTCCTG
CTCGAGTCCACCATGAACGAATACCACCGGCGCCTCAACTGCAACCTCACCCAGATCGGG
GGACTCCTCGACACCAAGGGCTACGGCATTGGCATGCCGCTGGGCTCCCCGTTCCGGGAT
GAGATCACACTGGCCATCCTGCAGCTTCAGGAGAACAACCGGCTGGAGATCCTGAAGCGC
AAGTGGTGGGAGGGGGGCCGGTGCCCCAAGGAGGAGGACCATCGAGCTAAAGGTTTGGGC
ATGGAGAACATTGGTGGCATTTTTATCGTGCTCATCTGTGGCCTCATCATTGCTGTCTTC
GTGGCGGTCATGGAATTCATATGGTCCACACGGAGGTCAGCTGAGTCCGAGGAGGTGTCG
GTGTGCCAGGAGATGCTGCAGGAGCTGCGCCACGCCGTTTCTTGCCGCAAGACGTCGCGT
TCCCGCCGGCGCCGACGCCCGGGCGGCCCGAGCCGGGCCCTGCTGTCACTGCGCGCGGTC
CGCGAGATGCGCCTCAGCAACGGCAAGCTCTACTCGGCCGGCGCGGGCGGGGATGCGGGC
AGCGCGCACGGGGGCCCGCAGCGCCTCCTGGACGACCCGGGGCCCCCCAGCGGAGCCCGA
CCCGCCGCCCCCACCCCCTGCACCCACGTGCGCGTCTGCCAGGAGTGCCGGCGCATCCAG
GCGCTGCGGGCCTCGGGGGCCGGCGCGCCTCCGCGTGGCCTGGGCGTCCCCGCCGAAGCC
ACCAGCCCGCCCCGGCCGCGGCCTGGCCCCGCCGGCCCCCGGGAGCTGGCGGAGCACGAG
TGA

# Drug_Target_4_General_Function:
Amino acid transport and metabolism

# Drug_Target_4_General_References:
1321949	Kamboj RK, Schoepp DD, Nutt S, Shekter L, Korczak B, True RA, Zimmerman DM, Wosnick MA: Molecular structure and pharmacological characterization of humEAA2, a novel human kainate receptor subunit. Mol Pharmacol. 1992 Jul;42(1):10-5.

# Drug_Target_4_HGNC_ID:
HGNC:4583

# Drug_Target_4_HPRD_ID:
02614

# Drug_Target_4_ID:
920

# Drug_Target_4_Locus:
19q13.2

# Drug_Target_4_Molecular_Weight:
109049

# Drug_Target_4_Name:
Glutamate receptor, ionotropic kainate 5

# Drug_Target_4_Number_of_Residues:
980

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00060	Lig_chan
PF01094	ANF_receptor

# Drug_Target_4_Protein_Sequence:
>Glutamate receptor, ionotropic kainate 5 precursor
MPAELLLLLIVAFASPSCQVLSSLRMAAILDDQTVCGRGERLALALAREQINGIIEVPAK
ARVEVDIFELQRDSQYETTDTMCQILPKGVVSVLGPSSSPASASTVSHICGEKEIPHIKV
GPEETPRLQYLRFASVSLYPSNEDVSLAVSRILKSFNYPSASLICAKAECLLRLEELVRG
FLISKETLSVRMLDDSRDPTPLLKEIRDDKVSTIIIDANASISHLILRKASELGMTSAFY
KYILTTMDFPILHLDGIVEDSSNILGFSMFNTSHPFYPEFVRSLNMSWRENCEASTYLGP
ALSAALMFDAVHVVVSAVRELNRSQEIGVKPLACTSANIWPHGTSLMNYLRMVEYDGLTG
RVEFNSKGQRTNYTLRILEKSRQGHREIGVWYSNRTLAMNATTLDINLSQTLANKTLVVT
TILENPYVMRRPNFQGLSGNERFEGFCVDMLRELAELLPFPYRLRLVEDGLYGAPEPNGS
WTGMVGELINRKADLAVAAFTITAEREKVIDFSKPFMTLGISILYRVHMGRKPGYFSFLD
PFSPAVWLFMLLAYLAVSCVLFLAARLSPYEWYNPHPCLRARPHILENQYTLGNSLWFPV
GGFMQQGSEIMPRALSTRCVSGVWWAFTLIIISSYTANLAAFLTVQRMEVPVESADDLAD
QTNIEYGTIHAGSTMTFFQNSRYQTYQRMWNYMQSKQPSVFVKSTEEGIAAVLNSRYAFL
LESTMNEYHRRLNCNLTQIGGLLDTKGYGIGMPLGSPFRDEITLAILQLQENNRLEILKR
KWWEGGRCPKEEDHRAKGLGMENIGGIFIVLICGLIIAVFVAVMEFIWSTRRSAESEEVS
VCQEMLQELRHAVSCRKTSRSRRRRRPGGPSRALLSLRAVREMRLSNGKLYSAGAGGDAG
SAHGGPQRLLDDPGPPSGARPAAPTPCTHVRVCQECRRIQALRASGAGAPPRGLGVPAEA
TSPPRPRPGPAGPRELAEHE

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
1-14

# Drug_Target_4_Specific_Function:
L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists. This receptor binds kainate > quisqualate > domoate > L-glutamate >> AMPA >> NMDA = 1S,3R-ACPD

# Drug_Target_4_SwissProt_ID:
Q16478

# Drug_Target_4_SwissProt_Name:
GRIK5_HUMAN

# Drug_Target_4_Synonyms:
EAA2
Excitatory amino acid receptor 2
Glutamate receptor KA-2
Glutamate receptor, ionotropic kainate 5 precursor
KA2

# Drug_Target_4_Theoretical_pI:
8.03

# Drug_Target_4_Transmembrane_Regions:
545-565
623-643
804-824

# Drug_Target_50_Cellular_Location:
Mitochondrion

# Drug_Target_50_Chromosome_Location:
Not Available

# Drug_Target_50_Drug_References:
12226216	Goncalves-Butruille M, Szajner P, Torigoi E, Leite A, Arruda P: Purification and Characterization of the Bifunctional Enzyme Lysine-Ketoglutarate Reductase-Saccharopine Dehydrogenase from Maize. Plant Physiol. 1996 Mar;110(3):765-771.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
687635	Noda C, Ichihara A: Purification and properties of L-lysine-alpha-ketoglutarate reductase from rat liver mitochondria. Biochim Biophys Acta. 1978 Aug 7;525(2):307-13.
9249048	Gaziola SA, Teixeira CM, Lugli J, Sodek L, Azevedo RA: The enzymology of lysine catabolism in rice seeds--isolation, characterization, and regulatory properties of a lysine 2-oxoglutarate reductase/saccharopine dehydrogenase bifunctional polypeptide. Eur J Biochem. 1997 Jul 1;247(1):364-71.

# Drug_Target_50_Essentiality:
Non-Essential

# Drug_Target_50_GenAtlas_ID:
AASS

# Drug_Target_50_GenBank_ID_Gene:
AF229180

# Drug_Target_50_GenBank_ID_Protein:
7264724

# Drug_Target_50_GeneCard_ID:
AASS

# Drug_Target_50_Gene_Name:
AASS

# Drug_Target_50_Gene_Sequence:
>2781 bp
ATGCTGCAAGTACATAGGACTGGACTGGGCAGGCTGGGGGTCAGCCTCTCCAAGGGTCTT
CACCACAAAGCTGTGTTGGCCGTCCGGAGGGAGGATGTGAACGCCTGGGAGAGAAGGGCC
CCGCTAGCTCCCAAGCACATCAAAGGCATCACCAATCTGGGATACAAGGTCTTGATACAG
CCTTCGAATCGGCGGGCCATTCATGATAAGGACTATGTCAAAGCTGGTGGCATTCTTCAG
GAGGATATTTCTGAAGCTTGTCTAATTTTAGGAGTTAAAAGACCTCCAGAGGAAAAATTA
ATGTCCAGGAAGACTTATGCATTTTTCTCCCACACAATAAAAGCTCAGGAGGCCAATATG
GGCTTGTTGGATGAGATTCTAAAACAGGAAATTCGCCTTATTGATTATGAGAAAATGGTG
GATCATAGAGGAGTACGGGTAGTGGCATTTGGACAGTGGGCTGGTGTGGCAGGAATGATC
AACATTTTACATGGAATGGGTTTAAGGCTCCTTGCTTTGGGACATCACACACCTTTTATG
CACATTGGCATGGCTCATAACTACAGGAATAGCAGTCAGGCTGTGCAAGCTGTCCGTGAT
GCTGGCTATGAAATATCTTTGGGTTTGATGCCTAAGTCAATAGGACCCTTAACATTTGTG
TTCACAGGAACTGGTAATGTTTCTAAGGGAGCCCAAGCAATCTTTAATGAGCTACCTTGT
GAATATGTGGAGCCCCATGAATTAAAAGAAGTTTCCCAAACTGGAGACCTCAGAAAAGTG
TATGGGACGGTGTTAAGTCGTCATCATCATCTTGTCAGGAAAACAGATGCTGTGTATGAT
CCTGCAGAGTATGACAAACATCCGGAGCGCTACATAAGTCGTTTTAATACTGATATTGCA
CCCTATACAACTTGCTTAATTAATGGAATCTACTGGGAACAAAACACTCCTCGCCTCCTA
ACCCGCCAAGATGCTCAGAGTCTCCTGGCTCCGGGCAAGTTCTCACCTGCTGGTGTGGAA
GGCTGCCCTGCATTACCACACAAACTCGTGGCAATATGTGACATTTCAGCTGACACAGGA
GGGTCTATAGAGTTTATGACTGAGTGTACAACAATAGAGCATCCCTTTTGCATGTATGAT
GCAGACCAGCATATTATTCATGACAGTGTTGAAGGCTCGGGGATCCTGATGTGTTCCATT
GACAATTTGCCGGCACAGCTCCCAATTGAAGCTACAGAATGCTTTGGAGACATGCTTTAC
CCTTATGTTGAAGAAATGATATTATCAGACGCGACACAGCCTCTTGAAAGTCAGAATTTT
TCTCCTGTGGTGAGAGATGCAGTGATTACATCCAACGGTACATTACCTGATAAATATAAA
TATATCCAGACACTCCGGGAGAGCAGGGAACGTGCTCAGTCACTTTCAATGGGCACCAGG
AGAAAGGTTTTGGTTCTTGGATCTGGCTACATATCTGAGCCTGTATTAGAATATTTATCA
AGAGATGGCAATATAGAAATAACAGTAGGATCTGACATGAAGAATCAAATTGAACAGTTA
GGCAAGAAATATAATATTAATCCTGTTAGCATGGACATTTGTAAACAAGAAGAGAAGCTG
GGCTTCTTGGTGGCAAAACAGGATCTTGTCATCAGCTTGTTGCCTTATGTATTGCACCCT
CTTGTGGCCAAGGCCTGCATCACAAACAAAGTTAACATGGTCACTGCAAGCTACATCACA
CCAGCACTAAAAGAATTGGAAAAGAGTGTGGAAGATGCTGGCATCACAATCATTGGTGAA
TTGGGATTGGACCCTGGTCTGGATCACATGTTAGCAATGGAAACAATAGATAAAGCCAAG
GAAGTGGGAGCCACGATTGAATCATATATTTCCTACTGTGGTGGGCTTCCAGCCCCTGAA
CATTCAAACAATCCATTGAGATATAAATTTAGCTGGAGTCCAGTGGGAGTTTTGATGAAT
GTAATGCAGTCTGCCACCTATCTGCTCGATGGAAAGGTTGTGAATGTTGCAGGAGGCATC
TCCTTTCTTGATGCCGTTACGTCCATGGATTTTTTTCCAGGATTAAATTTGGAAGGCTAT
CCTAACAGAGACAGTACGAAATATGCTGAGATTTATGGCATTTCTTCTGCTCACACTTTG
TTGCGGGGGACACTGAGATATAAGGGATATATGAAAGCTTTGAATGGATTTGTAAAATTA
GGTCTTATAAACAGAGAAGCGCTTCCTGCCTTTAGACCTGAGGCCAACCCTCTCACCTGG
AAACAACTCCTCTGTGACCTAGTTGGGATTTCACCCTCCTCTGAGCATGATGTGTTGAAG
GAAGCTGTTCTTAAGAAACTAGGAGGAGACAATACCCAGTTGGAGGCTGCTGAATGGTTG
GGCTTACTTGGGGATGAACAAGTTCCTCAGGCAGAGTCCATTCTGGATGCCCTCTCCAAG
CATTTGGTCATGAAGCTTTCCTATGGTCCTGAAGAAAAAGATATGATTGTGATGAGAGAC
AGCTTTGGAATCAGACATCCTTCTGGACATTTAGAACATAAAACGATTGATCTTGTGGCT
TATGGGGACATCAATGGCTTTTCAGCCATGGCTAAAACCGTGGGGTTACCCACCGCCATG
GCAGCCAAAATGTTGCTTGATGGTGAAATTGGAGCCAAAGGCCTAATGGGGCCCTTTTCA
AAGGAGATCTATGGACCAATATTGGAGCGAATTAAAGCAGAAGGCATTATATATACTACA
CAGAGTACAATTAAACCATAA

# Drug_Target_50_General_Function:
Amino acid transport and metabolism

# Drug_Target_50_General_References:
12853948	Hillier LW, Fulton RS, Fulton LA, Graves TA, Pepin KH, Wagner-McPherson C, Layman D, Maas J, Jaeger S, Walker R, Wylie K, Sekhon M, Becker MC, O'Laughlin MD, Schaller ME, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Cordes M, Du H, Sun H, Edwards J, Bradshaw-Cordum H, Ali J, Andrews S, Isak A, Vanbrunt A, Nguyen C, Du F, Lamar B, Courtney L, Kalicki J, Ozersky P, Bielicki L, Scott K, Holmes A, Harkins R, Harris A, Strong CM, Hou S, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Leonard S, Rohlfing T, Rock SM, Tin-Wollam AM, Abbott A, Minx P, Maupin R, Strowmatt C, Latreille P, Miller N, Johnson D, Murray J, Woessner JP, Wendl MC, Yang SP, Schultz BR, Wallis JW, Spieth J, Bieri TA, Nelson JO, Berkowicz N, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Bedell JA, Mardis ER, Clifton SW, Chissoe SL, Marra MA, Raymond C, Haugen E, Gillett W, Zhou Y, James R, Phelps K, Iadanoto S, Bubb K, Simms E, Levy R, Clendenning J, Kaul R, Kent WJ, Furey TS, Baertsch RA, Brent MR, Keibler E, Flicek P, Bork P, Suyama M, Bailey JA, Portnoy ME, Torrents D, Chinwalla AT, Gish WR, Eddy SR, McPherson JD, Olson MV, Eichler EE, Green ED, Waterston RH, Wilson RK: The DNA sequence of human chromosome 7. Nature. 2003 Jul 10;424(6945):157-64.

# Drug_Target_50_HGNC_ID:
HGNC:17366

# Drug_Target_50_HPRD_ID:
05489

# Drug_Target_50_ID:
83

# Drug_Target_50_Locus:
7q31.3

# Drug_Target_50_Molecular_Weight:
102133

# Drug_Target_50_Name:
Alpha-aminoadipic semialdehyde synthase, mitochondrial

# Drug_Target_50_Number_of_Residues:
926

# Drug_Target_50_PDB_ID:
Not Available

# Drug_Target_50_Pathway:
Not Available

# Drug_Target_50_Pfam_Domain_Function:
PF01262	AlaDh_PNT_C
PF03435	Saccharop_dh
PF05222	AlaDh_PNT_N

# Drug_Target_50_Protein_Sequence:
>Alpha-aminoadipic semialdehyde synthase, mitochondrial precursor
MLQVHRTGLGRLGVSLSKGLHHKAVLAVRREDVNAWERRAPLAPKHIKGITNLGYKVLIQ
PSNRRAIHDKDYVKAGGILQEDISEACLILGVKRPPEEKLMSRKTYAFFSHTIKAQEANM
GLLDEILKQEIRLIDYEKMVDHRGVRVVAFGQWAGVAGMINILHGMGLRLLALGHHTPFM
HIGMAHNYRNSSQAVQAVRDAGYEISLGLMPKSIGPLTFVFTGTGNVSKGAQAIFNELPC
EYVEPHELKEVSQTGDLRKVYGTVLSRHHHLVRKTDAVYDPAEYDKHPERYISRFNTDIA
PYTTCLINGIYWEQNTPRLLTRQDAQSLLAPGKFSPAGVEGCPALPHKLVAICDISADTG
GSIEFMTECTTIEHPFCMYDADQHIIHDSVEGSGILMCSIDNLPAQLPIEATECFGDMLY
PYVEEMILSDATQPLESQNFSPVVRDAVITSNGTLPDKYKYIQTLRESRERAQSLSMGTR
RKVLVLGSGYISEPVLEYLSRDGNIEITVGSDMKNQIEQLGKKYNINPVSMDICKQEEKL
GFLVAKQDLVISLLPYVLHPLVAKACITNKVNMVTASYITPALKELEKSVEDAGITIIGE
LGLDPGLDHMLAMETIDKAKEVGATIESYISYCGGLPAPEHSNNPLRYKFSWSPVGVLMN
VMQSATYLLDGKVVNVAGGISFLDAVTSMDFFPGLNLEGYPNRDSTKYAEIYGISSAHTL
LRGTLRYKGYMKALNGFVKLGLINREALPAFRPEANPLTWKQLLCDLVGISPSSEHDVLK
EAVLKKLGGDNTQLEAAEWLGLLGDEQVPQAESILDALSKHLVMKLSYGPEEKDMIVMRD
SFGIRHPSGHLEHKTIDLVAYGDINGFSAMAKTVGLPTAMAAKMLLDGEIGAKGLMGPFS
KEIYGPILERIKAEGIIYTTQSTIKP

# Drug_Target_50_Reaction:
N6-(L-1,3-dicarboxypropyl)-L-lysine + NADP+ + H2O = L-lysine + 2-oxoglutarate + NADPH + H+

# Drug_Target_50_Signals:
None

# Drug_Target_50_Specific_Function:
Bifunctional enzyme that catalyzes the first two steps in lysine degradation. The N-terminal and the C-terminal contain lysine-ketoglutarate reductase and saccharopine dehydrogenase activity, respectively

# Drug_Target_50_SwissProt_ID:
Q9UDR5

# Drug_Target_50_SwissProt_Name:
AASS_HUMAN

# Drug_Target_50_Synonyms:
Alpha-aminoadipic semialdehyde synthase, mitochondrial precursor
EC 1.5.1.8
EC 1.5.1.9
LKR
LKR/SDH
LOR
Saccharopine dehydrogenase

# Drug_Target_50_Theoretical_pI:
6.62

# Drug_Target_50_Transmembrane_Regions:
None

# Drug_Target_51_Cellular_Location:
Mitochondrion

# Drug_Target_51_Chromosome_Location:
Not Available

# Drug_Target_51_Drug_References:
16793004	Yoshimune K, Shirakihara Y, Shiratori A, Wakayama M, Chantawannakul P, Moriguchi M: Crystal structure of a major fragment of the salt-tolerant glutaminase from Micrococcus luteus K-3. Biochem Biophys Res Commun. 2006 Aug 11;346(4):1118-24. Epub 2006 Jun 6.
17321558	Kita K, Suzuki T, Ochi T: Down-regulation of glutaminase C in human hepatocarcinoma cell by diphenylarsinic acid, a degradation product of chemical warfare agents. Toxicol Appl Pharmacol. 2007 May 1;220(3):262-70. Epub 2007 Jan 24.
17373776	Dossena L, Curti B, Vanoni MA: Activation and coupling of the glutaminase and synthase reaction of glutamate synthase is mediated by E1013 of the ferredoxin-dependent enzyme, belonging to loop 4 of the synthase domain. Biochemistry. 2007 Apr 17;46(15):4473-85. Epub 2007 Mar 21.

# Drug_Target_51_Essentiality:
Non-Essential

# Drug_Target_51_GenAtlas_ID:
GLS2

# Drug_Target_51_GenBank_ID_Gene:
AF110330

# Drug_Target_51_GenBank_ID_Protein:
6650606

# Drug_Target_51_GeneCard_ID:
GLS2

# Drug_Target_51_Gene_Name:
GLS2

# Drug_Target_51_Gene_Sequence:
>1809 bp
ATGCGCTCCATGAAGGCTCTGCAGAAGGCCCTGAGCCGGGCTGGCAGTCACTGCGGGCGA
GGAGGCTGGGGTCACCCGAGCCGGAGCCCCCTCCTTGGCGGGGGCGTCCGGCACCACCTC
AGTGAGGCCGCGGCGCAGGGCAGAGAGACGCCACACAGCCACCAGCCGCAGCACCAGGAT
CATGATTCATCAGAAAGTGGCATGCTGTCCCGCCTGGGTGATTTGCTCTTTTACACTATT
GCTGAAGGACAGGAACGAACCCCTATCCACAAGTTCACCACTGCACTAAAGGCCACTGGA
CTGCAGACATCAGATCCTCGGCTCCGAGACTGCATGAGCGAGATGCACCGCGTGGTCCAA
GAGTCCAGTAGTGGTGGCCTCTTGGACCGAGATCTCTTCCGAAAGTGTGTGAGCAGCAGC
ATTGTGCTCCTGACCCAGGCATTCCGAAAGAAGTTTGTCATTCCTGATTTTGAGGAGTTC
ACGGGCCATGTGGATCGCATCTTTGAGGATGTCAAAGAGCTCACTGGAGGCAAAGTGGCA
GCCTACATCCCTCAGCTGGCCAAGTCAAACCCAGACCTGTGGGGTGTCTCCCTGTGCACT
GTGGATGGTCAACGGCACTCTGTGGGCCACACAAAGATCCCCTTCTGCCTGCAGTCCTGT
GTGAAGCCCCTCACCTATGCCATCTCCATAAGCACCCTAGGCACTGACTACGTGCACAAG
TTTGTGGGCAAAGAGCCAAGTGGCCTGCGCTACAACAAGCTCTCCCTCGATGAGGAAGGA
ATCCCCCATAACCCCATGGTCAATGCTGGTGCCATTGTTGTCAGCTCCCTGATCAAGATG
GACTGTAACAAAGCAGAGAAGTTTGATTTTGTGTTGCAGTATCTCAACAAAATGGCTGGG
AATGAATACATGGGTTTCAGCAATGCCACATTCCAGTCAGAGAAGGAAACAGGGGATCGG
AATTATGCCATCGGCTATTATCACGAGGAAAAGAAGTGCTTTCCTAAGGGGGTGGACATG
ATGGCTGCCCTTGATCTCTACTTCCAGCTGTGTTCTGTGGAGGTCACTTGTGAATCAGGC
AGTGTCATGGCAGCCACCCTCGCCAACGGTGGGATTTGCCCCATCACAGGCGAGAGTGTG
CTGAGTGCTGAAGCAGTGCGCAACACCCTCAGCCTCATGCATTCCTGCGGCATGTATGAC
TTCTCTGGCCAGTTTGCCTTCCACGTGGGCCTGCCAGCCAAGTCAGCTGTATCAGGAGCC
ATCCTCCTGGTGGTACCCAATGTCATGGGAATGATGTGCCTGTCACCCCCATTGGACAAG
CTGGGGAACAGCCATAGGGGGACCAGCTTCTGCCAGAAGTTGGTGTCTCTCTTCAATTTC
CACAACTATGACAACCTGAGGCACTGTGCTCGGAAGTTAGACCCACGGCGTGAAGGGGCA
GAAATTCGGAACAAGACTGTGGTCAACCTGTTATTTGCTGCCTATAGTGGCGATGTCTCA
GCTCTTCGAAGGTTTGCCTTGTCAGCCATGGATATGGAACAGAAAGACTATGACTCGCGC
ACAGCTCTGCATGTTGCTGCAGCTGAAGGACACATCGAAGTTGTTAAATTCCTGATCGAG
GCTTGCAAAGTGAATCCTTTTGCCAAGGACAGGTGGGGCAACATTCCCCTGGATGATGCT
GTGCAGTTCAACCATCTGGAGGTGGTCAAACTGCTTCAAGATTACCAGGACTCCTACACA
CTCTCTGAAACTCAGGCTGAGGCAGCAGCTGAGGCCCTGTCCAAAGAGAACTTAGAAAGC
ATGGTATGA

# Drug_Target_51_General_Function:
Amino acid transport and metabolism

# Drug_Target_51_General_References:
10620514	Gomez-Fabre PM, Aledo JC, Del Castillo-Olivares A, Alonso FJ, Nunez De Castro I, Campos JA, Marquez J: Molecular cloning, sequencing and expression studies of the human breast cancer cell glutaminase. Biochem J. 2000 Jan 15;345 Pt 2:365-75.
11163757	Olalla L, Aledo JC, Bannenberg G, Marquez J: The C-terminus of human glutaminase L mediates association with PDZ domain-containing proteins. FEBS Lett. 2001 Jan 19;488(3):116-22.

# Drug_Target_51_HGNC_ID:
HGNC:29570

# Drug_Target_51_HPRD_ID:
05901

# Drug_Target_51_ID:
5

# Drug_Target_51_Locus:
12q13

# Drug_Target_51_Molecular_Weight:
66310

# Drug_Target_51_Name:
Glutaminase liver isoform, mitochondrial

# Drug_Target_51_Number_of_Residues:
602

# Drug_Target_51_PDB_ID:
Not Available

# Drug_Target_51_Pathway:
Not Available

# Drug_Target_51_Pfam_Domain_Function:
PF00023	Ank
PF04960	Glutaminase

# Drug_Target_51_Protein_Sequence:
>Glutaminase liver isoform, mitochondrial precursor
MRSMKALQKALSRAGSHCGRGGWGHPSRSPLLGGGVRHHLSEAAAQGRETPHSHQPQHQD
HDSSESGMLSRLGDLLFYTIAEGQERTPIHKFTTALKATGLQTSDPRLRDCMSEMHRVVQ
ESSSGGLLDRDLFRKCVSSSIVLLTQAFRKKFVIPDFEEFTGHVDRIFEDVKELTGGKVA
AYIPQLAKSNPDLWGVSLCTVDGQRHSVGHTKIPFCLQSCVKPLTYAISISTLGTDYVHK
FVGKEPSGLRYNKLSLDEEGIPHNPMVNAGAIVVSSLIKMDCNKAEKFDFVLQYLNKMAG
NEYMGFSNATFQSEKETGDRNYAIGYYHEEKKCFPKGVDMMAALDLYFQLCSVEVTCESG
SVMAATLANGGICPITGESVLSAEAVRNTLSLMHSCGMYDFSGQFAFHVGLPAKSAVSGA
ILLVVPNVMGMMCLSPPLDKLGNSHRGTSFCQKLVSLFNFHNYDNLRHCARKLDPRREGA
EIRNKTVVNLLFAAYSGDVSALRRFALSAMDMEQKDYDSRTALHVAAAEGHIEVVKFLIE
ACKVNPFAKDRWGNIPLDDAVQFNHLEVVKLLQDYQDSYTLSETQAEAAAEALSKENLES
MV

# Drug_Target_51_Reaction:
L-glutamine + H2O = L-glutamate + NH3

# Drug_Target_51_Signals:
None

# Drug_Target_51_Specific_Function:
Plays an important role in the regulation of glutamine catabolism

# Drug_Target_51_SwissProt_ID:
Q9UI32

# Drug_Target_51_SwissProt_Name:
GLSL_HUMAN

# Drug_Target_51_Synonyms:
EC 3.5.1.2
GLS
Glutaminase liver isoform, mitochondrial precursor
L-glutaminase
L-glutamine amidohydrolase

# Drug_Target_51_Theoretical_pI:
7.03

# Drug_Target_51_Transmembrane_Regions:
None

# Drug_Target_52_Cellular_Location:
Cytoplasm

# Drug_Target_52_Chromosome_Location:
Not Available

# Drug_Target_52_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
17928682	Watanabe J, Tanaka H, Akagawa T, Mogi Y, Yamazaki T: Characterization of Aspergillus oryzae Aspartyl Aminopeptidase Expressed in Escherichia coli. Biosci Biotechnol Biochem. 2007 Oct 7;.

# Drug_Target_52_Essentiality:
Non-Essential

# Drug_Target_52_GenAtlas_ID:
DNPEP

# Drug_Target_52_GenBank_ID_Gene:
AF005050

# Drug_Target_52_GenBank_ID_Protein:
5902181

# Drug_Target_52_GeneCard_ID:
DNPEP

# Drug_Target_52_Gene_Name:
DNPEP

# Drug_Target_52_Gene_Sequence:
>1428 bp
ATGCAGGTGGCCATGAACGGTAAGGCCCGCAAAGAGGCGGTGCAGACTGCGGCTAAGGAA
CTCCTCAAGTTCGTGAACCGGAGTCCCTCTCCTTTCCATGCTGTGGCTGAATGCCGCAAC
CGCCTTCTCCAGGCTGGCTTCAGTGAACTCAAGGAGACTGAGAAATGGAATATTAAGCCC
GAGAGCAAGTACTTCATGACCAGGAACTCCTCCACCATCATAGCTTTTGCTGTAGGGGGC
CAGTACGTTCCTGGCAATGGCTTCAGCCTCATCGGGGCCCACACGGACAGCCCCTGCCTC
CGGGTGAAACGTCGGTCTCGCCGCAGCCAGGTGGGCTTCCAGCAAGTCGGTGTGGAGACC
TATGGTGGTGGGATCTGGAGCACCTGGTTTGACCGTGACCTGACTCTGGCTGGACGCGTC
ATTGTCAAGTGCCCTACCTCAGGTCGGCTGGAGCAGCAGCTGGTGCACGTGGAGCGGCCC
ATTCTTCGCATCCCACACCTGGCCATCCATCTGCAGCGAAATATCAACGAGAACTTTGGG
CCCAACACAGAGATGCATCTAGTCCCCATTCTTGCCACAGCCATCCAGGAGGAGCTGGAG
AAGGGGACTCCTGAGCCAGGGCCTCTCAATGCTGTGGATGAGCGGCACCATTCGGTCCTC
ATGTCCCTGCTCTGTGCCCATCTGGGGCTGAGCCCCAAGGACATAGTGGAGATGGAGCTC
TGCCTTGCAGACACCCAGCCTGCGGTCTTGGGTGGTGCCTATGATGAGTTCATCTTTGCT
CCTCGGCTGGACAATCTGCACAGCTGCTTCTGTGCCCTGCAGGCCTTGATAGATTCCTGT
GCAGGCCCTGGCTCCCTGGCCACAGAGCCTCACGTGCGCATGGTCACACTCTATGACAAC
GAAGAGGTGGGGTCTGAGAGTGCACAGGGAGCACAGTCACTGCTGACAGAGCTGGTGCTG
CGGCGGATCTCAGCCTCGTGCCAGCACCCGACAGCCTTCGAGGAAGCCATACCCAAGTCC
TTCATGATCAGCGCAGACATGGCCCATGCTGTGCATCCCAACTACCTGGACAAGCATGAG
GAGAACCACCGGCCTTTATTCCACAAGGGCCCCGTGATCAAGGTGAACAGCAAGCAACGC
TATGCTTCAAACGCGGTGTCAGAGGCCCTGATCCGAGAGGTGGCCAACAAAGTCAAGGTC
CCCCTGCAGGATCTCATGGTCCGGAATGACACCCCCTGTGGAACCACCATTGGACCTATC
TTGGCTTCTCGGCTGGGGCTGCGGGTGCTGGATTTAGGCAGCCCCCAACTGGCCATGCAC
TCTATCCGGGAGATGGCCTGCACCACAGGAGTCCTCCAGACCCTCACCCTCTTCAAGGGC
TTCTTTGAGCTGTTCCCTTCTCTAAGCCATAATCTCTTAGTGGATTGA

# Drug_Target_52_General_Function:
Amino acid transport and metabolism

# Drug_Target_52_General_References:
9632644	Wilk S, Wilk E, Magnusson RP: Purification, characterization, and cloning of a cytosolic aspartyl aminopeptidase. J Biol Chem. 1998 Jun 26;273(26):15961-70.

# Drug_Target_52_HGNC_ID:
HGNC:2981

# Drug_Target_52_HPRD_ID:
Not Available

# Drug_Target_52_ID:
4026

# Drug_Target_52_Locus:
2q35

# Drug_Target_52_Molecular_Weight:
52429

# Drug_Target_52_Name:
Aspartyl aminopeptidase

# Drug_Target_52_Number_of_Residues:
475

# Drug_Target_52_PDB_ID:
Not Available

# Drug_Target_52_Pathway:
Not Available

# Drug_Target_52_Pfam_Domain_Function:
PF02127	Peptidase_M18

# Drug_Target_52_Protein_Sequence:
>Aspartyl aminopeptidase
MQVAMNGKARKEAVQTAAKELLKFVNRSPSPFHAVAECRNRLLQAGFSELKETEKWNIKP
ESKYFMTRNSSTIIAFAVGGQYVPGNGFSLIGAHTDSPCLRVKRRSRRSQVGFQQVGVET
YGGGIWSTWFDRDLTLAGRVIVKCPTSGRLEQQLVHVERPILRIPHLAIHLQRNINENFG
PNTEMHLVPILATAIQEELEKGTPEPGPLNAVDERHHSVLMSLLCAHLGLSPKDIVEMEL
CLADTQPAVLGGAYDEFIFAPRLDNLHSCFCALQALIDSCAGPGSLATEPHVRMVTLYDN
EEVGSESAQGAQSLLTELVLRRISASCQHPTAFEEAIPKSFMISADMAHAVHPNYLDKHE
ENHRPLFHKGPVIKVNSKQRYASNAVSEALIREVANKVKVPLQDLMVRNDTPCGTTIGPI
LASRLGLRVLDLGSPQLAMHSIREMACTTGVLQTLTLFKGFFELFPSLSHNLLVD

# Drug_Target_52_Reaction:
Release of an N-terminal aspartate or glutamate from a peptide, with a preference for aspartate

# Drug_Target_52_Signals:
None

# Drug_Target_52_Specific_Function:
Likely to play an important role in intracellular protein and peptide metabolism

# Drug_Target_52_SwissProt_ID:
Q9ULA0

# Drug_Target_52_SwissProt_Name:
DNPEP_HUMAN

# Drug_Target_52_Synonyms:
EC 3.4.11.21

# Drug_Target_52_Theoretical_pI:
7.44

# Drug_Target_52_Transmembrane_Regions:
None

# Drug_Target_53_Cellular_Location:
Membrane

# Drug_Target_53_Chromosome_Location:
Not Available

# Drug_Target_53_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_53_Essentiality:
Non-Essential

# Drug_Target_53_GenAtlas_ID:
GRID1

# Drug_Target_53_GenBank_ID_Gene:
BC039263

# Drug_Target_53_GenBank_ID_Protein:
24657795

# Drug_Target_53_GeneCard_ID:
GRID1

# Drug_Target_53_Gene_Name:
GRID1

# Drug_Target_53_Gene_Sequence:
>1830 bp
ATGGAAGCGCTGACGCTGTGGCTTCTCCCCTGGATATGCCAGTGCGTGTCGGTGCGGGCC
GACTCCATCATCCACATCGGTGCCATCTTCGAGGAGAACGCGGCCAAGGACGACAGGGTG
TTCCAGTTGGCGGTATCCGACCTGAGCCTCAACGATGACATCCTGCAGAGCGAGAAGATC
ACCTACTCCATCAAGGTCATCGAGGCCAACAACCCATTCCAGGCTGTGCAGGAAGCCTGT
GACCTCATGACCCAGGGGATTTTGGCCTTGGTCACGTCCACTGGCTGTGCATCTGCCAAT
GCCCTGCAGTCCCTCACGGATGCCATGCACATCCCACACCTCTTTGTCCAGCGCAACCCG
GGAGGGTCGCCACGCACCGCATGCCACCTGAACCCCAGCCCCGATGGTGAGGCCTACACA
CTGGCTTCGAGACCACCCGTCCGCCTCAATGATGTCATGCTCAGGCTGGTGACGGAGCTG
CGCTGGCAGAAGTTCGTCATGTTCTACGACAGCGAGTATGATATCCGTGGGCTTCAAAGC
TTTCTGGACCAGGCCTCGCGGCTGGGCCTTGACGTCTCTTTACAAAAGGTGGACAAGAAC
ATTAGCCACGTATTCACCAGCCTCTTCACCACGATGAAGACAGAGGAGCTGAATCGCTAC
CGGGACACGCTTCGCCGCGCCATCCTGCTGCTCAGCCCACAGGGAGCCCACTCCTTCATC
AACGAGGCCGTGGAGACCAACCTGGCTTCCAAGGACAGCCACTGGGTCTTTGTGAATGAG
GAAATCAGTGACCCGGAGATCCTGGATCTGGTCCATAGTGCCCTTGGAAGGATGACCGTG
GTCCGGCAAATCTTTCCGTCTGCAAAGGACAATCAGAAATGCACGAGGAACAACCACCGC
ATCTCCTCCCTGCTCTGCGACCCCCAGGAAGGCTACCTCCAGATGCTGCAGATCTCCAAC
CTCTATCTGTATGACAGTGTTCTGATGCTGGCCAACGCCTTTCACAGGAAGCTGGAGGAC
CGGAAGTGGCATAGCATGGCGAGCCTCAACTGCATACGGAAATCCACTAAGCCATGGAAT
GGTGGGAGGTCCATGCTGGATACCATCAAAAAGGGCCACATCACTGGCCTCACTGGGGTG
ATGGAGTTTCGGGAGGACAGTTCGAATCCCTATGTCCAGTTTGAAATCCTTGGCACTACC
TATAGTGAGACTTTTGGCAAAGACATGCGCAAGTTGGCGACATGGGACTCAGAGAAGGGC
TTGAATGGCAGCTTGCAAGAGAGGCCCATGGGCAGCCGCCTCCAAGGATTGACTCTTAAA
GTGGTGACTGTCTTGGAAGAGCCTTTCGTGATGGTGGCTGAGAACATCCTAGGACAGCCC
AAGCGCTACAAAGGGTTCTCCATAGATGTCCTGGATGCACTGGCCAAGGCTCTGGGCTTT
AAATATGAGATTTACCAAGCCCCTGATGGCAGGTACGGTCACCAGCTCCATAACACCTCC
TGGAACGGGATGATCGGGGAGCTCATCAGCAAGAGAGCAGACTTGGCCATCTCTGCCATC
ACCATCACCCCAGAGAGGGAGAGCGTTGTGGACTTCAGCAAGCGGTACATGGACTATTCA
GTGGGGATTCTAATTAAGAAGCCCGAGGAGAAAATCAGCATCTTCTCCCTCTTTGCTCCA
TTTGATTTCGCTGTGTGGGCCTGCATTGCAGCAGCCATCCCTGTGGTTGGTGTGCTGATA
TTTGTGTTGAACAGGATACAGGCTGTGAGGGCTCAGAGTGCTGCCCAGCCCAGGCCGTCA
GCTTCTGCCACTCTGCACAGCGCCATCTAG

# Drug_Target_53_General_Function:
Amino acid transport and metabolism

# Drug_Target_53_General_References:
10574462	Nagase T, Ishikawa K, Kikuno R, Hirosawa M, Nomura N, Ohara O: Prediction of the coding sequences of unidentified human genes. XV. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. DNA Res. 1999 Oct 29;6(5):337-45.

# Drug_Target_53_HGNC_ID:
HGNC:4575

# Drug_Target_53_HPRD_ID:
Not Available

# Drug_Target_53_ID:
4027

# Drug_Target_53_Locus:
10q22

# Drug_Target_53_Molecular_Weight:
112132

# Drug_Target_53_Name:
Glutamate receptor delta-1 subunit

# Drug_Target_53_Number_of_Residues:
1009

# Drug_Target_53_PDB_ID:
Not Available

# Drug_Target_53_Pathway:
Not Available

# Drug_Target_53_Pfam_Domain_Function:
PF00060	Lig_chan
PF01094	ANF_receptor

# Drug_Target_53_Protein_Sequence:
>Glutamate receptor delta-1 subunit
MEALTLWLLPWICQCVSVRADSIIHIGAIFEENAAKDDRVFQLAVSDLSLNDDILQSEKI
TYSIKVIEANNPFQAVQEACDLMTQGILALVTSTGCASANALQSLTDAMHIPHLFVQRNP
GGSPRTACHLNPSPDGEAYTLASRPPVRLNDVMLRLVTELRWQKFVMFYDSEYDIRGLQS
FLDQASRLGLDVSLQKVDKNISHVFTSLFTTMKTEELNRYRDTLRRAILLLSPQGAHSFI
NEAVETNLASKDSHWVFVNEEISDPEILDLVHSALGRMTVVRQIFPSAKDNQKCTRNNHR
ISSLLCDPQEGYLQMLQISNLYLYDSVLMLANAFHRKLEDRKWHSMASLNCIRKSTKPWN
GGRSMLDTIKKGHITGLTGVMEFREDSSNPYVQFEILGTTYSETFGKDMRKLATWDSEKG
LNGSLQERPMGSRLQGLTLKVVTVLEEPFVMVAENILGQPKRYKGFSIDVLDALAKALGF
KYEIYQAPDGRYGHQLHNTSWNGMIGELISKRADLAISAITITPERESVVDFSKRYMDYS
VGILIKKPEEKISIFSLFAPFDFAVWACIAAAIPVVGVLIFVLNRIQAVRAQSAAQPRPS
ASATLHSAIWIVYGAFVQQGGESSVNSMAMRIVMGSWWLFTLIVCSSYTANLAAFLTVSR
MDNPIRTFQDLSKQVEMSYGTVRDSAVYEYFRAKGTNPLEQDSTFAELWRTISKNGGADN
CVSSPSEGIRKAKKGNYAFLWDVAVVEYAALTDDDCSVTVIGNSISSKGYGIALQHGSPY
RDLFSQRILELQDTGDLDVLKQKWWPHMGRCDLTSHASAQADGKSLKLHSFAGVFCILAI
GLLLACLVAALELWWNSNRCHQETPKEDKEVNLEQVHRRMNSLMDEDIAHKQISPASIEL
SALEMGGLAPTQTLEPTREYQNTQLSVSTFLPEQSSHGTSRTLSSGPSSNLPLPLSSSAT
MPSMQCKHRSPNGGLFRQSPVKTPIPMSFQPVPGGVLPEALDTSHGTSI

# Drug_Target_53_Reaction:
Not Available

# Drug_Target_53_Signals:
1-20

# Drug_Target_53_Specific_Function:
Receptor for glutamate. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists

# Drug_Target_53_SwissProt_ID:
Q9ULK0

# Drug_Target_53_SwissProt_Name:
GRID1_HUMAN

# Drug_Target_53_Synonyms:
GluR delta-1
Glutamate receptor delta-1 subunit precursor

# Drug_Target_53_Theoretical_pI:
6.67

# Drug_Target_53_Transmembrane_Regions:
563-583
638-658
831-851

# Drug_Target_54_Cellular_Location:
Membrane
multi-pass membrane protein (Probable)

# Drug_Target_54_Chromosome_Location:
Not Available

# Drug_Target_54_Drug_References:
16719820	Natale NR, Magnusson KR, Nelson JK: Can selective ligands for glutamate binding proteins be rationally designed? Curr Top Med Chem. 2006;6(8):823-47.

# Drug_Target_54_Essentiality:
Non-Essential

# Drug_Target_54_GenAtlas_ID:
SLC7A11

# Drug_Target_54_GenBank_ID_Gene:
AB026891

# Drug_Target_54_GenBank_ID_Protein:
5668545

# Drug_Target_54_GeneCard_ID:
SLC7A11

# Drug_Target_54_Gene_Name:
SLC7A11

# Drug_Target_54_Gene_Sequence:
>1506 bp
ATGGTCAGAAAGCCTGTTGTGTCCACCATCTCCAAAGGAGGTTACCTGCAGGGAAATGTT
AACGGGAGGCTGCCTTCCCTGGGCAACAAGGAGCCACCTGGGCAGGAGAAAGTGCAGCTG
AAGAGGAAAGTCACTTTACTGAGGGGAGTCTCCATTATCATTGGCACCATCATTGGAGCA
GGAATCTTCATCTCTCCTAAGGGCGTGCTCCAGAACACGGGCAGCGTGGGCATGTCTCTG
ACCATCTGGACGGTGTGTGGGGTCCTGTCACTATTTGGAGCTTTGTCTTATGCTGAATTG
GGAACAACTATAAAGAAATCTGGAGGTCATTACACATATATTTTGGAAGTCTTTGGTCCA
TTACCAGCTTTTGTACGAGTCTGGGTGGAACTCCTCATAATACGCCCTGCAGCTACTGCT
GTGATATCCCTGGCATTTGGACGCTACATTCTGGAACCATTTTTTATTCAATGTGAAATC
CCTGAACTTGCGATCAAGCTCATTACAGCTGTGGGCATAACTGTAGTGATGGTCCTAAAT
AGCATGAGTGTCAGCTGGAGCGCCCGGATCCAGATTTTCTTAACCTTTTGCAAGCTCACA
GCAATTCTGATAATTATAGTCCCTGGAGTTATGCAGCTAATTAAAGGTCAAACGCAGAAC
TTTAAAGACGCGTTTTCAGGAAGAGATTCAAGTATTACGCGGTTGCCACTGGCTTTTTAT
TATGGAATGTATGCATATGCTGGCTGGTTTTACCTCAACTTTGTTACTGAAGAAGTAGAA
AACCCTGAAAAAACCATTCCCCTTGCAATATGTATATCCATGGCCATTGTCACCATTGGC
TATGTGCTGACAAATGTGGCCTACTTTACGACCATTAATGCTGAGGAGCTGCTGCTTTCA
AATGCAGTGGCAGTGACCTTTTCTGAGCGGCTACTGGGAAATTTCTCATTAGCAGTTCCG
ATCTTTGTTGCCCTCTCCTGCTTTGGCTCCATGAACGGTGGTGTGTTTGCTGTCTCCAGG
TTATTCTATGTTGCGTCTCGAGAGGGTCACCTTCCAGAAATCCTCTCCATGATTCATGTC
CGCAAGCACACTCCTCTACCAGCTGTTATTGTTTTGCACCCTTTGACAATGATAATGCTC
TTCTCTGGAGACCTCGACAGTCTTTTGAATTTCCTCAGTTTTGCCAGGTGGCTTTTTATT
GGGCTGGCAGTTGCTGGGCTGATTTATCTTCGATACAAATGCCCAGATATGCATCGTCCT
TTCAAGGTGCCACTGTTCATCCCAGCTTTGTTTTCCTTCACATGCCTCTTCATGGTTGCC
CTTTCCCTCTATTCGGACCCATTTAGTACAGGGATTGGCTTCGTCATCACTCTGACTGGA
GTCCCTGCGTATTATCTCTTTATTATATGGGACAAGAAACCCAGGTGGTTTAGAATAATG
TCAGAGAAAATAACCAGAACATTACAAATAATACTGGAAGTTGTACCAGAAGAAGATAAG
TTATGA

# Drug_Target_54_General_Function:
Amino acid transport and metabolism

# Drug_Target_54_General_References:
11213471	Sato H, Tamba M, Kuriyama-Matsumura K, Okuno S, Bannai S: Molecular cloning and expression of human xCT, the light chain of amino acid transport system xc-. Antioxid Redox Signal. 2000 Winter;2(4):665-71.

# Drug_Target_54_HGNC_ID:
HGNC:11059

# Drug_Target_54_HPRD_ID:
09720

# Drug_Target_54_ID:
33

# Drug_Target_54_Locus:
4q28-q32

# Drug_Target_54_Molecular_Weight:
55424

# Drug_Target_54_Name:
Cystine/glutamate transporter

# Drug_Target_54_Number_of_Residues:
501

# Drug_Target_54_PDB_ID:
Not Available

# Drug_Target_54_Pathway:
Not Available

# Drug_Target_54_Pfam_Domain_Function:
PF00324	AA_permease

# Drug_Target_54_Protein_Sequence:
>Cystine/glutamate transporter
MVRKPVVSTISKGGYLQGNVNGRLPSLGNKEPPGQEKVQLKRKVTLLRGVSIIIGTIIGA
GIFISPKGVLQNTGSVGMSLTIWTVCGVLSLFGALSYAELGTTIKKSGGHYTYILEVFGP
LPAFVRVWVELLIIRPAATAVISLAFGRYILEPFFIQCEIPELAIKLITAVGITVVMVLN
SMSVSWSARIQIFLTFCKLTAILIIIVPGVMQLIKGQTQNFKDAFSGRDSSITRLPLAFY
YGMYAYAGWFYLNFVTEEVENPEKTIPLAICISMAIVTIGYVLTNVAYFTTINAEELLLS
NAVAVTFSERLLGNFSLAVPIFVALSCFGSMNGGVFAVSRLFYVASREGHLPEILSMIHV
RKHTPLPAVIVLHPLTMIMLFSGDLDSLLNFLSFARWLFIGLAVAGLIYLRYKCPDMHRP
FKVPLFIPALFSFTCLFMVALSLYSDPFSTGIGFVITLTGVPAYYLFIIWDKKPRWFRIM
SEKITRTLQIILEVVPEEDKL

# Drug_Target_54_Reaction:
Not Available

# Drug_Target_54_Signals:
None

# Drug_Target_54_Specific_Function:
Sodium-independent, high-affinity exchange of anionic amino acids with high specificity for anionic form of cystine and glutamate

# Drug_Target_54_SwissProt_ID:
Q9UPY5

# Drug_Target_54_SwissProt_Name:
XCT_HUMAN

# Drug_Target_54_Synonyms:
Amino acid transport system xc-
Calcium channel blocker resistance protein CCBR1
xCT

# Drug_Target_54_Theoretical_pI:
9.51

# Drug_Target_54_Transmembrane_Regions:
44-64
76-96
136-156
159-179
190-210
235-255
266-286
318-338
365-385
388-408
423-443
450-470

# Drug_Target_55_Cellular_Location:
Not Available

# Drug_Target_55_Chromosome_Location:
Not Available

# Drug_Target_55_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_55_Essentiality:
Non-Essential

# Drug_Target_55_GenAtlas_ID:
Not Available

# Drug_Target_55_GenBank_ID_Gene:
Not Available

# Drug_Target_55_GenBank_ID_Protein:
Not Available

# Drug_Target_55_GeneCard_ID:
Not Available

# Drug_Target_55_Gene_Name:
PGCP

# Drug_Target_55_Gene_Sequence:
Not Available

# Drug_Target_55_General_Function:
Not Available

# Drug_Target_55_General_References:
Not Available

# Drug_Target_55_HGNC_ID:
Not Available

# Drug_Target_55_HPRD_ID:
Not Available

# Drug_Target_55_ID:
7150

# Drug_Target_55_Locus:
Not Available

# Drug_Target_55_Molecular_Weight:
Not Available

# Drug_Target_55_Name:
Plasma glutamate carboxypeptidase

# Drug_Target_55_Number_of_Residues:
0

# Drug_Target_55_PDB_ID:
Not Available

# Drug_Target_55_Pathway:
Not Available

# Drug_Target_55_Pfam_Domain_Function:
Not Available

# Drug_Target_55_Protein_Sequence:
Not Available

# Drug_Target_55_Reaction:
Not Available

# Drug_Target_55_Signals:
Not Available

# Drug_Target_55_Specific_Function:
Not Available

# Drug_Target_55_SwissProt_ID:
Q9Y646

# Drug_Target_55_SwissProt_Name:
PGCP_HUMAN

# Drug_Target_55_Synonyms:
Not Available

# Drug_Target_55_Theoretical_pI:
Not Available

# Drug_Target_55_Transmembrane_Regions:
Not Available

# Drug_Target_56_Cellular_Location:
Not Available

# Drug_Target_56_Chromosome_Location:
Not Available

# Drug_Target_56_Drug_References:
10024454	Hester G, Stark W, Moser M, Kallen J, Markovic-Housley Z, Jansonius JN: Crystal structure of phosphoserine aminotransferase from Escherichia coli at 2.3 A resolution: comparison of the unligated enzyme and a complex with alpha-methyl-l-glutamate. J Mol Biol. 1999 Feb 26;286(3):829-50.
15103612	Katsura Y, Shirouzu M, Yamaguchi H, Ishitani R, Nureki O, Kuramitsu S, Hayashi H, Yokoyama S: Crystal structure of a putative aspartate aminotransferase belonging to subgroup IV. Proteins. 2004 May 15;55(3):487-92.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_56_Essentiality:
Non-Essential

# Drug_Target_56_GenAtlas_ID:
PSAT1

# Drug_Target_56_GenBank_ID_Gene:
AF113132

# Drug_Target_56_GenBank_ID_Protein:
5326802

# Drug_Target_56_GeneCard_ID:
PSAT1

# Drug_Target_56_Gene_Name:
PSAT1

# Drug_Target_56_Gene_Sequence:
>1113 bp
ATGGACGCCCCCAGGCAGGTGGTCAACTTTGGGCCTGGTCCCGCCAAGCTGCCGCACTCA
GTGTTGTTAGAGATACAAAAGGAATTATTAGACTACAAAGGAGTTGGCATTAGTGTTCTT
GAAATGAGTCACAGGTCATCAGATTTTGCCAAGATTATTAACAATACAGAGAATCTTGTG
CGGGAATTGCTAGCTGTTCCAGACAACTATAAGGTGATTTTTCTGCAAGGAGGTGGGTGC
GGCCAGTTCAGTGCTGTCCCCTTAAACCTCATTGGCTTGAAAGCAGGAAGGTGTGCGGAC
TATGTGGTGACAGGAGCTTGGTCAGCTAAGGCCGCAGAAGAAGCCAAGAAGTTTGGGACT
ATAAATATCGTTCACCCTAAACTTGGGAGTTATACAAAAATTCCAGATCCAAGCACCTGG
AACCTCAACCCAGATGCCTCCTACGTGTATTATTGCGCAAATGAGACGGTGCATGGTGTG
GAGTTTGACTTTATACCCGATGTCAAGGGAGCAGTACTGGTTTGTGACATGTCCTCAAAC
TTCCTGTCCAAGCCAGTGGATGTTTCCAAGTTTGGTGTGATTTTTGCTGGTGCCCAGAAG
AATGTTGGCTCTGCTGGGGTCACCGTGGTGATTGTCCGTGATGACCTGCTGGGGTTTGCC
CTCCGAGAGTGCCCCTCGGTCCTGGAATACAAGGTGCAGGCTGGAAACAGCTCCTTGTAC
AACACGCCTCCATGTTTCAGCATCTACGTCATGGGCTTGGTTCTGGAGTGGATTAAAAAC
AATGGAGGTGCCGCGGCCATGGAGAAGCTTAGCTCCATCAAATCTCAAACAATTTATGAG
ATTATTGATAATTCTCAAGGATTCTACGTTTGTCCAGTGGAGCCCCAAAATAGAAGCAAG
ATGAATATTCCATTCCGCATTGGCAATGCCAAAGGAGATGATGCTTTAGAAAAAAGATTT
CTTGATAAAGCTCTTGAACTCAATATGTTGTCCTTGAAAGGGCATAGGTCTGTGGGAGGC
ATCCGGGCCTCTCTGTATAATGCTGTCACAATTGAAGACGTTCAGAAGCTGGCCGCCTTC
ATGAAAAAATTTTTGGAGATGCATCAGCTATAG

# Drug_Target_56_General_Function:
Coenzyme transport and metabolism

# Drug_Target_56_General_References:
12633500	Baek JY, Jun DY, Taub D, Kim YH: Characterization of human phosphoserine aminotransferase involved in the phosphorylated pathway of L-serine biosynthesis. Biochem J. 2003 Jul 1;373(Pt 1):191-200.

# Drug_Target_56_HGNC_ID:
HGNC:19129

# Drug_Target_56_HPRD_ID:
17918

# Drug_Target_56_ID:
665

# Drug_Target_56_Locus:
9q21.2

# Drug_Target_56_Molecular_Weight:
40423

# Drug_Target_56_Name:
Phosphoserine aminotransferase

# Drug_Target_56_Number_of_Residues:
370

# Drug_Target_56_PDB_ID:
Not Available

# Drug_Target_56_Pathway:
Not Available

# Drug_Target_56_Pfam_Domain_Function:
PF00266	Aminotran_5

# Drug_Target_56_Protein_Sequence:
>Phosphoserine aminotransferase
MDAPRQVVNFGPGPAKLPHSVLLEIQKELLDYKGVGISVLEMSHRSSDFAKIINNTENLV
RELLAVPDNYKVIFLQGGGCGQFSAVPLNLIGLKAGRCADYVVTGAWSAKAAEEAKKFGT
INIVHPKLGSYTKIPDPSTWNLNPDASYVYYCANETVHGVEFDFIPDVKGAVLVCDMSSN
FLSKPVDVSKFGVIFAGAQKNVGSAGVTVVIVRDDLLGFALRECPSVLEYKVQAGNSSLY
NTPPCFSIYVMGLVLEWIKNNGGAAAMEKLSSIKSQTIYEIIDNSQGFYVCPVEPQNRSK
MNIPFRIGNAKGDDALEKRFLDKALELNMLSLKGHRSVGGIRASLYNAVTIEDVQKLAAF
MKKFLEMHQL

# Drug_Target_56_Reaction:
(1) O-phospho-L-serine + 2-oxoglutarate = 3-phosphonooxypyruvate + L-glutamate

# Drug_Target_56_Signals:
None

# Drug_Target_56_Specific_Function:
Not Available

# Drug_Target_56_SwissProt_ID:
Q9Y617

# Drug_Target_56_SwissProt_Name:
SERC_HUMAN

# Drug_Target_56_Synonyms:
EC 2.6.1.52
PSAT

# Drug_Target_56_Theoretical_pI:
7.77

# Drug_Target_56_Transmembrane_Regions:
None

# Drug_Target_57_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_57_Chromosome_Location:
Not Available

# Drug_Target_57_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
8288265	Anagnou NP, Seuanez H, Modi W, O'Brien SJ, Papamatheakis J, Moschonas NK: Chromosomal mapping of two members of the human glutamate dehydrogenase (GLUD) gene family to chromosomes 10q22.3-q23 and Xq22-q23. Hum Hered. 1993 Nov-Dec;43(6):351-6.

# Drug_Target_57_Essentiality:
Non-Essential

# Drug_Target_57_GenAtlas_ID:
GLUD1

# Drug_Target_57_GenBank_ID_Gene:
X07674

# Drug_Target_57_GenBank_ID_Protein:
31707

# Drug_Target_57_GeneCard_ID:
GLUD1

# Drug_Target_57_Gene_Name:
GLUD1

# Drug_Target_57_Gene_Sequence:
>1677 bp
ATGTACCGCTACCTGGGCGAAGCGCTGTTGCTGTCCCGGGCCGGGCCCGCTGCCCTGGGC
TCGGCGTCCGCCGACTCGGCCGCGTTGCTGGGCTGGGCCCGGGGACAGCCCGCCGCCGCC
CCGCAGCCGGGGCTGGCATTGGCCGCCCGGCGCCACTACAGCGAGGCGGTGGCCGACCGC
GAGGACGACCCCAACTTCTTCAAGATGGTGGAGGGCTTCTTCGATCGCGGCGCCAGCATC
GTGGAGGACAAGCTGGTGGAGGACCTGAGGACCCGGGAGAGCGAGGAGCAGAAGCGGAAC
CGGGTGCGCGGCATCCTGCGGATCATCAAGCCCTGCAACCATGTGCTGAGTCTCTCCTTC
CCCATCCGGCGCGACGACGGCTCCTGGGAGGTCATCGAAGGCTACCGGGCCCAGCACAGC
CAGCACCGCACGCCCTGCAAGGGAGGTATCCGTTACAGCACTGATGTGAGTGTAGATGAA
GTAAAAGCTTTGGCTTCTCTGATGACATACAAGTGTGCAGTGGTTGATGTGCCGTTTGGG
GGTGCTAAAGCTGGTGTTAAGATCAATCCCAAGAACTATACTGATAATGAATTGGAAAAG
ATCACAAGGAGGTTCACCATGGAGCTAGCAAAAAAGGGCTTTATTGGTCCTGGCATTGAT
GTGCCTGCTCCAGACATGAGCACAGGTGAGCGGGAGATGTCCTGGATCGCTGATACCTAT
GCCAGCACCATAGGGCACTATGATATTAATGCACACGCCTGTGTTACTGGTAAACCCATC
AGCCAAGGGGGAATCCATGGACGCATCTCTGCTACTGGCCGTGGTGTCTTCCATGGGATT
GAAAATTTCATCAATGAAGCTTCTTACATGAGCATTTTAGGAATGACACCAGGGTTTGGA
GATAAAACATTTGTTGTTCAGGGATTTGGTAATGTGGGCCTACACTCTATGAGATATTTA
CATCGTTTTGGTGCTAAATGTATTGCTGTTGGTGAGTCTGATGGGAGTATATGGAATCCA
GATGGTATTGACCCAAAGGAACTGGAAGACTTCAAATTGCAACATGGGTCCATTCTGGGC
TTCCCCAAGGCAAAGCCCTATGAAGGAAGCATCTTGGAGGCCGACTGTGACATACTGATC
CCAGCTGCCAGTGAGAAGCAGTTGACCAAATCCAACGCACCCAGAGTCAAAGCCAAGATC
ATTGCTGAAGGTGCCAATGGGCCAACAACTCCAGAAGCTGACAAGATCTTCCTGGAGAGA
AACATTATGGTTATTCCAGATCTCTACTTGAATGCTGGAGGAGTGACAGTATCTTACTTT
GAGTGGCTGAAGAATCTAAATCATGTCAGCTATGGCCGTTTGACCTTCAAATATGAAAGG
GATTCTAACTACCACTTGCTCATGTCTGTTCAAGAGAGTTTAGAAAGAAAATTTGGAAAG
CATGGTGGAACTATTCCCATTGTACCCACGGCAGAGTTCCAAGACAGGATATCGGGTGCA
TCTGAGAAAGACATCGTGCACTCTGGCTTGGCATACACAATGGAGCGTTCTGCCAGGCAA
ATTATGCGCACAGCCATGAAGTATAACCTGGGATTGGACCTGAGAACAGCTGCCTATGTT
AATGCCATTGAGAAAGTCTTCAAAGTGTACAATGAAGCTGGTGTGACCTTCACATAG

# Drug_Target_57_General_Function:
Replication, recombination and repair

# Drug_Target_57_General_References:
10338089	Meissner T, Beinbrech B, Mayatepek E: Congenital hyperinsulinism: molecular basis of a heterogeneous disease. Hum Mutat. 1999;13(5):351-61.
10636977	Miki Y, Taki T, Ohura T, Kato H, Yanagisawa M, Hayashi Y: Novel missense mutations in the glutamate dehydrogenase gene in the congenital hyperinsulinism-hyperammonemia syndrome. J Pediatr. 2000 Jan;136(1):69-72.
11214910	Santer R, Kinner M, Passarge M, Superti-Furga A, Mayatepek E, Meissner T, Schneppenheim R, Schaub J: Novel missense mutations outside the allosteric domain of glutamate dehydrogenase are prevalent in European patients with the congenital hyperinsulinism-hyperammonemia syndrome. Hum Genet. 2001 Jan;108(1):66-71.
11254391	Smith TJ, Peterson PE, Schmidt T, Fang J, Stanley CA: Structures of bovine glutamate dehydrogenase complexes elucidate the mechanism of purine regulation. J Mol Biol. 2001 Mar 23;307(2):707-20.
11297618	MacMullen C, Fang J, Hsu BY, Kelly A, de Lonlay-Debeney P, Saudubray JM, Ganguly A, Smith TJ, Stanley CA: Hyperinsulinism/hyperammonemia syndrome in children with regulatory mutations in the inhibitory guanosine triphosphate-binding domain of glutamate dehydrogenase. J Clin Endocrinol Metab. 2001 Apr;86(4):1782-7.
11903050	Fang J, Hsu BY, MacMullen CM, Poncz M, Smith TJ, Stanley CA: Expression, purification and characterization of human glutamate dehydrogenase (GDH) allosteric regulatory mutations. Biochem J. 2002 Apr 1;363(Pt 1):81-7.
12054821	Smith TJ, Schmidt T, Fang J, Wu J, Siuzdak G, Stanley CA: The structure of apo human glutamate dehydrogenase details subunit communication and allostery. J Mol Biol. 2002 May 3;318(3):765-77.
12653548	Banerjee S, Schmidt T, Fang J, Stanley CA, Smith TJ: Structural studies on ADP activation of mammalian glutamate dehydrogenase and the evolution of regulation. Biochemistry. 2003 Apr 1;42(12):3446-56.
1286669	Hochstrasser DF, Frutiger S, Paquet N, Bairoch A, Ravier F, Pasquali C, Sanchez JC, Tissot JD, Bjellqvist B, Vargas R, et al.: Human liver protein map: a reference database established by microsequencing and gel comparison. Electrophoresis. 1992 Dec;13(12):992-1001.
3368458	Mavrothalassitis G, Tzimagiorgis G, Mitsialis A, Zannis V, Plaitakis A, Papamatheakis J, Moschonas N: Isolation and characterization of cDNA clones encoding human liver glutamate dehydrogenase: evidence for a small gene family. Proc Natl Acad Sci U S A. 1988 May;85(10):3494-8.
3377777	Amuro N, Yamaura M, Goto Y, Okazaki T: Molecular cloning and nucleotide sequence of the cDNA for human liver glutamate dehydrogenase precursor. Biochem Biophys Res Commun. 1988 May 16;152(3):1395-400.
3399399	Nakatani Y, Schneider M, Banner C, Freese E: Complete nucleotide sequence of human glutamate dehydrogenase cDNA. Nucleic Acids Res. 1988 Jul 11;16(13):6237.
3426581	Nakatani Y, Banner C, von Herrath M, Schneider ME, Smith HH, Freese E: Comparison of human brain and liver glutamate dehydrogenase cDNAS. Biochem Biophys Res Commun. 1987 Dec 16;149(2):405-10.
3585334	Banner C, Silverman S, Thomas JW, Lampel KA, Vitkovic L, Huie D, Wenthold RJ: Isolation of a human brain cDNA for glutamate dehydrogenase. J Neurochem. 1987 Jul;49(1):246-52.
429360	Julliard JH, Smith EL: Partial amino acid sequence of the glutamate dehydrogenase of human liver and a revision of the sequence of the bovine enzyme. J Biol Chem. 1979 May 10;254(9):3427-38.
8314555	Tzimagiorgis G, Leversha MA, Chroniary K, Goulielmos G, Sargent CA, Ferguson-Smith M, Moschonas NK: Structure and expression analysis of a member of the human glutamate dehydrogenase (GLUD) gene family mapped to chromosome 10p11.2. Hum Genet. 1993 Jun;91(5):433-8.
8486350	Michaelidis TM, Tzimagiorgis G, Moschonas NK, Papamatheakis J: The human glutamate dehydrogenase gene family: gene organization and structural characterization. Genomics. 1993 Apr;16(1):150-60.
9571255	Stanley CA, Lieu YK, Hsu BY, Burlina AB, Greenberg CR, Hopwood NJ, Perlman K, Rich BH, Zammarchi E, Poncz M: Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene. N Engl J Med. 1998 May 7;338(19):1352-7.

# Drug_Target_57_HGNC_ID:
HGNC:4335

# Drug_Target_57_HPRD_ID:
11748

# Drug_Target_57_ID:
201

# Drug_Target_57_Locus:
10q23.3

# Drug_Target_57_Molecular_Weight:
61399

# Drug_Target_57_Name:
Glutamate dehydrogenase 1, mitochondrial

# Drug_Target_57_Number_of_Residues:
558

# Drug_Target_57_PDB_ID:
1L1F

# Drug_Target_57_Pathway:
Not Available

# Drug_Target_57_Pfam_Domain_Function:
PF00208	ELFV_dehydrog
PF02812	ELFV_dehydrog_N

# Drug_Target_57_Protein_Sequence:
>Glutamate dehydrogenase 1, mitochondrial precursor
MYRYLGEALLLSRAGPAALGSASADSAALLGWARGQPAAAPQPGLALAARRHYSEAVADR
EDDPNFFKMVEGFFDRGASIVEDKLVEDLRTRESEEQKRNRVRGILRIIKPCNHVLSLSF
PIRRDDGSWEVIEGYRAQHSQHRTPCKGGIRYSTDVSVDEVKALASLMTYKCAVVDVPFG
GAKAGVKINPKNYTDNELEKITRRFTMELAKKGFIGPGIDVPAPDMSTGEREMSWIADTY
ASTIGHYDINAHACVTGKPISQGGIHGRISATGRGVFHGIENFINEASYMSILGMTPGFG
DKTFVVQGFGNVGLHSMRYLHRFGAKCIAVGESDGSIWNPDGIDPKELEDFKLQHGSILG
FPKAKPYEGSILEADCDILIPAASEKQLTKSNAPRVKAKIIAEGANGPTTPEADKIFLER
NIMVIPDLYLNAGGVTVSYFEWLKNLNHVSYGRLTFKYERDSNYHLLMSVQESLERKFGK
HGGTIPIVPTAEFQDRISGASEKDIVHSGLAYTMERSARQIMRTAMKYNLGLDLRTAAYV
NAIEKVFKVYNEAGVTFT

# Drug_Target_57_Reaction:
L-glutamate + H2O + NAD(P)+ = 2-oxoglutarate + NH3 + NAD(P)H + H+

# Drug_Target_57_Signals:
None

# Drug_Target_57_Specific_Function:
May be involved in learning and memory reactions by increasing the turnover of the excitatory neurotransmitter glutamate

# Drug_Target_57_SwissProt_ID:
P00367

# Drug_Target_57_SwissProt_Name:
DHE3_HUMAN

# Drug_Target_57_Synonyms:
EC 1.4.1.3
GDH
Glutamate dehydrogenase 1, mitochondrial precursor

# Drug_Target_57_Theoretical_pI:
7.91

# Drug_Target_57_Transmembrane_Regions:
None

# Drug_Target_58_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_58_Chromosome_Location:
Not Available

# Drug_Target_58_Drug_References:
10513575	Stensbol TB, Borre L, Johansen TN, Egebjerg J, Madsen U, Ebert B, Krogsgaard-Larsen P: Resolution, absolute stereochemistry and molecular pharmacology of the enantiomers of ATPA. Eur J Pharmacol. 1999 Sep 10;380(2-3):153-62.
13129570	Valgeirsson J, Christensen JK, Kristensen AS, Pickering DS, Nielsen B, Fischer CH, Brauner-Osborne H, Nielsen EO, Krogsgaard-Larsen P, Madsen U: Synthesis and in vitro pharmacology at AMPA and kainate preferring glutamate receptors of 4-heteroarylmethylidene glutamate analogues. Bioorg Med Chem. 2003 Oct 1;11(20):4341-9.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9254673	Sahara Y, Noro N, Iida Y, Soma K, Nakamura Y: Glutamate receptor subunits GluR5 and KA-2 are coexpressed in rat trigeminal ganglion neurons. J Neurosci. 1997 Sep 1;17(17):6611-20.

# Drug_Target_58_Essentiality:
Non-Essential

# Drug_Target_58_GenAtlas_ID:
GRIK1

# Drug_Target_58_GenBank_ID_Gene:
L19058

# Drug_Target_58_GenBank_ID_Protein:
455448

# Drug_Target_58_GeneCard_ID:
GRIK1

# Drug_Target_58_Gene_Name:
GRIK1

# Drug_Target_58_Gene_Sequence:
>2757 bp
ATGGAGCACGGCACACTCCTCGCCCAGCCCGGGCTCTGGACCAGGGACACCAGCTGGGCA
CTCCTCTATTTCCTCTGCTATATCCTCCCTCAGACCGCCCCGCAAGTACTCAGGATCGGA
GGGATTTTTGAAACAGTGGAAAATGAGCCTGTTAATGTTGAAGAATTAGCTTTCAAGTTT
GCAGTCACCAGCATTAACAGAAACCGAACCCTGATGCCTAACACCACATTAACCTATGAC
ATCCAGAGAATTAACCTTTTTGATAGTTTTGAAGCCTCGCGGAGAGCATGTGACCAGCTG
GCTCTTGGTGTGGCTGCTCTCTTTGGCCCTTCCCATAGCTCCTCCGTCAGTGCTGTGCAG
TCGATTTGCAATGCTCTCGAAGTTCCACACATACAGACCCGCTGGAAACACCCCTCGGTG
GACAACAAAGATTTGTTTTACATCAACCTTTACCCAGATTATGCAGCTATCAGCAGGGCG
ATCCTGGATCTGGTCCTCTATTACAACTGGAAAACAGTGACCGTGGTGTATGAAGACAGC
ACAGGTCTAATTCGTCTACAAGAGCTCATCAAAGCTCCCTCCAGATATAATATTAAAATC
AAAATCCGCCAGCTGCCCTCTGGGAATAAAGATGCCAAGCCTTTACTCAAGGAGATGAAG
AAAGGCAAGGAGTTCTATGTGATATTTGATTGTTCACATGAAACAGCCGCTGAAATCCTT
AAGCAGATTCTGTTCATGGGCATGATGACCGAGTACTATCACTACTTTTTCACAACCCTG
GACTTATTTGCTTTGGATCTGGAACTCTATAGGTACAGTGGCGTAAACATGACCGGGTTT
CGGCTGCTTAACATTGACAACCCTCACGTGTCATCCATCATTGAGAAGTGGTCCATGGAG
AGACTGCAGGCCCCACCCAGGCCCGAGACTGGCCTTTTGGATGGCATGATGACAACTGAA
GCGGCTCTGATGTACGATGCTGTGTACATGGTGGCCATTGCCTCGCACCGGGCATCCCAG
CTGACCGTCAGCTCCCTGCAGTGCCATAGACATAAGCCATGGCGCCTCGGACCCAGATTT
ATGAACCTGATCAAAGAGGCCCGGTGGGATGGCTTGACTGGGCATATCACCTTTAATAAA
ACCAATGGCTTGAGGAAGGATTTTGATCTGGACATTATTAGTCTCAAAGAGGAAGGAACT
GAAAAGGCTGCTGGCGAAGTGTCTAAACACTTGTATAAAGTGTGGAAGAAGATTGGGATT
TGGAATTCCAACAGTGGGCTTAACATGACGGACAGCAACAAAGACAAGTCCAGCAATATC
ACTGATTCATTGGCCAACAGAACACTCATTGTCACCACCATTCTGGAAGAACCCTATGTT
ATGTACAGGAAATCTGATAAGCCTCTATATGGAAATGACAGATTTGAAGGATATTGCCTA
GACCTGTTGAAAGAATTGTCAAACATCCTGGGTTTCATTTATGATGTTAAACTAGTTCCC
GATGGCAAATATGGGGCCCAGAATGACAAAGGGGAGTGGAACGGGATGGTTAAAGAACTC
ATAGATCACAGGGCTGACCTGGCAGTGGCTCCTCTTACCATCACCTACGTGCGGGAGAAA
GTCATTGACTTCTCCAAACCCTTCATGACCCTAGGCATCAGCATTCTCTACCGGAAGCCC
AATGGTACCAATCCAGGCGTTTTCTCCTTCCTCAACCCCCTGTCTCCAGATATTTGGATG
TATGTGCTCTTAGCCTGCTTGGGAGTCAGCTGTGTACTCTTTGTGATTGCAAGGTTTACA
CCCTACGAGTGGTATAACCCCCACCCATGCAACCCTGACTCAGACGTGGTGGAAAACAAT
TTTACTTTACTAAATAGTTTCTGGTTTGGAGTTGGAGCTCTCATGCAGCAAGGATCAGAG
CTGATGCCCAAAGCTCTATCGACCAGAATAGTTGGAGGGATATGGTGGTTTTTCACCCTA
ATCATCATTTCATCCTACACGGCCAATCTGGCTGCCTTCTTGACAGTAGAGAGAATGGAA
TCCCCCATAGATTCGGCAGATGATCTGGCAAAGCAAACCAAGATAGAATATGGGGCGGTT
AGAGATGGATCAACAATGACCTTCTTCAAGAAATCAAAAATCTCCACCTATGAGAAGATG
TGGGCTTTCATGAGCAGCAGGCAGCAGACCGCCCTGGTAAGAAACAGTGATGAGGGGATC
CAGAGAGTGCTCACCACAGACTACGCGCTGCTGATGGAGTCCACCAGCATTGAGTATGTG
ACGCAGAGAAACTGCAACCTCACTCAGATCGGGGGCCTCATTGACTCCAAAGGTTACGGA
GTGGGAACACCTATTGGTTCTCCTTACCGGGATAAAATTACTATTGCTATTCTTCAACTC
CAAGAAGAAGGGAAGCTGCATATGATGAAAGAGAAGTGGTGGCGTGGGAATGGCTGCCCC
GAGGAAGACAACAAAGAAGCCAGTGCCCTGGGAGTGGAAAATATTGGAGGCATCTTCATT
GTTCTGGCTGCCGGACTGGTCCTTTCTGTATTTGTAGCTATTGGAGAATTCATATACAAA
TCACGGAAGAATAATGATATTGAACAGGCTTTTTGTTTCTTTTATGGACTGCAATGTAAG
CAAACCCATCCAACCAACTCCACTTCTGGAACTACTTTATCTACGGATTTAGAATGTGGT
AAATTAATTCGAGAGGAGAGAGGGATTCGAAAACAGTCCTCAGTTCATACTGTGTAA

# Drug_Target_58_General_Function:
Involved in ionotropic glutamate receptor activity

# Drug_Target_58_General_References:
11702055	Shibata H, Joo A, Fujii Y, Tani A, Makino C, Hirata N, Kikuta R, Ninomiya H, Tashiro N, Fukumaki Y: Association study of polymorphisms in the GluR5 kainate receptor gene (GRIK1) with schizophrenia. Psychiatr Genet. 2001 Sep;11(3):139-44.
7696618	Nutt SL, Kamboj RK: RNA editing of human kainate receptor subunits. Neuroreport. 1994 Dec 20;5(18):2625-9.
8260617	Gregor P, O'Hara BF, Yang X, Uhl GR: Expression and novel subunit isoforms of glutamate receptor genes GluR5 and GluR6. Neuroreport. 1993 Sep 30;4(12):1343-6.
8589992	Korczak B, Nutt SL, Fletcher EJ, Hoo KH, Elliott CE, Rampersad V, McWhinnie EA, Kamboj RK: cDNA cloning and functional properties of human glutamate receptor EAA3 (GluR5) in homomeric and heteromeric configuration. Receptors Channels. 1995;3(1):41-9.

# Drug_Target_58_HGNC_ID:
HGNC:4579

# Drug_Target_58_HPRD_ID:
00693

# Drug_Target_58_ID:
382

# Drug_Target_58_Locus:
Not Available

# Drug_Target_58_Molecular_Weight:
103982

# Drug_Target_58_Name:
Glutamate receptor, ionotropic kainate 1

# Drug_Target_58_Number_of_Residues:
918

# Drug_Target_58_PDB_ID:
1YAE

# Drug_Target_58_Pathway:
Not Available

# Drug_Target_58_Pfam_Domain_Function:
PF00060	Lig_chan
PF01094	ANF_receptor

# Drug_Target_58_Protein_Sequence:
>Glutamate receptor, ionotropic kainate 1 precursor
MEHGTLLAQPGLWTRDTSWALLYFLCYILPQTAPQVLRIGGIFETVENEPVNVEELAFKF
AVTSINRNRTLMPNTTLTYDIQRINLFDSFEASRRACDQLALGVAALFGPSHSSSVSAVQ
SICNALEVPHIQTRWKHPSVDNKDLFYINLYPDYAAISRAILDLVLYYNWKTVTVVYEDS
TGLIRLQELIKAPSRYNIKIKIRQLPSGNKDAKPLLKEMKKGKEFYVIFDCSHETAAEIL
KQILFMGMMTEYYHYFFTTLDLFALDLELYRYSGVNMTGFRLLNIDNPHVSSIIEKWSME
RLQAPPRPETGLLDGMMTTEAALMYDAVYMVAIASHRASQLTVSSLQCHRHKPWRLGPRF
MNLIKEARWDGLTGHITFNKTNGLRKDFDLDIISLKEEGTEKAAGEVSKHLYKVWKKIGI
WNSNSGLNMTDSNKDKSSNITDSLANRTLIVTTILEEPYVMYRKSDKPLYGNDRFEGYCL
DLLKELSNILGFIYDVKLVPDGKYGAQNDKGEWNGMVKELIDHRADLAVAPLTITYVREK
VIDFSKPFMTLGISILYRKPNGTNPGVFSFLNPLSPDIWMYVLLACLGVSCVLFVIARFT
PYEWYNPHPCNPDSDVVENNFTLLNSFWFGVGALMQQGSELMPKALSTRIVGGIWWFFTL
IIISSYTANLAAFLTVERMESPIDSADDLAKQTKIEYGAVRDGSTMTFFKKSKISTYEKM
WAFMSSRQQTALVRNSDEGIQRVLTTDYALLMESTSIEYVTQRNCNLTQIGGLIDSKGYG
VGTPIGSPYRDKITIAILQLQEEGKLHMMKEKWWRGNGCPEEDNKEASALGVENIGGIFI
VLAAGLVLSVFVAIGEFIYKSRKNNDIEQAFCFFYGLQCKQTHPTNSTSGTTLSTDLECG
KLIREERGIRKQSSVHTV

# Drug_Target_58_Reaction:
Not Available

# Drug_Target_58_Signals:
1-30

# Drug_Target_58_Specific_Function:
L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists. May be involved in the transmission of light information from the retina to the hypothalamus. This receptor binds domoate > kainate > L-glutamate = quisqualate > CNQX = DNQX > AMPA > dihydrokainate > NMDA

# Drug_Target_58_SwissProt_ID:
P39086

# Drug_Target_58_SwissProt_Name:
GRIK1_HUMAN

# Drug_Target_58_Synonyms:
EAA3
Excitatory amino acid receptor 3
GluR-5
GluR5
Glutamate receptor 5
Glutamate receptor, ionotropic kainate 1 precursor

# Drug_Target_58_Theoretical_pI:
7.09

# Drug_Target_58_Transmembrane_Regions:
577-597
616-636
654-674
835-855

# Drug_Target_59_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_59_Chromosome_Location:
Not Available

# Drug_Target_59_Drug_References:
1279377	Stein E, Cox JA, Seeburg PH, Verdoorn TA: Complex pharmacological properties of recombinant alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor subtypes. Mol Pharmacol. 1992 Nov;42(5):864-71.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
7679210	Henley JM, Jenkins R, Hunt SP: Localisation of glutamate receptor binding sites and mRNAs to the dorsal horn of the rat spinal cord. Neuropharmacology. 1993 Jan;32(1):37-41.
7838123	Li F, Owens N, Verdoorn TA: Functional effects of mutations in the putative agonist binding region of recombinant alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Mol Pharmacol. 1995 Jan;47(1):148-54.

# Drug_Target_59_Essentiality:
Non-Essential

# Drug_Target_59_GenAtlas_ID:
GRIA1

# Drug_Target_59_GenBank_ID_Gene:
M64752

# Drug_Target_59_GenBank_ID_Protein:
183281

# Drug_Target_59_GeneCard_ID:
GRIA1

# Drug_Target_59_Gene_Name:
GRIA1

# Drug_Target_59_Gene_Sequence:
>2724 bp
ATGCAGCACATTTTTGCCTTCTTCTGCACCGGTTTCCTAGGCGCGGTAGTAGGTGCCAAT
TTCCCCAACAATATCCAGATCGGGGGATTATTTCCAAACCAGCAGTCACAGGAACATGCT
GCTTTTAGATTTGCTTTGTCGCAACTCACAGAGCCCCCGAAGCTGCTCCCCCAGATTGAT
ATTGTGAACATCAGCGACAGCTTTGAGATGACCTATAGATTCTGTTCCCAGTTCTCCAAA
GGAGTCTATGCCATCTTTGGGTTTTATGAACGTAGGACTGTCAACATGCTGACCTCCTTT
TGTGGGGCCCTCCACGTCTGCTTCATTACGCCGAGCTTTCCCGTTGATACATCCAATCAG
TTTGTCCTTCAGCTGCGCCCTGAACTGCAGGATGCCCTCATCAGCATCATTGACCATTAC
AAGTGGCAGAAATTTGTCTACATTTATGATGCCGACCGGGGCTTATCCGTCCTGCAGAAA
GTCCTGGATACAGCTGCTGAGAAGAACTGGCAGGTGACAGCAGTCAACATCTTGACAACC
ACAGAGGAGGGATACCGGATGCTCTTTCAGGACCTGGAGAAGAAAAAGGAGCGGCTGGTG
GTGGTGGACTGTGAATCAGAACGCCTCAATGCTATCTTGGGCCAGATTATAAAGCTAGAG
AAGAATGGCATCGGCTACCACTACATTCTTGCAAATCTGGGCTTCATGGACATTGACTTA
AACAAATTCAAGGAGAGTGGCGCCAATGTGACAGGTTTCCAGCTGGTGAACTACACAGAC
ACTATTCCGGCCAAGATCATGCAGCAGTGGAAGAATAGTGATGCTCGAGACCACACACGG
GTGGACTGGAAGAGACCCAAGTACACCTCTGCGCTCACCTACGATGGGGTGAAGGTGATG
GCTGAGGCTTTCCAGAGCCTGCGGAGGCAGAGAATTGATATATCTCGCCGGGGGAATGCT
GGGGATTGTCTGGCTAACCCAGCTGTTCCCTGGGGCCAAGGGATCGACATCCAGAGAGCT
CTGCAGCAGGTGCGATTTGAAGGTTTAACAGGAAACGTGCAGTTTAATGAGAAAGGACGC
CGGACCAACTACACGCTCCACGTGATTGAAATGAAACATGACGGCATCCGAAAGATTGGT
TACTGGAATGAAGATGATAAGTTTGTCCCTGCAGCCACCGATGCCCAAGCTGGGGGCGAT
AATTCAAGTGTTCAGAACAGAACATACATCGTCACAACAATCCTAGAAGATCCTTATGTG
ATGCTCAAGAAGAACGCCAATCAGTTTGAGGGCAATGACCGTTACGAGGGCTACTGTGTA
GAGCTGGCGGCAGAGATTGCCAAGCACGTGGGCTACTCCTACCGTCTGGAGATTGTCAGT
GATGGAAAATACGGAGCCCGAGACCCTGACACGAAGGCCTGGAATGGCATGGTGGGAGAG
CTGGTCTATGGAAGAGCAGATGTGGCTGTGGCTCCCTTAACTATCACTTTGGTCCGGGAA
GAAGTTATAGATTTCTCCAAACCATTTATGAGTTTGGGGATCTCCATCATGATTAAAAAA
CCACAGAAATCCAAGCCGGGTGTCTTCTCCTTCCTTGATCCTTTGGCTTATGAGATTTGG
ATGTGCATTGTTTTTGCCTACATTGGAGTGAGTGTTGTCCTCTTCCTGGTCAGCCGCTTC
AGTCCCTATGAATGGCACAGTGAAGAGTTTGAGGAAGGACGGGACCAGACAACCAGTGAC
CAGTCCAATGAGTTTGGGATATTCAACAGTTTGTGGTTCTCCCTGGGAGCCTTCATGCAG
CAAGGATGTGACATTTCTCCCAGGTCCCTGTCTGGTCGCATCGTTGGTGGCGTCTGGTGG
TTCTTCACCTTAATCATCATCTCCTCATATACAGCCAATCTGGCCGCCTTCCTGACCGTG
GAGAGGATGGTGTCTCCCATTGAGAGTGCAGAGGACCTAGCGAAGCAGACAGAAATTGCC
TACGGGACGCTGGAAGCAGGATCTACTAAGGAGTTCTTCAGGAGGTCTAAAATTGCTGTG
TTTGAGAAGATGTGGACATACATGAAGTCAGCAGAGCCATCAGTTTTTGTGCGGACCACA
GAGGAGGGGATGATTCGAGTGAGGAAATCCAAAGGCAAATATGCCTACCTCCTGGAGTCC
ACCATGAATGAGTACATTGAGCAGCGGAAACCCTGTGACACCATGAAGGTGGGAGGTAAC
TTGGATTCCAAAGGCTATGGCATTGCAACACCCAAGGGGTCTGCCCTGAGAGGTCCCGTA
AACCTAGCGGTTTTGAAACTCAGTGAGCAAGGCGTCTTAGACAAGCTGAAAAGCAAATGG
TGGTACGATAAAGGGGAATGTGGAAGCAAGGACTCCGGAAGTAAGGACAAGACAAGCGCT
CTGAGCCTCAGCAATGTGGCAGGCGTGTTCTACATCCTGATCGGAGGACTTGGACTAGCC
ATGCTGGTTGCCTTAATCGAGTTCTGCTACAAATCCCGTAGTGAATCCAAGCGGATGAAG
GGTTTTTGTTTGATCCCACAGCAATCCATCAACGAAGCCATACGGACATCGACCCTCCCC
CGCAACAGCGCGGGCACGGCACCGAGCAGCGGCGGCAGTGGAGAGAATGGTCGGGTGGTC
AGCCATGACTTCCCCAAGTCCATGCAATCGATTCCTTGCATGAGCCACAGTTCAGGGATG
CCCTTGGGAGCCACGGGATTGTAA

# Drug_Target_59_General_Function:
Involved in ionotropic glutamate receptor activity

# Drug_Target_59_General_References:
1311100	Sun W, Ferrer-Montiel AV, Schinder AF, McPherson JP, Evans GA, Montal M: Molecular cloning, chromosomal mapping, and functional expression of human brain glutamate receptors. Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1443-7.
1320959	Potier MC, Spillantini MG, Carter NP: The human glutamate receptor cDNA GluR1: cloning, sequencing, expression and localization to chromosome 5. DNA Seq. 1992;2(4):211-8.
1652753	Puckett C, Gomez CM, Korenberg JR, Tung H, Meier TJ, Chen XN, Hood L: Molecular cloning and chromosomal localization of one of the human glutamate receptor genes. Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7557-61.

# Drug_Target_59_HGNC_ID:
HGNC:4571

# Drug_Target_59_HPRD_ID:
00695

# Drug_Target_59_ID:
705

# Drug_Target_59_Locus:
5q33|5q31.1

# Drug_Target_59_Molecular_Weight:
101507

# Drug_Target_59_Name:
Glutamate receptor 1

# Drug_Target_59_Number_of_Residues:
906

# Drug_Target_59_PDB_ID:
1WVJ

# Drug_Target_59_Pathway:
Not Available

# Drug_Target_59_Pfam_Domain_Function:
PF00060	Lig_chan
PF01094	ANF_receptor

# Drug_Target_59_Protein_Sequence:
>Glutamate receptor 1 precursor
MQHIFAFFCTGFLGAVVGANFPNNIQIGGLFPNQQSQEHAAFRFALSQLTEPPKLLPQID
IVNISDSFEMTYRFCSQFSKGVYAIFGFYERRTVNMLTSFCGALHVCFITPSFPVDTSNQ
FVLQLRPELQDALISIIDHYKWQKFVYIYDADRGLSVLQKVLDTAAEKNWQVTAVNILTT
TEEGYRMLFQDLEKKKERLVVVDCESERLNAILGQIIKLEKNGIGYHYILANLGFMDIDL
NKFKESGANVTGFQLVNYTDTIPAKIMQQWKNSDARDHTRVDWKRPKYTSALTYDGVKVM
AEAFQSLRRQRIDISRRGNAGDCLANPAVPWGQGIDIQRALQQVRFEGLTGNVQFNEKGR
RTNYTLHVIEMKHDGIRKIGYWNEDDKFVPAATDAQAGGDNSSVQNRTYIVTTILEDPYV
MLKKNANQFEGNDRYEGYCVELAAEIAKHVGYSYRLEIVSDGKYGARDPDTKAWNGMVGE
LVYGRADVAVAPLTITLVREEVIDFSKPFMSLGISIMIKKPQKSKPGVFSFLDPLAYEIW
MCIVFAYIGVSVVLFLVSRFSPYEWHSEEFEEGRDQTTSDQSNEFGIFNSLWFSLGAFMQ
QGCDISPRSLSGRIVGGVWWFFTLIIISSYTANLAAFLTVERMVSPIESAEDLAKQTEIA
YGTLEAGSTKEFFRRSKIAVFEKMWTYMKSAEPSVFVRTTEEGMIRVRKSKGKYAYLLES
TMNEYIEQRKPCDTMKVGGNLDSKGYGIATPKGSALRNPVNLAVLKLNEQGLLDKLKNKW
WYDKGECGSGGGDSKDKTSALSLSNVAGVFYILIGGLGLAMLVALIEFCYKSRSESKRMK
GFCLIPQQSINEAIRTSTLPRNSGAGASSGGSGENGRVVSHDFPKSMQSIPCMSHSSGMP
LGATGL

# Drug_Target_59_Reaction:
Not Available

# Drug_Target_59_Signals:
1-18

# Drug_Target_59_Specific_Function:
L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists

# Drug_Target_59_SwissProt_ID:
P42261

# Drug_Target_59_SwissProt_Name:
GRIA1_HUMAN

# Drug_Target_59_Synonyms:
AMPA-selective glutamate receptor 1
GluR-1
GluR-A
GluR-K1
Glutamate receptor 1 precursor
Glutamate receptor ionotropic, AMPA 1

# Drug_Target_59_Theoretical_pI:
7.78

# Drug_Target_59_Transmembrane_Regions:
537-557
585-605
618-638
806-826

# Drug_Target_5_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
17360958	Suzuki G, Kimura T, Satow A, Kaneko N, Fukuda J, Hikichi H, Sakai N, Maehara S, Kawagoe-Takaki H, Hata M, Azuma T, Ito S, Kawamoto H, Ohta H: Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N- methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC). J Pharmacol Exp Ther. 2007 Jun;321(3):1144-53. Epub 2007 Mar 14.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
GRM7

# Drug_Target_5_GenBank_ID_Gene:
X94552

# Drug_Target_5_GenBank_ID_Protein:
1370111

# Drug_Target_5_GeneCard_ID:
GRM7

# Drug_Target_5_Gene_Name:
GRM7

# Drug_Target_5_Gene_Sequence:
>2748 bp
ATGGTCCAGCTGAGGAAGCTGCTCCGCGTCCTGACTTTGATGAAGTTCCCCTGCTGCGTG
CTGGAGGTGCTCCTGTGCGCGCTGGCGGCGGCGGCGCGCGGCCAGGAGATGTACGCCCCG
CACTCAATCCGGATCGAGGGGGACGTCACCCTCGGGGGGCTGTTCCCCGTGCACGCCAAG
GGTCCCAGCGGAGTGCCCTGCGGCGACATCAAGAGGGAAAACGGGATCCACAGGCTGGAA
GCGATGCTCTACGCCCTGGACCAGATCAACAGTGATCCCAACCTACTGCCCAACGTGACG
CTGGGCGCGCGGATCCTGGACACTTGTTCCAGGGACACTTACGCGCTCGAACAGTCGCTT
ACTTTCGTCCAGGCGCTCATCCAGAAGGACACCTCCGACGTGCGCTGCACCAACGGCGAA
CCGCCGGTTTTCGTCAAGCCGGAGAAAGTAGTTGGAGTGATTGGGGCTTCGGGGAGTTCG
GTCTCCATCATGGTAGCCAACATCCTGAGGCTCTTCCAGATCCCCCAGATTAGTTATGCA
TCAACGGCACCCGAGCTAAGTGATGACCGGCGCTATGACTTCTTCTCTCGCGTGGTGCCA
CCCGATTCCTTCCAAGCCCAGGCCATGGTAGACATTGTAAAGGCCCTAGGCTGGAATTAT
GTGTCTACCCTCGCATCGGAAGGAAGTTATGGAGAGAAAGGTGTGGAGTCCTTCACGCAG
ATTTCCAAAGAGGCAGGTGGACTCTGCATTGCCCAGTCCGTGAGAATCCCCCAGGAACGC
AAAGACAGGACCATTGACTTTGATAGAATTATCAAACAGCTCCTGGACACCCCCAACTCC
AGGGCCGTCGTGATTTTTGCCAACGATGAGGATATAAAGCAGATCCTTGCAGCAGCCAAA
AGAGCTGACCAAGTTGGCCATTTTCTTTGGGTGGGATCAGACAGCTGGGGATCCAAAATA
AACCCACTGCACCAGCATGAAGATATCGCAGAAGGGGCCATCACCATTCAGCCCAAGCGA
GCCACGGTGGAAGGGTTTGATGCCTACTTTACGTCCCGTACACTTGAAAACAACAGAAGA
AATGTATGGTTTGCCGAATACTGGGAGGAAAACTTCAACTGCAAGTTGACGATTAGTGGG
TCAAAAAAAGAAGACACAGATCGCAAATGCACAGGACAGGAGAGAATTGGAAAAGATTCC
AACTATGAGCAGGAGGGTAAAGTCCAGTTCGTGATTGACGCAGTCTATGCTATGGCTCAC
GCCCTTCACCACATGAACAAGGATCTCTGTGCTGACTACCGGGGTGTCTGCCCAGAGATG
GAGCAAGCTGGAGGCAAGAAGTTGCTGAAGTATATACGCAATGTTAATTTCAATGGTAGT
GCTGGCACTCCAGTGATGTTTAACAAGAACGGGGATGCACCTGGGCGTTATGACATCTTT
CAGTACCAGACCACAAACACCAGCAACCCGGGTTACCGTCTGATCGGGCAGTGGACAGAC
GAACTTCAGCTCAATATAGAAGACATGCAGTGGGGTAAAGGAGTCCGAGAGATACCCGCC
TCAGTGTGCACACTACCATGTAAGCCAGGACAGAGAAAGAAGACACAGAAAGGAACTCCT
TGCTGTTGGACCTGTGAGCCTTGCGATGGTTACCAGTACCAGTTTGATGAGATGACATGC
CAGCATTGCCCCTATGACCAGAGGCCCAATGAAAATCGAACCGGATGCCAGGATATTCCC
ATCATCAAACTGGAGTGGCACTCCCCCTGGGCTGTGATTCCTGTCTTCCTGGCAATGTTG
GGGATCATTGCCACCATCTTTGTCATGGCCACTTTCATCCGCTACAATGACACGCCCATT
GTCCGGGCATCTGGGCGGGAACTCAGCTATGTTCTTTTGACGGGCATCTTTCTTTGCTAC
ATCATCACTTTCCTGATGATTGCCAAACCAGATGTGGCAGTGTGTTCTTTCCGGCGAGTT
TTCTTGGGCTTGGGTATGTGCATCAGTTATGCAGCCCTCTTGACGAAAACAAATCGGATT
TATCGCATATTTGAGCAGGGCAAGAAATCAGTAACAGCTCCCAGACTCATAAGCCCAACA
TCACAACTGGCAATCACTTCCAGTTTAATATCAGTTCAGCTTCTAGGGGTGTTCATTTGG
TTTGGTGTTGATCCACCCAACATCATCATAGACTACGATGAACACAAGACAATGAACCCT
GAGCAAGCCAGAGGGGTTCTCAAGTGTGACATTACAGATCTCCAAATCATTTGCTCCTTG
GGATATAGCATTCTTCTCATGGTCACATGTACTGTGTATGCCATCAAGACTCGGGGTGTA
CCCGAGAATTTTAACGAAGCCAAGCCCATTGGATTCACTATGTACACGACATGTATAGTA
TGGCTTGCCTTCATTCCAATTTTTTTTGGCACCGCTCAATCAGCGGAAAAGCTCTACATA
CAAACTACCACGCTTACAATCTCCATGAACCTAAGTGCATCAGTGGCGCTGGGGATGCTA
TACATGCCGAAAGTGTACATCATCATTTTCCACCCTGAACTCAATGTCCAGAAACGGAAG
CGAAGCTTCAAGGCGGTAGTCACAGCAGCCACCATGTCATCGAGGCTGTCACACAAACCC
AGTGACAGACCCAACGGTGAGGCAAAGACCGAGCTCTGTGAAAACGTAGACCCAAACAGC
CCTGCTGCAAAAAAGAAGTATGTCAGTTATAATAACCTGGTTATCTAA

# Drug_Target_5_General_Function:
Amino acid transport and metabolism

# Drug_Target_5_General_References:
11163549	Bolonna AA, Kerwin RW, Munro J, Arranz MJ, Makoff AJ: Polymorphisms in the genes for mGluR types 7 and 8: association studies with schizophrenia. Schizophr Res. 2001 Jan 15;47(1):99-103.
12052533	Schulz HL, Stohr H, Weber BH: Characterization of three novel isoforms of the metabotrobic glutamate receptor 7 (GRM7). Neurosci Lett. 2002 Jun 21;326(1):37-40.
8840028	Makoff A, Pilling C, Harrington K, Emson P: Human metabotropic glutamate receptor type 7: molecular cloning and mRNA distribution in the CNS. Brain Res Mol Brain Res. 1996 Aug;40(1):165-70.
9473604	Wu S, Wright RA, Rockey PK, Burgett SG, Arnold JS, Rosteck PR Jr, Johnson BG, Schoepp DD, Belagaje RM: Group III human metabotropic glutamate receptors 4, 7 and 8: molecular cloning, functional expression, and comparison of pharmacological properties in RGT cells. Brain Res Mol Brain Res. 1998 Jan;53(1-2):88-97.

# Drug_Target_5_HGNC_ID:
HGNC:4599

# Drug_Target_5_HPRD_ID:
04979

# Drug_Target_5_ID:
926

# Drug_Target_5_Locus:
3p26.1-p25.1

# Drug_Target_5_Molecular_Weight:
102252

# Drug_Target_5_Name:
Metabotropic glutamate receptor 7

# Drug_Target_5_Number_of_Residues:
915

# Drug_Target_5_PDB_ID:
Not Available

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00003	7tm_3
PF01094	ANF_receptor
PF07562	NCD3G

# Drug_Target_5_Protein_Sequence:
>Metabotropic glutamate receptor 7 precursor
MVQLRKLLRVLTLMKFPCCVLEVLLCALAAAARGQEMYAPHSIRIEGDVTLGGLFPVHAK
GPSGVPCGDIKRENGIHRLEAMLYALDQINSDPNLLPNVTLGARILDTCSRDTYALEQSL
TFVQALIQKDTSDVRCTNGEPPVFVKPEKVVGVIGASGSSVSIMVANILRLFQIPQISYA
STAPELSDDRRYDFFSRVVPPDSFQAQAMVDIVKALGWNYVSTLASEGSYGEKGVESFTQ
ISKEAGGLCIAQSVRIPQERKDRTIDFDRIIKQLLDTPNSRAVVIFANDEDIKQILAAAK
RADQVGHFLWVGSDSWGSKINPLHQHEDIAEGAITIQPKRATVEGFDAYFTSRTLENNRR
NVWFAEYWEENFNCKLTISGSKKEDTDRKCTGQERIGKDSNYEQEGKVQFVIDAVYAMAH
ALHHMNKDLCADYRGVCPEMEQAGGKKLLKYIRNVNFNGSAGTPVMFNKNGDAPGRYDIF
QYQTTNTSNPGYRLIGQWTDELQLNIEDMQWGKGVREIPASVCTLPCKPGQRKKTQKGTP
CCWTCEPCDGYQYQFDEMTCQHCPYDQRPNENRTGCQDIPIIKLEWHSPWAVIPVFLAML
GIIATIFVMATFIRYNDTPIVRASGRELSYVLLTGIFLCYIITFLMIAKPDVAVCSFRRV
FLGLGMCISYAALLTKTNRIYRIFEQGKKSVTAPRLISPTSQLAITSSLISVQLLGVFIW
FGVDPPNIIIDYDEHKTMNPEQARGVLKCDITDLQIICSLGYSILLMVTCTVYAIKTRGV
PENFNEAKPIGFTMYTTCIVWLAFIPIFFGTAQSAEKLYIQTTTLTISMNLSASVALGML
YMPKVYIIIFHPELNVQKRKRSFKAVVTAATMSSRLSHKPSDRPNGEAKTELCENVDPNS
PAAKKKYVSYNNLVI

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
1-34

# Drug_Target_5_Specific_Function:
Receptor for glutamate. The activity of this receptor is mediated by a G-protein that inhibits adenylate cyclase activity

# Drug_Target_5_SwissProt_ID:
Q14831

# Drug_Target_5_SwissProt_Name:
GRM7_HUMAN

# Drug_Target_5_Synonyms:
Metabotropic glutamate receptor 7 precursor
mGluR7

# Drug_Target_5_Theoretical_pI:
7.94

# Drug_Target_5_Transmembrane_Regions:
591-615
628-648
655-675
703-723
754-775
789-810
826-850

# Drug_Target_60_Cellular_Location:
Not Available

# Drug_Target_60_Chromosome_Location:
Not Available

# Drug_Target_60_Drug_References:
17000861	Giordano G, White CC, McConnachie LA, Fernandez C, Kavanagh TJ, Costa LG: Neurotoxicity of domoic Acid in cerebellar granule neurons in a genetic model of glutathione deficiency. Mol Pharmacol. 2006 Dec;70(6):2116-26. Epub 2006 Sep 25.

# Drug_Target_60_Essentiality:
Non-Essential

# Drug_Target_60_GenAtlas_ID:
GCLM

# Drug_Target_60_GenBank_ID_Gene:
L35546

# Drug_Target_60_GenBank_ID_Protein:
530137

# Drug_Target_60_GeneCard_ID:
GCLM

# Drug_Target_60_Gene_Name:
GCLM

# Drug_Target_60_Gene_Sequence:
>825 bp
ATGGGCACCGACAGCCGCGCGGCCAAGGCGCTCCTGGCGCGGGCCCGCACCCTGCACCTG
CAGACGGGGAACCTGCTGAACTGGGGCCGCCTGCGGAAGAAGTGCCCGTCCACGCACAGC
GAGGAGCTTCATGATTGTATCCAAAAAACCTTGAATGAATGGAGTTCCCAAATCAACCCA
GATTTGGTCAGGGAGTTTCCAGATGTCTTGGAATGCACTGTATCTCATGCAGTAGAAAAG
ATAAATCCTGATGAAAGAGAAGAAATGAAAGTTTCTGCAAAACTGTTCATTGTAGAATCA
AACTCTTCATCATCAACTAGAAGTGCAGTTGACATGGCCTGTTCAGTCCTTGGAGTTGCA
CAGCTGGATTCTGTGATCATTGCTTCACCTCCTATTGAAGATGGAGTTAATCTTTCCTTG
GAGCATTTACAGCCTTACTGGGAGGAATTAGAAAACTTAGTTCAGAGCAAAAAGATTGTT
GCCATAGGTACCTCTGATCTAGACAAAACACAGTTGGAACAGCTGTATCAGTGGGCACAG
GTAAAACCAAATAGTAACCAAGTTAATCTTGCCTCCTGCTGTGTGATGCCACCAGATTTG
ACTGCATTTGCTAAACAATTTGACATACAGCTGTTGACTCACAATGATCCAAAAGAACTG
CTTTCTGAAGCAAGTTTCCAAGAAGCTCTTCAGGAAAGCATTCCTGACATTCAAGCGCAC
GAGTGGGTGCCGCTGTGGCTACTGCGGTATTCGGTCATTGTGAAAAGTAGAGGAATTATC
AAATCAAAAGGCTACATTTTACAAGCTAAAAGAAGGGGTTCTTAA

# Drug_Target_60_General_Function:
Involved in glutamate-cysteine ligase catalytic subunit binding

# Drug_Target_60_General_References:
7826375	Gipp JJ, Bailey HH, Mulcahy RT: Cloning and sequencing of the cDNA for the light subunit of human liver gamma-glutamylcysteine synthetase and relative mRNA levels for heavy and light subunits in human normal tissues. Biochem Biophys Res Commun. 1995 Jan 17;206(2):584-9.

# Drug_Target_60_HGNC_ID:
HGNC:4312

# Drug_Target_60_HPRD_ID:
03106

# Drug_Target_60_ID:
668

# Drug_Target_60_Locus:
1p22.1

# Drug_Target_60_Molecular_Weight:
30727

# Drug_Target_60_Name:
Glutamate--cysteine ligase regulatory subunit

# Drug_Target_60_Number_of_Residues:
274

# Drug_Target_60_PDB_ID:
Not Available

# Drug_Target_60_Pathway:
Not Available

# Drug_Target_60_Pfam_Domain_Function:
Not Available

# Drug_Target_60_Protein_Sequence:
>Glutamate--cysteine ligase regulatory subunit
MGTDSRAAKALLARARTLHLQTGNLLNWGRLRKKCPSTHSEELHDCIQKTLNEWSSQINP
DLVREFPDVLECTVSHAVEKINPDEREEMKVSAKLFIVESNSSSSTRSAVDMACSVLGVA
QLDSVIIASPPIEDGVNLSLEHLQPYWEELENLVQSKKIVAIGTSDLDKTQLEQLYQWAQ
VKPNSNQVNLASCCVMPPDLTAFAKQFDIQLLTHNDPKELLSEASFQEALQESIPDIQAH
EWVPLWLLRYSVIVKSRGIIKSKGYILQAKRRGS

# Drug_Target_60_Reaction:
ATP + L-glutamate + L-cysteine = ADP + phosphate + gamma-L-glutamyl-L-cysteine

# Drug_Target_60_Signals:
None

# Drug_Target_60_Specific_Function:
Not Available

# Drug_Target_60_SwissProt_ID:
P48507

# Drug_Target_60_SwissProt_Name:
GSH0_HUMAN

# Drug_Target_60_Synonyms:
EC 6.3.2.2
GCS light chain
Gamma- glutamylcysteine synthetase
Gamma-ECS
Glutamate--cysteine ligase modifier subunit

# Drug_Target_60_Theoretical_pI:
5.91

# Drug_Target_60_Transmembrane_Regions:
None

# Drug_Target_61_Cellular_Location:
Cell membrane
single-pass type II membrane protein. Isoform PSMA':Cytoplasm

# Drug_Target_61_Chromosome_Location:
Not Available

# Drug_Target_61_Drug_References:
11916141	Rodriguez CE, Lu H, Martinez AR, Hu Y, Brunelle A, Berkman CE: Inhibition of glutamate carboxypeptidase II by phosphonamidothionate derivatives of glutamic acid. J Enzyme Inhib. 2001 Oct;16(4):359-65.
15336276	Maung J, Mallari JP, Girtsman TA, Wu LY, Rowley JA, Santiago NM, Brunelle AN, Berkman CE: Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates. Bioorg Med Chem. 2004 Sep 15;12(18):4969-79.
15837926	Davis MI, Bennett MJ, Thomas LM, Bjorkman PJ: Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):5981-6. Epub 2005 Apr 18.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_61_Essentiality:
Non-Essential

# Drug_Target_61_GenAtlas_ID:
FOLH1

# Drug_Target_61_GenBank_ID_Gene:
M99487

# Drug_Target_61_GenBank_ID_Protein:
190664

# Drug_Target_61_GeneCard_ID:
FOLH1

# Drug_Target_61_Gene_Name:
FOLH1

# Drug_Target_61_Gene_Sequence:
>2253 bp
ATGTGGAATCTCCTTCACGAAACCGACTCGGCTGTGGCCACCGCGCGCCGCCCGCGCTGG
CTGTGCGCTGGGGCGCTGGTGCTGGCGGGTGGCTTCTTTCTCCTCGGCTTCCTCTTCGGG
TGGTTTATAAAATCCTCCAATGAAGCTACTAACATTACTCCAAAGCATAATATGAAAGCA
TTTTTGGATGAATTGAAAGCTGAGAACATCAAGAAGTTCTTATATAATTTTACACAGATA
CCACATTTAGCAGGAACAGAACAAAACTTTCAGCTTGCAAAGCAAATTCAATCCCAGTGG
AAAGAATTTGGCCTGGATTCTGTTGAGCTAGCACATTATGATGTCCTGTTGTCCTACCCA
AATAAGACTCATCCCAACTACATCTCAATAATTAATGAAGATGGAAATGAGATTTTCAAC
ACATCATTATTTGAACCACCTCCTCCAGGATATGAAAATGTTTCGGATATTGTACCACCT
TTCAGTGCTTTCTCTCCTCAAGGAATGCCAGAGGGCGATCTAGTGTATGTTAACTATGCA
CGAACTGAAGACTTCTTTAAATTGGAACGGGACATGAAAATCAATTGCTCTGGGAAAATT
GTAATTGCCAGATATGGGAAAGTTTTCAGAGGAAATAAGGTTAAAAATGCCCAGCTGGCA
GGGGCCAAAGGAGTCATTCTCTACTCCGACCCTGCTGACTACTTTGCTCCTGGGGTGAAG
TCCTATCCAGATGGTTGGAATCTTCCTGGAGGTGGTGTCCAGCGTGGAAATATCCTAAAT
CTGAATGGTGCAGGAGACCCTCTCACACCAGGTTACCCAGCAAATGAATATGCTTATAGG
CGTGGAATTGCAGAGGCTGTTGGTCTTCCAAGTATTCCTGTTCATCCAATTGGATACTAT
GATGCACAGAAGCTCCTAGAAAAAATGGGTGGCTCAGCACCACCAGATAGCAGCTGGAGA
GGAAGTCTCAAAGTGCCCTACAATGTTGGACCTGGCTTTACTGGAAACTTTTCTACACAA
AAAGTCAAGATGCACATCCACTCTACCAATGAAGTGACAAGAATTTACAATGTGATAGGT
ACTCTCAGAGGAGCAGTGGAACCAGACAGATATGTCATTCTGGGAGGTCACCGGGACTCA
TGGGTGTTTGGTGGTATTGACCCTCAGAGTGGAGCAGCTGTTGTTCATGAAATTGTGAGG
AGCTTTGGAACACTGAAAAAGGAAGGGTGGAGACCTAGAAGAACAATTTTGTTTGCAAGC
TGGGATGCAGAAGAATTTGGTCTTCTTGGTTCTACTGAGTGGGCAGAGGAGAATTCAAGA
CTCCTTCAAGAGCGTGGCGTGGCTTATATTAATGCTGACTCATCTATAGAAGGAAACTAC
ACTCTGAGAGTTGATTGTACACCGCTGATGTACAGCTTGGTACACAACCTAACAAAAGAG
CTGAAAAGCCCTGATGAAGGCTTTGAAGGCAAATCTCTTTATGAAAGTTGGACTAAAAAA
AGTCCTTCCCCAGAGTTCAGTGGCATGCCCAGGATAAGCAAATTGGGATCTGGAAATGAT
TTTGAGGTGTTCTTCCAACGACTTGGAATTGCTTCAGGCAGAGCACGGTATACTAAAAAT
TGGGAAACAAACAAATTCAGCGGCTATCCACTGTATCACAGTGTCTATGAAACATATGAG
TTGGTGGAAAAGTTTTATGATCCAATGTTTAAATATCACCTCACTGTGGCCCAGGTTCGA
GGAGGGATGGTGTTTGAGCTAGCCAATTCCATAGTGCTCCCTTTTGATTGTCGAGATTAT
GCTGTAGTTTTAAGAAAGTATGCTGACAAAATCTACAGTATTTCTATGAAACATCCACAG
GAAATGAAGACATACAGTGTATCATTTGATTCACTTTTTTCTGCAGTAAAGAATTTTACA
GAAATTGCTTCCAAGTTCAGTGAGAGACTCCAGGACTTTGACAAAAGCAACCCAATAGTA
TTAAGAATGATGAATGATCAACTCATGTTTCTGGAAAGAGCATTTATTGATCCATTAGGG
TTACCAGACAGGCCTTTTTATAGGCATGTCATCTATGCTCCAAGCAGCCACAACAAGTAT
GCAGGGGAGTCATTCCCAGGAATTTATGATGCTCTGTTTGATATTGAAAGCAAAGTGGAC
CCTTCCAAGGCCTGGGGAGAAGTGAAGAGACAGATTTATGTTGCAGCCTTCACAGTGCAG
GCAGCTGCAGAGACTTTGAGTGAAGTAGCCTAA

# Drug_Target_61_General_Function:
Involved in peptidase activity

# Drug_Target_61_General_References:
10085079	Pangalos MN, Neefs JM, Somers M, Verhasselt P, Bekkers M, van der Helm L, Fraiponts E, Ashton D, Gordon RD: Isolation and expression of novel human glutamate carboxypeptidases with N-acetylated alpha-linked acidic dipeptidase and dipeptidyl peptidase IV activity. J Biol Chem. 1999 Mar 26;274(13):8470-83.
12754519	Zhang H, Li XJ, Martin DB, Aebersold R: Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol. 2003 Jun;21(6):660-6. Epub 2003 May 18.
7882349	Su SL, Huang IP, Fair WR, Powell CT, Heston WD: Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res. 1995 Apr 1;55(7):1441-3.
8417812	Israeli RS, Powell CT, Fair WR, Heston WD: Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 1993 Jan 15;53(2):227-30.
9187245	Rawlings ND, Barrett AJ: Structure of membrane glutamate carboxypeptidase. Biochim Biophys Acta. 1997 May 23;1339(2):247-52.
9375657	Bzdega T, Turi T, Wroblewska B, She D, Chung HS, Kim H, Neale JH: Molecular cloning of a peptidase against N-acetylaspartylglutamate from a rat hippocampal cDNA library. J Neurochem. 1997 Dec;69(6):2270-7.
9622670	Luthi-Carter R, Barczak AK, Speno H, Coyle JT: Hydrolysis of the neuropeptide N-acetylaspartylglutamate (NAAG) by cloned human glutamate carboxypeptidase II. Brain Res. 1998 Jun 8;795(1-2):341-8.
9694964	Luthi-Carter R, Barczak AK, Speno H, Coyle JT: Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase). J Pharmacol Exp Ther. 1998 Aug;286(2):1020-5.
9809977	Grauer LS, Lawler KD, Marignac JL, Kumar A, Goel AS, Wolfert RL: Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line. Cancer Res. 1998 Nov 1;58(21):4787-9.
9838072	O'Keefe DS, Su SL, Bacich DJ, Horiguchi Y, Luo Y, Powell CT, Zandvliet D, Russell PJ, Molloy PL, Nowak NJ, Shows TB, Mullins C, Vonder Haar RA, Fair WR, Heston WD: Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim Biophys Acta. 1998 Nov 26;1443(1-2):113-27.
9882712	Speno HS, Luthi-Carter R, Macias WL, Valentine SL, Joshi AR, Coyle JT: Site-directed mutagenesis of predicted active site residues in glutamate carboxypeptidase II. Mol Pharmacol. 1999 Jan;55(1):179-85.

# Drug_Target_61_HGNC_ID:
HGNC:3788

# Drug_Target_61_HPRD_ID:
02961

# Drug_Target_61_ID:
625

# Drug_Target_61_Locus:
11p11.2

# Drug_Target_61_Molecular_Weight:
84331

# Drug_Target_61_Name:
Glutamate carboxypeptidase 2

# Drug_Target_61_Number_of_Residues:
750

# Drug_Target_61_PDB_ID:
1Z8L

# Drug_Target_61_Pathway:
Not Available

# Drug_Target_61_Pfam_Domain_Function:
PF02225	PA
PF04253	TFR_dimer
PF04389	Peptidase_M28

# Drug_Target_61_Protein_Sequence:
>Glutamate carboxypeptidase 2
MWNLLHETDSAVATARRPRWLCAGALVLAGGFFLLGFLFGWFIKSSNEATNITPKHNMKA
FLDELKAENIKKFLYNFTQIPHLAGTEQNFQLAKQIQSQWKEFGLDSVELAHYDVLLSYP
NKTHPNYISIINEDGNEIFNTSLFEPPPPGYENVSDIVPPFSAFSPQGMPEGDLVYVNYA
RTEDFFKLERDMKINCSGKIVIARYGKVFRGNKVKNAQLAGAKGVILYSDPADYFAPGVK
SYPDGWNLPGGGVQRGNILNLNGAGDPLTPGYPANEYAYRRGIAEAVGLPSIPVHPIGYY
DAQKLLEKMGGSAPPDSSWRGSLKVPYNVGPGFTGNFSTQKVKMHIHSTNEVTRIYNVIG
TLRGAVEPDRYVILGGHRDSWVFGGIDPQSGAAVVHEIVRSFGTLKKEGWRPRRTILFAS
WDAEEFGLLGSTEWAEENSRLLQERGVAYINADSSIEGNYTLRVDCTPLMYSLVHNLTKE
LKSPDEGFEGKSLYESWTKKSPSPEFSGMPRISKLGSGNDFEVFFQRLGIASGRARYTKN
WETNKFSGYPLYHSVYETYELVEKFYDPMFKYHLTVAQVRGGMVFELANSIVLPFDCRDY
AVVLRKYADKIYSISMKHPQEMKTYSVSFDSLFSAVKNFTEIASKFSERLQDFDKSNPIV
LRMMNDQLMFLERAFIDPLGLPDRPFYRHVIYAPSSHNKYAGESFPGIYDALFDIESKVD
PSKAWGEVKRQIYVAAFTVQAAAETLSEVA

# Drug_Target_61_Reaction:
Release of an unsubstituted, C-terminal glutamyl residue, typically from Ac-Asp-Glu or folylpoly-gamma-glutamates EFFECTOR Metal

# Drug_Target_61_Signals:
None

# Drug_Target_61_Specific_Function:
Also exhibits a dipeptidyl-peptidase IV type activity. In vitro, cleaves Gly-Pro-AMC

# Drug_Target_61_SwissProt_ID:
Q04609

# Drug_Target_61_SwissProt_Name:
FOLH1_HUMAN

# Drug_Target_61_Synonyms:
EC 3.4.17.21
FGCP
Folate hydrolase 1
Folylpoly-gamma- glutamate carboxypeptidase
Glutamate carboxypeptidase II
Membrane glutamate carboxypeptidase
N- acetylated-alpha-linked acidic dipeptidase I
NAALADase I
PSM
PSMA
Prostate- specific membrane antigen
Pteroylpoly-gamma-glutamate carboxypeptidase
mGCP

# Drug_Target_61_Theoretical_pI:
6.97

# Drug_Target_61_Transmembrane_Regions:
20-43

# Drug_Target_62_Cellular_Location:
Cytoplasm
cytosol. Cytoplasmic vesicle. Associated to cytoplasmic vesicles. In neurons, cytosolic l

# Drug_Target_62_Chromosome_Location:
Not Available

# Drug_Target_62_Drug_References:
16643338	Wang FY, Zhu RM, Maemura K, Hirata I, Katsu K, Watanabe M: Expression of gamma-aminobutyric acid and glutamic acid decarboxylases in rat descending colon and their relation to epithelial differentiation. Chin J Dig Dis. 2006;7(2):103-8.
16879709	Wei J, Lin CH, Wu H, Jin Y, Lee YH, Wu JY: Activity-dependent cleavage of brain glutamic acid decarboxylase 65 by calpain. J Neurochem. 2006 Sep;98(5):1688-95. Epub 2006 Jul 31.
17317763	Pop SM, Wong CP, He Q, Wang Y, Wallet MA, Goudy KS, Tisch R: The type and frequency of immunoregulatory CD4+ T-cells govern the efficacy of antigen-specific immunotherapy in nonobese diabetic mice. Diabetes. 2007 May;56(5):1395-402. Epub 2007 Feb 22.
17507169	Castelli MP, Piras AP, Melis T, Succu S, Sanna F, Melis MR, Collu S, Grazia Ennas M, Diaz G, Mackie K, Argiolas A: Cannabinoid CB1 receptors in the paraventricular nucleus and central control of penile erection: immunocytochemistry, autoradiography and behavioral studies. Neuroscience. 2007 Jun 15;147(1):197-206. Epub 2007 May 15.
17600364	Manto MU, Laute MA, Aguera M, Rogemond V, Pandolfo M, Honnorat J: Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. Ann Neurol. 2007 Jun;61(6):544-51.

# Drug_Target_62_Essentiality:
Non-Essential

# Drug_Target_62_GenAtlas_ID:
GAD2

# Drug_Target_62_GenBank_ID_Gene:
M81882

# Drug_Target_62_GenBank_ID_Protein:
182934

# Drug_Target_62_GeneCard_ID:
GAD2

# Drug_Target_62_Gene_Name:
GAD2

# Drug_Target_62_Gene_Sequence:
>1758 bp
ATGGCATCTCCGGGCTCTGGCTTTTGGTCTTTCGGGTCGGAAGATGGCTCTGGGGATTCC
GAGAATCCCGGCACAGCGCGAGCCTGGTGCCAAGTGGCTCAGAAGTTCACGGGCGGCATC
GGAAACAAACTGTGCGCCCTGCTCTACGGAGACGCCGAGAAGCCGGCGGAGAGCGGCGGG
AGCCAACCCCCGCGGGCCGCCGCCCGGAAGGCCGCCTGCGCCTGCGACCAGAAGCCCTGC
AGCTGCTCCAAAGTGGATGTCAACTACGCGTTTCTCCATGCAACAGACCTGCTGCCGGCG
TGTGATGGAGAAAGGCCCACTTTGGCGTTTCTGCAAGATGTTATGAACATTTTACTTCAG
TATGTGGTGAAAAGTTTCGATAGATCAACCAAAGTGATTGATTTCCATTATCCTAATGAG
CTTCTCCAAGAATATAATTGGGAATTGGCAGACCAACCACAAAATTTGGAGGAAATTTTG
ATGCATTGCCAAACAACTCTAAAATATGCAATTAAAACAGGGCATCCTAGATACTTCAAT
CAACTTTCTACTGGTTTGGATATGGTTGGATTAGCAGCAGACTGGCTGACATCAACAGCA
AATACTAACATGTTCACCTATGAAATTGCTCCAGTATTTGTGCTTTTGGAATATGTCACA
CTAAAGAAAATGAGAGAAATCATTGGCTGGCCAGGGGGCTCTGGCGATGGGATATTTTCT
CCCGGTGGCGCCATATCTAACATGTATGCCATGATGATCGCACGCTTTAAGATGTTCCCA
GAAGTCAAGGAGAAAGGAATGGCTGCTCTTCCCAGGCTCATTGCCTTCACGTCTGAACAT
AGTCATTTTTCTCTCAAGAAGGGAGCTGCAGCCTTAGGGATTGGAACAGACAGCGTGATT
CTGATTAAATGTGATGAGAGAGGGAAAATGATTCCATCTGATCTTGAAAGAAGGATTCTT
GAAGCCAAACAGAAAGGGTTTGTTCCTTTCCTCGTGAGTGCCACAGCTGGAACCACCGTG
TACGGAGCATTTGACCCCCTCTTAGCTGTCGCTGACATTTGCAAAAAGTATAAGATCTGG
ATGCATGTGGATGCAGCTTGGGGTGGGGGATTACTGATGTCCCGAAAACACAAGTGGAAA
CTGAGTGGCGTGGAGAGGGCCAACTCTGTGACGTGGAATCCACACAAGATGATGGGAGTC
CCTTTGCAGTGCTCTGCTCTCCTGGTTAGAGAAGAGGGATTGATGCAGAATTGCAACCAA
ATGCATGCCTCCTACCTCTTTCAGCAAGATAAACATTATGACCTGTCCTATGACACTGGA
GACAAGGCCTTACAGTGCGGACGCCACGTTGATGTTTTTAAACTATGGCTGATGTGGAGG
GCAAAGGGGACTACCGGGTTTGAAGCGCATGTTGATAAATGTTTGGAGTTGGCAGAGTAT
TTATACAACATCATAAAAAACCGAGAAGGATATGAGATGGTGTTTGATGGGAAGCCTCAG
CACACAAATGTCTGCTTCTGGTACATTCCTCCAAGCTTGCGTACTCTGGAAGACAATGAA
GAGAGAATGAGTCGCCTCTCGAAGGTGGCTCCAGTGATTAAAGCCAGAATGATGGAGTAT
GGAACCACAATGGTCAGCTACCAACCCTTGGGAGACAAGGTCAATTTCTTCCGCATGGTC
ATCTCAAACCCAGCGGCAACTCACCAAGACATTGACTTCCTGATTGAAGAAATAGAACGC
CTTGGACAAGATTTATAA

# Drug_Target_62_General_Function:
Amino acid transport and metabolism

# Drug_Target_62_General_References:
12356867	Kanaani J, el-Husseini Ael-D, Aguilera-Moreno A, Diacovo JM, Bredt DS, Baekkeskov S: A combination of three distinct trafficking signals mediates axonal targeting and presynaptic clustering of GAD65. J Cell Biol. 2002 Sep 30;158(7):1229-38.
1549570	Bu DF, Erlander MG, Hitz BC, Tillakaratne NJ, Kaufman DL, Wagner-McPherson CB, Evans GA, Tobin AJ: Two human glutamate decarboxylases, 65-kDa GAD and 67-kDa GAD, are each encoded by a single gene. Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2115-9.
1924293	Karlsen AE, Hagopian WA, Grubin CE, Dube S, Disteche CM, Adler DA, Barmeier H, Mathewes S, Grant FJ, Foster D, et al.: Cloning and primary structure of a human islet isoform of glutamic acid decarboxylase from chromosome 10. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8337-41.
7680313	Mauch L, Abney CC, Berg H, Scherbaum WA, Liedvogel B, Northemann W: Characterization of a linear epitope within the human pancreatic 64-kDa glutamic acid decarboxylase and its autoimmune recognition by sera from insulin-dependent diabetes mellitus patients. Eur J Biochem. 1993 Mar 1;212(2):597-603.
8088791	Bu DF, Tobin AJ: The exon-intron organization of the genes (GAD1 and GAD2) encoding two human glutamate decarboxylases (GAD67 and GAD65) suggests that they derive from a common ancestral GAD. Genomics. 1994 May 1;21(1):222-8.
8243826	Kim J, Richter W, Aanstoot HJ, Shi Y, Fu Q, Rajotte R, Warnock G, Baekkeskov S: Differential expression of GAD65 and GAD67 in human, rat, and mouse pancreatic islets. Diabetes. 1993 Dec;42(12):1799-808.
8999827	Namchuk M, Lindsay L, Turck CW, Kanaani J, Baekkeskov S: Phosphorylation of serine residues 3, 6, 10, and 13 distinguishes membrane anchored from soluble glutamic acid decarboxylase 65 and is restricted to glutamic acid decarboxylase 65alpha. J Biol Chem. 1997 Jan 17;272(3):1548-57.

# Drug_Target_62_HGNC_ID:
HGNC:4093

# Drug_Target_62_HPRD_ID:
11817

# Drug_Target_62_ID:
664

# Drug_Target_62_Locus:
10p11.23

# Drug_Target_62_Molecular_Weight:
65412

# Drug_Target_62_Name:
Glutamate decarboxylase 2

# Drug_Target_62_Number_of_Residues:
585

# Drug_Target_62_PDB_ID:
Not Available

# Drug_Target_62_Pathway:
Not Available

# Drug_Target_62_Pfam_Domain_Function:
PF00282	Pyridoxal_deC

# Drug_Target_62_Protein_Sequence:
>Glutamate decarboxylase 2
MASPGSGFWSFGSEDGSGDSENPGTARAWCQVAQKFTGGIGNKLCALLYGDAEKPAESGG
SQPPRAAARKAACACDQKPCSCSKVDVNYAFLHATDLLPACDGERPTLAFLQDVMNILLQ
YVVKSFDRSTKVIDFHYPNELLQEYNWELADQPQNLEEILMHCQTTLKYAIKTGHPRYFN
QLSTGLDMVGLAADWLTSTANTNMFTYEIAPVFVLLEYVTLKKMREIIGWPGGSGDGIFS
PGGAISNMYAMMIARFKMFPEVKEKGMAALPRLIAFTSEHSHFSLKKGAAALGIGTDSVI
LIKCDERGKMIPSDLERRILEAKQKGFVPFLVSATAGTTVYGAFDPLLAVADICKKYKIW
MHVDAAWGGGLLMSRKHKWKLSGVERANSVTWNPHKMMGVPLQCSALLVREEGLMQNCNQ
MHASYLFQQDKHYDLSYDTGDKALQCGRHVDVFKLWLMWRAKGTTGFEAHVDKCLELAEY
LYNIIKNREGYEMVFDGKPQHTNVCFWYIPPSLRTLEDNEERMSRLSKVAPVIKARMMEY
GTTMVSYQPLGDKVNFFRMVISNPAATHQDIDFLIEEIERLGQDL

# Drug_Target_62_Reaction:
L-glutamate = 4-aminobutanoate + CO2

# Drug_Target_62_Signals:
None

# Drug_Target_62_Specific_Function:
Catalyzes the production of GABA

# Drug_Target_62_SwissProt_ID:
Q05329

# Drug_Target_62_SwissProt_Name:
DCE2_HUMAN

# Drug_Target_62_Synonyms:
65 kDa glutamic acid decarboxylase
EC 4.1.1.15
GAD-65
Glutamate decarboxylase 65 kDa isoform

# Drug_Target_62_Theoretical_pI:
6.89

# Drug_Target_62_Transmembrane_Regions:
None

# Drug_Target_63_Cellular_Location:
Not Available

# Drug_Target_63_Chromosome_Location:
Not Available

# Drug_Target_63_Drug_References:
16643338	Wang FY, Zhu RM, Maemura K, Hirata I, Katsu K, Watanabe M: Expression of gamma-aminobutyric acid and glutamic acid decarboxylases in rat descending colon and their relation to epithelial differentiation. Chin J Dig Dis. 2006;7(2):103-8.
16769115	Tueting P, Doueiri MS, Guidotti A, Davis JM, Costa E: Reelin down-regulation in mice and psychosis endophenotypes. Neurosci Biobehav Rev. 2006;30(8):1065-77.
17445798	Tronci E, Simola N, Borsini F, Schintu N, Frau L, Carminati P, Morelli M: Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. Eur J Pharmacol. 2007 Jul 2;566(1-3):94-102. Epub 2007 Mar 24.
17562689	Akama K, Takaiwa F: C-terminal extension of rice glutamate decarboxylase (OsGAD2) functions as an autoinhibitory domain and overexpression of a truncated mutant results in the accumulation of extremely high levels of GABA in plant cells. J Exp Bot. 2007;58(10):2699-707. Epub 2007 Jun 11.
17600364	Manto MU, Laute MA, Aguera M, Rogemond V, Pandolfo M, Honnorat J: Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. Ann Neurol. 2007 Jun;61(6):544-51.

# Drug_Target_63_Essentiality:
Non-Essential

# Drug_Target_63_GenAtlas_ID:
GAD1

# Drug_Target_63_GenBank_ID_Gene:
M81883

# Drug_Target_63_GenBank_ID_Protein:
182936

# Drug_Target_63_GeneCard_ID:
GAD1

# Drug_Target_63_Gene_Name:
GAD1

# Drug_Target_63_Gene_Sequence:
>1785 bp
ATGGCGTCTTCGACCCCATCTTCGTCCGCAACCTCCTCGAACGCGGGAGCGGACCCCAAT
ACCACTAACCTGCGCCCCACAACGTACGATACCTGGTGCGGCGTGGCCCATGGATGCACC
AGAAAACTGGGGCTCAAGATCTGCGGCTTCTTGCAAAGGACCAACAGCCTGGAAGAGAAG
AGTCGCCTTGTGAGTGCCTTCAGGGAGAGGCAATCCTCCAAGAACCTGCTTTCCTGTGAA
AACAGCGACCGGGATGCCCGCTTCCGGCGCACAGAGACTGACTTCTCTAATCTGTTTGCT
AGAGATCTGCTTCCGGCTAAGAACGGTGAGGAGCAAACCGTGCAATTCCTCCTGGAAGTG
GTGGACATACTCCTCAACTATGTCCGCAAGACATTTGATCGCTCCACCAAGGTGCTGGAC
TTTCATCACCCACACCAGTTGCTGGAAGGCATGGAGGGCTTCAACTTGGAGCTCTCTGAC
CACCCCGAGTCCCTGGAGCAGATCCTGGTTGACTGCAGAGACACCTTGAAGTATGGGGTT
CGCACAGGTCATCCTCGATTTTTCAACCAGCTCTCCACTGGATTGGATATTATTGGCCTA
GCTGGAGAATGGCTGACATCAACGGCCAATACCAACATGTTTACATATGAAATTGCACCA
GTGTTTGTCCTCATGGAACAAATAACACTTAAGAAGATGAGAGAGATAGTTGGATGGTCA
AGTAAAGATGGTGATGGGATATTTTCTCCTGGGGGCGCCATATCCAACATGTACAGCATC
ATGGCTGCTCGCTACAAGTACTTCCCGGAAGTTAAGACAAAGGGCATGGCGGCTGTGCCT
AAACTGGTCCTCTTCACCTCAGAACAGAGTCACTATTCCATAAAGAAAGCTGGGGCTGCA
CTTGGCTTTGGAACTGACAATGTGATTTTGATAAAGTGCAATGAAAGGGGGAAAATAATT
CCAGCTGATTTTGAGGCAAAAATTCTTGAAGCCAAACAGAAGGGATATGTTCCCTTTTAT
GTCAATGCAACTGCTGGCACGACTGTTTATGGAGCTTTTGATCCGATACAAGAGATTGCA
GATATATGTGAGAAATATAACCTTTGGTTGCATGTCGATGCTGCCTGGGGAGGTGGGCTG
CTCATGTCCAGGAAGCACCGCCATAAACTCAACGGCATAGAAAGGGCCAACTCAGTCACC
TGGAACCCTCACAAGATGATGGGCGTGCTGTTGCAGTGCTCTGCCATTCTCGTCAAGGAA
AAGGGTATACTCCAAGGATGCAACCAGATGTGTGCAGGATATCTCTTCCAGCCAGACAAG
CAGTATGATGTCTCCTACGACACCGGGGACAAGGCAATTCAGTGTGGCCGCCACGTGGAT
ATCTTCAAGTTCTGGCTGATGTGGAAAGCAAAGGGCACAGTGGGATTTGAAAACCAGATC
AACAAATGCCTGGAACTGGCTGAATACCTCTATGCCAAGATTAAAAACAGAGAAGAATTT
GAGATGGTTTTCAATGGCGAGCCTGAGCACACAAACGTCTGTTTTTGGTATATTCCACAA
AGCCTCAGGGGTGTGCCAGACAGCCCTCAACGACGGGAAAAGCTACACAAGGTGGCTCCA
AAAATCAAAGCCCTGATGATGGAGTCAGGTACGACCATGGTTGGCTACCAGCCCCAAGGG
GACAAGGCCAACTTCTTCCGGATGGTCATCTCCAACCCAGCCGCTACCCAGTCTGACATT
GACTTCCTCATTGAGGAGATAGAAAGACTGGGCCAGGATCTGTAA

# Drug_Target_63_General_Function:
Amino acid transport and metabolism

# Drug_Target_63_General_References:
10671565	Chessler SD, Lernmark A: Alternative splicing of GAD67 results in the synthesis of a third form of glutamic-acid decarboxylase in human islets and other non-neural tissues. J Biol Chem. 2000 Feb 18;275(7):5188-92.
1339255	Kelly CD, Edwards Y, Johnstone AP, Harfst E, Nogradi A, Nussey SS, Povey S, Carter ND: Nucleotide sequence and chromosomal assignment of a cDNA encoding the large isoform of human glutamate decarboxylase. Ann Hum Genet. 1992 Jul;56(Pt 3):255-65.
1549570	Bu DF, Erlander MG, Hitz BC, Tillakaratne NJ, Kaufman DL, Wagner-McPherson CB, Evans GA, Tobin AJ: Two human glutamate decarboxylases, 65-kDa GAD and 67-kDa GAD, are each encoded by a single gene. Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2115-9.
1697032	Persson H, Pelto-Huikko M, Metsis M, Soder O, Brene S, Skog S, Hokfelt T, Ritzen EM: Expression of the neurotransmitter-synthesizing enzyme glutamic acid decarboxylase in male germ cells. Mol Cell Biol. 1990 Sep;10(9):4701-11.
2039509	Cram DS, Barnett LD, Joseph JL, Harrison LC: Cloning and partial nucleotide sequence of human glutamic acid decarboxylase cDNA from brain and pancreatic islets. Biochem Biophys Res Commun. 1991 May 15;176(3):1239-44.
8088791	Bu DF, Tobin AJ: The exon-intron organization of the genes (GAD1 and GAD2) encoding two human glutamate decarboxylases (GAD67 and GAD65) suggests that they derive from a common ancestral GAD. Genomics. 1994 May 1;21(1):222-8.
8507202	Yamashita K, Cram DS, Harrison LC: Molecular cloning of full-length glutamic acid decarboxylase 67 from human pancreas and islets. Biochem Biophys Res Commun. 1993 May 14;192(3):1347-52.
8507203	Kawasaki E, Moriuchi R, Watanabe M, Saitoh K, Brunicardi FC, Watt PC, Yamaguchi T, Mullen Y, Akazawa S, Miyamoto T, et al.: Cloning and expression of large isoform of glutamic acid decarboxylase from human pancreatic islet. Biochem Biophys Res Commun. 1993 May 14;192(3):1353-9.

# Drug_Target_63_HGNC_ID:
HGNC:4092

# Drug_Target_63_HPRD_ID:
12011

# Drug_Target_63_ID:
420

# Drug_Target_63_Locus:
2q31

# Drug_Target_63_Molecular_Weight:
66897

# Drug_Target_63_Name:
Glutamate decarboxylase 1

# Drug_Target_63_Number_of_Residues:
594

# Drug_Target_63_PDB_ID:
Not Available

# Drug_Target_63_Pathway:
Not Available

# Drug_Target_63_Pfam_Domain_Function:
PF00282	Pyridoxal_deC

# Drug_Target_63_Protein_Sequence:
>Glutamate decarboxylase 1
MASSTPSSSATSSNAGADPNTTNLRPTTYDTWCGVAHGCTRKLGLKICGFLQRTNSLEEK
SRLVSAFKERQSSKNLLSCENSDRDARFRRTETDFSNLFARDLLPAKNGEEQTVQFLLEV
VDILLNYVRKTFDRSTKVLDFHHPHQLLEGMEGFNLELSDHPESLEQILVDCRDTLKYGV
RTGHPRFFNQLSTGLDIIGLAGEWLTSTANTNMFTYEIAPVFVLMEQITLKKMREIVGWS
SKDGDGIFSPGGAISNMYSIMAARYKYFPEVKTKGMAAVPKLVLFTSEQSHYSIKKAGAA
LGFGTDNVILIKCNERGKIIPADFEAKILEAKQKGYVPFYVNATAGTTVYGAFDPIQEIA
DICEKYNLWLHVDAAWGGGLLMSRKHRHKLNGIERANSVTWNPHKMMGVLLQCSAILVKE
KGILQGCNQMCAGYLFQPDKQYDVSYDTGDKAIQCGRHVDIFKFWLMWKAKGTVGFENQI
NKCLELAEYLYAKIKNREEFEMVFNGEPEHTNVCFWYIPQSLRGVPDSPQRREKLHKVAP
KIKALMMESGTTMVGYQPQGDKANFFRMVISNPAATQSDIDFLIEEIERLGQDL

# Drug_Target_63_Reaction:
L-glutamate = 4-aminobutanoate + CO2

# Drug_Target_63_Signals:
None

# Drug_Target_63_Specific_Function:
Catalyzes the production of GABA

# Drug_Target_63_SwissProt_ID:
Q99259

# Drug_Target_63_SwissProt_Name:
DCE1_HUMAN

# Drug_Target_63_Synonyms:
67 kDa glutamic acid decarboxylase
EC 4.1.1.15
GAD-67
Glutamate decarboxylase 67 kDa isoform

# Drug_Target_63_Theoretical_pI:
7.67

# Drug_Target_63_Transmembrane_Regions:
None

# Drug_Target_64_Cellular_Location:
Cytoplasm

# Drug_Target_64_Chromosome_Location:
Not Available

# Drug_Target_64_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9837973	Gao YS, Alvarez C, Nelson DS, Sztul E: Molecular cloning, characterization, and dynamics of rat formiminotransferase cyclodeaminase, a Golgi-associated 58-kDa protein. J Biol Chem. 1998 Dec 11;273(50):33825-34.

# Drug_Target_64_Essentiality:
Non-Essential

# Drug_Target_64_GenAtlas_ID:
FTCD

# Drug_Target_64_GenBank_ID_Gene:
AF169017

# Drug_Target_64_GenBank_ID_Protein:
6537208

# Drug_Target_64_GeneCard_ID:
FTCD

# Drug_Target_64_Gene_Name:
FTCD

# Drug_Target_64_Gene_Sequence:
>1626 bp
ATGTCCCAGCTGGTGGAATGCGTCCCCAACTTTTCGGAGGGGAAGAACCAGGAGGTGATC
GACGCCATCTCTGGAGCCATCACACAGACCCCGGGCTGCGTGCTGCTGGATGTGGACGCA
GGCCCTTCCACCAACCGCACCGTGTACACCTTCGTGGGGCCGCCGGAGTGCGTGGTGGAG
GGGGCCCTCAACGCTGCCCGGGTAGCTTCCCGACTTATCGACATGAGCAGGCACCAAGGA
GAGCACCCCCGCATGGGGGCCCTAGACGTCTGCCCCTTCATCCCCGTGAGGGGCGTCAGC
GTGGATGAGTGTGTGCTCTGCGCCCAGGCCTTTGGCCAGAGGCTGGCAGAGGAGCTGGAC
GTGCCAGTTTACCTGTACGGCGAGGCAGCCAGGATGGACAGTCGCCGGACCCTGCCGGCC
ATCCGGGCCGGGGAGTACGAGGCCCTCCCTAAGAAGCTCCAGCAGGCCGACTGGGCGCCC
GACTTTGGTCCCAGCTCCTTTGTCCCCAGTTGGGGGGCCACGGCCACGGGGGCGAGGAAG
TTCCTCATTGCTTTTAACATCAACCTGCTCGGCACAAAGGAGCAAGCCCACCGCATCGCG
CTCAACCTGCGGGAGCAGGGCCGCGGGAAGGACCAGCCAGGACGTCTGAAGAAAGTTCAG
GGCATTGGCTGGTACCTGGATGAGAAGAACCTGGCTCAGGTGTCCACCAATCTTCTGGAC
TTTGAGGTCACGGCACTGCACACGGTCTACGAGGAGACCTGCCGAGAAGCACAGGAGCTG
AGCCTCCCAGTGGTGGGCTCACAGCTGGTGGGCCTGGTGCCCCTGAAGGCTCTGCTGGAT
GCGGCCGCCTTCTACTGCGAGAAGGAGAACCTCTTCATCCTGGAGGAGGAGCAGCGGATC
AGGCTGGTGGTGAGCCGGCTGGGCCTGGACTCCCTGTGCCCCTTCAGCCCTAAGGAGCGG
ATCATCGAGTACCTGGTCCCTGAGCGCGGGCCTGAGCGAGGCCTGGGCAGCAAGTCCCTG
CGCGCCTTCGTGGGGGAGGTGGGTGCCCGCTCTGCGGCCCCCGGGGGCGGCTCGGTGGCG
GCGGCCGCTGCGGCCATGGGTGCGGCGCTGGGCTCCATGGTGGGCCTCATGACCTACGGG
CGGCGCCAATTCCAGTCCCTGGACACGACGATGCGGCGCCTGATCCCGCCCTTCCGCGAG
GCTTCGGCCAAGCTAACCACGCTGGTGGATGCCGACGCCGAGGCCTTCACCGCCTACCTG
GAAGCAATGAGGCTCCCCAAGAACACACCTGAGGAAAAGGACAGGCGCACGGCGGCCCTA
CAGGAGGGTCTGAGGCGGGCAGTCTCTGTGCCGCTGACGCTGGCGGAGACGGTGGCCTCG
CTGTGGCCGGCGCTGCAGGAACTGGCCCGGTGTGGGAACCTGGCCTGCCGGTCAGACCTC
CAGGTGGCGGCCAAAGCCCTGGAGATGGGCGTGTTTGGCGCATATTTCAACGTGCTCATC
AACCTGAGGGACATCACAGACGAGGCATTTAAGGACCAGATCCACCATCGTGTTTCCAGC
CTCCTGCAGGAAGCCAAGACCCAGGCTGCACTGGTGCTGGACTGCTTGGAGACCCGGCAG
GAGTGA

# Drug_Target_64_General_Function:
Amino acid transport and metabolism

# Drug_Target_64_General_References:
10029623	Lapierre P, Hajoui O, Homberg JC, Alvarez F: Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology. 1999 Mar;116(3):643-9.
10773664	Solans A, Estivill X, de la Luna S: Cloning and characterization of human FTCD on 21q22.3, a candidate gene for glutamate formiminotransferase deficiency. Cytogenet Cell Genet. 2000;88(1-2):43-9.
12815595	Hilton JF, Christensen KE, Watkins D, Raby BA, Renaud Y, de la Luna S, Estivill X, MacKenzie RE, Hudson TJ, Rosenblatt DS: The molecular basis of glutamate formiminotransferase deficiency. Hum Mutat. 2003 Jul;22(1):67-73.

# Drug_Target_64_HGNC_ID:
HGNC:3974

# Drug_Target_64_HPRD_ID:
08430

# Drug_Target_64_ID:
914

# Drug_Target_64_Locus:
Not Available

# Drug_Target_64_Molecular_Weight:
58927

# Drug_Target_64_Name:
Formimidoyltransferase-cyclodeaminase

# Drug_Target_64_Number_of_Residues:
541

# Drug_Target_64_PDB_ID:
Not Available

# Drug_Target_64_Pathway:
Not Available

# Drug_Target_64_Pfam_Domain_Function:
PF04961	FTCD_C
PF07837	FTCD_N

# Drug_Target_64_Protein_Sequence:
>Formimidoyltransferase-cyclodeaminase
MSQLVECVPNFSEGKNQEVIDAISGAITQTPGCVLLDVDAGPSTNRTVYTFVGPPECVVE
GALNAARVASRLIDMSRHQGEHPRMGALDVCPFIPVRGVSVDECVLCAQAFGQRLAEELD
VPVYLYGEAARMDSRRTLPAIRAGEYEALPKKLQQADWAPDFGPSSFVPSWGATATGARK
FLIAFNINLLGTKEQAHRIALNLREQGRGKDQPGRLKKVQGIGWYLDEKNLAQVSTNLLD
FEVTALHTVYEETCREAQELSLPVVGSQLVGLVPLKALLDAAAFYCEKENLFILEEEQRI
RLVVSRLGLDSLCPFSPKERIIEYLVPERGPERGLGSKSLRAFVGEVGARSAAPGGGSVA
AAAAAMGAALGSMVGLMTYGRRQFQSLDTTMRRLIPPFREASAKLTTLVDADAEAFTAYL
EAMRLPKNTPEEKDRRTAALQEGLRRAVSVPLTLAETVASLWPALQELARCGNLACRSDL
QVAAKALEMGVFGAYFNVLINLRDITDEAFKDQIHHRVSSLLQEAKTQAALVLDCLETRQ
E

# Drug_Target_64_Reaction:
5-formimidoyltetrahydrofolate + L-glutamate = tetrahydrofolate + N-formimidoyl-L-glutamate

# Drug_Target_64_Signals:
None

# Drug_Target_64_Specific_Function:
Folate-dependent enzyme, that displays both transferase and deaminase activity. Serves to channel one-carbon units from formiminoglutamate to the folate pool

# Drug_Target_64_SwissProt_ID:
O95954

# Drug_Target_64_SwissProt_Name:
FTCD_HUMAN

# Drug_Target_64_Synonyms:
EC 2.1.2.5
EC 4.3.1.4
FTCD
Formimidoyltetrahydrofolate cyclodeaminase
Formiminotransferase- cyclodeaminase
Glutamate formiminotransferase
Glutamate formyltransferase
LCHC1

# Drug_Target_64_Theoretical_pI:
5.45

# Drug_Target_64_Transmembrane_Regions:
None

# Drug_Target_65_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_65_Chromosome_Location:
Not Available

# Drug_Target_65_Drug_References:
1279377	Stein E, Cox JA, Seeburg PH, Verdoorn TA: Complex pharmacological properties of recombinant alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor subtypes. Mol Pharmacol. 1992 Nov;42(5):864-71.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
7679210	Henley JM, Jenkins R, Hunt SP: Localisation of glutamate receptor binding sites and mRNAs to the dorsal horn of the rat spinal cord. Neuropharmacology. 1993 Jan;32(1):37-41.
7838123	Li F, Owens N, Verdoorn TA: Functional effects of mutations in the putative agonist binding region of recombinant alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Mol Pharmacol. 1995 Jan;47(1):148-54.

# Drug_Target_65_Essentiality:
Non-Essential

# Drug_Target_65_GenAtlas_ID:
GRIA2

# Drug_Target_65_GenBank_ID_Gene:
L20814

# Drug_Target_65_GenBank_ID_Protein:
493134

# Drug_Target_65_GeneCard_ID:
GRIA2

# Drug_Target_65_Gene_Name:
GRIA2

# Drug_Target_65_Gene_Sequence:
>2652 bp
ATGCAAAAGATTATGCATATTTCTGTCCTCCTTTCTCCTGTTTTATGGGGACTGATTTTT
GGTGTCTCTTCTAACAGCATACAGATAGGGGGGCTATTTCCTAGGGGCGCCGATCAAGAA
TACAGTGCATTTCGAGTAGGGATGGTTCAGTTTTCCACTTCGGAGTTCAGACTGACACCC
CACATCGACAATTTGGAGGTGGCAAACAGCTTCGCAGTCACTAATGCTTTCTGCTCCCAG
TTTTCGAGAGGAGTCTATGCTATTTTTGGATTTTATGACAAGAAGTCTGTAAATACCATC
ACATCATTTTGCGGAACACTCCACGTCTCCTTCATCACTCCCAGCTTCCCAACAGATGGC
ACACATCCATTTGTCATTCAGATGAGACCCGACCTCAAAGGAGCTCTCCTTAGCTTGATT
GAATACTATCAATGGGACAAGTTTGCATACCTCTATGACAGTGACAGAGGCTTATCAACA
CTGCAAGCTGTGCTGGATTCTGCTGCTGAAAAGAAATGGCAAGTGACTGCTATCAATGTG
GGAAACATTAACAATGACAAGAAAGATGAGATGTACCGATCACTTTTTCAAGATCTGGAG
TTAAAAAAGGAACGGCGTGTAATTCTGGACTGTGAAAGGGATAAAGTAAACGACATTGTA
GACCAGGTTATTACCATTGGAAAACACGTTAAAGGGTACCACTACATCATTGCAAATCTG
GAATTTACTGATGGAGACCTATTAAAAATCCAGTTTGGAGGTGCAAATGTCTCTGGATTT
CAGATAGTGGACTATGATGATTCGTTGGTATCTAAATTTATAGAAAGATGGTCAACACTG
GAAGAAAAAGAATACCCTGGAGCTCACACAACAACAATTAAGTATACTTCTGCTCTGACC
TATGATGCCGTTCAAGTGATGACTGAAGCCTTCCGCAACCTAAGGAAGCAAAGAATTGAA
ATCTCCCGAAGGGGGAATGCAGGAGACTGTCTGGCAAACCCAGCAGTGCCCTGGGGACAA
GGTGTAGAAATAGAAAGGGCCCTCAAACAGGTTCAGGTTGAAGGTCTCTCAGGAAATATA
AAGTTTGACCAGAATGGAAAAAGAATAAACTATACAATTAACATCATGGAGCTCAAAACT
AATGGGCCCCGGAAGATTGGCTACTGGAGTGAAGTGGACAAAATGGTTGTTACCCTTACT
GAGCTCCCTTCTGGAAATGACACCTCTGGGCTTGAGAATAAGACTGTTGTTGTCACCACA
ATTTTGGAATCTCCGTATGTTATGATGAAGAAAAATCATGAAATGCTTGAAGGCAATGAG
CGCTATGAGGGCTACTGTGTTGACCTGGCTGCAGAAATCGCCAAACATTGTGGGTTCAAG
TACAAGTTGACAATTGTTGGTGATGGCAAGTATGGGGCCAGGGATGCAGACACGAAAATT
TGGAATGGGATGGTTGGAGAACTTGTATATGGGAAAGCTGATATTGCAATTGCTCCATTA
ACTATTACCCTTGTGAGAGAAGAGGTGATTGACTTCTCAAAGCCCTTCATGAGCCTCGGG
ATATCTATCATGATCAAGAAGCCTCAGAAGTCCAAACCAGGAGTGTTTTCCTTTCTTGAT
CCTTTAGCCTATGAGATCTGGATGTGCATTGTTTTTGCCTACATTGGGGTCAGTGTAGTT
TTATTCCTGGTCAGCAGATTTAGCCCCTACGAGTGGCACACTGAGGAGTTTGAAGATGGA
AGAGAAACACAAAGTAGTGAATCAACTAATGAATTTGGGATTTTTAATAGTCTCTGGTTT
TCCTTGGGTGCCTTTATGCGGCAAGGATGCGATATTTCGCCAAGATCCCTCTCTGGGCGC
ATTGTTGGAGGTGTGTGGTGGTTCTTTACCCTGATCATAATCTCCTCCTACACGGCTAAC
TTAGCTGCCTTCCTGACTGTAGAGAGGATGGTGTCTCCCATCGAAAGTGCTGAGGATCTT
TCTAAGCAAACAGAAATTGCTTATGGAACATTAGACTCTGGCTCCACTAAAGAGTTTTTC
AGGAGATCTAAAATTGCAGTGTTTGATAAAATGTGGACCTACATGCGGAGTGCGGAGCCC
TCTGTGTTTGTGAGGACTACGGCCGAAGGGGTGGCTAGAGTGCGGAAGTCCAAAGGGAAA
TATGCCTACTTGTTGGAGTCCACGATGAACGAGTACATTGAGCAAAGGAAGCCTTGCGAC
ACCATGAAAGTTGGTGGAAACCTGGATTCCAAAGGCTATGGCATCGCAACACCTAAAGGA
TCCTCATTAGGAACCCCAGTAAATCTTGCAGTATTGAAACTCAGTGAGCAAGGCGTCTTA
GACAAGCTGAAAAACAAATGGTGGTACGATAAAGGTGAATGTGGAGCCAAGGACTCTGGA
AGTAAGGAAAAGACCAGTGCCCTCAGTCTGAGCAACGTTGCTGGAGTATTCTACATCCTT
GTCGGGGGCCTTGGTTTGGCAATGCTGGTGGCTTTGATTGAGTTCTGTTACAAGTCAAGG
GCCGAGGCGAAACGAATGAAGGTGGCAAAGAATGCACAGAATATTAACCCATCTTCCTCG
CAGAATTCACAGAATTTTGCAACTTATAAGGAAGGTTACAACGTATATGGCATCGAAAGT
GTTAAAATTTAG

# Drug_Target_65_General_Function:
Amino acid transport and metabolism

# Drug_Target_65_General_References:
7523595	Paschen W, Hedreen JC, Ross CA: RNA editing of the glutamate receptor subunits GluR2 and GluR6 in human brain tissue. J Neurochem. 1994 Nov;63(5):1596-602.
8003671	Sun W, Ferrer-Montiel AV, Montal M: Primary structure and functional expression of the AMPA/kainate receptor subunit 2 from human brain. Neuroreport. 1994 Jan 12;5(4):441-4.

# Drug_Target_65_HGNC_ID:
HGNC:4572

# Drug_Target_65_HPRD_ID:
04726

# Drug_Target_65_ID:
921

# Drug_Target_65_Locus:
4q32-q33

# Drug_Target_65_Molecular_Weight:
98822

# Drug_Target_65_Name:
Glutamate receptor 2

# Drug_Target_65_Number_of_Residues:
883

# Drug_Target_65_PDB_ID:
1WVJ

# Drug_Target_65_Pathway:
Not Available

# Drug_Target_65_Pfam_Domain_Function:
PF00060	Lig_chan
PF01094	ANF_receptor

# Drug_Target_65_Protein_Sequence:
>Glutamate receptor 2 precursor
MQKIMHISVLLSPVLWGLIFGVSSNSIQIGGLFPRGADQEYSAFRVGMVQFSTSEFRLTP
HIDNLEVANSFAVTNAFCSQFSRGVYAIFGFYDKKSVNTITSFCGTLHVSFITPSFPTDG
THPFVIQMRPDLKGALLSLIEYYQWDKFAYLYDSDRGLSTLQAVLDSAAEKKWQVTAINV
GNINNDKKDEMYRSLFQDLELKKERRVILDCERDKVNDIVDQVITIGKHVKGYHYIIANL
GFTDGDLLKIQFGGANVSGFQIVDYDDSLVSKFIERWSTLEEKEYPGAHTTTIKYTSALT
YDAVQVMTEAFRNLRKQRIEISRRGNAGDCLANPAVPWGQGVEIERALKQVQVEGLSGNI
KFDQNGKRINYTINIMELKTNGPRKIGYWSEVDKMVVTLTELPSGNDTSGLENKTVVVTT
ILESPYVMMKKNHEMLEGNERYEGYCVDLAAEIAKHCGFKYKLTIVGDGKYGARDADTKI
WNGMVGELVYGKADIAIAPLTITLVREEVIDFSKPFMSLGISIMIKKPQKSKPGVFSFLD
PLAYEIWMCIVFAYIGVSVVLFLVSRFSPYEWHTEEFEDGRETQSSESTNEFGIFNSLWF
SLGAFMQQGCDISPRSLSGRIVGGVWWFFTLIIISSYTANLAAFLTVERMVSPIESAEDL
SKQTEIAYGTLDSGSTKEFFRRSKIAVFDKMWTYMRSAEPSVFVRTTAEGVARVRKSKGK
YAYLLESTMNEYIEQRKPCDTMKVGGNLDSKGYGIATPKGSSLRNAVNLAVLKLNEQGLL
DKLKNKWWYDKGECGSGGGDSKEKTSALSLSNVAGVFYILVGGLGLAMLVALIEFCYKSR
AEAKRMKVAKNAQNINPSSSQNSQNFATYKEGYNVYGIESVKI

# Drug_Target_65_Reaction:
Not Available

# Drug_Target_65_Signals:
1-24

# Drug_Target_65_Specific_Function:
Receptor for glutamate. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists. This receptor binds AMPA(quisqualate) > glutamate > kainate

# Drug_Target_65_SwissProt_ID:
P42262

# Drug_Target_65_SwissProt_Name:
GRIA2_HUMAN

# Drug_Target_65_Synonyms:
AMPA-selective glutamate receptor 2
GluR-2
GluR-B
GluR-K2
Glutamate receptor 2 precursor
Glutamate receptor ionotropic, AMPA 2

# Drug_Target_65_Theoretical_pI:
7.66

# Drug_Target_65_Transmembrane_Regions:
485-505
544-564
625-645
813-833

# Drug_Target_66_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_66_Chromosome_Location:
Not Available

# Drug_Target_66_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
7679210	Henley JM, Jenkins R, Hunt SP: Localisation of glutamate receptor binding sites and mRNAs to the dorsal horn of the rat spinal cord. Neuropharmacology. 1993 Jan;32(1):37-41.

# Drug_Target_66_Essentiality:
Non-Essential

# Drug_Target_66_GenAtlas_ID:
GRIA3

# Drug_Target_66_GenBank_ID_Gene:
U10302

# Drug_Target_66_GenBank_ID_Protein:
507829

# Drug_Target_66_GeneCard_ID:
GRIA3

# Drug_Target_66_Gene_Name:
GRIA3

# Drug_Target_66_Gene_Sequence:
>2685 bp
ATGGCCAGGCAGAAGAAAATGGGGCAAAGCGTGCTCCGGGCGGTCTTCTTTTTAGTCCTG
GGGCTTTTGGGTCATTCTCACGGAGGATTCCCCAACACCATCAGCATAGGTGGACTTTTC
ATGAGAAACACAGTGCAGGAGCACAGCGCTTTCCGCTTTGCCGTGCAGTTATACAACACC
AACCAGAACACCACCGAGAAGCCCTTCCATTTGAATTACCACGTAGATCACTTGGATTCC
TCCAATAGTTTTTCCGTGACAAATGCTTTCTGCTCCCAGTTCTCGAGAGGGGTGTATGCC
ATCTTTGGATTCTATGACCAGATGTCAATGAACACCCTGACCTCCTTCTGTGGGGCCCTG
CACACATCCTTTGTTACGCCTAGCTTCCCCACTGACGCAGATGTGCAGTTTGTCATCCAG
ATGCGCCCAGCCTTGAAGGGCGCTATTCTGAGTCTTCTGGGTCATTACAAGTGGGAGAAG
TTTGTGTACCTCTATGACACAGAACGAGGATTTTCCATCCTCCAAGCGATTATGGAAGCA
GCAGTGCAAAACAACTGGCAAGTAACAGCAAGGTCTGTGGGAAACATAAAGGACGTCCAA
GAATTCAGGCGCATCATTGAAGAAATGGACAGGAGGCAGGAAAAGCGATACTTGATTGAC
TGCGAAGTCGAAAGGATTAACACAATTTTGGAACAGGTTGTGATCCTAGGGAAACACTCA
AGAGGTTATCACTACATGCTCGCTAACCTGGGTTTTACTGATATTTTACTGGAAAGAGTC
ATGCATGGGGGAGCCAACATTACAGGTTTCCAGATTGTCAACAATGAAAACCCTATGGTT
CAGCAGTTCATACAGCGCTGGGTGAGGCTGGATGAAAGGGAATTCCCTGAAGCCAAGAAT
GCACCACTAAAGTATACATCTGCATTGACACACGACGCAATACTGGTCATAGCAGAAGCT
TTCCGCTACCTGAGGAGGCAGCGAGTAGATGTGTCCCGGAGAGGAAGTGCTGGAGACTGC
TTAGCAAATCCTGCTGTGCCCTGGAGTCAAGGAATTGATATTGAGAGAGCTCTGAAAATG
GTGCAAGTACAAGGAATGACTGGAAATATTCAATTTGACACTTATGGACGTAGGACAAAT
TATACCATCGATGTGTATGAAATGAAAGTCAGTGGCTCTCGAAAAGCTGGCTACTGGAAC
GAGTATGAAAGGTTTGTGCCTTTCTCAGATCAGCAAATCAGCAATGACAGTGCATCCTCA
GAGAATCGGACCATAGTAGTGACTACCATTCTGGAATCACCATATGTAATGTACAAGAAG
AACCATGAGCAACTGGAAGGAAATGAACGATATGAAGGCTATTGTGTAGACCTAGCCTAT
GAAATAGCCAAACATGTAAGGATCAAATACAAATTGTCCATCGTTGGTGACGGGAAATAT
GGTGCAAGGGATCCAGAGACTAAAATATGGAACGGCATGGTTGGGGAACTTGTCTATGGG
AGAGCTGATATAGCTGTTGCTCCACTCACTATAACATTGGTCCGTGAAGAAGTCATAGAT
TTTTCAAAGCCATTAATGAGCCTGGGCATCTCCATCATGATAAAGAAGCCTCAGAAATCA
AAACCAGGCGTATTCTCATTTCTGGATCCCCTGGCTTATGAAATCTGGATGTGCATTGTC
TTTGCTTACATTGGAGTCAGCGTAGTTCTTTTCCTAGTCAGCAGGTTCAGTCCTTATGAA
TGGCACTTGGAAGACAACAATGAAGAACCTCGTGACCCACAAAGTCCTCCTGATCCTCCA
AATGAATTTGGAATATTTAACAGTCTTTGGTTTTCCTTGGGTGCCTTTATGCAGCAAGGA
TGTGATATTTCTCCAAGATCACTCTCCGGGCGCATTGTTGGAGGGGTTTGGTGGTTCTTC
ACCCTGATCATAATTTCTTCCTATACTGCCAATCTCGCTGCTTTCCTGACTGTGGAGAGG
ATGGTTTCTCCCATAGAGAGTGCTGAAGACTTAGCTAAACAGACTGAAATTGCATATGGG
ACCCTGGACTCCGGTTCAACAAAAGAATTTTTCAGAAGATCCAAAATTGCTGTGTACGAG
AAAATGTGGTCTTACATGAAATCAGCGGAGCCATCTGTGTTTACCAAAACAACAGCAGAC
GGAGTGGCCCGAGTGCGAAAGTCCAAGGGAAAGTTCGCCTTCCTGCTGGAGTCAACCATG
AATGAGTACATTGAGCAGAGAAAACCATGTGATACGATGAAAGTTGGTGGAAATCTGGAT
TCCAAAGGCTATGGTGTGGCAACCCCTAAAGGCTCAGCATTAGGAAATGCTGTTAACCTG
GCAGTATTAAAACTGAATGAGCAAGGCCTCTTGGACAAATTGAAAAACAAATGGTGGTAC
GACAAAGGAGAGTGCGGCAGCGGGGGCGGTGACTCCAAGGACAAGACCAGCGCTCTGAGC
CTGAGCAATGTGGCAGGCGTTTTCTATATACTTGTCGGAGGTCTGGGGCTGGCCATGATG
GTGGCTTTGATAGAATTCTGTTACAAATCACGGGCAGAGTCCAAACGCATGAAACTCACA
AAGAACACCCAAAACTTTAAGCCTGCTCCTGCCACCAACACTCAGAATTATGCTACATAC
AGAGAAGGCTACAACGTGTATGGAACAGAGAGTGTTAAGATCTAG

# Drug_Target_66_General_Function:
Involved in ionotropic glutamate receptor activity

# Drug_Target_66_General_References:
10602120	Amir R, Dahle EJ, Toriolo D, Zoghbi HY: Candidate gene analysis in Rett syndrome and the identification of 21 SNPs in Xq. Am J Med Genet. 2000 Jan 3;90(1):69-71.
7918660	Rampersad V, Elliott CE, Nutt SL, Foldes RL, Kamboj RK: Human glutamate receptor hGluR3 flip and flop isoforms: cloning and sequencing of the cDNAs and primary structure of the proteins. Biochim Biophys Acta. 1994 Oct 18;1219(2):563-6.

# Drug_Target_66_HGNC_ID:
HGNC:4573

# Drug_Target_66_HPRD_ID:
02378

# Drug_Target_66_ID:
923

# Drug_Target_66_Locus:
Xq25-q26

# Drug_Target_66_Molecular_Weight:
101158

# Drug_Target_66_Name:
Glutamate receptor 3

# Drug_Target_66_Number_of_Residues:
894

# Drug_Target_66_PDB_ID:
1XHY

# Drug_Target_66_Pathway:
Not Available

# Drug_Target_66_Pfam_Domain_Function:
PF00060	Lig_chan
PF01094	ANF_receptor

# Drug_Target_66_Protein_Sequence:
>Glutamate receptor 3 precursor
MARQKKMGQSVLRAVFFLVLGLLGHSHGGFPNTISIGGLFMRNTVQEHSAFRFAVQLYNT
NQNTTEKPFHLNYHVDHLDSSNSFSVTNAFCSQFSRGVYAIFGFYDQMSMNTLTSFCGAL
HTSFVTPSFPTDADVQFVIQMRPALKGAILSLLGHYKWEKFVYLYDTERGFSILQAIMEA
AVQNNWQVTARSVGNIKDVQEFRRIIEEMDRRQEKRYLIDCEVERINTILEQVVILGKHS
RGYHYMLANLGFTDILLERVMHGGANITGFQIVNNENPMVQQFIQRWVRLDEREFPEAKN
APLKYTSALTHDAILVIAEAFRYLRRQRVDVSRRGSAGDCLANPAVPWSQGIDIERALKM
VQVQGMTGNIQFDTYGRRTNYTIDVYEMKVSGSRKAGYWNEYERFVPFSDQQISNDSASS
ENRTIVVTTILESPYVMYKKNHEQLEGNERYEGYCVDLAYEIAKHVRIKYKLSIVGDGKY
GARDPETKIWNGMVGELVYGRADIAVAPLTITLVREEVIDFSKPFMSLGISIMIKKPQKS
KPGVFSFLDPLAYEIWMCIVFAYIGVSVVLFLVSRFSPYEWHLEDNNEEPRDPQSPPDPP
NEFGIFNSLWFSLGAFMQQGCDISPRSLSGRIVGGVWWFFTLIIISSYTANLAAFLTVER
MVSPIESAEDLAKQTEIAYGTLDSGSTKEFFRRSKIAVYEKMWSYMKSAEPSVFTKTTAD
GVARVRKSKGKFAFLLESTMNEYIEQRKPCDTMKVGGNLDSKGYGVATPKGSALRNAVNL
AVLKLNEQGLLDKLKNKWWYDKGECGSGGGDSKDKTSALSLSNVAGVFYILVGGLGLAMM
VALIEFCYKSRAESKRMKLTKNTQNFKPAPATNTQNYATYREGYNVYGTESVKI

# Drug_Target_66_Reaction:
Not Available

# Drug_Target_66_Signals:
1-28

# Drug_Target_66_Specific_Function:
Receptor for glutamate. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of GLU are mediated by a variety of receptors that are named according to their selective agonists

# Drug_Target_66_SwissProt_ID:
P42263

# Drug_Target_66_SwissProt_Name:
GRIA3_HUMAN

# Drug_Target_66_Synonyms:
AMPA-selective glutamate receptor 3
GluR-3
GluR-C
GluR-K3
Glutamate receptor 3 precursor
Glutamate receptor ionotropic, AMPA 3

# Drug_Target_66_Theoretical_pI:
8.74

# Drug_Target_66_Transmembrane_Regions:
553-573
603-623
636-656
824-844

# Drug_Target_67_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_67_Chromosome_Location:
Not Available

# Drug_Target_67_Drug_References:
11406192	Linden AM, Yu H, Zarrinmayeh H, Wheeler WJ, Skolnick P: Binding of an AMPA receptor potentiator ([3H]LY395153) to native and recombinant AMPA receptors. Neuropharmacology. 2001 Jun;40(8):1010-8.
12008069	Cristovao AJ, Oliveira CR, Carvalho CM: Expression of AMPA/kainate receptors during development of chick embryo retina cells: in vitro versus in vivo studies. Int J Dev Neurosci. 2002 Feb;20(1):1-9.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
7679210	Henley JM, Jenkins R, Hunt SP: Localisation of glutamate receptor binding sites and mRNAs to the dorsal horn of the rat spinal cord. Neuropharmacology. 1993 Jan;32(1):37-41.

# Drug_Target_67_Essentiality:
Non-Essential

# Drug_Target_67_GenAtlas_ID:
GRIA4

# Drug_Target_67_GenBank_ID_Gene:
U16129

# Drug_Target_67_GenBank_ID_Protein:
790538

# Drug_Target_67_GeneCard_ID:
GRIA4

# Drug_Target_67_Gene_Name:
GRIA4

# Drug_Target_67_Gene_Sequence:
>2709 bp
ATGAGGATTATTTCCAGACAGATTGTCTTGTTATTTTCTGGATTTTGGGGACTCGCCATG
GGAGCCTTTCCGAGCAGCGTGCAAATAGGTGGTCTCTTCATCCGAAACACAGATCAGGAA
TACACTGCTTTTCGATTAGCAATTTTTCTTCATAACACCGCCCCCAATGCGTCGGAAGCT
CCTTTTAATTTGGTACCTCATGTGGACAACATTGAGACAGCCAACAGTTTTGCTGTAACA
AACGCCTTCTGTTCCCAGTATTCTAGAGGAGTATTTGCCATTTTTGGACTCTATGATAAG
AGGTCGGTACATACCTTGACCTCATTCTGCAGCGCCTTACATATCTCCCTCATCACACCA
AGTTTCCCTACTGAGGGGGAGAGCCAGTTTGTGCTGCAACTAAGACCTTCGTTACGAGGA
GCACTCTTGAGTTTGCTGGATCACTACGAATGGAACTGTTTTGTCTTCCTGTATGACACA
GACAGGGGATACTCGATACTCCAAGCTATTATGGAAAAAGCAGGACAAAATGGTTGGCAT
GTCAGCGCTATATGTGTGGAAAATTTTAATGATGTCAGCTATAGGCAACTTCTAGAAGAA
CTTGACAGAAGACAAGAGAAGAAGTTTGTAATAGACTGTGAGATAGAGAGACTTCAAAAC
ATATTAGAACAGATTGTAAGTGTTGGAAAGCATGTTAAAGGCTACCATTATATCATTGCA
AACTTGGGATTCAAGGATATTTCTCTTGAGAGGTTTATACATGGTGGAGCCAATGTTACT
GGATTCCAGTTGGTGGATTTTAATACACCCATGGTAACCAAACTAATGGATCGCTGGAAG
AAACTAGATCAGAGAGAGTATCCAGGATCTGAGACTCCTCCAAAGTACACCTCTGCTCTG
ACTTATGATGGAGTCCTTGTGATGGCTGAAACTTTCCGAAGTCTTAGGAGGCAGAAAATT
GATATCTCAAGGAGAGGAAAGTCTGGGGATTGTCTGGCAAATCCTGCTGCTCCATGGGGC
CAGGGAATTGACATGGAGAGGACACTCAAACAGGTTCGAATTCAAGGGCTGACAGGGAAT
GTTCAGTTTGACCACTATGGACGTAGAGTCAATTACACAATGGATGTGTTTGAGCTGAAA
AGCACAGGACCTAGAAAGGTTGGTTACTGGAATGATATGGATAAGTTAGTCTTGATTCAA
GATGTACCAACTCTTGGCAATGACACAGCTGCTATTGAGAACAGAACAGTGGTTGTAACC
ACAATTATGGAATCCCCATATGTTATGTACAAGAAAAATCATGAAATGTTTGAAGGAAAT
GACAAGTATGAAGGATACTGTGTAGATTTGGCATCTGAAATTGCAAAACATATTGGTATC
AAGTATAAAATTGCCATTGTCCCTGATGGAAAATATGGAGCAAGGGATGCAGACACAAAA
ATCTGGAATGGGATGGTAGGAGAACTTGTTTATGGGAAAGCAGAGATTGCTATTGCCCCT
CTGACAATCACTTTGGTACGAGAGGAGGTCATTGACTTTTCTAAGCCCTTCATGAGTTTG
GGCATATCTATCATGATCAAAAAGCCTCAGAAATCCAAACCAGGAGTGTTTTCCTTCTTG
GATCCTCTGGCCTATGAGATTTGGATGTGCATAGTCTTTGCCTACATTGGTGTCAGCGTG
GTCTTATTCCTAGTTAGTAGATTTAGTCCATATGAGTGGCACACAGAAGAGCCAGAGGAC
GGAAAGGAAGGACCCAGCGACCAGCCTCCCAATGAGTTTGGCATCTTTAACAGCCTCTGG
TTTTCCCTGGGTGCTTTTATGCAGCAAGGATGTGACATTTCACCCAGATCCCTCTCAGGT
CGAATTGTTGGAGGTGTTTGGTGGTTCTTTACACTCATCATTATATCATCTTATACTGCT
AACCTGGCTGCTTTCCTGACGGTTGAGCGAATGGTCTCTCCCATAGAAAGTGCAGAAGAC
CTGGCCAAACAAACAGAAATTGCCTATGGAACACTGGATTCAGGATCAACAAAAGAATTC
TTCAGAAGATCAAAAATAGCAGTGTATGAAAAGATGTGGACCTACATGCGATCAGCAGAG
CCATCAGTATTCACTAGGACTACAGCTGAGGGAGTAGCTCGTGTCCGCAAATCCAAGGGC
AAATTTGCCTTTCTCCTGGAGTCCACTATGAATGATAACATTGAGCAGCGAAAGCCATGT
GACACGATGAAAGTGGGAGGAAATCTGGATTCCAAAGGCTATGGAGTAGCAACGCCCAAG
GGTTCCTCATTAAGAACTCCTGTAAACCTTGCCGTTTTGAAACTCAGTGAGGCAGGCGTC
TTAGACAAGCTGAAAAACAAATGGTGGTACGATAAAGGTGAATGTGGACCCAAAGACTCT
GGAAGCAAGGACAAGACGAGTGCCTTGAGCCTGAGCAATGTAGCAGGCGTCTTCTACATT
CTGGTTGGCGGCTTGGGCTTGGCAATGCTGGTGGCTTTGATAGAGTTCTGTTACAAGTCC
AGGGCAGAAGCGAAGAGAATGAAGCTGACCTTTTCTGAAGCCATAAGAAACAAAGCCAGA
TTATCCATCACTGGGAGTGTGGGAGAGAATGGCCGCGTCTTGACGCCTGACTGCCCAAAG
GCTGTACACACTGGAACTGCAATCAGACAAAGTTCAGGATTGGCTGTCATTGCATCGGAC
CTACCATAA

# Drug_Target_67_General_Function:
Amino acid transport and metabolism

# Drug_Target_67_General_References:
8589990	Fletcher EJ, Nutt SL, Hoo KH, Elliott CE, Korczak B, McWhinnie EA, Kamboj RK: Cloning, expression and pharmacological characterization of a human glutamate receptor: hGluR4. Receptors Channels. 1995;3(1):21-31.

# Drug_Target_67_HGNC_ID:
HGNC:4574

# Drug_Target_67_HPRD_ID:
00694

# Drug_Target_67_ID:
922

# Drug_Target_67_Locus:
11q22

# Drug_Target_67_Molecular_Weight:
100811

# Drug_Target_67_Name:
Glutamate receptor 4

# Drug_Target_67_Number_of_Residues:
902

# Drug_Target_67_PDB_ID:
1XHY

# Drug_Target_67_Pathway:
Not Available

# Drug_Target_67_Pfam_Domain_Function:
PF00060	Lig_chan
PF01094	ANF_receptor

# Drug_Target_67_Protein_Sequence:
>Glutamate receptor 4 precursor
MRIISRQIVLLFSGFWGLAMGAFPSSVQIGGLFIRNTDQEYTAFRLAIFLHNTAPNASEA
PFNLVPHVDNIETANSFAVTNAFCSQYSRGVFAIFGLYDKRSVHTLTSFCSALHISLITP
SFPTEGESQFVLQLRPSLRGALLSLLDHYEWNCFVFLYDTDRGYSILQAIMEKAGQNGWH
VSAICVENFNDVSYRQLLEELDRRQEKKFVIDCEIERLQNILEQIVSVGKHVKGYHYIIA
NLGFKDISLERFIHGGANVTGFQLVDFNTPMVTKLMDRWKKLDQREYPGSETPPKYTSAL
TYDGVLVMAETFRSLRRQKIDISRRGKSGDCLANPAAPWGQGIDMERTLKQVRIQGLTGN
VQFDHYGRRVNYTMDVFELKSTGPRKVGYWNDMDKLVLIQDVPTLGNDTAAIENRTVVVT
TIMESPYVMYKKNHEMFEGNDKYEGYCVDLASEIAKHIGIKYKIAIVPDGKYGARDADTK
IWNGMVGELVYGKAEIAIAPLTITLVREEVIDFSKPFMSLGISIMIKKPQKSKPGVFSFL
DPLAYEIWMCIVFAYIGVSVVLFLVSRFSPYEWHTEEPEDGKEGPSDQPPNEFGIFNSLW
FSLGAFMQQGCDISPRSLSGRIVGGVWWFFTLIIISSYTANLAAFLTVERMVSPIESAED
LAKQTEIAYGTLDSGSTKEFFRRSKIAVYEKMWTYMRSAEPSVFTRTTAEGVARVRKSKG
KFAFLLESTMNDNIEQRKPCDTMKVGGNLDSKGYGVATPKGSSLRTPVNLAVLKLSEAGV
LDKLKNKWWYDKGECGPKDSGSKDKTSALSLSNVAGVFYILVGGLGLAMLVALIEFCYKS
RAEAKRMKLTFSEAIRNKARLSITGSVGENGRVLTPDCPKAVHTGTAIRQSSGLAVIASD
LP

# Drug_Target_67_Reaction:
Not Available

# Drug_Target_67_Signals:
1-20

# Drug_Target_67_Specific_Function:
L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists

# Drug_Target_67_SwissProt_ID:
P48058

# Drug_Target_67_SwissProt_Name:
GRIA4_HUMAN

# Drug_Target_67_Synonyms:
AMPA-selective glutamate receptor 4
GluR-4
GluR-D
GluR4
Glutamate receptor 4 precursor
Glutamate receptor ionotropic, AMPA 4

# Drug_Target_67_Theoretical_pI:
8.32

# Drug_Target_67_Transmembrane_Regions:
547-566
593-611
622-640
814-834

# Drug_Target_68_Cellular_Location:
Mitochondrion
mitochondrial inner membrane

# Drug_Target_68_Chromosome_Location:
Not Available

# Drug_Target_68_Drug_References:
114173	Krishna RV, Beilstein P, Leisinger T: Biosynthesis of proline in Pseudomonas aeruginosa. Properties of gamma-glutamyl phosphate reductase and 1-pyrroline-5-carboxylate reductase. Biochem J. 1979 Jul 1;181(1):223-30.
12513997	Morita Y, Nakamori S, Takagi H: L-proline accumulation and freeze tolerance of Saccharomyces cerevisiae are caused by a mutation in the PRO1 gene encoding gamma-glutamyl kinase. Appl Environ Microbiol. 2003 Jan;69(1):212-9.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9622938	Kamoun P, Aral B, Saudubray JM: [A new inherited metabolic disease: delta1-pyrroline 5-carboxylate synthetase deficiency] Bull Acad Natl Med. 1998;182(1):131-7; discussion 138-9.

# Drug_Target_68_Essentiality:
Non-Essential

# Drug_Target_68_GenAtlas_ID:
ALDH18A1

# Drug_Target_68_GenBank_ID_Gene:
X94453

# Drug_Target_68_GenBank_ID_Protein:
1304314

# Drug_Target_68_GeneCard_ID:
ALDH18A1

# Drug_Target_68_Gene_Name:
ALDH18A1

# Drug_Target_68_Gene_Sequence:
>2388 bp
ATGTTGAGTCAAGTTTACCGCTGTGGGTTCCAGCCCTTCAACCAACATCTTCTGCCCTGG
GTCAAGTGTACAACCGTCTTCAGATCTCATTGTATCCAGCCTTCAGTCATCAGACATGTT
CGTTCTTGGAGCAACATCCCGTTTATCACTGTACCCCTCAGTCGTACACATGGCAAGTCC
TTCGCCCACCGCAGTGAGCTGAAGCATGCCAAGAGAATCGTGGTGAAGCTCGGCAGTGCC
GTGGTGACCCGAGGGGATGAATGTGGCCTGGCCCTGGGGCGCTTGGCATCTATTGTTGAG
CAGGTATCAGTGCTGCAGAATCAGGGCAGAGAGATGATGCTGGTGACCAGTGGAGCCGTA
GCCTTTGGCAAACAAACGTTGCGCCATGAGATCCTTCTGTCTCAGAGCGTGCGGCAGGCC
CTCCACTCGGGGCAGAACCAGCTGAAAGAAATGGCAATTCCAGTCTTAGAGGCACGAGCC
TGTGCAGCTGCCGGACAGAGTGGGCTGATGGCCTTGTATGAGGCTATGTTTACCCAGTAC
AGCATCTGTGCTGCCCAGATTTTGGTGACCAATTTGGATTTCCATGATGAGCAGAAGCGC
CGGAACCTCAATGGAACACTTCATGAACTCCTTAGAATGAACATTGTCCCCATTGTCAAC
ACAAATGATGCTGTTGTCCCCCCAGCTGAGCCCAACAGTGACCTGCAGGGGGTAAATGTT
ATTAGTGTTAAAGATAATGATAGCCTGGCTGCCCGACTGGCTGTGGAAATGAAAACTGAT
CTCTTGATTGTCCTTCCAGATGTAGAAGGCCTTTTTGACAGCCCCCCAGGTTCAGATGAT
GCAAAGCTTATTGATATATTTTATCCCGGAGATCAGCAGTCTGTGACATTTGGACCCAAG
TCTAGAGTGGGAAATGGGTGCATGGAAGCCAAGGTGAAAAGCACCCTCTGGGCTTTGCAA
GGTGGCACTTCTGTTGTTATTGCCAATGGAACCCACCCAAAGGTGTCTGGGCACGTCATC
ACAGACATTGTGGAGGGGAAGAAAGTTGGTACCTTCTTTTCAGAAGTAAAGCCTGCAGGC
CCTACTGTTGAGCAGCAGGGAGAAATGGCGCGATCTGGAGGAAGGATGTTGGCCACCTTG
GAACCTGAGCAGAGAGCAGAAATTATCCATCATCTGGCTGATCTGTTGACGGACCAGCGT
GATGAGATCCTGTTAGCCAACAAAAAAGACTTGGAGGAGGCAGAGGGGAGACTTGCAGCT
CCTCTGCTGAAACGTTTAAGCCTCTCCACATCCAAATTGAACAGCCTGGCCATCGGTCTG
CGACAGATCGCAGCCTCCTCCCAGGACAGCGTGGGACGTGTTTTGCGCCGCACCCGAATC
GCCAAAAACTTGGAACTGGAACAAGTGACTGTCCCAATTGGAGTTCTGCTGGTGATCTTT
GAATCTCGTCCTGACTGTCCTACCCCAGGTGGCAGCTTTGCTATCGCAAGTGGCAATGGC
TTGTTACTCAAAGGAGGGAAGGAGGCTGCACACAGCAACCGGATTCTCCACCTCCTGACC
CAGGAGGCTCTCTCAATCCATGGAGTCAAGGAGGCCGTGCAACTGGTGAATACCAGAGAA
GAAGTTGAAGATCTTTGCCGCCTAGACAAAATGATAGATCTGATCATTCCACGTGGCTCT
TCCCAGCTGGTCAGAGACATCCAGAAAGCTGCTAAGGGGATTCCAGTGATGGGGCACAGC
GAAGGGATCTGTCACATGTATGTGGATTCCGAGGCCAGTGTTGATAAGGTCACCAGGCTA
GTCAGAGACTCTAAATGTGAATATCCAGCTGCCTGTAATGCTTTGGAGACTTTGTTAATC
CACCGGGATCTGCTCAGGACACCATTATTTGACCAGATCATTGATATGCTGAGAGTGGAA
CAGGTAAAAATTCATGCAGGCCCCAAATTTGCCTCCTATCTGACCTTCAGCCCCTCCGAA
GTGAAGTCACTCCGAACTGAGTATGGGGACCTGGAATTATGCATTGAAGTAGTGGACAAC
GTTCAGGATGCCATTGACCACATCCACAAGTATGGCAGCTCCCACACGGATGTCATCGTC
ACAGAGGACGAAAACACAGCGGAGTTCTTCCTGCAGCACGTAGACAGTGCCTGTGTGTTC
TGGAATGCCAGCACTCGCTTTTCTGATGGTTACCGCTTTGGACTGGGAGCTGAAGTGGGA
ATCAGTACATCGAGAATCCACGCCCGGGGACCAGTAGGACTTGAGGGACTGCTTACTACT
AAGTGGCTGCTGCGAGGGAAGGACCACGTGGTCTCAGATTTCTCAGAGCATGGAAGTTTA
AAATATCTTCATGAGAACCTCCCTATTCCTCAGAGAAACACCAACTGA

# Drug_Target_68_General_Function:
Amino acid transport and metabolism

# Drug_Target_68_General_References:
10037775	Hu CA, Lin WW, Obie C, Valle D: Molecular enzymology of mammalian Delta1-pyrroline-5-carboxylate synthase. Alternative splice donor utilization generates isoforms with different sensitivity to ornithine inhibition. J Biol Chem. 1999 Mar 5;274(10):6754-62.
8761662	Aral B, Schlenzig JS, Liu G, Kamoun P: Database cloning human delta 1-pyrroline-5-carboxylate synthetase (P5CS) cDNA: a bifunctional enzyme catalyzing the first 2 steps in proline biosynthesis. C R Acad Sci III. 1996 Mar;319(3):171-8.

# Drug_Target_68_HGNC_ID:
HGNC:9722

# Drug_Target_68_HPRD_ID:
00696

# Drug_Target_68_ID:
915

# Drug_Target_68_Locus:
10q24.3

# Drug_Target_68_Molecular_Weight:
87304

# Drug_Target_68_Name:
Delta 1-pyrroline-5-carboxylate synthetase

# Drug_Target_68_Number_of_Residues:
795

# Drug_Target_68_PDB_ID:
Not Available

# Drug_Target_68_Pathway:
Not Available

# Drug_Target_68_Pfam_Domain_Function:
PF00696	AA_kinase

# Drug_Target_68_Protein_Sequence:
>Delta 1-pyrroline-5-carboxylate synthetase
MLSQVYRCGFQPFNQHLLPWVKCTTVFRSHCIQPSVIRHVRSWSNIPFITVPLSRTHGKS
FAHRSELKHAKRIVVKLGSAVVTRGDECGLALGRLASIVEQVSVLQNQGREMMLVTSGAV
AFGKQRLRHEILLSQSVRQALHSGQNQLKEMAIPVLEARACAAAGQSGLMALYEAMFTQY
SICAAQILVTNLDFHDEQKRRNLNGTLHELLRMNIVPIVNTNDAVVPPAEPNSDLQGVNV
ISVKDNDSLAARLAVEMKTDLLIVLSDVEGLFDSPPGSDDAKLIDIFYPGDQQSVTFGTK
SRVGMGGMEAKVKAALWALQGGTSVVIANGTHPKVSGHVITDIVEGKKVGTFFSEVKPAG
PTVEQQGEMARSGGRMLATLEPEQRAEIIHHLADLLTDQRDEILLANKKDLEEAEGRLAA
PLLKRLSLSTSKLNSLAIGLRQIAASSQDSVGRVLRRTRIAKNLELEQVTVPIGVLLVIF
ESRPDCLPQVAALAIASGNGLLLKGGKEAAHSNRILHLLTQEALSIHGVKEAVQLVNTRE
EVEDLCRLDKMIDLIIPRGSSQLVRDIQKAAKGIPVMGHSEGICHMYVDSEASVDKVTRL
VRDSKCEYPAACNALETLLIHRDLLRTPLFDQIIDMLRVEQVKIHAGPKFASYLTFSPSE
VKSLRTEYGDLELCIEVVDNVQDAIDHIHKYGSSHTDVIVTEDENTAEFFLQHVDSACVF
WNASTRFSDGYRFGLGAEVGISTSRIHARGPVGLEGLLTTKWLLRGKDHVVSDFSEHGSL
KYLHENLPIPQRNTN

# Drug_Target_68_Reaction:
L-glutamate 5-semialdehyde + phosphate + NADP+ = L-glutamyl 5-phosphate + NADPH + H+

# Drug_Target_68_Signals:
None

# Drug_Target_68_Specific_Function:
Not Available

# Drug_Target_68_SwissProt_ID:
P54886

# Drug_Target_68_SwissProt_Name:
P5CS_HUMAN

# Drug_Target_68_Synonyms:
Aldehyde dehydrogenase 18 family member A1
EC 1.2.1.41
EC 2.7.2.11
GK
GPR
Gamma-glutamyl kinase
Gamma-glutamyl phosphate reductase
Glutamate-5-semialdehyde dehydrogenase
P5CS

# Drug_Target_68_Theoretical_pI:
7.13

# Drug_Target_68_Transmembrane_Regions:
None

# Drug_Target_69_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_69_Chromosome_Location:
Not Available

# Drug_Target_69_Drug_References:
17581967	Wong AY, MacLean DM, Bowie D: Na+/Cl- dipole couples agonist binding to kainate receptor activation. J Neurosci. 2007 Jun 20;27(25):6800-9.

# Drug_Target_69_Essentiality:
Non-Essential

# Drug_Target_69_GenAtlas_ID:
GRIK2

# Drug_Target_69_GenBank_ID_Gene:
U16126

# Drug_Target_69_GenBank_ID_Protein:
790532

# Drug_Target_69_GeneCard_ID:
GRIK2

# Drug_Target_69_Gene_Name:
GRIK2

# Drug_Target_69_Gene_Sequence:
>2727 bp
ATGAAGATTATTTTCCCGATTCTAAGTAATCCAGTCTTCAGGCGCACCGTTAAACTCCTG
CTCTGTTTACTGTGGATTGGATATTCTCAAGGAACCACACATGTATTAAGATTTGGTGGT
ATTTTTGAATATGTGGAATCTGGCCCAATGGGAGCTGAGGAACTTGCATTCAGATTTGCT
GTGAACACAATTAACAGAAACAGAACATTGCTACCCAATACTACCCTTACCTATGATACC
CAGAAGATAAACCTTTATGATAGTTTTGAAGCATCCAAGAAAGCCTGTGATCAGCTGTCT
CTTGGGGTGGCTGCCATCTTCGGGCCTTCACACAGCTCATCAGCAAACGCAGTGCAGTCC
ATCTGCAATGCTCTGGGAGTTCCCCACATACAGACCCGCTGGAAGCACCAGGTGTCAGAC
AACAAAGATTCCTTCTATGTCAGTCTCTACCCAGACTTCTCTTCACTCAGCCGTGCCATT
TTAGACCTGGTGCAGTTTTTCAAGTGGAAAACCGTCACGGTTGTGTATGATGACAGCACT
GGTCTCATTCGTTTGCAAGAGCTCATCAAAGCTCCATCAAGGTATAATCTTCGACTCAAA
ATTCGTCAGTTACCTGCTGATACAAAGGATGCAAAACCCTTACTAAAAGAAATGAAAAGA
GGCAAGGAGTTTCATGTAATCTTTGATTGTAGCCATGAAATGGCAGCAGGCATTTTAAAA
CAGGCATTAGCTATGGGAATGATGACAGAATACTATCATTATATCTTTACCACTCTGGAC
CTCTTTGCTCTTGATGTTGAGCCCTACCGATACAGTGGTGTTAACATGACAGGGTTCAGA
ATATTAAATACAGAAAATACCCAAGTCTCCTCCATCATTGAAAAGTGGTCGATGGAACGA
TTGCAGGCACCTCCGAAACCCGATTCAGGTTTGCTGGATGGATTTATGACGACTGATGCT
GCTCTAATGTATGATGCTGTGCATGTGGTGTCTGTGGCCGTTCAACAGTTTCCCCAGATG
ACAGTCAGTTCCTTGCAGTGTAATCGACATAAACCCTGGCGCTTCGGGACCCGCTTTATG
AGTCTAATTAAAGAGGCACATTGGGAAGGCCTCACAGGCAGAATAACTTTCAACAAAACC
AATGGCTTGAGAACAGATTTTGATTTGGATGTGATCAGTCTGAAGGAAGAAGGTCTAGAA
AAGATTGGAACGTGGGATCCAGCCAGTGGCCTGAATATGACAGAAAGTCAAAAGGGAAAG
CCAGCGAACATCACAGATTCCTTATCCAATCGTTCTTTGATTGTTACCACCATTTTGGAA
GAGCCTTATGTCCTTTTTAAGAAGTCTGACAAACCTCTCTATGGTAATGATCGATTTGAA
GGCTATTGCATTGATCTCCTCAGAGAGTTATCTACAATCCTTGGCTTTACATATGAAATT
AGACTTGTGGAAGATGGGAAATATGGAGCCCAGGATGATGCCAATGGACAATGGAATGGA
ATGGTTCGTGAACTAATTGATCATAAAGCTGACCTTGCAGTTGCTCCACTGGCTATTACC
TATGTTCGAGAGAAGGTCATCGACTTTTCCAAGCCCTTTATGACACTTGGAATAAGTATT
TTGTACCGCAAGCCCAATGGTACAAACCCAGGCGTCTTCTCCTTCCTGAATCCTCTCTCC
CCTGATATCTGGATGTATATTCTGCTGGCTTACTTGGGTGTCAGTTGTGTGCTCTTTGTC
ATAGCCAGGTTTAGTCCTTATGAGTGGTATAATCCACACCCTTGCAACCCTGACTCAGAC
GTGGTGGAAAACAATTTTACCTTGCTAAATAGTTTCTGGTTTGGAGTTGGAGCTCTCATG
CAGCAAGGTTCTGAGCTCATGCCCAAAGCACTGTCCACCAGGATAGTGGGAGGCATTTGG
TGGTTTTTCACACTTATCATCATTTCTTCGTATACTGCTAACTTAGCCGCCTTTCTGACA
GTGGAACGCATGGAATCCCCTATTGACTCTGCTGATGATTTAGCTAAACAAACCAAGATA
GAATATGGAGCAGTAGAGGATGGTGCAACCATGACTTTTTTCAAGAAATCAAAAATCTCC
ACGTATGACAAAATGTGGGCCTTTATGAGTAGCAGAAGGCAGTCAGTGCTGGTCAAAAGT
AATGAAGAAGGAATCCAGCGAGTCCTCACCTCTGATTATGCTTTCCTAATGGAGTCAACA
ACCATCGAGTTTGTTACCCAGCGGAACTGTAACCTGACACAGATTGGCGGCCTTATAGAC
TCTAAAGGTTATGGCGTTGGCACTCCCATGGGTTCTCCATATCGAGACAAAATTACCATA
GCAATTCTTCAGCTGCAAGAGGAAGGCAAACTGCATATGATGAAGGAGAAATGGTGGAGG
GGCAATGGTTGCCCAGAAGAGGAAAGCAAAGAGGCCAGTGCCCTGGGGGTTCAGAATATT
GGTGGCATCTTCATTGTTCTGGCAGCCGGCTTGGTGCTTTCAGTTTTTGTGGCAGTGGGA
GAATTTTTATACAAATCCAAAAAAAACGCTCAATTGGAAAAGAGGTCCTTCTGTAGTGCC
ATGGTAGAAGAATTGAGGATGTCCCTGAAGTGCCAGCGTCGGTTAAAACATAAGCCACAG
GCCCCAGTTATTGTGAAAACAGAAGAAGTTATCAACATGCACACATTTAACGACAGAAGG
TTGCCAGGTAAAGAAACCATGGCATAA

# Drug_Target_69_General_Function:
Involved in ionotropic glutamate receptor activity

# Drug_Target_69_General_References:
11744724	Piserchio A, Pellegrini M, Mehta S, Blackman SM, Garcia EP, Marshall J, Mierke DF: The PDZ1 domain of SAP90. Characterization of structure and binding. J Biol Chem. 2002 Mar 1;277(9):6967-73. Epub 2001 Dec 14.
7523595	Paschen W, Hedreen JC, Ross CA: RNA editing of the glutamate receptor subunits GluR2 and GluR6 in human brain tissue. J Neurochem. 1994 Nov;63(5):1596-602.
7536611	Hoo KH, Nutt SL, Fletcher EJ, Elliott CE, Korczak B, Deverill RM, Rampersad V, Fantaske RP, Kamboj RK: Functional expression and pharmacological characterization of the human EAA4 (GluR6) glutamate receptor: a kainate selective channel subunit. Receptors Channels. 1994;2(4):327-37.
7696618	Nutt SL, Kamboj RK: RNA editing of human kainate receptor subunits. Neuroreport. 1994 Dec 20;5(18):2625-9.
8034316	Paschen W, Blackstone CD, Huganir RL, Ross CA: Human GluR6 kainate receptor (GRIK2): molecular cloning, expression, polymorphism, and chromosomal assignment. Genomics. 1994 Apr;20(3):435-40.

# Drug_Target_69_HGNC_ID:
HGNC:4580

# Drug_Target_69_HPRD_ID:
00692

# Drug_Target_69_ID:
918

# Drug_Target_69_Locus:
6q16.3-q21

# Drug_Target_69_Molecular_Weight:
102585

# Drug_Target_69_Name:
Glutamate receptor, ionotropic kainate 2

# Drug_Target_69_Number_of_Residues:
908

# Drug_Target_69_PDB_ID:
1YAE

# Drug_Target_69_Pathway:
Not Available

# Drug_Target_69_Pfam_Domain_Function:
PF00060	Lig_chan
PF01094	ANF_receptor

# Drug_Target_69_Protein_Sequence:
>Glutamate receptor, ionotropic kainate 2 precursor
MKIIFPILSNPVFRRTVKLLLCLLWIGYSQGTTHVLRFGGIFEYVESGPMGAEELAFRFA
VNTINRNRTLLPNTTLTYDTQKINLYDSFEASKKACDQLSLGVAAIFGPSHSSSANAVQS
ICNALGVPHIQTRWKHQVSDNKDSFYVSLYPDFSSLSRAILDLVQFFKWKTVTVVYDDST
GLIRLQELIKAPSRYNLRLKIRQLPADTKDAKPLLKEMKRGKEFHVIFDCSHEMAAGILK
QALAMGMMTEYYHYIFTTLDLFALDVEPYRYSGVNMTGFRILNTENTQVSSIIEKWSMER
LQAPPKPDSGLLDGFMTTDAALMYDAVHVVSVAVQQFPQMTVSSLQCNRHKPWRFGTRFM
SLIKEAHWEGLTGRITFNKTNGLRTDFDLDVISLKEEGLEKIGTWDPASGLNMTESQKGK
PANITDSLSNRSLIVTTILEEPYVLFKKSDKPLYGNDRFEGYCIDLLRELSTILGFTYEI
RLVEDGKYGAQDDANGQWNGMVRELIDHKADLAVAPLAITYVREKVIDFSKPFMTLGISI
LYRKPNGTNPGVFSFLNPLSPDIWMYILLAYLGVSCVLFVIARFSPYEWYNPHPCNPDSD
VVENNFTLLNSFWFGVGALMQQGSELMPKALSTRIVGGIWWFFTLIIISSYTANLAAFLT
VERMESPIDSADDLAKQTKIEYGAVEDGATMTFFKKSKISTYDKMWAFMSSRRQSVLVKS
NEEGIQRVLTSDYAFLMESTTIEFVTQRNCNLTQIGGLIDSKGYGVGTPMGSPYRDKITI
AILQLQEEGKLHMMKEKWWRGNGCPEEESKEASALGVQNIGGIFIVLAAGLVLSVFVAVG
EFLYKSKKNAQLEKRSFCSAMVEELRMSLKCQRRLKHKPQAPVIVKTEEVINMHTFNDRR
LPGKETMA

# Drug_Target_69_Reaction:
Not Available

# Drug_Target_69_Signals:
1-31

# Drug_Target_69_Specific_Function:
L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists. May be involved in the transmission of light information from the retina to the hypothalamus. This receptor binds domoate > kainate > quisqualate > 6-cyano-7-nitroquinoxaline-2,3-dione > L-glutamate = 6,7- dinitroquinoxaline-2,3-dione > dihydrokainate

# Drug_Target_69_SwissProt_ID:
Q13002

# Drug_Target_69_SwissProt_Name:
GRIK2_HUMAN

# Drug_Target_69_Synonyms:
EAA4
Excitatory amino acid receptor 4
GluR-6
GluR6
Glutamate receptor 6
Glutamate receptor, ionotropic kainate 2 precursor

# Drug_Target_69_Theoretical_pI:
8.01

# Drug_Target_69_Transmembrane_Regions:
562-582
601-621
636-656
820-840

# Drug_Target_6_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
16957773	Morimoto R, Uehara S, Yatsushiro S, Juge N, Hua Z, Senoh S, Echigo N, Hayashi M, Mizoguchi T, Ninomiya T, Udagawa N, Omote H, Yamamoto A, Edwards RH, Moriyama Y: Secretion of L-glutamate from osteoclasts through transcytosis. EMBO J. 2006 Sep 20;25(18):4175-86. Epub 2006 Sep 7.
17360958	Suzuki G, Kimura T, Satow A, Kaneko N, Fukuda J, Hikichi H, Sakai N, Maehara S, Kawagoe-Takaki H, Hata M, Azuma T, Ito S, Kawamoto H, Ohta H: Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N- methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC). J Pharmacol Exp Ther. 2007 Jun;321(3):1144-53. Epub 2007 Mar 14.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
GRM8

# Drug_Target_6_GenBank_ID_Gene:
U92459

# Drug_Target_6_GenBank_ID_Protein:
1935043

# Drug_Target_6_GeneCard_ID:
GRM8

# Drug_Target_6_Gene_Name:
GRM8

# Drug_Target_6_Gene_Sequence:
>2727 bp
ATGGTATGCGAGGGAAAGCGATCAGCCTCTTGCCCTTGTTTCTTCCTCTTGACCGCCAAG
TTCTACTGGATCCTCACAATGATGCAAAGAACTCACAGCCAGGAGTATGCCCATTCCATA
CGGGTGGATGGGGACATTATTTTGGGGGGTCTCTTCCCTGTCCACGCAAAGGGAGAGAGA
GGGGTGCCTTGTGGGGAGCTGAAGAAGGAAAAGGGGATTCACAGACTGGAGGCCATGCTT
TATGCAATTGACCAGATTAACAAGGACCCTGATCTCCTTTCCAACATCACTCTGGGTGTC
CGCATCCTCGACACGTGCTCTAGGGACACCTATGCTTTGGAGCAGTCTCTAACATTCGTG
CAGGCATTAATAGAGAAAGATGCTTCGGATGTGAAGTGTGCTAATGGAGATCCACCCATT
TTCACCAAGCCCGACAAGATTTCTGGCGTCATAGGTGCTGCAGCAAGCTCCGTGTCCATC
ATGGTTGCTAACATTTTAAGACTTTTTAAGATACCTCAAATCAGCTATGCATCCACAGCC
CCAGAGCTAAGTGATAACACCAGGTATGACTTTTTCTCTCGAGTGGTTCCGCCTGACTCC
TACCAAGCCCAAGCCATGGTGGACATCGTGACAGCACTGGGATGGAATTATGTTTCGACA
CTGGCTTCTGAGGGGAACTATGGTGAGAGCGGTGTGGAGGCCTTCACCCAGATCTCGAGG
GAGATTGGTGGTGTTTGCATTGCTCAGTCACAGAAAATCCCACGTGAACCAAGACCTGGA
GAATTTGAAAAAATTATCAAACGCCTGCTAGAAACACCTAATGCTCGAGCAGTGATTATG
TTTGCCAATGAGGATGACATCAGGAGGATATTGGAAGCAGCAAAAAAACTAAACCAAAGT
GGGCATTTTCTCTGGATTGGCTCAGATAGTTGGGGATCCAAAATAGCACCTGTCTATCAG
CAAGAGGAGATTGCAGAAGGGGCTGTGACAATTTTGCCCAAACGAGCATCAATTGATGGA
TTTGATCGATACTTTAGAAGCCGAACTCTTGCCAATAATCGAAGAAATGTGTGGTTTGCA
GAATTCTGGGAGGAGAATTTTGGCTGCAAGTTAGGATCACATGGGAAAAGGAACAGTCAT
ATAAAGAAATGCACAGGGCTGGAGCGAATTGCTCGGGATTCATCTTATGAACAGGAAGGA
AAGGTCCAATTTGTAATTGATGCTGTATATTCCATGGCTTACGCCCTGCACAATATGCAC
AAAGATCTCTGCCCTGGATACATTGGCCTTTGTCCACGAATGAGTACCATTGATGGGAAA
GAGCTACTTGGTTATATTCGGGCTGTAAATTTTAATGGCAGTGCTGGCACTCCTGTCACT
TTTAATGAAAACGGAGATGCTCCTGGACGTTATGATATCTTCCAGTATCAAATAACCAAC
AAAAGCACAGAGTACAAAGTCATCGGCCACTGGACCAATCAGCTTCATCTAAAAGTGGAA
GACATGCAGTGGGCTCATAGAGAACATACTCACCCGGCGTCTGTCTGCAGCCTGCCGTGT
AAGCCAGGGGAGAGGAAGAAAACGGTGAAAGGGGTCCCTTGCTGCTGGCACTGTGAACGC
TGTGAAGGTTACAACTACCAGGTGGATGAGCTGTCCTGTGAACTTTGCCCTCTGGATCAG
AGACCCAACATGAACCGCACAGGCTGCCAGCTTATCCCCATCATCAAATTGGAGTGGCAT
TCTCCCTGGGCTGTGGTGCCTGTGTTTGTTGCAATATTGGGAATCATCGCCACCACCTTT
GTGATCGTGACCTTTGTCCGCTATAATGACACACCTATCGTGAGGGCTTCAGGACGCGAA
CTTAGTTACGTGCTCCTAACGGGGATTTTTCTCTGTTATTCAATCACGTTTTTAATGATT
GCAGCACCAGATACAATCATATGCTCCTTCCGACGGGTCTTCCTAGGACTTGGCATGTGT
TTCAGCTATGCAGCCCTTCTGACCAAAACAAACCGTATCCACCGAATATTTGAGCAGGGG
AAGAAATCTGTCACAGCGCCCAAGTTCATTAGTCCAGCATCTCAGCTGGTGATCACCTTC
AGCCTCATCTCCGTCCAGCTCCTTGGAGTGTTTGTCTGGTTTGTTGTGGATCCCCCCCAC
ATCATCATTGACTATGGAGAGCAGCGGACACTAGATCCAGAGAAGGCCAGGGGAGTGCTC
AAGTGTGACATTTCTGATCTCTCACTCATTTGTTCACTTGGATACAGTATCCTCTTGATG
GTCACTTGTACTGTTTATGCCAATAAAACGAGAGGTGTCCCAGAGACTTTCAATGAAGCC
AAACCTATTGGATTTACCATGTATACCACCTGCATCATTTGGTTAGCTTTCATCCCCATC
TTTTTTGGTACAGCCCAGTCAGCAGAAAAGATGTACATCCAGACAACAACACTTACTGTC
TCCATGAGTTTAAGTGCTTCAGTATCTCTGGGCATGCTCTATATGCCCAAGGTTTATATT
ATAATTTTTCATCCAGAACAGAATGTTCAAAAACGCAAGAGGAGCTTCAAGGCTGTGGTG
ACAGCTGCCACCATGCAAAGCAAACTGATCCAAAAAGGAAATGACAGACCAAATGGCGAG
GTGAAAAGTGAACTCTGTGAGAGTCTTGAAACCAACACTTCCTCTACCAAGACAACATAT
ATCAGTTACAGCAATCATTCAATCTGA

# Drug_Target_6_General_Function:
Amino acid transport and metabolism

# Drug_Target_6_General_References:
10216218	Malherbe P, Kratzeisen C, Lundstrom K, Richards JG, Faull RL, Mutel V: Cloning and functional expression of alternative spliced variants of the human metabotropic glutamate receptor 8. Brain Res Mol Brain Res. 1999 Apr 20;67(2):201-10.
9299241	Scherer SW, Soder S, Duvoisin RM, Huizenga JJ, Tsui LC: The human metabotropic glutamate receptor 8 (GRM8) gene: a disproportionately large gene located at 7q31.3-q32.1. Genomics. 1997 Sep 1;44(2):232-6.
9473604	Wu S, Wright RA, Rockey PK, Burgett SG, Arnold JS, Rosteck PR Jr, Johnson BG, Schoepp DD, Belagaje RM: Group III human metabotropic glutamate receptors 4, 7 and 8: molecular cloning, functional expression, and comparison of pharmacological properties in RGT cells. Brain Res Mol Brain Res. 1998 Jan;53(1-2):88-97.

# Drug_Target_6_HGNC_ID:
HGNC:4600

# Drug_Target_6_HPRD_ID:
03071

# Drug_Target_6_ID:
927

# Drug_Target_6_Locus:
7q31.3-q32.1

# Drug_Target_6_Molecular_Weight:
101742

# Drug_Target_6_Name:
Metabotropic glutamate receptor 8

# Drug_Target_6_Number_of_Residues:
908

# Drug_Target_6_PDB_ID:
Not Available

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF00003	7tm_3
PF01094	ANF_receptor
PF07562	NCD3G

# Drug_Target_6_Protein_Sequence:
>Metabotropic glutamate receptor 8 precursor
MVCEGKRSASCPCFFLLTAKFYWILTMMQRTHSQEYAHSIRVDGDIILGGLFPVHAKGER
GVPCGELKKEKGIHRLEAMLYAIDQINKDPDLLSNITLGVRILDTCSRDTYALEQSLTFV
QALIEKDASDVKCANGDPPIFTKPDKISGVIGAAASSVSIMVANILRLFKIPQISYASTA
PELSDNTRYDFFSRVVPPDSYQAQAMVDIVTALGWNYVSTLASEGNYGESGVEAFTQISR
EIGGVCIAQSQKIPREPRPGEFEKIIKRLLETPNARAVIMFANEDDIRRILEAAKKLNQS
GHFLWIGSDSWGSKIAPVYQQEEIAEGAVTILPKRASIDGFDRYFRSRTLANNRRNVWFA
EFWEENFGCKLGSHGKRNSHIKKCTGLERIARDSSYEQEGKVQFVIDAVYSMAYALHNMH
KDLCPGYIGLCPRMSTIDGKELLGYIRAVNFNGSAGTPVTFNENGDAPGRYDIFQYQITN
KSTEYKVIGHWTNQLHLKVEDMQWAHREHTHPASVCSLPCKPGERKKTVKGVPCCWHCER
CEGYNYQVDELSCELCPLDQRPNMNRTGCQLIPIIKLEWHSPWAVVPVFVAILGIIATTF
VIVTFVRYNDTPIVRASGRELSYVLLTGIFLCYSITFLMIAAPDTIICSFRRVFLGLGMC
FSYAALLTKTNRIHRIFEQGKKSVTAPKFISPASQLVITFSLISVQLLGVFVWFVVDPPH
IIIDYGEQRTLDPEKARGVLKCDISDLSLICSLGYSILLMVTCTVYAIKTRGVPETFNEA
KPIGFTMYTTCIIWLAFIPIFFGTAQSAEKMYIQTTTLTVSMSLSASVSLGMLYMPKVYI
IIFHPEQNVQKRKRSFKAVVTAATMQSKLIQKGNDRPNGEVKSELCESLETNTSSTKTTY
ISYSNHSI

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
1-33

# Drug_Target_6_Specific_Function:
Receptor for glutamate. The activity of this receptor is mediated by a G-protein that inhibits adenylate cyclase activity

# Drug_Target_6_SwissProt_ID:
O00222

# Drug_Target_6_SwissProt_Name:
GRM8_HUMAN

# Drug_Target_6_Synonyms:
Metabotropic glutamate receptor 8 precursor
mGluR8

# Drug_Target_6_Theoretical_pI:
8.21

# Drug_Target_6_Transmembrane_Regions:
584-608
621-641
648-668
696-716
747-768
782-803
819-843

# Drug_Target_70_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_70_Chromosome_Location:
Not Available

# Drug_Target_70_Drug_References:
11058796	Takeda M, Haga M, Yamada H, Kinoshita M, Otsuka M, Tsuboi S, Moriyama Y: Ionotropic glutamate receptors expressed in human retinoblastoma Y79 cells. Neurosci Lett. 2000 Nov 17;294(2):97-100.
1371217	Bettler B, Egebjerg J, Sharma G, Pecht G, Hermans-Borgmeyer I, Moll C, Stevens CF, Heinemann S: Cloning of a putative glutamate receptor: a low affinity kainate-binding subunit. Neuron. 1992 Feb;8(2):257-65.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
8622118	Stuhmer T, Amar M, Harvey RJ, Bermudez I, van Minnen J, Darlison MG: Structure and pharmacological properties of a molluscan glutamate-gated cation channel and its likely role in feeding behavior. J Neurosci. 1996 May 1;16(9):2869-80.

# Drug_Target_70_Essentiality:
Non-Essential

# Drug_Target_70_GenAtlas_ID:
GRIK3

# Drug_Target_70_GenBank_ID_Gene:
U16127

# Drug_Target_70_GenBank_ID_Protein:
790534

# Drug_Target_70_GeneCard_ID:
GRIK3

# Drug_Target_70_Gene_Name:
GRIK3

# Drug_Target_70_Gene_Sequence:
>2760 bp
ATGACCGCTCCCTGGCGGCGCCTCCGGAGTCTGGTTTGGGAATACTGGGCCGGGCTCCTC
GTGTGCGCCTTCTGGATCCCGGACTCGCGCGGGATGCCCCACGTCATCCGGATCGGAGGA
ATCTTCGAGTATGCGGACGGCCCCAACGCCCAGGTCATGAATGCCGAGGAGCATGCCTTT
CGATTTTCTGCCAACATCATCAACAGGAACAGGACTCTGCTGCCCAACACAACCTTGACC
TATGACATACAGAGGATTCACTTCCATGACAGCTTCGAGGCGACCAAAAAGGCCTGTGAC
CAGCTGGCACTGGGCGTGGTGGCGATCTTCGGCCCATCACAGGGCTCCTGCACCAATGCC
GTCCAGTCCATCTGCAATGCCCTGGAGGTGCCCCACATCCAGCTGCGTTGGAAGCACCAC
CCGCTGGACAACAAGGACACCTTCTACGTGAACCTCTACCCCGACTACGCCTCGCTCAGC
CATGCCATCCTCGACCTGGTCCAGTACCTCAAGTGGCGGTCAGCCACCGTGGTCTATGAC
GACAGTACAGGGCTCATCCGACTGCAGGAGCTCATCATGGCCCCATCAAGATACAACATC
CGCCTGAAGATCCGTCAGCTCCCCATCGACTCTGACGACTCGCGCCCCTTGCTCAAGGAG
ATGAAGCGAGGCCGGGAATTCCGCATTATCTTCGACTGCAGCCACACTATGGCGGCCCAG
ATCCTCAAGCAGGCCATGGCCATGGGCATGATGACTGAGTACTACCACTTCATCTTCACC
ACTCTGGATCTCTACGCTTTAGACCTGGAGCCCTACCGCTACTCAGGCGTGAACCTGACA
GGATTCCGGATTCTCAATGTGGACAACCCACACGTCTCGGCCATTGTGGAGAAGTGGTCC
ATGGAGCGGCTGCAGGCAGCTCCCCGGGCCGAGTCTGGCCTGCTGGATGGAGTGATGATG
ACTGATGCAGCCTTACTGTACGACGCCGTCCATATCGTGTCCGTGTGCTACCAGCGGGCA
CCACAGATGACCGTGAACTCCCTGCAGTGCCATCGGCACAAGGCCTGGCGCTTTGGCGGC
CGCTTCATGAACTTCATCAAGGAGGCTCAATGGGAAGGATTAACTGGACGAATTGTTTTC
AACAAAACTAGTGGCTTGCGGACGGATTTTGATCTGGACATCATCAGCCTGAAAGAGGAT
GGCCTGGAGAAGGTTGGGGTGTGGAGTCCTGCCGACGGGCTCAACATCACTGAGGTTGCC
AAAGGCCGAGGCCCTAATGTCACCGACTCTCTGACAAACAGATCACTCATTGTCACCACA
GTGCTGGAGGAGCCCTTCGTCATGTTTCGGAAATCAGACAGGACGCTATATGGGAATGAC
CGGTTCGAGGGCTACTGCATCGACCTGCTAAAGGAGCTGGCCCACATCCTTGGTTTCTCC
TATGAGATCCGGCTGGTGGAGGACGGCAAGTACGGGGCACAGGATGACAAGGGCCAGTGG
AACGGCATGGTCAAGGAGCTCATCGACCACAAGGCAGATCTGGCCGTGGCCCCCCTGACC
ATCACCCATGTTCGAGAGAAGGCCATCGACTTCTCCAAGCCCTTCATGACACTTGGTGTG
AGCATCCTGTATCGAAAGCCCAATGGCACCAACCCCAGCGTCTTCTCCTTCCTCAATCCC
CTGTCCCCAGACATCTGGATGTATGTTCTCCTCGCCTACCTGGGGGTCAGCTGTGTCCTC
TTCGTCATCGCCAGGTTCAGCCCTTATGAGTGGTACGATGCTCACCCCTGCAACCCTGGC
TCCGAGGTGGTGGAAAATAACTTCACTCTGCTTAACAGCTTCTGGTTTGGAATGGGATCC
CTGATGCAGCAAGGGTCTGTGCTGATGCCCAAAGCCCTGTCCACACGCATCATTGGTGGC
ATCTGGTGGTTCTTTACGCTCATCATCATCTCTTCCTACACGGCCAACCTGGCTGCCTTT
CTGACCGTGGAGCGCATGGAATCACCCATTGACTCTGCTGATGACCTGGCCAAGCAAACC
AAAATCGAGTATGGGGCTGTCAAGGATGGGGCCACCATGACCTTCTTCAAGAAATCCAAG
ATCTCCACCTTCGAGAAGATGTGGGCCTTCATGAGCAGGAAGCCATCGGCGCTGGTGAAG
AACAACGAGGAGGGCATCCAGAGGGCCCTGACGGCCGACTACGCGCTGCTCATGGAGTCC
ACCACCATCGAGTACGTCACGCAGAGGAACTGCAACCTCACCCAGATCGGGGGCCTCATT
GACTCCAAGGGCTACGGCATCGGCACGCCCATGGGCTCCCCATACCGGGACAAGATCACC
ATCGCCATCCTGCAGCTTCAGGAGGAGGACAAGCTGCATATCATGAAGGAGAAGTGGTGG
CGGGGCAGCGGGTGTCCTGAGGAGGAAAACAAAGAGGCCAGTGCCCTGGGGATCCAGAAG
ATCGGGGGCATCTTCATTGTCCTGGCCGCCGGGCTGGTCCTCTCTGTGCTGGTGGCCGTG
GGCGAGTTTGTGTACAAGCTCCGCAAAACAGCAGAGAGAGAGCAGCGTTCCTTCTGCAGC
ACCGTGGCCGATGAGATCCGTTTCTCCCTTACCTGCCAGCGTCGAGTCAAGCACAAGCCT
CAGCCTCCCATGATGGTCAAGACTGACGCCGTCATCAACATGCACACATTCAATGACCGC
CGGCTTCCCGGCAAGGACAGCATGGCCTGCAGCACATCCTTAGCCCCTGTGTTCCCCTAG

# Drug_Target_70_General_Function:
Involved in ionotropic glutamate receptor activity

# Drug_Target_70_General_References:
11124978	Schiffer HH, Swanson GT, Masliah E, Heinemann SF: Unequal expression of allelic kainate receptor GluR7 mRNAs in human brains. J Neurosci. 2000 Dec 15;20(24):9025-33.
7719709	Nutt SL, Hoo KH, Rampersad V, Deverill RM, Elliott CE, Fletcher EJ, Adams SL, Korczak B, Foldes RL, Kamboj RK: Molecular characterization of the human EAA5 (GluR7) receptor: a high-affinity kainate receptor with novel potential RNA editing sites. Receptors Channels. 1994;2(4):315-26.
8128318	Puranam RS, Eubanks JH, Heinemann SF, McNamara JO: Chromosomal localization of gene for human glutamate receptor subunit-7. Somat Cell Mol Genet. 1993 Nov;19(6):581-8.

# Drug_Target_70_HGNC_ID:
HGNC:4581

# Drug_Target_70_HPRD_ID:
00691

# Drug_Target_70_ID:
924

# Drug_Target_70_Locus:
1p34-p33

# Drug_Target_70_Molecular_Weight:
104033

# Drug_Target_70_Name:
Glutamate receptor, ionotropic kainate 3

# Drug_Target_70_Number_of_Residues:
919

# Drug_Target_70_PDB_ID:
1YAE

# Drug_Target_70_Pathway:
Not Available

# Drug_Target_70_Pfam_Domain_Function:
PF00060	Lig_chan
PF01094	ANF_receptor

# Drug_Target_70_Protein_Sequence:
>Glutamate receptor, ionotropic kainate 3 precursor
MTAPWRRLRSLVWEYWAGLLVCAFWIPDSRGMPHVIRIGGIFEYADGPNAQVMNAEEHAF
RFSANIINRNRTLLPNTTLTYDIQRIHFHDSFEATKKACDQLALGVVAIFGPSQGSCTNA
VQSICNALEVPHIQLRWKHHPLDNKDTFYVNLYPDYASLSHAILDLVQYLKWRSATVVYD
DSTGLIRLQELIMAPSRYNIRLKIRQLPIDSDDSRPLLKEMKRGREFRIIFDCSHTMAAQ
ILKQAMAMGMMTEYYHFIFTTLDLYALDLEPYRYSGVNLTGFRILNVDNPHVSAIVEKWS
MERLQAAPRAESGLLDGVMMTDAALLYDAVHIVSVCYQRAPQMTVNSLQCHQHKAWRFGG
RFMNFIKEAQWEGLTGRIVFNKTSGLRTDFDLDIISLKEDGLEKVGVWSPADGLNITEVA
KGRGPNVTDSLTNRSLIVTTVLEEPFVMFRKSDRTLYGNDRFEGYCIDLLKELAHILGFS
YEIRLVEDGKYGAQDDKGQWNGMVKELIDHKADLAVAPLTITHVREKAIDFSKPFMTLGV
SILYRKPNGTNPSVFSFLNPLSPDIWMYVLLAYLGVSCVLFVIARFSPYEWYDAHPCNPG
SEVVENNFTLLNSFWFGMGSLMQQGSVLMPKALSTRIIGGIWWFFTLIIISSYTANLAAF
LTVERMESPIDSADDLAKQTKIEYGAVKDGATMTFFKKSKISTFEKMWAFMSRKPSALVK
NNEEGIQRALTADYALLMESTTIEYVTQRNCNLTQIGGLIDSKGYGIGTPMGSPYRDKIT
IAILQLQEEDKLHIMKEKWWRGSGCPEEENKEASALGIQKIGGIFIVLAAGLVLSVLVAV
GEFVYKLRKTAEREQRSFCSTVADEIRFSLTCQRRVKHKPQPPMMVKTDAVINMHTFNDR
RLPGKDSMACSTSLAPVFP

# Drug_Target_70_Reaction:
Not Available

# Drug_Target_70_Signals:
1-31

# Drug_Target_70_Specific_Function:
Receptor for glutamate. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists. This receptor binds domoate > kainate >> L-glutamate = quisqualate >> AMPA = NMDA

# Drug_Target_70_SwissProt_ID:
Q13003

# Drug_Target_70_SwissProt_Name:
GRIK3_HUMAN

# Drug_Target_70_Synonyms:
EAA5
Excitatory amino acid receptor 5
GluR-7
GluR7
Glutamate receptor 7
Glutamate receptor, ionotropic kainate 3 precursor

# Drug_Target_70_Theoretical_pI:
7.69

# Drug_Target_70_Transmembrane_Regions:
564-584
637-657
821-841

# Drug_Target_7_Cellular_Location:
Membrane

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
15128272	Takarada T, Hinoi E, Balcar VJ, Taniura H, Yoneda Y: Possible expression of functional glutamate transporters in the rat testis. J Endocrinol. 2004 May;181(2):233-44.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9108121	Arriza JL, Eliasof S, Kavanaugh MP, Amara SG: Excitatory amino acid transporter 5, a retinal glutamate transporter coupled to a chloride conductance. Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4155-60.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
SLC1A7

# Drug_Target_7_GenBank_ID_Gene:
U76362

# Drug_Target_7_GenBank_ID_Protein:
2076762

# Drug_Target_7_GeneCard_ID:
SLC1A7

# Drug_Target_7_Gene_Name:
SLC1A7

# Drug_Target_7_Gene_Sequence:
>1683 bp
ATGGTGCCGCATACCATCTTGGCACGGGGGAGGGACGTGTGCAGGCGGAATGGACTCCTC
ATCCTGTCTGTGCTGTCTGTCATCGTGGGCTGCCTCCTCGGCTTCTTCTTGAGGACCCGG
CGCCTCTCACCACAGGAAATTAGTTACTTCCAGTTCCCCGGAGAGCTCCTGATGAGGATG
CTGAAGATGATGATCCTGCCACTGGTGTTCTCCAGCTTGATGTCCGGACTTGCCTCCCTG
GATGCCAAGACCTCTAGCCGCCTGGGCGTCCTCACCGTGGCGTACTACCTGTGGACCACC
TTCATGGCTGTCATCGTGGGCATCTTCATGGTCTCCATCATCCACCCAGGCAGCGCGGCC
CAGAAGGAGACCACGGAGCAGAGTGGGAAGCCCATCATGAGCTCAGCCGATGCCCTGTTG
GACCTCATCCGGAACATGTTCCCAGCCAACCTAGTAGAAGCCACATTCAAACAGTACCGC
ACCAAGACCACCCCAGTTGTCAAGTCCCCCAAGGTGGCACCAGAGGAGGCCCCTCCTCGG
CGGATCCTCATCTACGGGGTCCAGGAGGAGAATGGCTCCCATGTGCAGAACTTCGCCCTG
GACCTGACCCCGCCGCCCGAGGTCGTTTACAAGTCAGAGCCGGGCACCAGCGATGGCATG
AATGTGCTGGGCATCGTCTTCTTCTCTGCCACCATGGGCATCATGCTGGGCCGCATGGGT
GACAGCGGGGGCCCCCTGGTCAGCTTCTGCCAGTGCCTCAATGAGTCGGTCATGAAGATC
GTGGCGGTGGCTGTGTGGTATTTCCCCTTCGGCATTGTGTTCCTCATTGCGGGTAAGATC
CTGGAGATGGACGACCCCAGGGCCGTCGGCAAGAAGCTGGGCTTCTACTCAGTCACCGTG
GTGTGCGGGCTGGTGCTCCACGGGCTCTTTATCCTGCCCCTGCTCTACTTCTTCATCACC
AAGAAGAATCCCATCGTCTTCATCCGCGGCATCCTGCAGGCTCTGCTCATCGCGCTGGCC
ACCTCCTCCAGCTCAGCCACACTGCCCATCACCTTCAAGTGCCTGCTGGAGAACAACCAC
ATCGACCGGCGCATCGCTCGCTTCGTGCTGCCCGTGGGTGCCACCATCAACATGGACGGC
ACTGCGCTCTACGAGGCTGTGGCCGCCATCTTCATCGCCCAGGTCAACAACTACGAGCTG
GACTTTGGCCAGATCATCACCATCAGTATCACAGGCACTGCAGCCAGCATTGGGGCAGCT
GGCATCCCCCAGGCCGGCCTCGTCACCATGGTCATCGTGCTCACCTCCGTGGGACTGCCC
ACCGATGACATCACCCTCATCATTGGCGTTGACTGGGCTCTGGACCGTTTCCGCACCATG
ATTAACGTGCTGGGTGATGCGCTGGCAGCGGGGATCATGGCCCATATATGTCGGAAGGAT
TTTGCCCGGGACACAGGCACCGAGAAACTGCTGCCCTGCGAGACCAAGCCAGTGAGCCTC
CAGGAGATCGTGGCAGCCCAGCAGAATGGCTGTGTGAAGAGTGTAGCCGAGGCCTCCGAG
CTCACCCTGGGCCCCACCTGCCCCCACCACGTCCCCGTTCAAGTGGAGCGGGATGAGGAG
CTGCCCGCTGCGAGTCTGAACCACTGCACCATCCAGATCAGCGAGCTGGAGACCAATGTC
TGA

# Drug_Target_7_General_Function:
Energy production and conversion

# Drug_Target_7_General_References:
9108121	Arriza JL, Eliasof S, Kavanaugh MP, Amara SG: Excitatory amino acid transporter 5, a retinal glutamate transporter coupled to a chloride conductance. Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4155-60.

# Drug_Target_7_HGNC_ID:
HGNC:10945

# Drug_Target_7_HPRD_ID:
Not Available

# Drug_Target_7_ID:
4016

# Drug_Target_7_Locus:
1p32.3

# Drug_Target_7_Molecular_Weight:
60723

# Drug_Target_7_Name:
Excitatory amino acid transporter 5

# Drug_Target_7_Number_of_Residues:
560

# Drug_Target_7_PDB_ID:
Not Available

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF00375	SDF

# Drug_Target_7_Protein_Sequence:
>Excitatory amino acid transporter 5
MVPHTILARGRDVCRRNGLLILSVLSVIVGCLLGFFLRTRRLSPQEISYFQFPGELLMRM
LKMMILPLVFSSLMSGLASLDAKTSSRLGVLTVAYYLWTTFMAVIVGIFMVSIIHPGSAA
QKETTEQSGKPIMSSADALLDLIRNMFPANLVEATFKQYRTKTTPVVKSPKVAPEEAPPR
RILIYGVQEENGSHVQNFALDLTPPPEVVYKSEPGTSDGMNVLGIVFFSATMGIMLGRMG
DSGGPLVSFCQCLNESVMKIVAVAVWYFPFGIVFLIAGKILEMDDPRAVGKKLGFYSVTV
VCGLVLHGLFILPLLYFFITKKNPIVFIRGILQALLIALATSSSSATLPITFKCLLENNH
IDRRIARFVLPVGATINMDGTALYEAVAAIFIAQVNNYELDFGQIITISITGTAASIGAA
GIPQAGLVTMVIVLTSVGLPTDDITLIIGVDWALDRFRTMINVLGDALAAGIMAHICRKD
FARDTGTEKLLPCETKPVSLQEIVAAQQNGCVKSVAEASELTLGPTCPHHVPVQVERDEE
LPAASLNHCTIQISELETNV

# Drug_Target_7_Reaction:
Not Available

# Drug_Target_7_Signals:
None

# Drug_Target_7_Specific_Function:
Transports L-glutamate; the L-glutamate uptake is sodium- and voltage-dependent and chloride-independent. Its associated chloride conductance may participate in visual processing

# Drug_Target_7_SwissProt_ID:
O00341

# Drug_Target_7_SwissProt_Name:
EAA5_HUMAN

# Drug_Target_7_Synonyms:
Retinal glutamate transporter
Solute carrier family 1 member 7

# Drug_Target_7_Theoretical_pI:
6.97

# Drug_Target_7_Transmembrane_Regions:
17-37
60-80
94-114
217-237
260-280
300-320
330-350
372-392
414-434
457-477

# Drug_Target_8_Cellular_Location:
Cytoplasmic

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
11302195	Nishimura A, Itoh H, Oyama H, Murao S, Oda K: A simultaneous assay method for L-glutamate and L-pyroglutamate contents in soy sauce using a 5-oxoprolinase (without ATP hydrolyzing activity). Biosci Biotechnol Biochem. 2001 Feb;65(2):477-9.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
4514988	Van der Werf P, Stephani RA, Orlowski M, Meister A: Inhibition of 5-oxoprolinase by 2-imidazolidone-4-carboxylic acid. Proc Natl Acad Sci U S A. 1973 Mar;70(3):759-61.
6145710	Seddon AP, Li LY, Meister A: Resolution of 5-oxo-L-prolinase into a 5-oxo-L-proline-dependent ATPase and a coupling protein. J Biol Chem. 1984 Jul 10;259(13):8091-4.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
OPLAH

# Drug_Target_8_GenBank_ID_Gene:
AB122018

# Drug_Target_8_GenBank_ID_Protein:
46020040

# Drug_Target_8_GeneCard_ID:
OPLAH

# Drug_Target_8_Gene_Name:
OPLAH

# Drug_Target_8_Gene_Sequence:
>3867 bp
ATGGGCAGCCCCGAGGGCCGCTTCCACTTTGCCATCGACCGTGGGGGTACCTTCACAGAC
GTCTTTGCCCAGTGCCCAGGGGGGCACGTGCGGGTCTTAAAACTGCTCTCAGAGGACCCT
GCCAACTATGCGGACGCGCCAACCGAAGGCATCCGCCGCATCCTGGAGCAGGAGGCCGGC
ATGCTCCTGCCCCGGGACCAGCCGCTGGACTCCAGTCATATCGCCAGCATCCGCATGGGC
ACCACAGTGGCCACCAACGCACTGCTGGAGCGGAAGGGGGAGCGGGTGGCGCTGCTGGTG
ACACGTGGCTTCCGAGACCTGCTGCACATTGGCACCCAAGCCCGTGGGGACCTCTTTGAC
CTGGCCGTGCCCATGCCTGAGGTGCTGTATGAAGAGGTGCTGGAGGTGGACGAACGCGTG
GTGCTGCACCGTGGAGAGGCGGGCACCGGGACGCCTGTGAAAGGCCGCACGGGGGACCTG
CTGGAAGTGCAGCAGCCTGTGGACCTGGGGGCCCTGCGTGGGAAGCTGGAGGGGCTGCTA
TCTCGAGGCATCCGCAGCCTGGCTGTGGTGCTCATGCACTCGTACACGTGGGCCCAGCAT
GAGCAGCAGGTGGGTGTGCTGGCCCGGGAGCTGGGCTTCACGCACGTGTCACTGTCCTCG
GAGGCCATGCCCATGGTGCGCATCGTCCCTCGGGGGCACACGGCCTGTGCCGACGCCTAC
CTCACGCCCGCCATCCAGCGCTACGTGCAGGGCTTCTGCCGTGGCTTCCAGGGCCAACTC
AAGGATGTGCAGGTGTTGTTCATGCGCTCCGATGGCGGCCTGGCGCCCATGGACACCTTC
AGCGGCTCCAGTGCTGTGCTCTCGGGCCCGGCCGGCGGCGTGGTGGGCTACTCAGCCACC
ACCTACCAGCAGGAGGGTGGCCAGCCTGTCATCGGCTTTGACATGGGAGGCACGTCCACG
GATGTGAGCCGCTATGCTGGGGAATTCGAGCACGTCTTCGAGGCCAGCACAGCTGGCGTC
ACCCTCCAGGCCCCGCAGCTGGACATCAACACCGTGGCAGCGGGAGGGGGTTCCCGCCTC
TTCTTCAGGTCTGGCCTCTTTGTGGTTGGGCCCGAGTCAGCAGGAGCCCACCCAGGACCC
GCCTGCTACCGCAAAGGGGGCCCTGTGACAGTGACGGATGCTAATCTGGTCCTGGGTCGC
CTGCTGCCTGCCTCCTTCCCCTGCATTTTTGGGCCGGGAGAGAACCAACCACTTTCCCCT
GAGGCCTCCCGCAAAGCCCTGGAGGCTGTGGCCACTGAGGTCAACAGCTTCCTGACCAAC
GGGCCCTGCCCGGCCTCCCCGCTGAGCCTGGAGGAGGTGGCCATGGGGTTCGTGCGCGTG
GCCAACGAGGCCATGTGCCGGCCCATCCGTGCACTCACGCAGGCAAGAGGCCATGACCCC
TCAGCCCATGTGCTGGCCTGCTTTGGGGGAGCTGGTGGGCAGCATGCATGTGCCATCGCC
CGGGCCCTGGGCATGGACACGGTGCACATCCACAGGCACAGTGGGCTGCTGTCGGCCCTG
GGGCTGGCCCTGGCTGACGTGGTGCATGAGGCACAGGAACCCTGCTCCCTGCTCTACGCG
CCTGAGACCTTCGTGCAGCTGGACCAGAGGCTGAGCCGCCTGGAGGAGCAGTGTGTGGAT
GCTCTGCAGGCCCAGGGCTTCCCCAGGTCCCAGATCAGCACTGAGAGCTTCCTGCACCTG
CGCTACCAGGGCACGGACTGTGCTCTGATGGTGTCTGCCCACCAGCACCCAGCCACAGCC
CGCTCGCCCCGTGCGGGGGACTTCGGGGCAGCCTTTGTGGAGCGGTACATGAGGGAGTTT
GGCTTTGTCATACCTGAGCGGCCGGTGGTCGTGGACGATGTGCGAGTGCGGGGCACCGGC
CGCAGTGGTCTTCGCCTCGAGGATGCCCCCAAAGCCCAGACCGGGCCTCCCCGGGTGGAC
AAGATGACCCAGTGCTACTTTGAGGGGGGCTACCAGGAGACCCCTGTGTACCTGCTGGCA
GAGCTGGGCTATGGGCACAAGCTCCATGGGCCCTGCCTCATCATCGACAGTAACAGCACC
ATCCTGGTGGAGCCAGGTTGCCAGGCAGAGGTGACCAAGACAGGGGACATCTGCATCTCC
GTGGGGGCCGAAGTCCCCGGCACAGTGGGCCCCCAGCTGGACCCTATCCAGCTGTCCATC
TTCTCACACCGCTTCATGAGCATTGCTGAGCAGATGGGCCGCATCCTGCAGCGCACAGCC
ATCTCCACCAACATCAAGGAGCGTCTGGACTTCTCCTGTGCCCTCTTTGGGCCCGATGGG
GGGCTGGTGTCCAATGCCCCCCACATCCCTGTGCACCTGGGTGCCATGCAGGAGACGGTG
CAGTTCCAGATTCAGCACCTGGGGGCCGATCTCCACCCTGGCGACGTGCTACTGAGCAAC
CATCCCAGTGCCGGGGGCAGCCACCTGCCAGACCTGACTGTTATCACACCGGTGTTTTGG
CCGGGTCAGACGCGGCCTGTGTTCTATGTGGCCAGCCGAGGGCACCACGCAGACATCGGG
GGCATCACACCAGGCTCCATGCCCCCCCACTCCACCATGCTGCAACAGGAGGGTGCCGTC
TTTCTGTCCTTCAAACTTGTCCAGGGGGGCGTCTTCCAGGAGGAGGCGGTGACGGAGGCC
CTGCGGGCGCCAGGCAAGGTCCCCAACTGCAGCGGAACCAGAAACCTGCACGACAACCTG
TCGGACCTCCGTGCCCAGGTGGCAGCCAACCAGAAGGGCATCCAGCTGGTGGGGGAGCTC
ATTGGGCAGTACGGCCTGGACGTGGTGCAGGCCTACATGGGCCATATTCAGGCAAACGCT
GAGCTGGCCGTGCGAGACATGTTGCGTGCCTTTGGAACCTCCCGGCAGGCCCGGGGCCTG
CCCCTGGAGGTGTCCTCGGAAGACCACATGGACGACGGTTCCCCCATCCGCCTCCGTGTG
CAGATCAGCCTGAGTCAGGGCAGCGCTGTGTTTGACTTCAGCGGCACTGGGCCGGAGGTG
TTTGGTAATCTCAACGCACCGCGGGCCGTAACCCTGTCCGCCCTCATCTACTGCCTGCGC
TGTCTGGTGGGCCGCGACATCCCACTCAACCAGGGCTGCCTGGCGCCAGTGCGCGTGGTC
ATTCCCCGAGGCTCCATCCTGGACCCGTCGCCCGAGGCGGCGGTGGTGGGCGGCAACGTG
CTCACGTCGCAGCGCGTGGTGGATGTCATCCTGGGGGCCTTTGGGGCCTGCGCCGCCTCC
CAGGGCTGCATGAACAACGTGACCCTGGGCAACGCCCACATGGGCTACTACGAGACGGTG
GCGGGCGGCGCGGGCGCGGGTCCCAGCTGGCACGGGCGCAGCGGTGTGCACAGCCACATG
ACCAACACACGCATCACCGACCCTGAGATCCTGGAGAGCCGGTACCCGGTCATCCTGCGC
CGCTTCGAGCTGCGGCGGGGCTCGGGGGGCAGAGGCCGCTTCCGAGGCGGCGACGGCGTC
ACCCGCGAGCTGCTCTTTCGTGAGGAGGCGCTGCTGTCAGTGCTGACCGAGCGCCGCGCC
TTCCGGCCATACGGGCTCCACGGGGGCGAGCCTGGCGCCCGCGGCCTAAACCTGCTGATC
CGCAAAAACGGCCGGACGGTGAATCTGGGCGGCAAGACGTCGGTGACCGTGTACCCCGGG
GATGTGTTCTGTCTCCACACGCCCGGCGGCGGTGGCTATGGGGACCCGGAGGACCCCGCC
CCACCGCCGGGGTCGCCCCCGCAAGCACTGGCCTTTCCCGAGCACGGCAGCGTCTATGAG
TATCGCCGGGCCCAGGAGGCCGTGTGA

# Drug_Target_8_General_Function:
Amino acid transport and metabolism

# Drug_Target_8_General_References:
Not Available

# Drug_Target_8_HGNC_ID:
HGNC:8149

# Drug_Target_8_HPRD_ID:
Not Available

# Drug_Target_8_ID:
4017

# Drug_Target_8_Locus:
8q24.3

# Drug_Target_8_Molecular_Weight:
137459

# Drug_Target_8_Name:
5-oxoprolinase

# Drug_Target_8_Number_of_Residues:
1288

# Drug_Target_8_PDB_ID:
Not Available

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF01968	Hydantoinase_A
PF02538	Hydantoinase_B
PF05378	Hydant_A_N

# Drug_Target_8_Protein_Sequence:
>5-oxoprolinase
MGSPEGRFHFAIDRGGTFTDVFAQCPGGHVRVLKLLSEDPANYADAPTEGIRRILEQEAG
MLLPRDQPLDSSHIASIRMGTTVATNALLERKGERVALLVTRGFRDLLHIGTQARGDLFD
LAVPMPEVLYEEVLEVDERVVLHRGEAGTGTPVKGRTGDLLEVQQPVDLGALRGKLEGLL
SRGIRSLAVVLMHSYTWAQHEQQVGVLARELGFTHVSLSSEAMPMVRIVPRGHTACADAY
LTPAIQRYVQGFCRGFQGQLKDVQVLFMRSDGGLAPMDTFSGSSAVLSGPAGGVVGYSAT
TYQQEGGQPVIGFDMGGTSTDVSRYAGEFEHVFEASTAGVTLQAPQLDINTVAAGGGSRL
FFRSGLFVVGPESAGAHPGPACYRKGGPVTVTDANLVLGRLLPASFPCIFGPGENQPLSP
EASRKALEAVATEVNSFLTNGPCPASPLSLEEVAMGFVRVANEAMCRPIRALTQARGHDP
SAHVLACFGGAGGQHACAIARALGMDTVHIHRHSGLLSALGLALADVVHEAQEPCSLLYA
PETFVQLDQRLSRLEEQCVDALQAQGFPRSQISTESFLHLRYQGTDCALMVSAHQHPATA
RSPRAGDFGAAFVERYMREFGFVIPERPVVVDDVRVRGTGRSGLRLEDAPKAQTGPPRVD
KMTQCYFEGGYQETPVYLLAELGYGHKLHGPCLIIDSNSTILVEPGCQAEVTKTGDICIS
VGAEVPGTVGPQLDPIQLSIFSHRFMSIAEQMGRILQRTAISTNIKERLDFSCALFGPDG
GLVSNAPHIPVHLGAMQETVQFQIQHLGADLHPGDVLLSNHPSAGGSHLPDLTVITPVFW
PGQTRPVFYVASRGHHADIGGITPGSMPPHSTMLQQEGAVFLSFKLVQGGVFQEEAVTEA
LRAPGKVPNCSGTRNLHDNLSDLRAQVAANQKGIQLVGELIGQYGLDVVQAYMGHIQANA
ELAVRDMLRAFGTSRQARGLPLEVSSEDHMDDGSPIRLRVQISLSQGSAVFDFSGTGPEV
FGNLNAPRAVTLSALIYCLRCLVGRDIPLNQGCLAPVRVVIPRGSILDPSPEAAVVGGNV
LTSQRVVDVILGAFGACAASQGCMNNVTLGNAHMGYYETVAGGAGAGPSWHGRSGVHSHM
TNTRITDPEILESRYPVILRRFELRRGSGGRGRFRGGDGVTRELLFREEALLSVLTERRA
FRPYGLHGGEPGARGLNLLIRKNGRTVNLGGKTSVTVYPGDVFCLHTPGGGGYGDPEDPA
PPPGSPPQALAFPEHGSVYEYRRAQEAV

# Drug_Target_8_Reaction:
ATP + 5-oxo-L-proline + 2 H2O = ADP + phosphate + L-glutamate

# Drug_Target_8_Signals:
None

# Drug_Target_8_Specific_Function:
Catalyzes the cleavage of 5-oxo-L-proline to form L- glutamate coupled to the hydrolysis of ATP to ADP and inorganic phosphate

# Drug_Target_8_SwissProt_ID:
O14841

# Drug_Target_8_SwissProt_Name:
OPLA_HUMAN

# Drug_Target_8_Synonyms:
5- OPase
5-oxo-L-prolinase
EC 3.5.2.9
Pyroglutamase

# Drug_Target_8_Theoretical_pI:
6.56

# Drug_Target_8_Transmembrane_Regions:
None

# Drug_Target_9_Cellular_Location:
Cytoplasm

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2347042	Jayaram HN, Lui MS, Plowman J, Pillwein K, Reardon MA, Elliott WL, Weber G: Oncolytic activity and mechanism of action of a novel L-cysteine derivative, L-cysteine, ethyl ester, S-(N-methylcarbamate) monohydrochloride. Cancer Chemother Pharmacol. 1990;26(2):88-92.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
PFAS

# Drug_Target_9_GenBank_ID_Gene:
AB002359

# Drug_Target_9_GenBank_ID_Protein:
2224663

# Drug_Target_9_GeneCard_ID:
PFAS

# Drug_Target_9_Gene_Name:
PFAS

# Drug_Target_9_Gene_Sequence:
>4117 bp
GGCCGCGAGTGCATCTTCCACGAACCTAATTCATCTCTCCAGCAAAGGACACATCTCTCC
AGCAAAGGACACCTCTCTCCAGCAAAGGACACCTGCAGAGATGTCCCCAGTCCTTCACTT
CTATGTTCGTCCCTCTGGCCATGAGGGGGCAGCCTCTGGACACACTCGGAGGAAACTGCA
AGGGAAACTGCCAGAGCTGCAGGGCGTCGAGACTGAACTGTGCTACAACGTGAACTGGAC
AGCTGAGGCCCTCCCCAGTGCTGAGGAGACAAAGAAGCTGATGTGGCTGTTTGGTTGCCC
CTTACTGCTGGATGATGTTGCTCGGGAGTCCTGGCTCCTTCCTGGCTCCAATGACCTGCT
GCTGGAGGTCGGGCCCAGGCTGAACTTCTCCACCCCAACATCCACCAACATCGTGTCAGT
GTGCCGCGCCACTGGGCTGGGGCCTGTGGATCGTGTGGAGACCACCCGGCGCTACCGGCT
CTCGTTTGCCCACCCCCCGTCAGCTGAGGTGGAAGCCATTGCTCTGGCTACCCTGCACGA
CCGGATGACAGAGCAGCACTTCCCCCATCCCATCCAGAGTTTCTCCCCTGAGAGCATGCC
GGAACCCCTCAATGGCCCTATCAATATACTGGGTGAGGGCCGGCTTGCGCTGGAGAAGGC
CAACCAGGAGCTTGGTCTGGCTTTAGACTCTTGGGACCTAGACTTCTACACCAAGCGCTT
CCAGGAGCTACAGCGGAACCCGAGCACTGTGGAGGCCTTTGACTTGGCGCAGTCCAATAG
CGAGCACAGCCGACACTGGTTCTTCAAGGGCCAGCTCCACGTGGATGGGCAGAAGCTGGT
GCACTCACTGTTTGAGTCCATCATGAGCACCCAGGAATCCTCGAACCCCAACAACGTCCT
CAAATTCTGTGATAACAGCAGTGCAATCCAGGGAAAGGAAGTCCGATTCCTACGGCCTGA
GGACCCCACACGGCCAAGCCGCTTCCAGCAACAGCAAGGGCTGAGACATGTTGTCTTCAC
AGCAGAGACTCACAACTTTCCCACAGGAGTATGCCCCTTTAGTGGTGCAACCACTGGCAC
AGGGGGCCGGATTCGAGATGTCCAGTGCACAGGCCGCGGGGCCCACGTGGTGGCTGGCAC
TGCCGGCTATTGCTTTGGAAATCTGCATATTCCAGGTTACAATCTGCCCTGGGAGGATCT
AAGCTTCCAGTATCCTGGGAATTTTGCCCGGCCCCTGGAGGTTGCCATTGAAGCCAGTAA
TGGAGCTTCTGACTATGGCAACAAGTTTGGGGAACCAGTGCTGGCTGGCTTCGCCCGCTC
CTTGGGCCTCCAGCTCCCAGACGGCCAGCGGCGTGAGTGGATCAAGCCCATCATGTTTAG
TGGGGGCATTGGGTCCATGGAAGCTGACCACATAAGCAAGGAGGCCCCAGAGCCAGGCAT
GGAAGTTGTAAAGGTTGGAGGTCCCGTCTACAGGATTGGAGTTGGAGGTGGAGCTGCTTC
ATCTGTGCAGGTGCAGGGAGATAACACCAGTGACCTGGACTTTGGGGCTGTGCAGCGAGG
AGACCCGGAGATGGAACAGAAGATGAACCGTGTGATCAGGGCTTGTGTGGAGGCCCCCAA
GGGAAACCCCATCTGCAGCCTTCATGATCAGGGCGCTGGTGGCAATGGCAATGTCCTAAA
AGAGCTGAGTGACCCAGCTGGAGCCATCATTTACACCAGCCGCTTCCAGCTTGGGGACCC
AACCCTGAATGCCCTGGAAATCTGGGGGGCTGAGTACCAGGAATCAAATGCTCTTCTGCT
GAGGTCCCCCAACCGGGACTTCCTGACTCATGTCAGTGCCCGTGAACGTTGCCCGGCTTG
CTTCGTGGGCACCATCACTGGAGACCGGAGAATAGTGCTGGTGGACGATCGGGAGTGTCC
TGTCAGAAGAAATGGCCAGGGGGATGCCCCCCCGACACCCCCGCCAACCCCTGTGGACCT
GGAGCTCGAATGGGTGCTGGGCAAGATGCCTCGGAAGGAGTTCTTCCTGCAGAGGAAGCC
CCCCATGCTGCAGCCTCTGGCCTTGCCCCCAGGGCTGAGCGTGCACCAGGCTCTGGAGAG
GGTTCTGAGGCTGCCCGCCGTGGCCAGCAAGCGCTACCTCACCAATAAGGTGGACCGCTC
CGTGGGAGGCCTGGTGGCCCAGCAGCAGTGCGTGGGGCCCCTGCAAACTCCTCTGGCAGA
TGTAGCGGTTGTGGCACTGAGCCATGAGGAGCTCATAGGGGCTGCCACAGCCTTGGGAGA
ACAGCCAGTCAAGAGCCTGCTGGACCCAAAAGTCGCCGCCCGGCTGGCCGTGGCCGAAGC
CCTCACCAACCTGGTGTTTGCTCTGGTCACTGACCTCCGGGATGTGAAGTGTAGCGGGAA
CTGGATGTGGGCAGCCAAGCTCCCAGGGGAGGGCGCAGCTTTGGCGGATGCCTGTGAGGC
TATGGTGGCAGTGATGGCAGCCCTGGGTGTGGCAGTGGATGGTGGCAAGGACTCCCTCAG
CATGGCTGCTCGGGTTGGCACTGAGACCGTGCGGGCTCCTGGGTCACTGGTCATCTCAGC
CTATGCCGTCTGCCCAGACATCACAGCCACTGTGACCCCAGACCTCAAGCATCCTGAAGG
GAGAGGCCATCTGCTCTATGTGGCTCTGAGCCCTGGGCAGCACCGGCTCGGGGGCACAGC
TCTGGCCCAGTGCTTCTCCCAGCTTGGGGAACACCCTCCAGACCTGGACCTTCCTGAGAA
CTTGGTGCGGGCCTTCAGCATCACTCAGGGGCTGCTGAAAGACCGCCTCCTCTGCTCAGG
CCACGATGTCAGTGACGGAGGCCTCGTCACATGCCTGCTGGAGATGGCCTTTGCTGGAAA
TTGCGGGCTACAGGTGGATGTGCCTGTCCCCAGGGTTGATGTCCTGTCTGTGCTGTTCGC
TGAGGAGCCAGGCCTCGTGCTGGAGGTGCAGGAGCCAGACCTGGCCCAGGTGCTGAAGCG
TTACCGGGATGCTGGCCTCCATTGCCTGGAGCTGGGCCACACAGGCGAGGCCGGGCCCCA
CGCCATGGTCCGGGTGTCAGTGAACGGGGCTGTGGTTCTGGAGGAGCCTGTTGGGGAGCT
GCGAGCCCTCTGGGAGGAGACGAGTTTCCAGCTGGACCGGCTACAGGCAGAGCCTCGCTG
TGTGGCAGAGGAGGAACGGGGCCTGAGGGAGCGGATGGGGCCCAGCTATTGCCTGCCCCC
CACCTTTCCCAAAGCCTCCGTGCCCCGTGAGCCTGGTGGTCCCAGCCCCCGAGTCGCCAT
CTTGCGAGAGGAGGGCAGTAATGGAGACCGGGAGATGGCCGATGCCTTCCACTTAGCTGG
GTTTGAGGTATGGGACGTGACCATGCAGGACCTCTGCTCTGGGGCAATTGGGCTGGACAC
TTTCCGTGGCGTGGCCTTCGTGGGCGGCTTCAGCTATGCAGATGTCCTGGGCTCTGCCAA
AGGGTGGGCAGCTGCTGTGACCTTTCATCCCAGGGCTGGGGCTGAGCTGAGGCGCTTCCG
GAAGCGGCCAGACACCTTCAGCCTGGGCGTGTGTAATGGCTGTCAACTGCTGGCTCTGCT
CGGCTGGGTGGGAGGCGACCCCAATGAGGATGCTGCAGAGATGGGCCCTGACTCCCAGCC
AGCCCGGCCAGGCCTTCTGCTACGCCACAACCTGTCTGGGCGCTACGAGTCTCGCTGGGC
CAGCGTGCGTGTGGGGCCTGGGCCAGCCCTGATGCTGCGAGGGATGGAGGGCGCCGTGCT
GCCCGTGTGGAGTGCGCACGGGGAAGGTTACGTAGCATTTTCTTCTCCGGAACTCCAAGC
TCAGATTGAGGCCAGGGGCTTGGCTCCACTGCACTGGGCTGATGATGACGGGAACCCCAC
AGAGCAGTACCCTCTGAATCCCAATGGGTCCCCAGGGGGCGTGGCTGGCATCTGCTCCTG
TGATGGCCGCCACCTGGCTGTCATGCCTCACCCTGAGCGGGCCGTTAGGCCTTGGCAGTG
GGCATGGCGACCCCCTCCATTTGATACTCTGACCACCTCCCCCTGGCTCCAGCTCTCTAT
CAATGCCCGAAACTGGACCCTGGAAGGGAGCTGCTGA

# Drug_Target_9_General_Function:
Nucleotide transport and metabolism

# Drug_Target_9_General_References:
10548741	Patterson D, Bleskan J, Gardiner K, Bowersox J: Human phosphoribosylformylglycineamide amidotransferase (FGARAT): regional mapping, complete coding sequence, isolation of a functional genomic clone, and DNA sequence analysis. Gene. 1999 Nov 1;239(2):381-91.
9205841	Nagase T, Ishikawa K, Nakajima D, Ohira M, Seki N, Miyajima N, Tanaka A, Kotani H, Nomura N, Ohara O: Prediction of the coding sequences of unidentified human genes. VII. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro. DNA Res. 1997 Apr 28;4(2):141-50.

# Drug_Target_9_HGNC_ID:
HGNC:8863

# Drug_Target_9_HPRD_ID:
Not Available

# Drug_Target_9_ID:
3982

# Drug_Target_9_Locus:
17p13.1

# Drug_Target_9_Molecular_Weight:
144666

# Drug_Target_9_Name:
Phosphoribosylformylglycinamidine synthase

# Drug_Target_9_Number_of_Residues:
1338

# Drug_Target_9_PDB_ID:
Not Available

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
PF00586	AIRS
PF02769	AIRS_C

# Drug_Target_9_Protein_Sequence:
>Phosphoribosylformylglycinamidine synthase
MSPVLHFYVRPSGHEGAASGHTRRKLQGKLPELQGVETELCYNVNWTAEALPSAEETKKL
MWLFGCPLLLDDVARESWLLPGSNDLLLEVGPRLNFSTPTSTNIVSVCRATGLGPVDRVE
TTRRYRLSFAHPPSAEVEAIALATLHDRMTEQHFPHPIQSFSPESMPEPLNGPINILGEG
RLALEKANQELGLALDSWDLDFYTKRFQELQRNPSTVEAFDLAQSNSEHSRHWFFKGQLH
VDGQKLVHSLFESIMSTQESSNPNNVLKFCDNSSAIQGKEVRFLRPEDPTRPSRFQQQQG
LRHVVFTAETHNFPTGVCPFSGATTGTGGRIRDVQCTGRGAHVVAGTAGYCFGNLHIPGY
NLPWEDLSFQYPGNFARPLEVAIEASNGASDYGNKFGEPVLAGFARSLGLQLPDGQRREW
IKPIMFSGGIGSMEADHISKEAPEPGMEVVKVGGPVYRIGVGGGAASSVQVQGDNTSDLD
FGAVQRGDPEMEQKMNRVIRACVEAPKGNPICSLHDQGAGGNGNVLKELSDPAGAIIYTS
RFQLGDPTLNALEIWGAEYQESNALLLRSPNRDFLTHVSARERCPACFVGTITGDRRIVL
VDDRECPVRRNGQGDAPPTPPPTPVDLELEWVLGKMPRKEFFLQRKPPMLQPLALPPGLS
VHQALERVLRLPAVASKRYLTNKVDRSVGGLVAQQQCVGPLQTPLADVAVVALSHEELIG
AATALGEQPVKSLLDPKVAARLAVAEALTNLVFALVTDLRDVKCSGNWMWAAKLPGEGAA
LADACEAMVAVMAALGVAVDGGKDSLSMAARVGTETVRAPGSLVISAYAVCPDITATVTP
DLKHPEGRGHLLYVALSPGQHRLGGTALAQCFSQLGEHPPDLDLPENLVRAFSITQGLLK
DRLLCSGHDVSDGGLVTCLLEMAFAGNCGLQVDVPVPRVDVLSVLFAEEPGLVLEVQEPD
LAQVLKRYRDAGLHCLELGHTGEAGPHAMVRVSVNGAVVLEEPVGELRALWEETSFQLDR
LQAEPRCVAEEERGLRERMGPSYCLPPTFPKASVPREPGGPSPRVAILREEGSNGDREMA
DAFHLAGFEVWDVTMQDLCSGAIGLDTFRGVAFVGGFSYADVLGSAKGWAAAVTFHPRAG
AELRRFRKRPDTFSLGVCNGCQLLALLGWVGGDPNEDAAEMGPDSQPARPGLLLRHNLSG
RYESRWASVRVGPGPALMLRGMEGAVLPVWSAHGEGYVAFSSPELQAQIEARGLAPLHWA
DDDGNPTEQYPLNPNGSPGGVAGICSCDGRHLAVMPHPERAVRPWQWAWRPPPFDTLTTS
PWLQLSINARNWTLEGSC

# Drug_Target_9_Reaction:
ATP + N2-formyl-N1-(5-phospho-D-ribosyl)glycinamide + L-glutamine + H2O = ADP + phosphate + 2-(formamido)-N1-(5-phospho-D-ribosyl)acetamidine + L-glutamate

# Drug_Target_9_Signals:
None

# Drug_Target_9_Specific_Function:
ATP + 2-N-formyl-1-N-(5-phospho-D- ribosyl)glycinamide + L-glutamine + H(2)O = ADP + phosphate + 2- (formamido)-1-N-(5-phospho-D-ribosyl)acetamidine + L-glutamate

# Drug_Target_9_SwissProt_ID:
O15067

# Drug_Target_9_SwissProt_Name:
PUR4_HUMAN

# Drug_Target_9_Synonyms:
EC 6.3.5.3
FGAM synthase
FGAMS
FGARAT
Formylglycinamide ribotide amidotransferase
Formylglycinamide ribotide synthetase

# Drug_Target_9_Theoretical_pI:
5.55

# Drug_Target_9_Transmembrane_Regions:
None

#END_DRUGCARD DB00142
